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CHAPTER 1 
INTRODUCTION 
 
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the main bacterial 
pathogens responsible for nosocomial and community-acquired infections, including 
pneumonia, skin and soft-tissue infections, bloodstream infections, osteomyelitis and 
endocarditis (Perez Vazquez et al., 2009). In Malaysia, S. aureus was reported as the 
second most common pathogens isolated from blood specimens, and MRSA contributed 
to 21% of bacteremia cases due to S. aureus infections in year 2008 (Ministry of Health 
Malaysia, 2008; Ahmad et al., 2010).  
S. aureus also produces a variety of toxins that cause food poisoning 
(Staphylococcal food poisoning), and they are classified as one of the leading causes of 
gastroenteritides due to the consumption of food contaminated by this bacterium (Lee 
Loir et al., 2003; Ray and Bhunia, 2008).  
MRSA was reported in Malaysia since early 1970 (Lim and Zulkifli, 1987) and 
the prevalence of MRSA in Malaysian hospitals has increased from 17% in 1986 
(Rohani et al., 1999) to 26% in 2008 (Ministry of Health Malaysia, 2008). Elsewhere, 
an increase of 62% of MRSA was reported in the United States (Klein et al., 2007). 
Since most MRSA is also resistant to many commonly used antibiotics, this has raised a 
concern over the limited choice of antimicrobial agents for treatment of life-threatening 
cases. This could lead to prolonged stay in the hospital and increase the cost of health 
care (Akpaka et al., 2006; Udo et al., 2006). A death rate of 34% within 30 days was 
observed among patients with MRSA infections as compared to 27% in methicillin-
sensitive S. aureus (MSSA) patients (Wyllie et al., 2006). 
Although there is no report on the presence of vancomycin-resistant S. aureus 
(VRSA) and vancomycin-intermediate S. aureus (VISA) in Malaysia, increased of 
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minimum inhibitory concentrations (MIC) of vancomycin among S. aureus strains in 
Malaysia was observed (Ahmad et al., 2010). The increase of MIC in vancomycin is a 
cause of concern as it could affect the success of treatment using vancomycin (Ahmad 
et al., 2010) and vancomycin treatment failure in vancomycin-susceptible MRSA has 
also been reported in Malaysia (Norazah et al., 2009).   
Rifampicin is used with fusidic acid as an alternative therapy of vancomycin 
against MRSA infections in Malaysia. There is an increasing trend of fusidic acid-
resistant MRSA strains in Malaysia from 3 - 5% in the year 1992-1996 (Rohani et al., 
1999) to 21% in year 2004 (Thong et al., 2009). In another Malaysian local report, Sam 
et al. (2008) reported that the MRSA strains in University Malaya Medical Centre 
(UMMC) were often resistant to erythromycin, gentamicin and ciprofloxacin. The 
increased resistance to fusidic acid, erythromycin, gentamicin and ciprofloxacin will 
limit the choice of the antibiotic options for MRSA infections in this country.     
Rapid and discriminative subtyping methods are essential for determining the 
epidemiology of pathogenic strains and are useful in the design of rational pathogen 
control methods. Several methods are available and these include pulsed-field gel 
electrophoresis (PFGE), multilocus sequence typing (MLST), mec-associated direct 
repeat unit (dru) typing, spa typing and other PCR-associated typing methods (Goering 
et al., 2008; Park et al., 2008).  
MLST has been shown to be useful in global epidemiological studies of S. 
aureus. Ghaznavi-Rad et al. (2010) reported that over 90% of MRSA infections in a 
tertiary hospital (HKL) in Malaysia belonged to MLST type ST239 and their latter 
report (Ghaznavi-Rad et al., 2011) also indicated that mec-associated dru typing can be 
used to enhance discrimination of ST239.  
There is limited information of the molecular evolution of multidrug resistant 
MRSA in Malaysia. Most of the local studies concentrated on the antimicrobial 
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resistance rates and the molecular epidemiology of the strains within the same hospital. 
There aare no studies on the dynamics of MRSA strains over a longer period of time. 
This is important because understanding of molecular epidemiology of MRSA strains 
will help in controlling the spread and emergence of MRSA clones. Therefore, in this 
study I examined a set of strains isolated in year 2003, 2004, 2007 and 2008 to 
determine the molecular epidemiology of MRSA, their evolutionary relationship and the 
presence of different resistance and virulence genes among the MRSA strains. 
Specifically, the objectives of the study are: 
 
 
1.1 Objectives of this study 
1. To determine the antimicrobial susceptibility patterns of MRSA by disk diffusion 
test and minimum inhibitory concentrations. 
2. To determine the presence of selected plasmid-mediated erythromycin, tetracycline, 
mupirocin and β-lactam resistance genes in MRSA strains by polymerase chain 
reactions (PCR) and their transferability by transformation.  
3. To determine the chromosomal gene mutations, rpoB and fusA involved in 
rifampicin and fusidic acid resistance in MRSA strains.  
4.  To determine the prevalence of virulence gene and agr grouping in MRSA strains 
by PCR.  
5. To determine the genomic relatedness of MRSA by SCCmec typing, PCR-RFLP of 
coa gene, pulsed-field gel electrophoresis (PFGE), multilocus sequence typing 
(MLST), mec-associated dru typing and spa typing.  
6. To investigate the MRSA evolution between the years 2003, 2004, 2007 and 2008 
by using combined MLST-spa-dru typing. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Staphylococcus aureus 
2.1.1 Organisms characteristics 
Staphylococcus aureus is catalase and coagulase positive, non-motile, non-
capsular, non-sporulating, gram positive facultative anaerobe coccus (individual cells 
approximately 1 µm in diameter) that appears as grape-like clusters when viewed under 
the microscope (Mims et al., 2004; Whitehead et al., 2005; Ray and Bhunia, 2008; Plata 
et al., 2009). The name Staphylococcus is originates from the Greek staphyle meaning a 
bunch of grapes whereas kokkos meaning berry (Brown and Grilli, 1998).  
S. aureus cells form convex, round and golden-yellow colonies in agar plate and 
often produce β-hemolysis and appeared as white or golden colonies when grown on the 
blood agar plate (Mims et al., 2004; Plata et al., 2009). They also appear as yellow halo 
colonies in mannitol salt agar (Shimeld and Rodgers, 1998). 
The natural habitat of S. aureus includes nose, skin, throat and hair (feathers) of 
healthy human, birds, pig and animals (Ray and Bhunia, 2008; Neela et al., 2009b). It is 
reported that about 20% of individuals are persistent S. aureus nasal carriers and around 
30% of individuals are intermittent carriers (Wertheim et al., 2005).  
 
 
2.1.2 Clinical significance of S. aureus 
 S. aureus is one of the main nosocomial bacterial pathogens that causes a wide 
range of illnesses such as boils, pimples, folliculitis, urinary tract infections, bullous 
impetigo, skin sepsis, septic arthritis, impetigo, carbuncles, staphylococcal scalded skin 
syndrome, wound infections, traumatic and surgical wounds, ear's infections, mastitis, 
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pleura (empyema), meningitis, respiratory tract infections, gastrointestinal tract 
infections, uterus infections, abscesses, pneumonia, meningitis, osteomyelitis, 
endocarditis, toxic shock syndrome (TSS), chest pain, bacteremia, post-operative wound 
infection, catheter associated infections, furunculosis, food-borne infection and blood-
stream infections (Shimeld and Rodgers, 1998; Scholar and Pratt, 2000; Moore and 
Lindsay, 2001; Mims et al., 2004; Lindsay and Holden, 2006; Perez-Vazquez et al., 
2009; Plata et al., 2009; Yamamoto et al., 2010). In Malaysia, S. aureus was reported as 
the second most common pathogens isolated from blood specimens (Ministry of Health 
Malaysia, 2008; Ahmad et al., 2010). Although, there is no report of an outbreak due to 
nosocomial S. aureus infections in Malaysia, outbreaks due to this bacterium have been 
reported in other countries. Table 2.1 summarizes a few of the outbreaks caused by 
nosocomial S. aureus in other countries.     
 
Table 2.1: Outbreak caused by nosocomial S. aureus. 
Places/country Year Person affected Infections References 
Health care ward 
and nursing home 
in Finland 
2003 13 patients Bacteraemia Kerttula et al., 
2005 
Hospital of 
Perigueux, France 
2005 7 neonates Bullous impetigo Occelli et al., 
2007 
Notre Dame de 
Bon Secours 
Hospital, Paris, 
France 
2007 13 neonates Staphylococcal 
scaled skin 
syndrome 
El Helali et al., 
2005 
Neonatal intensive 
care unit in a 
tertiary hospital, 
Autralia 
2008 5 neonates Sepsis Schlebusch et 
al., 2010 
Hospital in Nan-
Province, Thailand 
2008 30 neonates Bullous impetigo Pawun et al., 
2009 
Hospital Clı´nico 
San Carlos, Spain 
2008 12 patients  Linezolid-resistant 
S. aureus 
Sanchez Garcia 
et al., 2010 
 
 Besides, S. aureus also produces a variety of toxins that causes food poisoning 
(Staphylococcal food poisoning), and they are considered to be one of the most 
frequently food-borne diseases worldwide (Ray and Bhunia, 2008). In addition, S. 
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aureus is classified as one of the leading causes of gastroenteritidis due to the 
consumption of food contaminated by this bacterium (Le Loir et al., 2003).   
The only outbreak due to S. aureus food-borne disease in Malaysia was reported 
in Kapar in year 1983 (Rampal, 1983). Outbreaks of staphylococcal food-borne 
poisoning have also been reported in other countries as summarized in Table 2.2. 
 
Table 2.2: Outbreak of staphylococcal food-borne poisoning in various countries 
Country Year Person affected Toxin References 
University 
Hospital 
Rotterdam, The 
Netherland 
Nov 1992- Apr 
1993 
41 persons  - Kluytmans et 
al., 1995 
Brazil 1998 180 persons Enterotoxin A Colombari et 
al., 2007 
Osaka, Japan 2000 13, 420 cases Enterotoxin 
SEA and SEH 
Ikeda et al., 
2005 
Brazil 2003 31 persons Enterotoxin A, 
B and D 
Do Carmo et 
al., 2003 
Taiwan 2003 229 strains 
from 10 
outbreaks 
Ten strains 
positive for sec 
gene 
Wang et al., 
2003 
France 2009 23 persons Enterotoxin 
SEE 
Ostyn et al., 
2010 
„-‟: no toxin reported  
 
2.2 Virulence determinants in S. aureus 
2.2.1 The capsule and cell wall structure of S. aureus 
 The staphylococcal cell wall is mainly composed of peptidoglycan, teichoic acid 
and surface protein (Plata et al., 2009). Peptidoglycan is the major component of the 
staphylococcal cell wall as it makes up of 50% of the cell wall mass whereas teichoic 
acid contributes around 40% of the cell wall mass (Harris et al., 2002). The S. aureus 
cell wall is sensitive to lysostaphin; an enzyme that specifically cleaves the 
peptidoglycan bridge of the bacterium (Le Loir et al., 2003).   
The production of capsular polysaccharides by S. aureus or better known as 
virulence factors has allowed the organism to form biofilms leading to the development 
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of device-related infections. It represents a serious medical problem as a majority of 
hospitalized patients are given insertion of foreign devices such as catheter tips, 
pacemakers, artificial heart valves and many mores (El-Din et al., 2011). Furthermore, 
it is known that 20% and 30% of individuals are persistently colonized in the nose and 
transiently colonized, respectively (Liu, 2009).     
  
 
2.2.2 Adhesins 
 Adhesion and colonization of host tissues are the initial step of the pathogenic 
process, and they are often mediated by proteins on the bacterial surface (adhesions) 
which bind specifically to complimentary ligands (Podbielska et al., 2011). The surface 
protein that promotes attachment to the host proteins includes fibronectin, collagen, 
laminin, bone sialoprotein (BSP) and elastin (Persson et al., 2009; Podbielska et al., 
2011).   
 Fibronectin is a protein which belongs to the group of microbial surface 
components recognizing adhesive matric molecules (MSCRAMMs) and it is known to 
bind at α5β1 Integrin of the host cell surface resulting of a bridge formation between the 
bacterial FnBP adhesion and host cell Integrin (Plata et al., 2009; Podbielska et al., 
2011). This fibronectins (FnBP-A and FnBP-B) are crucial for the invasion of host cells 
and S. aureus mutants that lacks fibronectin, which are often impaired by host cells. 
 Collagen binding protein or better known as CNA is encoded by cna gene (Plata 
et al., 2009). The CNA are composed of an N terminal 55-kDa A domain which 
contains a unique sequence; a B domain that is composed of 1, 2, 3, or 4 repeats of a 25-
kDa unit, and a C-terminal domain containing of cell wall attachment site, and finally, a 
short cytoplasmics segment which is rich in positively charged residues. Presence of 
cna gene is often associated with osteomyelitis and septic arthritis (Podbielska et al., 
2011).    
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2.2.3 The Staphylococcal enterotoxins and its role in pathogenesis 
 Staphylococcal enterotoxins are short secreted proteins that are usually heat-
resistant, and usually resistant to most of the proteolytic enzymes produced by the 
human body (Ortega et al., 2010). These staphylococcal enterotoxins are rich in tyrosine 
residues, lysine, aspartic acid and glutamic acid (Le Loir et al., 2003). There are more 
than 20 different types of enterotoxins (SEA to SEE, SEG to SEI, SEIJ, SEIK-SEIQ, 
SER to SET, SEW, SEIU) (Argudin et al., 2010) produced by S. aureus, and they are 
distributed into four or five groups depending on whether SEH should be places within 
group I or group V. Basically, Group I consist of SEA, SED, SEE, (SEH), SEIJ, SEIN, 
SEIO, SEIP, SES, Group II consists of SEB, SEC, SEG, SER, SEIU, SEIU2, Group III 
consists of SEI, SEIK, SEIL, SEIM, SEIQ, SEIV, Group IV consists of SET alone and 
finally Group V consist of SEH (if this SEH or not placed in Group I) (Argudin et al., 
2010).         
Staphylococcal enterotoxins genes are known to be located on mobile genetic 
elements, including plasmids, prophages, S. aureus pathogenicity islands (SAPIs), egc 
gene cluster or genomic island vSa (Argudin et al., 2010). Both staphylococcal 
enterotoxins and toxic shock syndrome toxins (TSST) are members of the 
superantigenic toxin family that stimulate nonspecific T-cell proliferation (Ferry et al., 
2005; Ortega et al., 2010; Demir et al., 2011). 
The location of staphylococcal enterotoxins gene and their general properties are 
summarized in Table 2.3. 
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Table 2.3: General properties and location of S. aureus enterotoxins genes  
Toxin Molecular 
Mass (kDa) 
Emetic 
Activity 
Gene Accessory Genetic Element 
SEA 27.1 Yes sea ΦSa3ms, ΦSa3mw, Φ252B, 
ΦNM3, ΦMu50a 
SEB 28.4 Yes seb pZA10, SaPI3  
SEC 27.5- 27.6 Yes sec SaPIn1, SaPIm1, SaPImw2, 
SaPIbov1  
SED 26.9  Yes sed pIB485-like  
SEE 26.4 No see ΦSab  
SEG 27.0 Yes seg egc1 (vSaβ I); egc2 (vSaβ 
III); egc3; egc4  
SEH 25.1 Yes seh MGEmw2/mssa476 
seh/Δseo  
SEI 24.9 Weak sei egc1 (vSaβ I); egc2 (vSaβ 
III) ); egc3  
SElJ 28.5 Nd selj pIB485-like; pF5  
SElK 26.0 Nd selk ΦSa3ms, ΦSa3mw, SaPI1, 
SaPI3, SaPIbov1, SaPI5  
SElL 26.0 Noa sell SaPIn1, SaPIm1, SaPImw2, 
SaPIbov1  
SElM 24.8 Nd selm egc1 (vSaβ I); egc2 (vSaβ 
III)  
SElN 26.1 Nd seln egc1 (vSaβ I); egc2 (vSaβ 
III); egc3; egc4  
SElO 26.7 Nd selo egc1 (vSaβ I); egc2 (vSaβ 
III); egc3; egc4; 
MGEmw2/mssa476 
seh/Δseo  
SElP 27.0 nd a selp ΦN315, ΦMu3A  
SElQ 25.0 No selq ΦSa3ms, ΦSa3mw, SaPI1, 
SaPI3, SaPI5  
SER 27.0 Yes ser pIB485-like; pF5  
SES 26.2 Yes ses pF5  
SET 22.6 Weak set pF5 
SElU 27.1 Nd selu egc2 (vSaβ III); egc3  
SElU2  nd D selu2 egc4  
SElV nd Nd selv egc4  
nd, not determined; a Emetic activity demonstrated in rabbits (SElL) or in the small insectivore Suncus murinus (SElP) but not in a 
primate model; bHypothetical location in a prophage. . 
 Table 2.3 adapted from Argudin et al, (2010).  
 
 
On the other hand, both toxin shock syndrome toxin-1 (TSST-1) and exfoliative 
toxin (ETs) A and B, are toxins produced by S. aureus, and they are described as being 
responsible for specific acute staphylococcal toxaemia syndromes, such as toxic shock 
syndrome (TSS) and staphylococcal scarlet fever (SSF) (Podbielska et al., 2011). It is 
noted that staphylococcal enterotoxins and TSST-1 toxin shared a common structure 
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and biological properties suggesting that they might be derived from a common 
ancestor. 
Exfoliative toxin (ETs) A and B are often associated with scalded skin 
syndromes that resulted in the separation of living layers and superficial dead layers of 
epidermis cells (Yamaguchi et al., 2002). On the other hand, exfoliative toxin D (ETD) 
is associated with skin and soft-tissue infections such as furuncles, abscesses and finger 
pulp infections. Most of the exfoliatin-producing strains belong to agr group IV 
(Podbielska et al., 2011).  
 
 
2.2.4 Panton valentine leukocidin (PVL) and its role in pathogenesis 
 Panton valentine leukocidin (PVL) is a bicomponent cytotoxin that targets 
human and rabbit mononuclear and polymorphonuclear cells that lead to leukocyte 
destruction and tissue necrosis (Lina et al., 1999; Deurenberg and Stobberingh, 2008).  
 PVL is encoded by lukF-PV and lukS-PV that produce proteins of 32 and 38 
kDA, respectively. These genes are located on four different phages namely x108PVL, 
wPVL, wSLT and wSA2mw (Ma et al., 2006; Deurenberg and Stobberingh, 2008; Feng 
et al., 2008). PVL with SCCmec type IV and V is often associated with CA-MRSA 
strains (Tristan et al., 2007a; Deurenberg and Stobberingh, 2008).     
 PVL is often associated with skin and mucous membrane infections such as 
cellulitis, abscesses, boils and carbuncles, necrotizing pneumonia, urinary tract 
infections, endocarditis, septic arthritis and bacteremia (Deurenberg and Stobberingh, 
2008; Pathirage, 2008).  
The prevalence of PVL among invasive (i.e blood, skin and soft-tissue 
infections) and carriage (nasal swabs from healthy humans) MRSA strains from 
Malaysia were reported at less than 5% rate and fatality case caused by PVL-producing 
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hospital-acquired S. aureus has also been reported in Hospital Kuala Lumpur 
(Malaysia) in year 2009 (Neela et al., 2009; Al-Talib et al., 2011). It is noted that, 
around 2% of S. aureus isolates from general hospital in France in year 1995 are tested 
positive for PVL (Prevost et al., 1995; Holmes et al., 2005). Besides, less than 2% of S. 
aureus isolates from United Kingdom were also tested positive for PVL (Holmes et al., 
2005; Pathirage, 2008).  
Outbreak caused by pvl positive community-acquired MRSA (CA-MRSA) has 
been reported in Ho Chih Minh city, Vietnam between April 28, 2006 and May 10, 
2006 involving nine childrens. All nine childrens developed severe infections ranging 
from fatal toxic shock syndrome, purulent abscesses, necrotizing soft-tissue infections 
to fever after they were given out-patients vaccination. Among the nine childrens, eight 
had been vaccinated by the same health care worker showing that this outbreak was 
transmitted by an asymptomatic colonised health care worker (Thuong et al., 2007).   
 
 
2.2.5 Accessory gene regulator (agr) 
An accessory gene regulator (agr) is known to be a global regulator of 
staphylococcal virulon which coordinates the expression of secreted and cell-associated 
virulence factors (Traber et al., 2008).  
agr locus of S. aureus is composed of two divergent transcriptional units, RNAII 
and RNAIII, that are driven by P2 and P3 promoters, respectively (Peerayeh et al., 
2009). Both components will signal the transduction system, leading to down-regulation 
of surface proteins as well as the up-regulation of secreted proteins during the bacteria 
in vitro growth (Robinson et al., 2005). 
The P2 operon encodes for four proteins (AgrA, AgrB, AgrC and AgrD) with 
AgrA and AgrC shared similar sequence homology with elements of the other bacterial 
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transduction systems (McNamara et al., 2000; Peerayeh et al., 2009). AgrC is known to 
function as a sensor whereas AgrA acts as the response regulator (McNamara et al., 
2000). Activity by AgrA will result in an increase of P2 and P3 transcription (Peerayeh 
et al., 2009). AgrB is a trans-membrane protein involved in processing and /or secretion 
of the 8-amino-acid peptide pheromone that are found in AgrD (McNamara et al., 2000; 
Peerayeh et al., 2009). 
There are four major agr types (designated agr type I to agr type IV) in S. 
aureus based on the sequence diversity in the variable region of AgrA, AgrD and AgrC 
(Lina et al., 2003; Peerayeh et al., 2009) 
 
 
2.3 Molecular subtyping of S. aureus 
 Various subtyping techniques have been developed in order to track the spread 
of MRSA. This is important in the design of rational pathogen control procedures and 
helps the infectious disease physicians in the development of treatment regimens to treat 
patients affected by MRSA (Singh et al., 2006). The commonly used MRSA subtyping 
methods are pulsed-field gel electrophoresis (PFGE), SCCmec typing, agr, coa and spa 
typing and multilocus sequence typing (MLST) (Deurenberg et al., 2007; Yamamoto et 
al., 2010). Among them, PFGE and MLST are considered as „gold standards‟ in typing 
MRSA strains, although these typing methods are often time-consuming, expensive and 
laborious (Ishino et al., 2007).  
 Other alternative simpler typing methods such as PCR based subtyping methods, 
PCR-restriction fragment length polymorphism (RFLP) typing of the coagulase gene 
(coa) and mec-associated direct repeat units (dru typing) have been used in subtyping of 
MRSA strains as they are simple, rapid and inexpensive (Olorunfemi et al., 2005; 
Goering et al., 2008; Himabindu et al., 2009).   
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2.3.1 PCR-based method for subtyping of S. aureus 
Polymerase chain reaction (PCR) is an enzymatic method used to exponentially 
amplify a specific pre-selected fragment of DNA (Towner and Cockayne, 1993). PCR 
uses a thermo-stable DNA polymerase to produce multiple copies of a specific nucleic 
acid region exponentially (Towner and Cockayne, 1993). The procedures require 
template DNA from the organisms being typed, thermostable DNA polymerase, two 
synthetic oligonucleotide primers and four standard deoxyribonuclease triphosphate that 
are incorporated into newly synthesized DNA (Towner and Cockayne, 1993). PCR-
based amplification methods such as random amplification of polymorphic DNA 
(RAPD) and amplified fragment lenth polymorphism (AFLP) have been used widely in 
the subtyping of various microorganisms, including S. aureus (Gardella et al., 2005; 
Singh et al., 2006).   
   
  
2.3.2 PCR-RFLP of coa gene 
 Coagulase protein is known as an important virulence factor in S. aureus and its 
production act as one of the key‟s principal criteria used in the clinical laboratory for the 
identification of S. aureus infections (Hookey et al., 1998; Tiwari et al., 2008). The 3‟ 
coding region of coagulase gene (coa) comprised of a series of 81 bp tandem short 
sequence repeats that varied between each strain (Lawrence et al., 1996).     
 The PCR-RFLP of coa gene is based on the restriction digest of the 
heterogenicity of the coagulase region (Himabindu et al., 2009). The use of coa typing 
was introduced by Goh et al. (1992).  
 Although PCR-RFLP of coa gene is less discriminative when compared to 
PFGE in subtyping MRSA, this typing method is simple, rapid and inexpensive 
(Himabindu et al., 2009). This method can be used as a preliminary screening method 
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for epidemiological studies of infections caused by MRSA because it still provides good 
discriminatory power (Mitani et al., 2005). In addition, this typing method could be 
useful for epidemiological investigation as PCR-RFLP of coa gene can analyze a large 
number of strains within a short period of time (Himabindu et al., 2009).  
 
 
2.3.3 Pulsed-field gel electrophoresis (PFGE) 
PFGE which uses a specialized electrophoresis device to separate chromosomal 
fragments produced by enzymatic digestions of intact bacterial genomic DNA, is one of 
the most common genotypic methods used in clinical laboratories for subtyping of 
MRSA strains (Murchan et al., 2003). This subtyping method involves the digestion of 
small pieces of agarose plugs with SmaI restriction enzyme (McDougal et al., 2003; 
Murchan et al., 2003).  
 In order to achieve separation of a broad range of DNA, parameters such as 
temperature, voltage, agarose concentration and pulse time should be determined. This 
is because increase of „pulse‟ time gradually over a course of the experiment will ensure 
that each different size range of DNA molecules will be subjected to their respective 
optimal separation conditions. 
 The PFGE banding patterns are analyzed by using BioNumerics with the Dice 
coefficient and un-weight pair group matching analysis (UPGMA) setting according to 
the criteria of Tenover et al. (1995).   
 PFGE has been found to show a higher discriminatory power than PCR-RFLP of 
coa gene and other PCR-based fingerprinting methods as PFGE enables the entire 
chromosome to be analyzed whereas the PCR-based fingerprinting methods explore 
only selected (random) portions of it (Hookey et al., 1998; Murchan et al., 2003).  
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2.3.4 Multilocus sequence typing (MLST) 
 MLST is considered as the rapid method for subtyping MRSA, and has been 
shown to be useful in global epidemiological studies of S. aureus (Deurenberg et al., 
2007). MLST which is based on the sequence analysis of circa 500 bp fragment of 
seven housekeeping genes (arcc, gmk, tpi, aroe, yqil, pta and glp) is a useful and 
excellent method to study the molecular evolution of S. aureus (Deurenberg et al., 
2007). All the difference sequences of each housekeeping gene are assigned as distinct 
alleles and sequence type (ST) or allelic profiles is defined based on the combination of 
seven genes (Deurenberg et al., 2006).     
 The data generated by MLST is highly comparable between laboratories via 
web-based electronic data (www.mlst.net.). Besides, the software package eBURST in 
www.mlst.net based on related MLST sequence types can analyze the evolutionary 
events within S. aureus populations (Deurenberg et al., 2007). In MLST subtyping, 
MRSA isolates will be are grouped within a single clonal complex (CC) when five out 
of seven housekeeping genes in that particular MRSA isolates having identical 
sequences and isolates with the seven same allelic profiles may be descended from a 
common ancestor (Deurenberg et al., 2006; Campanile et al., 2010).     
 The disadvantage of MLST is the technique is laborious and expensive as one has 
to sequence seven housekeeping genes in order to get its identity.   
 
 
2.3.5 spa typing 
spa typing which is based on the sequence analysis of the polymorphic region X 
of the S. aureus protein A (spa) gene is reported to be a highly effective tool in 
subtyping S. aureus (Ruppitsch et al., 2010).  
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The region X of spa gene consists of a number of 24 bp repeats sequences, and 
the diversity of the strains is attributed by duplications and deletions of the sequence in 
the region X of the gene (Shopsin et al., 1999; Kahl et al., 2005; Deurenberg and 
Stobberingh, 2008).   
Both BioNumerics 6.0 (Applied Maths, Kotrijik, Belgium) and Ridom 
Bioinformatics (Ridom GmBH, Germany) software provides tools for the analysis of 
spa sequences. The nomenclature and identification of different spa datas are 
synchronized via the internet with the central spa server 
(http://www.spaserver.ridom.de/) which is curated by the European SeqNet.org 
(Deurenburg et al., 2006). The spa server database also provides global frequencies 
information regarding mapping of spa with the MLST S. aureus database 
(http://www.spaserver.ridom.de/).   
The advantage of this typing method is the results generated are easy to 
interpret, less time-consuming, highly reproducible, less laborious and highly 
comparable between laboratories via ridom.spa.server (Hallin et al., 2006; Deurenberg 
et al., 2007). Furthermore, this typing method is less expensive when compared to 
MLST and can be used to the study the molecular evolution of S. aureus (Deurenberg et 
al., 2007; Deurenberg and Stobberingh, 2008).   
 
 
2.3.6 SCCmec typing 
The characteristics of SCCmec can be determined by identifications and 
determination of the presence of different ccr genes and the class of the mec complex by 
PCR. The ccr gene complex is composed of ccr genes whereas mec gene complex is 
composed of mecA gene and its regulatory genes, mecI and mecRI (Chongtrakool et al., 
2006; Plata et al., 2009). 
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Several multiplex PCR were available for the characterization and 
identifications of SCCmec types (Oliveira and de Lencastre, 2002; Okuma et al., 2002; 
Zhang et al., 2005; Hisata et al., 2005; Milheirico et al., 2007; Kondo et al., 2007).  
Oliveira and de Lencastre, (2002) developed a multiplex PCR that uses eight 
pairs of primers for detection of eight loci (Locus A to Locus H) on SCCmec types and 
one internal primer for detection of mecA gene. This multiplex PCR can identify four 
different SCCmec types, including SCCmec I to SCCmec IV (Oliveira and de Lencastre, 
2002).  
On the other hand, Okuma et al. (2002) developed primers that were specific for 
SCCmec IVa and SCCmec type IVb whereas Hisata et al. (2005) developed multiplex 
PCR for the specific identifications of SCCmec type IIa, IIb, IVc and IVd.  
Zhang et al. (2005) and Milheirico et al. (2007) also developed two different 
multiplex PCR for the specific characterization of SCCmec types I to SCCmec type V. 
Nine pairs of primers were used in the multiplex developed by Zhang et al. (2005) for 
the identifications of SCCmec type I, II, III, IVa, IVb, IVd and V and mecA gene while 
ten pairs of primers were used for the identifications of SCCmec type I to SCCmec type 
V using multiplex PCR developed by Milheirico et al. (2007).  
In the multiplex PCR developed by Kondo et al. (2007), six multiplex PCR (M-
PCRs) were used for the identifications of ccr gene complex (ccr), the mec gene 
compex (mec) and specific structures in the junkyard (J) regions. Multiplex PCR 1 (M-
PCR 1) (using primer set 1) identified five different types of ccr genes; Multiplex PCR 
2 (M-PCR 2) identified three classes of mec gene (Class A to Class C); Multiplex PCR 
3 (M-PCR 3) and Multiplex PCR 4 (M-PCR 4) identified the open reading frames in J1 
regions of type I to type V SCCmec elements; Multiplex PCR 5 (M-PCR 5) identified 
the transposon ΨTn554 and Tn554 which integrated within the J2 regions of type II and 
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III SCCmec elements and finally, Multiplex 6 (M-PCR 6) identified two plasmids 
(pT181 and pUB110) which integrated within the J3 regions.   
 
 
2.3.7 mec associated direct repeat unit (dru typing) 
 mec-associated direct repeat unit (dru typing) which is based on the sequence 
analysis of mec gene in differentiating MRSA strains, which are indistinguishable by 
PFGE analysis (Georing et al., 2008a). The dru locus consists of a number of 40 bp 
repeats sequences located in the hypervariable region between IS431mec and mecA of 
the SCCmec (Georing et al., 2008).   
 The advantages of dru typing over MLST are its simplicity and low costs as this 
method only involve sequencing of a single locus. Identification and analysis of dru 
types could be carried out by using BioNumerics programme (Applied Maths, Kotrijik, 
Belgium). In addition, the identification of dru types could also be carried out using a 
„stand-alone dru typing tool‟ that could be downloaded from url 
„http://www.mystrains.com/druid‟.  
 The result from this typing method is highly comparable between laboratories 
via dru.server (www.dru-typing.org.).  
 
 
2.3.8 Mutiple-locus variable-number tandem repeat assay  
  Multiple-locus variable-number tandem repeat assay (MLVA) of S. aureus is 
based on the analysis of five (sdr, clfA, clfB, ssp and spa) tandem repeat loci composed 
of seven individual genes (Sabat et al., 2003). The variability in the number of short 
tandem repeat sequenced is used to create DNA profiles for epidemiological studies. 
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This method has high level of inter-laboratory reproducibility (Lindstedt, 2005; Collery 
et al., 2008) and discriminatory and clustering capacity equivalent to PFGE 
(Malachowa et al., 2005; Collery et al., 2008).   
 The disadvantage of this technique is the results of sizing of PCR products by 
DNA sequencer standardization may be differed as different laboratories use different 
type or model of sequencers, different buffers and different capillaries 
(http://www.mlva.net/saureus/default.asp).   
 
 
2.4 Methicillin-resistant Staphylococcus aureus  
2.4.1 Mobile genetic elements Staphylococcal cassette chromosome mec 
(SCCmec)  
Methicillin resistant S. aureus (MRSA) is known to have evolved from 
methicillin-susceptible S. aureus (MSSA) after they acquired the staphylococcal 
cassette chromosome mec (SCCmec) element. This SCCmec generally consists of two 
essential components, the ccr gene complex (ccr) and the mec gene complex (mec) 
(Chongtrakool et al., 2006).  
The ccr gene complex is composed of ccr genes whereas mec gene complex is 
composed of mecA gene and its regulatory genes, mecI and mecRI (Chongtrakool et al., 
2006; Plata et al., 2009). The mecA gene is known to code for 78-kDA penicillin-
binding protein (PBP)2a than often resulted in methicillin and other β-lactam antibiotic 
resistance (Deurenberg et al., 2007).  
There are three classes of mec gene complex (class A, B and C) and four 
allotypes (type 1, 2, 3 and 5) of ccr complex (Podbielska et al., 2011). Currently, 11 
different SCCmec types have been reported worldwide based on the combinations of 
different complex classes of mec gene and allotypes.     
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Table 2.4: Characteristic of 11 types of SCCmec elements 
SCCmec type mec complex ccr genes Size 
I class B-E ccrA1B1 34 kb 
II class A ccrA2B2 52–58 kb 
III class A ccrA3B3 67 kb 
IV class B–E ccrA2B2 or 
ccrA4B4 
20–25 kb 
V class B–E ccrC 28 kb 
VI class B ccrB4 20–25 kb 
VII class C ccrC2, ccrC8 28–30 kb 
VIII class A ccrA4, ccrB4 32 kb 
IX class C2 ccrA1B1 43 kb 
X class C1 ccrA1B6 50 kb 
XI class E ccrA1B3 30 kb 
Table 2.4 adapted from Plata et al. (2009); Li et al. (2011) and Shore et al. (2011) 
 
The predominant SCCmec type in Malaysia was SCCmec type III (Ahmad et al., 
2009) and this SCCmec type III is also common in Singapore, Indonesia and Thailand 
(Chongtrakool et al., 2006).  
 
 
2.4.2 Epidemiology and prevalence of MRSA in Malaysia and worldwide 
MRSA is known to have evolved from MSSA via an acquisition of 
chromosomal gene (mecA) that encodes for penicillin-binding proteins (PBP2a) 
(Chambers, 1997; Corrente et al., 2007).  
The first MRSA isolate which belonged to SCCmec type I was reported in an 
Irish hospital, United Kingdom in year 1961, around two years after the introduction of 
methicillin antibiotic (Oliveira et al., 2002; Deurenberg et al., 2006; Deurenberg et al., 
2007) and they have disseminated to other European countries. In 1970s, MRSA was 
reported in Australia, USA and Japan (Deurenberg et al., 2007). It is known that 
worldwide spread of MRSA clones is driven by the dissemination of various clones 
from a specific genetic background (Deurenberg et al., 2007).     
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It is estimated that 20 to 40% of normal individuals are S. aureus carriers 
whereas the prevalence of MRSA carriage on hospital admission ranged between 1% 
and 12% (Weigelt, 2007).  
The MRSA infection rate in a Malaysian tertiary hospital (Hospital Universiti 
Sains Malaysia) was reported at 10 among 1000 hospital admission (Al-Talib et al., 
2010).  
The incidence of MRSA hospital infections in Japan was between 0.7 and 0.8 
per 100 admissions in year 1999 to 2003 (Kobayashi, 2006). Bell et al. (2002) indicated 
that the rate of MRSA infections among hospitalized patients in Asia-Pacific region was 
around 45.9% whereas the prevalence rate of MRSA in hospitals in some Asia 
countries, including Taiwan, Korea, Japan and China were reported to be around 70 – 
80% (Voss and Doebbeling, 1995; Lee et al., 2000; Aires de Sousa et al., 2003; Boyce 
et al., 2005; Song et al., 2011). In addition, MRSA is also known as one of the most 
common causes of nosocomial infections which accounting of 40 - 70% of S. aureus 
infections in intensive care units (Zetola et al., 2005).   
In Malaysia, the prevalence of MRSA in Malaysian hospitals has increased from 
17% in year 1986 (Rohani et al., 1999) to 26% in year 2008 (Ministry of Health 
Malaysia, 2008). Elsewhere, an increase of 62% of MRSA was reported in the United 
States (Klein et al., 2005). 
 
 
2.4.3 Hospital-acquired MRSA (HA-MRSA) in Malaysia and worldwide  
 HA-MRSA refers to infection spread from patient to patient by health workers‟ 
hands and medical instruments (Udo et al., 2008). In Malaysia, Ahmad et al. (2009) 
reported the presence of 11 different MRSA clones (ST22, ST30, ST45, ST80, ST101, 
ST188, ST1284, ST1285, ST1286, ST1287 and ST1288) from four referral hospitals 
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(Hospital Kuala Lumpur, Hospital Selayang, Hospital Queen Elizabeth and Hospital 
Kota Bharu). Ghaznavi-Rad et al. (2010) reported that majority (92.5%) of the MRSA 
strains isolated from the largest government tertiary hospital in Kuala Lumpur, 
Malaysia belonged to MLST type ST239, spa type t037 and SCCmec type III 
(Ghaznavi-Rad et al., 2010). This MRSA clone ST239 which is also known as 
Brazilian/Hungarian clone was evolved from ST30 through the transfer of a 557 kb 
fragment, and it is cluster under CC8 lineages. Apart from Malaysia, this ST239 clone is 
also the major HA-MRSA clone in Australasia and China (Ko et al., 2005; Xu et al., 
2009; Howden et al., 2011). Other MRSA clones reported in Hospital Kuala Lumpur, 
Malaysia included ST1 (CC1), ST7 (CC7), ST22 (CC22), ST188 (CC1) and ST1283 
(CC8) (Ghaznavi-Rad et al., 2010; Ghaznavi-Rad et al., 2011).  
 In a prospective surveillance study conducted by the Asian Network for 
Surveillance of Resistant Pathogens (ANSORP) from Sept 2004 to August 2006, HA-
MRSA accounted for 64.7% of the total MRSA infection in 17 ANSORP hospitals 
located in eight ASIAN countries namely Taiwan (n=3), Korea (n=7), Hong Kong 
(n=1), Thailand (n=2), Philippines (n=1), India (n=1), and Sri Lanka (n=1) (Song et al., 
2011).  
 The predominance HA-MRSA clones in Korea and Japan was MLST type ST5 
(CC5), spa type t002 or t601 and SCCmec type II (Ko et al., 2005; Song et al., 2011). 
On the other hand, the most frequent MRSA clone in Taiwan, Thailand, Hong Kong, 
Vietnam and India was MLST type ST239 (CC8), spa type t037 and SCCmec type III 
whereas the predominant MRSA clone in Sri Lanka was MLST type ST368, spa type 
t425 and SCCmec type III (Song et al., 2011). In China and Indonesia, the most 
common MRSA clone was MLST ST239 with SCCmec type III (Ko et al., 2005; Xu et 
al., 2009).   
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 Enright et al. (2002) reported that major MRSA clones within 359 MRSA 
strains from 20 countries were associated with ST22, clonal complex CC30 or CC45. 
Furthermore, they also indicated that different SCCmec types had been acquired by S. 
aureus strains with different genetic backgrounds. 
 Deurenberg et al. (2007) observed that ST8-MSSA (CC8) was the ancestor of 
MLST ST250 as they are only differed by a point mutation in the yqiL locus while this 
MRSA clone, ST250 is also related to MRSA clone ST247 as they differs by a point 
mutation in the gmk locus.   
 Other pandemic clones reported worldwide includes UK-EMRSA-15 (ST22), 
UK-EMRSA-16 (USA200, ST36), UK-EMRSA-3 (ST5), UK EMRSA-2/-6 (ST8), 
Southern Germany (ST228), Paediatric (ST5), New York/Japan (ST5), Irish-I (ST8), 
Iberian (ST247), Berlin (ST45) and Archaic (ST25) (Deurenberg and Stobberingh, 
2008).   
Tristan et al. (2007b) reported that all their representative MRSA clones 
grouped under CC5 to CC45 shared the same locus, enterotoxin gene cluster (egc) that 
encodes for five superantigenic enterotoxin genes (seg, sei, sem, sen and seo) and 
occasionally harboured tst gene.     
  
 
2.4.4 Community-acquired MRSA (CA-MRSA)  
CA-MRSA refers to MRSA strains isolated from outpatient setting, of which the 
patients must have no medical history of MRSA infection or colonization, admission to 
nursing home, dialysis and surgery (Deurenberg et al., 2006). Furthermore, the patients 
should not have permanent medical devices or indwelling catheters that inserted through 
the skin (Deurenberg et al., 2006). CA-MRSA is known to be more virulent when 
compared to HA-MRSA as they often associated with virulence factors (Chambers, 
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2001; Deurenberg and Stobberingh, 2008). CA-MRSA is known to be responsible for a 
wide range of infections ranging from soft-tissue infections through left-threatening 
disease, including necrotizing pneumonia, bacteremia and necrotizing fascilitis (O‟Brien 
et al., 2009).     
Unlike HA-MRSA, CA-MRSA strains are generally susceptible to antibiotic 
other than β-lactam, and they are known to have different phenotypic and genotypic 
characterization when compared to HA-MRSA (Deurenberg and Stobberingh, 2008). In 
Malaysia, CA-MRSA strains were known to be susceptible to gentamicin, mupirocin 
and vancomycin (National Antibiotic Guidelines Malaysia, 2008).  
The origin of CA-MRSA remained unclear. Okuma et al. (2002) showed that 
CA-MRSA has evolved from MSSA after acquisition of SCCmec type IV from the 
community whereas de Sousa and de Lencastre (2003) indicated that CA-MRSA may 
have originated from the hospital. 
Majority of CA-MRSA strains harbour SCCmec type IV, V or VII (Deurenberg 
and Stobberingh, 2008), although some reports showed that CA-MRSA strains harbour 
SCCmec type I, II or III (Chung et al., 2004; Wannet et al., 2005; Deurenberg et al., 
2007).  
PVL is often associated with CA-MRSA and is known as a stable genetic 
marker for CA-MRSA (Vandenesch et al., 2003; Tristan et al., 2007a) although some 
report dispute this notion (Rossney et al., 2007).   
 
 
2.4.4.1 CA-MRSA in Malaysia and Worldwide 
  The first CA-MRSA strain was isolated from patient from remote communities 
in Western Australia in year 1993 (Udo et al., 1993) and the first CA-MRSA strain in 
Malaysia was reported in year 2008 (Nor Shamsudin et al., 2008). Ahmad et al. (2009) 
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showed that CA-MRSA from Malaysian hospitals was from MLST type ST30 and 
ST80 while Sam et al. (2008) indicated that multisensitive CA-MRSA strains from 
another tertiary hospital in Malaysia were from MLST type ST6, ST22, ST30, ST1178 
and ST1179.   
 In a prospective surveillance study conducted by the Asian Network for 
Surveillance of Resistant Pathogens (ANSORP) from September 2004 to August 2006, 
CA-MRSA accounted for 25.4% of the total MRSA infections in 17 ANSORP hospitals 
located in eight ASIAN countries namely Taiwan (n=3), Korea (n=7), Hong Kong 
(n=1), Thailand (n=2), Philippines (n=1), India (n=1), and Sri Lanka (n=1) (Song et al., 
2011). In Hong Kong, the most frequent SCCmec type of CA-MRSA strain was 
SCCmec type III. The predominant SCCmec type among CA-MRSA isolated in 
Philippines and Korea was SCCmec type IV, and they were from spa types t019 and 
t324 (Song et al., 2011). On the other hand, the most frequent SCCmec type among CA-
MRSA isolated in Taiwan was SCCmec type III followed by SCCmec type IV with both 
associated with spa type‟s t002 and t425. Both t002 and t425 spa types were also 
common in Sri Lanka (Song et al., 2011).   
 The predominant MRSA clones among CA-MRSA in Philippines and Korea 
was MSLT type ST30, SCCmec type IV, spa type 019 and MLST type ST72, SCCmec 
type IV and spa type t324, respectively (Song et al., 2011).  
 On the other hand, Deurenburg and Stobberingh, (2008) reported that PVL-
positive CA-MRSA clones reported worldwide were mostly from MLST type ST1, 
ST8, ST30, ST59 and ST80. Among them, ST1 is reported in Asia, Europe and USA; 
ST8 in Europe and USA; ST30 in Australia, Europe and South America; ST59 in Asia 
and USA; and finally, ST80 reported in Asia, Europe and the Middle-East (Larsen et 
al., 2008; Deurenberg and Stobberingh, 2008). ST80 has also been reported as the 
predominant CA-MRSA clone affecting Europe (Larsen et al., 2008).     
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 Although there is no report of an outbreak caused in CA-MRSA in Malaysia, 
outbreaks caused by CA-MRSA has been reported in other countries. For example, 42 
persons with history of drug abuse, homeless or incarcerations from the communities 
were affected in an outbreak caused by CA-MRSA reported in Alberta, USA between 
January and September 2004 (Gilbert et al., 2006). In another community-acquired 
food-borne illness MRSA outbreak, three adults were affected after they ate 
contaminated shredded pork barbeque of which they had bought from a convenience 
shop (Jones et al., 2002). Other outbreaks cause by CA-MRSA was summarized in 
Table 2.5. 
 
Table 2.5: Outbreak associated with by CA-MRSA 
Places/country Year Person affected Infections References 
San Diego, USA 2002 34 persons Skin infections Campbell et 
al., 2004 
Cancer center, 
Texas, USA 
2003 13 employees Boils Kassis et al., 
2011 
North York 
General Hospital, 
Toronto, Ontaria, 
Canada 
2004 15 neonates 
and 8 
postpartum 
mothers 
MRSA infections Saunders et al., 
2007 
High school 
Athletes in Illinios, 
USA  
2004 10 cases MRSA skin 
infections 
Borchardt, 
2005 
Ho Chih Mind 
city, Vietnam 
2006 9 children with 
1 fatal case 
Severe CA-MRSA 
infections 
including fatal 
toxic shock 
syndrome, 
necrotizing soft 
tissue infections, 
purulent abscesses 
to fever with rash 
Thuong et al., 
2007 
  
 On the other hand, an outbreak caused by invasive CA-MRSA infections within 
a family has also been reported in Tennessee, United States. Three members of the 
family of nine have history of cough, fever and nasal congestion with the mother died of 
fulminant pneumonia, and the subtyping by PFGE showed that they were infected by 
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USA300-0114 clone (Jones et al., 2006). In addition, two of the seven childrens of this 
family had boils one month before their mother past away and the other one 
asymptomatic child also had MRSA. The subsequent subtyping indicated that all three 
isolates had similar antibiotic susceptibility profiles with their mother isolate (Jones et 
al., 2006).  
 Besides, the spread on human CA-MRSA to animal transmission has also been 
reported between September 1993 and October 1994. In this particular outbreak, 11 
horses which have therapeutic procedures in Machigan State University Veterinary 
Teaching Hospital has developed wound infection at the site of therapeutic procedures 
and PFGE subtyping of four veterinary health-care workers and 11 horses samples 
confirmed that they belong to PFGE pattern type B (Seguin et al., 1999).     
 
 
2.5 Phenotypic and genotypic detection of MRSA strains 
Various phenotypic methods can be used for detection of MRSA. This includes 
oxacillin disk diffusion test, oxacillin agar screen test, cefoxitin test, minimal inhibitory 
concentration (MIC) and CHROMagar MRSA (Corrente et al., 2007; Karami et al., 
2011).  
The use of oxacillin disk (1 µg) for screening MRSA was recommended by the 
National Committee for Clinical Laboratory Standards (NCCLS) (now re-named as 
Clinical Laboratory Standards Institute) in year 1992 (Krishnan et al., 2002). In this test, 
an organism is considered as MRSA if their zone diameter is ≤ 10 mm (CLSI, 2010). 
Krishnan et al. (2002) reported that oxacillin disk diffusion test is known to show more 
than 96.5% sensitivity. However, this oxacillin disk diffusion test could not be applied 
on S. lugdunensis and other coagulase-negative staphylococci (CLSI, 2010).  
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On the other hand, oxacillin agar dilution method for the screening of MRSA 
has also been proposed by CLSI. An organism is considered as MRSA if they are able 
to growth on Mueller-Hinton agar supplemented with 2% NaCl and 6 µg/ml oxacillin 
(CLSI, 2010).  
The use of cefoxitin test for detection of MRSA has been recommended by the 
European Antimicrobial Resistance Surveillance System (EARSS) and CLSI (Corrente 
et al., 2007; CLSI 2010). In this test, cefoxitin disc 30 µg is used and an organism is 
considered as MRSA if their zone diameter is ≤ 19 mm (Corrente et al., 2007). CLSI 
indicated that cefoxin disk diffusion could be more favourable than oxacillin disk 
diffusion test as it gave a better prediction of the presence of mecA gene when compared 
to oxacillin disk diffusion test and other oxacillin-based methods (CLSI, 2010). 
Limitation of the disk diffusion test is the result obtained might be varied between 
laboratories as it depends on the heterogeneous expression of resistance from the 
MRSA strains (Kaya et al., 2005).  
Minimal inhibitory concentration (MIC) of cefoxitin by using E-test for the 
screening of MRSA has also been proposed by CLSI and strains with MIC > 4 µg/ml 
should be reported as MRSA (CLSI, 2010). Skov et al. (2006) reported that both 
cefoxitin disk diffusion test and E-test cefoxitin was highly effective in the 
determination of MRSA and accuracy of the test can be increased by using incubation 
temperature of 35 - 36°C with incubation time of 18 to 22 hours.   
In addition, MRSA strains could also be determined by using CHROMagar-
MRSA as this method provides a high sensitivity and specificity result. An evaluation 
of 294 S. aureus strains by using CHROMagar-MRSA showed that this method was 
100% sensitive and 97.9% specific (Karami et al., 2011).  
Besides, commercially available Slidex MRSA Detection (bioMe‟rieux, France), 
Phoenix Oxacillin MIC, Phoenix Cefoxitic MIC, MicroScan oxacillin MIC and MRSA-
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Screen (Denka Seiken Co., Ltd, Japan) can also be used for the detection of MRSA 
strains (Velasco et al., 2005).  
Molecular detection methods such as PCR-based methods, Real-time PCR and 
loop-mediated isothermal amplification (LAMP) can be used for the detection of MRSA 
strains (Huletsky et al., 2004; Velasco et al., 2005; Xu et al., 2011).  
PCR-based method for the detection of mecA gene is considered as the most 
reliable and reference method for rapid determination of MRSA strains (Kaya et al., 
2009; Velasco et al., 2005). Although PCR-based method provides fast reliable results, 
however, this technique is not practical for routine used in the hospital setting as its 
required special equipment (i.e PCR thermocycler and gel electrophoresis set) (Brown 
et al., 2005).   
  MRSA could also be determined by using multiplex Real-time PCR assay 
(Huletsky et al., 2004). The advantage of this Real-time PCR is it can be performed 
directly from non-sterile clinical specimens such as blood and provide the result in less 
than an hour's time (Huletsky et al., 2004). However, this technique is not practical for 
routine used as it is cost expensive and required a special machine for the amplification 
of Real-time PCR assay.   
 Another new technique for determination of MRSA is by using LAMP. This 
method depends on the auto-cycling strand displacement DNA synthesis using four or 
six primers (two inner, two outer with or without two loop primers) with Bst DNA 
polymerase large fragment generated under isothermal conditions (Xu et al., 2011).   
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2.6 Problems with antibiotic resistance among MRSA strains 
Drug resistance is a difficult problem for hospitals as hospitals are places for 
critically ill patients who are more vulnerable to infection. In addition, the heavy use of 
drugs in these patients hastens the mutations among bacteria that harbour drug 
resistance genes (Levy and Marshall, 2004).  
Since most MRSA strains are resistant to many commonly used antibiotics 
including macrolides, lincosamides, fluoroquinolones, tetracyclines, aminoglycosides 
and chloramphenicol (Almer et al., 2002), this has raised a concern over the limited 
choice of antimicrobial agents for treatment of life-threatening cases. This could lead to 
prolonged stay in the hospital and increase the cost of care (Akpaka et al., 2006; Udo et 
al., 2006). A death rate of 34% within 30 days was observed among patients with 
MRSA infections as compared to 27% in MSSA patients (Wyllie et al., 2006).   
The National Antibiotic Guidelines 2008 in Malaysia indicated that 
erythromycin, gentamicin, trimethoprim-sulfamethoxazole, rifampicin, fusidic acid and 
clindamycin were commonly used in 16 different hospitals (Hospital Kangar, Hospital 
Alor Setar, Hospital Pulau Pinang, Hospital Ipoh, Hospital Kuala Lumpur, Hospital 
Selayang, Hospital Sungai Buloh, Hospital Klang, Hospital Seremban, Hospital Melaka, 
Hospital Johor Bharu, Hospital Kuantan, Hospital Terengganu, Hospital Kota Bharu, 
Hospital Kuching and Hospital Queen Elizabeth) in Malaysia to treat patients with 
MRSA infections. Other antimicrobial agents used to treat MRSA infections include 
linezolid, mupirocin and vancomycin. The MRSA resistance rates reported in 15 
different hospitals in Malaysia were as follows: erythromycin (84.3%), gentamicin 
(81.7%), trimethoprim-sulfamethoxazole (78.2%), clindamycin (26.2%), fusidic acid 
(14.9%) and rifampicin (10.3%) (National Antibiotic Guidelines Malaysia, 2008).   
In another Malaysian local report, Sam et al. (2008) indicated that the MRSA 
strains in University Malaya Medical centre (UMMC) are often resistant to 
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erythromycin, gentamicin and ciprofloxacin. Furthermore, David et al. (2008) indicated 
that HA-MRSA strains are typically resistant to clindamycin and other non-β-lactam 
antibiotics.  
Specifically, the mechanisms of resistance of selected antimicrobial agents are 
summarized as described in Table 2.6.  
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Table 2.6: Mechanism of S. aureus resistance to selected antimicrobials  
Antibiotic Resistance gene Gene product (s) Mechanism(s) of resistance  
β-lactam 
(penicillins) 
blaZ β-lactamases Enzymatic hydrolysis of β-
lactam nucleus 
 mecA PBP2a  Reduced affinity for PBP 
Glycopeptides 
(Vancomycin, 
teicoplanin) 
vanA, vanB Altered 
peptidoglycan 
Trapping of vancomycin in 
the cell wall 
  D-Ala-D-Lac Synthesis of dipeptide with 
reduced affinity for 
vancomycin 
Quinolones (eg. 
ciprofloxacin) 
parC parC (or GrlA) 
component of 
topoisomerase IV 
Mutations in the QRDR 
region, reducing the 
affinity of enzyme-DNA 
complex for quinolones 
 gyrA or gyrB GyrA or GyrB 
components of 
gyrase 
 
Aminoglycosides 
(eg. gentamicin, 
netilmicin) 
Aminoglycoside-
modifying 
enzymes (eg. 
aac, aph) 
Acetyltransferase, 
phosphotransferase 
Acetylating and/or 
phosphorylating enzymes 
modify aminoglycosides 
Trimethoprim-
sulfamethaxazole 
Sulfonamide: 
sulA 
Dihydropteroate 
synthase 
Overproduction of p-
aminobenzoic acid by 
enzyme 
 TMP: dfrB Dihydrofolate 
reductase (DHFR)  
Reduced affinity for DHFR 
Tetracycline tetK, tetL, tetM, 
tetO, tetS 
Tetracycline effux 
protein 
Enzyme inactivation, 
ribosomal protection‟s 
protein and efflux protein 
Oxazolidinones 
(e.g. linezolid) 
rrn, cfrA 23S rRNA Mutations in domain V of 
23S rRNA component of 
the 50S ribosome. 
Interferes with ribosomal 
binding 
Quinupristin- 
dalfopristin (Q-D) 
(erythromycin) 
Q: ermA, ermB, 
ermC 
Ribosomal 
methylases 
Reduce binding to the 23S 
ribosomal subunit 
 D: vat, vatB Acetyltransferases Enzymatic modification of 
dalfopristin 
Lincosamides 
(clindamycin) 
msrA Ribosomal 
methylases 
Reduce binding to the 23S 
ribosomal subunit 
 Mupirocin ileS, ileS2, mupA Isoleucyl-RNA 
synthetase (IRS) 
Inhibits protein synthesis 
Fusidic acid fusB, fusC, fusD - protects the staphylococcal 
translation apparatus 
Rifampicin rpoB - β-subunit mutational 
change 
Table 2.6 was adapted from Lowy (2003); Yun et al. (2003); Rotger et al. (2005); Mick et al. (2010); Castanheira et al. (2010b); 
Chopra and Roberts (2002).  
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2.6.1 Mupirocin resistance  
Mupirocin (pseudomonic acid A) is a topical antimicrobial agent used for 
treatment of superficial skin infections (Yun et al., 2003). This topical drug binds 
competitively to bacterial isoleucyl-RNA synthetase (IRS) and inhibits protein synthesis 
(Yun et al., 2003). High level resistance to mupirocin is often associated with the 
acquisition of mupA gene while low level resistance to mupirocin is due to mutation in 
endogenous bacterial isoleucyl-tRNA synthetase (Rotger et al., 2005).  
The increase usage of this agent has led to rapid emergence of mupirocin 
resistant strains in some parts of the world (Leski et al., 1999). Mupirocin drug has been 
used in Malaysian hospitals since year 1998 and the only report on mupirocin resistance 
(1.25%) in Malaysia was reported by Norazah et al. (2002). However, in UMMC, 
mupirocin drug is still of limited usage as it is only recommended for out-patients and 
not for in-patients. This drug is also used for treatment of MRSA colonization in 
medical staff for five days and then re-tested on the seventh day for ensure clearance. 
The presence of high-level mupirocin resistance can be determined by using disk 
diffusion test or broth micro dilution test. An organism is considered as exhibiting high-
level mupirocin resistance if they are resistant to 200 µg mupirocin disks or having MIC 
256 µg/ml (CLSI, 2010).  
 
 
2.6.2 Erythromycin resistance  
Erythromycin is a macrolide antibiotic that consists of a large lactone ring. This 
antibiotic is often used for the treatment of respiratory tract infection (Scholar and Pratt, 
2000). Erythromycin resistance is also associated with resistance to other macrolides, 
lincosamides and type B streptogramin (MLSB). 
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There are three mechanisms involved in erythromycin resistance, which are (i) 
the use of an energy-dependent efflux, (ii) production of inactivating enzymes and (iii) 
alteration of 23S rRNA methylases (Wang et al., 2008).  
Alteration of 23S rRNA methylases is mediated by the presence of erm genes 
[i.e erm(A), erm(B) and erm(C)] whereas the energy-dependent efflux pump is often 
affected by membrane proteins encoded by msr(A) or msr(B) genes (Spiliopoulou et al., 
2004). The production of inactivating enzymes, which hydrolyze the macrocycles 
lactone ring of erythromycin, is mediated by ereA or ereB genes (Schmitz et al., 2000).   
 
 
2.6.3 Clindamycin resistance 
 Clindamycin belongs to lincosamide A, an antibiotic that is known to have a 
wide antibacterial spectrum against gram-positive cocci, anaerobe's gram-negative 
organisms and certain protozoa (Scholar and Pratt, 2000). It is often used to treat 
osteomyelitis, bone infections related to diabetic foot and decubitus ulcers (Scholar and 
Pratt, 2000). However, this antibiotic can cause side effect such as diarrhoea, 
hypersensitivity reactions and may occasionally cause irritation at local 
thrombophlebitis (Scholar and Pratt, 2000).   
 Clindamycin resistance can be grouped as either inducible clindamycin 
resistance (known as inducible macrolides, lincosamides and streptograminB, iMLSB) or 
constitutive clindamycin resistance (also known as constitutive clindamycin resistance, 
cMLSB). An isolate that is resistant to both erythromycin, and clindamycin is 
considered showing constitutive clindamycin resistance while isolate that was resistant 
to erythromycin, sensitive to erythromycin and shows flattening of the clindamycin 
zone of inhibition adjacent to erythromycin disc, forming a D-shape is described as 
inducible clindamycin resistance (Mallick et al., 2009). 
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 The clindamycin resistance mechanism is often associated with the ribosomal 
modification by methylases encoded by erm genes. This erm gene will cause in the 
methylation of 23S rRNA that resulting in a decrease of affinity for clindamycin and 
type B streptogramins (Lim et al., 2006).   
 Detection of inducible clindamycin resistance can be performed by using D zone 
test (CLSI, 2010). In D-test, a disk containing erythromycin (15 µg) is placed on the 
Mueller-Hinton agar plate and disk containing clindamycin (2 µg) are applied 15 - 26 
mm distance away from the erythromycin disk (CLSI, 2010).  
 
 
2.6.4 Rifampicin resistance  
Rifampicin which is a semi-synthetic derivative of rifamycin B, is an important 
antibiotic used in combination therapy for treatment of deep-seated staphylococcal 
infections and tuberculosis (Yu et al., 2005).  
Rifampicin resistance is often associated with mutations in the β-subunit of 
RNA polymerase encoded by the rpoB gene. This mutation is related to amino acid 
changes found in two particular regions of rpoB gene, namely cluster I and II (Mick et 
al., 2010).  
In Malaysia, rifampicin is used with fusidic acid as an alternative or switch 
therapy of vancomycin against Staphylococcal infections (Norazah et al., 2002). Little 
is known about the rifampicin resistance mechanisms in S. aureus isolated in Malaysia. 
Rohani et al. (2000) reported rifampicin resistant rate of 3.3% (in year 1996) by using 
disk diffusion test while Norazah et al. (2002) reported a 5% (year 1997 to 1999) 
rifampicin-resistant rate.   
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2.6.5 Fusidic acid resistance 
Fusidic acid can be used as topical antibiotic or systemically for the treatment of 
Staphylococcal infections (Alreshidi and Mariana, 2011). This drug binds to elongation 
factor G (EF-G) on the ribosome and inhibits protein synthesis (Castanheira et al., 
2010a, b). Fusidic acid in known as bacteriostatic but it can become bacteriocidal when 
this antibiotic was applied at high concentration (Howden and Grayson, 2006).  
Resistance to fusidic acid is often associated with mutations in fusA gene leading 
to the alteration of EF-G structures or to the acquisition of plasmid mediated resistant 
genes such as fusB, fusC or fusD gene (Howden and Grayson, 2006; O‟Neill et al., 
2007; Norstrom et al., 2007; Lannergard et al., 2009; Chen et al., 2010). The plasmid 
mediated fusB, fusC and fusD resistance genes encode at the EF-G binding proteins and 
protect the staphylococcal translation apparatus against the inhibitory action of fusidic 
acid (O‟Neill and Chopra, 2006; Chen et al., 2011). fusB gene is usually carried by 
plasmid with size of 21 kb (pUB101) (Chen et al., 2011). The third mechanism involved 
in fusidic acid-resistance is mutations in the riboprotein L6 operon of the rplF gene 
(Norstrom et al., 2007; Castanheira et al., 2010b).   
Fusidic acid can also be used together with rifampicin as an alternative or switch 
therapy of vancomycin against MRSA infections in Malaysia (Norazah et al., 2002). In 
addition, O‟Neill et al. (2001) also indicated that combination use of rifampicin and 
fusidic acid gave a wider role in the prevention of MRSA and vancomycin-intermediate 
S. aureus (VISA) infections. The prevalence of fusidic acid resistance among MRSA 
strains from Malaysia increased from 3.8% in year 1996 (Rohani et al., 2000) to 5% in 
year 1997 - 1998 (Norazah et al., 2002). 
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2.6.6 Linezolid resistance  
 Linezolid is an oxazolidinone antibiotic that has a board spectrum activity 
against gram-positive bacteria, including MRSA, VRSA and vancomycin-resistant 
Enterococcus (Longmore et al., 2008). This antibiotic inhibits bacterial protein 
synthesis by binding to the 50 S subunit of the bacterial ribosomes and interacts with the 
23S rRNA resulting in the inhibition of 70S initiation complex formation (Hortiwakul et 
al., 2004; Besier et al., 2008). Linezolid is known to be more effective than teicoplanin 
in treating skin and soft-tissue infections caused by MRSA (Hayman et al., 2007).   
 Linezolid resistance is often associated with mutations in domain V of the 23S 
rRNA gene, including amino acid alteration of G244T, T2500A and G2576T or by the 
presence of cfr (chloramphenicol-florfenicol resistance) gene that encodes a 23S rRNA 
methyltransferase of host cells (Arias et al., 2008; Besier et al., 2008).   
Outbreak due to linezolid resistant S. aureus has been reported in an intensive 
care department of a 1000-bed tertiary care University teaching hospital located in 
Madrid, Spain in year 2008 (Sanchez Garcia et al., 2010).  
 
 
2.6.7 Vancomycin resistance  
 Vancomycin is glycopeptides antibiotic that act actively against most species 
gram positive bacilli and coccus, such as S. aureus, Staphylococcus epidermidis, 
Clostrium species, Streptococcus pneumoniae, Clostridium species, Listeria 
monocytogenes, Actinomyces species, Lactobacillus species (Scholar and Pratt, 2000). It 
binds tightly to the acyl-D-alanyl-D-alanine terminus of the bacterial cells that will lead 
to cell lysis (Scholar and Pratt, 2000).   
 Vancomycin resistance is either conferred by the presence of several van genes, 
i.e vanA, vanB and vanD (Sanakal and Kaliwal, 2011) or S. aureus cell wall thickening 
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(Hiramatsu, 2001). It is reported that vanA gene often confers inducible high-level of 
resistance whereas vanB confers to various levels of resistance, and finally vanD 
confers resistance to intermediate level of vancomycin resistance (Quintiliani et al., 
1993; Sanakal and Kaliwal, 2011).   
 The presence of VRSA or vancomycin intermediate S. aureus (VISA) can be 
determined by using agar dilution test or E-test (CLSI, 2010). An isolate is considered 
as VRSA if the MIC of vancomycin is ≥ 16 µg/ml or as VISA if the MIC ranges from 4 
to 8 µg/ml (CLSI, 2010).      
 Although there is no report on the presence of VRSA or VISA in Malaysia, the 
number of MRSA with an increased vancomycin minimum inhibitory concentration 
among MRSA has been observed (Ahmad et al., 2010). Elsewhere, the presence of 
VISA and VRSA is increasing globally (Tenover et al., 2007; Howden et al., 2008) as 
summarized in Table 2.7 
 
 
Table 2.7: Occurrence of VISA or VRSA in various countries 
VRSA/VISA Country Author 
VISA Japan Hiramatsu et al., 1997 
VISA Korea Kim et al., 2000 
VISA Vietnam, China, Indonesia, 
Philippines, Saudi Arabia, 
Singapore, Sri Lanka and 
Taiwan 
Song et al., 2004 
 
VISA Thailand Lulitanond et al., 2009 
VRSA Iran Saderi et al., 2005 
VRSA Northern India Tiwari and Sen, 2006 
VRSA  Kokalta hospital, India Saha et al., 2008 
VRSA Michigan, USA Zhu et al., 2008 
VRSA Nigeria Taiwo et al., 2011 
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2.6.8 Gentamicin resistance  
 Gentamicin is a broad-spectrum antibiotic from aminoglycoside antibiotic, often 
used to treat serious infections due to gram-negative bacilli and is also active against S. 
aureus (Scholar and Pratt, 2000).This antibiotic works by binding to the 30S subunit of 
the bacterial ribosome and thus interrupt the synthesis of protein.     
 In S. aureus, the main mechanism involved in gentamicin resistance is by the 
production of aminoglycoside modifying enzymes (AME) (Klingenberg et al., 2004). 
Three AME, including aminoglycoside-6′-N-acetyltransferase/2″-O-
phosphoryltransferase [AAC(6′)/APH(2″)], aminoglycoside-4′-O-nucleotidyltransferase 
I [ANT(4′)-I] and aminoglycoside-3′-O-phosphoryltransferase III [APH(3′)-III] 
responsible for gentamicin resistance in S. aureus (Miller et al., 1997; Schmitz et al., 
1999; Livermore et al., 2001; Klingenberg et al., 2004). Among the three AME genes, 
aminoglycoside-6′-N-acetyltransferase/2″-O-phosphoryltransferase [AAC(6′)/APH(2″)] 
is encoded by transposon Tn4001 (Rouch et al., 1987).  
 
 
2.6.9 Netilmicin resistance 
 Netilmicin is an aminoglycoside antibiotic that is known to be active against 
gentamicin-resistant Escherichia coli, Klebsiella and Enterobacter (Scholar and Pratt, 
2000). They are known to be less ototoxic when compared to other aminoglycosides in 
animal models (Scholar and Pratt, 2000).         
 Resistance to netilmicin is often associated with the presence of 
aminoglycoside-modifying enzymes (AME) which are encoded within the mobile 
genetic elements (Vakulenko and Mobashery, 2003; Hauschild et al., 2008). Presence of 
this AME will result in drug inactivation (Hauschild et al., 2008). 
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2.6.10 Tetracycline resistance  
Tetracycline is a broad-spectrum antibiotic often used to treat sinuses, acne, 
respiratory and urinary tract infections, intestines and used for the treatments of 
gonorrhoea for patients who are allergic to macrolides and β-lactam (Chopra and 
Roberts, 2001; El-Mahdy et al., 2010).           
Tetracycline resistance is mediated by enzyme inactivation, ribosomal 
protection‟s proteins and efflux proteins (Chopra and Roberts, 2001; Villedieu et al., 
2003). In the efflux proteins, the tet efflux genes are able to encode for membrane-
associated proteins and thus removing the tetracycline from the cells (Dorsch, 2007) 
whereas ribosomal protection's proteins are cytoplasmics proteins that protect the 
bacterial ribosome against tetracycline (Dorsch, 2007) and finally enzyme inactivation 
refers to the inactivation of tetracycline by enzymatic modifications (Dorsch, 2007). 
 
 
2.6.11 Teicoplanin resistance 
 Teicoplanin is a lipoglycopeptide antibiotic that has mechanisms of action very 
similar to vancomycin (Scholar and Pratt, 2000; Svetitsky et al., 2009). This antibiotic 
is safely administered intramuscularly and has long life-times ranging from 33 to 190 
hours or even longer, thus can be used on once-daily maintenance dosing (Scholar and 
Pratt, 2000).  
 Teicoplanin is used as an alternative to vancomycin, and it appears to be 
affective against vancomycin-resistant enterococcal infections (Scholar and Pratt, 2000). 
Teicoplanin resistance is often associated with bacterial cell wall thickening or over 
expression of penicillin binding proteins 2 (PBP2) in bacterial cells (Hiramatsu, 2001). 
On the other hand, teicoplanin resistance can also be conferred by vancomycin 
resistance genes (van) such as vanA and vanB (Sanakal and Kaliwal, 2011). Outbreak 
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involving MRSA strains with reduced susceptibility towards teicoplanin has been 
reported between January and March, 2000 in France (Heym et al., 2002).   
 
 
2.6.12 Ciprofloxacin resistance 
 Ciprofloxacin, a synthetic chemotherapeutic antibiotic from the flouroquinolone 
drug class is often used to treat adult cystic fibrosis, and it is known to be active against 
Salmonella and Campylobacter infections (Longmore et al., 2008). It is also being used 
for the topical treatment of recurrent purulent otitis (Sachse et al., 2008).   
 Ciprofloxacin resistance is often associated with mutations in the topoisomerase 
IV or DNA gyrase, or by the induction of multidrug efflux pump (Lowy, 2003). 
Nucleotide mutation that leads to amino acid changes in topoisomerase IV, DNA gyrase 
A will reduce the quinolone affinity to its targets and thus confer the resistance (Lowy, 
2003).  
 
 
2.6.13 Trimethoprim-sulfamethoxazole resistance 
 Trimethoprim-sulfamethoxazole or also known as co-trimoxazole, a 
combination of trimethoprim and sulfamethoxazole in the ratio of one to five, is often 
used in the treatment of upper and lower respiratory tract infections, skin and wound 
infections, septicemias, renal and urinary tract infections caused by bacterial (Masters et 
al., 2003).   
 Resistance to trimethoprim is associated with mutations in the chromosomal 
gene for dihydrofolate reductase or by uptakes of transposon Tn4003-borne dfrA gene 
or Tn559-borne dfrK gene (Rouch et al., 1989; Dale et al., 1993; Qi et al., 2005; Kadlec 
and Schwarz, 2010). Resistance to sulfonamides is associated with mutations in the 
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chromosomal dihydropteroic synthase gene (Rouch et al., 1989; Dale et al., 1993; Qi et 
al., 2005).   
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1 Materials 
3.1.1 Bacterial Strains 
Initially, all the MRSA strains from year 2003 to 2008 stock cultures were 
included in this retrospective study conducted in year 2009. However, no MRSA strains 
from year 2005 and 2006 were available as they were not viable. Therefore, a total of 
188 methicillin-resistant Staphylococcus aureus (MRSA) strains was examined in this 
study. All MRSA strains were obtained from University Malaya Medical Centre 
(UMMC). The clinical strains were isolated from various types of specimens.  
All strains were identified by standard biochemical methods by laboratory staff 
of the microbial diagnosis laboratory of UMMC. Briefly, all the clinical specimens were 
streaked on blood and MacConkey agars and inoculated overnight at 35°C. The 
suspected S. aureus colonies in blood agar (showed β-haemolysin with golden-yellow 
colonies) were further tested with coagulase test and cefoxitin disk diffusion test 
following CLSI guidelines (2010). The strains were identified as MRSA if zone 
diameter were ≤ 21 mm and tested positive in coagulase test. Upon receipt, the purity of 
the bacterial cultures was determined by streaking on mannitol-salt agar (Oxoid Ltd, 
Basingtoke, Hampshire, UK).  
Bacterial cultures of the strains were stored in Tryptone Soy Broth (TSB) 
supplemented with 50% glycerol at -20
o
C and -85
o
C as well as in Tryptone Soy Agar 
(TSA) stab cultures at room temperature. Details of the strains used in this study are 
listed in Appendix 1.  
S. aureus ATCC25923 was used as positive control for antimicrobial 
susceptibility test, whereas strains NCTC10442, N315, 85/2082, JCSC4744, JCSC2172, 
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JCSC4469, JCSC4788, and W15 were used as positive controls for SCCmec type I, II, 
III, IVa, IVb, IVc, IVd and V, respectively. For transformation experiments, E. coli 
strain DH10B was used as positive control whereas S. aureus ATCC29213 was used as 
the recipient (Table 3.1).     
 
 
Table 3.1: Details of E. coli strain used in this study 
Bacterial 
Strain 
Genotype/Phenotype Source 
E. coli 
DH10B 
F
-
 mcrA Δ(mrr-hsdRMS-mcrBC)ф80lacZ 
ΔlacX74 recA1 endA1 araD139 Δ (ara, 
leu)7697 galU galK λ-rpsL nupG tonA 
Invitrogen, 
USA 
 
 
 
3.1.2  Chemicals, Reagents and Consumables  
 All chemicals and solvents used were of Analar grade purchased from Sigma 
Chemical Co., U.S.A., BDH Chemicals Ltd., England, and Invitrogen
TM
., USA.  
 Seakem gold agarose powder for DNA plug preparation was purchased from 
Camrex Bio Science Rockland, Inc, USA. Low EEO agarose powder and Promega LE 
Analytical for standard gels were from Sigma Aldrich, USA and Promega, Madison 
Wis, USA.   
Yeast extracts; bacteriological agar, Mueller-Hinton agar, Brain-Heart Infusion 
agar, Manittol-Salt Agar, Typtone Soy agar, sucrose and tryptone for bacterial culture 
media were from Oxoid Ltd, Basingstoke, Hampshire, England. Glycerol was 
purchased from Invitrogen, California, USA. Sodium chloride, potassium dihydrogen 
phosphate, potassium hydrogen phosphate, sodium hydrogen maleate, maleic anhydride 
was from Merck, USA whereas congo red was from VWR Prolabo, Fonteay-sous-Bois, 
France. 
All the antimicrobial disks used were purchased from Oxoid Ltd., Basingstoke, 
Hampshire, England. E-test strips were purchased from Ab Biodisk, Sweden. 
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Rifampicin, oxacillin, trimethoprim-sulfamethoxazole, vancomycin, erythromycin, 
tetracycline, ciprofloxacin, lysozyme, lysostaphin and bovine albumin's powders were 
purchased from Sigma, USA. All medias, buffers and solution preparations are listed in 
Appendix 2. 
 
3.1.3 Restriction enzymes 
Restriction endonucleases (RE) used in this study are listed in Table 3.2. 
Table 3.2: List of enzymes used in this study 
Enzyme Sources 
EcoRI Promega Madison Wis, USA 
XbaI Promega Madison Wis, USA 
SmaI Promega Madison Wis, USA 
AluI Promega Madison Wis, USA 
 
 
 
3.1.4 DNA molecular weight markers 
DNA molecular weight markers used in this study are listed in Table 3.3. 
     Table 3.3:  List of DNA molecular weight markers used in this study 
DNA marker Range (bp) Source 
100 bp DNA marker 100 - 1,500 Promega Madison Wis, USA 
1kb DNA marker 250 - 10,000 Promega Madison Wis, USA 
Lambda DNA/HindIII Marker 125 - 23,130 Promega Madison Wis, USA 
 
 
 
3.1.5 Primers and Oligonucleotides 
Commercially synthesized primers and oligonucleotides were purchased from 
Bioneers, Korea. All primers and oligonucleotides used in this study were salt-free 
purified. Primers that amplify the 16S ribosomal RNA genes were included as a positive 
control in all the PCR detection for erythromycin, tetracycline and mupirocin resistant 
genes. The primer sequences are as follows: Primer 1 (5‟- AGT TTG ATC ATG GCT 
CAG-3‟) and primer 2 (5‟-GGA CTA CCA GGG TAT CTA AT-3‟) (Shukla et al., 
2003; Varela et al., 2004) which yield an expected amplicon size of 720 bp.  
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3.1.6 Commercial Kits for extraction of genomic DNA and purification of PCR 
products 
Commercially DNA purification kits used in this study are listed in Table 3.4. 
   Table 3.4: List of commercial kits used in this study 
Name Source 
QIAquick Gel Extraction Kit Qiagen GmBH, Germany 
QIAprep Spin Miniprep Kit Qiagen GmBH, Germany 
Wizard Genomic DNA purification kit Promega Madison Wis, USA 
PCRquick-spin PCR product purification 
kit 
Intron Biotechnology, Korea 
 
 
 
3.1.7 Softwares 
 The various softwares used in this study are listed in Table 3.5. 
  Table 3.5: List of software used in this study 
Software Sources 
BioRad Imager BioRad, USA 
Primer 3 http://frodo.wi.mit.edu/primer3/ 
In-silico PCR 
programme 
http://insilico.ehu.es/PCR/ 
Mega 4 The Biodesign Institute, USA 
BioNumerics 6.0 Applied Maths, Kortrijk, Belgium  
Simpson‟s index http://insilico.ehu.es/mini_tools/discriminatory_power/index.php 
Statistica 8.0 StatSoft, Inc, USA 
MLST http://saureus.mlst.net 
BURST algorithm http://eburst.mlst.net 
BLAST search 
program  
http://www.ncbi.nih.gov/BLAST 
 
 
 
3.2 Methods 
3.2.1 Antibiotic Susceptibility Tests 
The antimicrobial susceptibility of MRSA strains to 14 antimicrobial agents 
[vancomycin (30 μg), oxacillin (1 μg), mupirocin (5 μg), ciprofloxacin (5 μg), 
tetracycline (30 μg), erythromycin (15 μg), fusidic acid (75 μg), netilmicin (30 μg), 
teicoplanin (30 μg), gentamicin (10 μg), linezolid (30 μg), rifampicin (5 μg), 
trimethoprim-sulfamethoxazole (75 μg) and clindamycin (2 μg) (Oxoid Ltd., 
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Basingstoke, Hampshire UK)] were determined by the disk diffusion method according 
to Clinical Laboratory Standard Institutes guidelines (CLSI, 2010).  
The minimum inhibitory concentration (MIC) for vancomycin and fusidic acid 
was confirmed using Etest (Ab Biodisk, Sweden) whereas MIC for erythromycin, 
tetracycline, oxacillin, rifampicin and ciprofloxacin was done by using agar 
microdilution test according to CLSI guidelines (CLSI, 2010). Briefly, various 
concentrations of stock solutions (5120 µg/ml, 640 µg/ml, 80 µg/ml and 10 µg/ml) were 
prepared according to CLSI guidelines (CLSI, 2010). Intermediate (10x) antimicrobial 
agent solutions of serial twofold dilutions were prepared by referring to Table 3.6 and 
the antimicrobial solutions were added to molten Mueller-Hinton agar (45°C to 50°C). 
The agar and antimicrobial solution was mix thoroughly before being poured into petri 
dishes on a level surface in an agar depth of 4 mm. The agar was allow to solidify at 
room temperature and can be either used immediately or store at 4°C for up to five days.  
 
Table 3.6: Scheme for preparing dilutions of antimicrobial agents to be used in agar 
dilution susceptibility tests.  
Antimicrobial solutions 
Step Concentrati
on (µg/ml) 
Source Vol 
(ml) 
Diluent 
(ml) 
Intermediate 
concentration 
(µg/ml) 
Final concentration 
at 1:10 dilution in 
agar (µg/ml) 
1 5120 Stock 2 2 2560 256 
2 5120 Stock 1 3 1280 128 
3 5120 Stock 1 7 640 64 
4 640 Step 3 2 2 320 32 
5 640 Step 3 1 3 160 16 
6 640 Step 3 1 7 80 8 
7 80 Step 6 2 2 40 4 
8 80 Step 6 1 3 20 2 
9 80 Step 6 1 7 10 1 
10 10 Step 9 2 2 5 0.5 
11 10 Step 9 1 3 2.5 0.25 
12 10 Step 9 1 7 1.25 0.125 
Table 3.6 adapted from CLSI, (2010). 
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The bacterial suspension used for MIC test was adjusted to the 0.5 McFarland 
standards (turbidity of 0.08 to 0.10). Aliquots of inoculum were applied on the agar 
surface by using replicators with 1 mm pins, and the agar plates were incubated at 37°C 
for 16 to 20 hours.  
D-zone test method, which is used for the detection of inducible clindamycin 
resistance (known as inducible macrolides, lincosamides and streptograminB, i-MLSB) 
and constitutive clindamycin resistance (known as constitutive macrolides, lincosamides 
and streptograminB (cMLSB) were performed on all erythromycin-resistant strains 
according to established protocols (Mallick et al., 2009). Briefly, erythromycin (15 µg) 
disk was placed at a distance of 15 mm (center to center) from clindamycin (2 µg) disk 
on Mueller-Hinton agar (Oxoid Ltd, Basingstoke, Hampshire, UK) and incubated at 
37°C for overnight. Any enhancement of inhibition that produces a D-shape of the 
clindamycin zone is an indication of inducible-clindamycin resistance (Mallick et al., 
2009). Strains that were resistant to both clindamycin, and erythromycin are defined as 
showing constitutive clindamycin resistance (Mallick et al., 2009).   
 S. aureus ATCC25923 was used as quality control strain for susceptibility 
testing as recommended by CLSI (CLSI, 2010).  
 
 
3.2.2 DNA template preparation 
3.2.2.1 Genomic DNA preparation   
 DNA template from bacterial strains was prepared for PCR amplification by 
simple boiling method and by using Wizard, Genomic DNA purification kit (Promega, 
Madison Wis, USA).  
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3.2.2.2 Crude lysate DNA template preparation by simple boiling method 
One loopful of bacterial colonies was picked and suspended in 100 l ddH2O in 
a microcentrifuge tube containing 2 l of lysostaphin (1 mg/ml). The microcentrifuge 
tube containing a loopful of bacterial colonies and lysistaphin was incubated for 5 min 
at 37°C before being boiled for 10 min at 100°C and immediately snap-cooled on ice for 
10 min. The cell lysates were then centrifuged at 10, 000 X g or 90 seconds. Five 
microlitres (approximately 50 ng measured by using Eppendorf Biophotometer) of the 
supernatant were used in the PCR assay. The lysate was stored in -20°C and could be 
used for several PCR reactions. 
 
 
3.2.2.3 Genomic DNA preparation by using a commercial Genomic DNA 
purification kit 
One loopful of bacterial colonies from overnight culture was picked and 
suspended in 480 µl of 0.5 M EDTA in a microcentrifuge tube containing 10 µl of 
lysozyme (10 mg/ml) and 10 µl of lysostaphin (1 mg/ml). The mixture was incubated 
for 30 min at 37°C before being centrifuged for 5 min at 4°C. After centrifugation, all 
supernatant was removed and 600 µl of nuclei lysis solution (Promega Madison Wis, 
USA) was added into the microcentrifuge tube, and the solution was re-suspended 
gently. The tube was incubated at 80°C for 5 minutes in order to lyse the cells and then 
cool to room temperature.   
Three microliters of RNase solutions (10 mg/ml) were added into the 
microcentrifuge tube and the tube was inverted for 2 to 5 times before being incubated 
at 37°C for 30 min. After incubation, 200 µl of protein precipitation solution (Promega 
Madison Wis, USA) was added to RNase-treated cell lysate, and the microcentrifuge 
tube was vortex vigorously at high speed for 20 sec before being incubated on ice for 5 
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min. The microcentrifuge tube was centrifuged at 13, 000 x g for 3 min and supernatant 
containing the DNA was transferred to a clean 1.5 ml microcentrifuge tube which 
contained 600 µl room temperature isopropanol. The microcentrifuge tube was then 
centrifuged at 13, 000 x g for 2 min and all supernatant was carefully removed, and the 
DNA was washed with 70% ethanol.   
The dried pellet was resuspended in 100 µl of deonised water, and the genomic 
DNA was stored at - 20°C for PCR reaction.   
 
 
3.2.3 Plasmid extraction by alkaline lysis method  
 Plasmid extraction was carried out as described by Zuccarelli et al. (1990) with 
minor modifications. Briefly, a single bacterial colony was inoculated into 20 ml of 
TSB broth and incubated overnight at 37°C with shaking at 180 rpm. The overnight 
culture was harvested by centrifugation at 5000 x g for 10 min at 4°C. The supernatant 
was discarded, and the pellet was resuspended in 1 ml of TES Solution I (10 mM Tris, 1 
mM EDTA and 0.1 mM NaCl, pH 8.0) and 10 µl of lysozyme (10 mg/ml) plus 10 µl of 
lysostaphin (1 mg/ml) were added to the mixture before being incubated for 30 min at 
37°C with shaking at 180 rpm. One mililitre of Solution II (0.2 M NaOH, 1% SDS) was 
added into the mixture and incubated at ice for 10 min. After that, 1 ml of Solution 3 (3 
M Kac) was added into the mixture and incubated at ice for another 10 min. The 
mixture was centrifuged at 10 000 x g for 10 min at 4°C. Following that, the supernatant 
was transferred into a 15 ml polypropylene tube containing of 2 µl of RNase (100 
mg/ml) and incubated at 37°C for 1 hour.   
After addition of 3 ml of phenol-chloroform, the polypropylene tube was 
inverted for 20 times and then centrifuged at 8 000 x g for 10 min at 4°C. The upper 
aqueous phase was transferred to a new polypropylene tube that containing equal 
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volume of room temperature isopropanol and left for 2 min before being centrifuged at 
10 000 x g for 10 min. After centrifugation, the supernatant was carefully discarded. 
The pellet was washed with 200 µl of 70% ethanol and centrifuged at 10 000 x g for 5 
min at 4°C. The supernatant was discarded carefully, and the DNA pellet was air-dried. 
The dried pellet was resuspended in 50 µl of pre-warmed (60°C) sterile deonised water 
and stored at -20°C for PCR amplification and transformation.     
 
 
3.2.4 PCR detection of β-lactam, mupirocin, gentamicin, vancomycin, linezolid, 
erythromycin, tetracycline and fusidic acid resistance genes 
PCR was used to detect various resistant genes encoding for penicillin (blaZ), 
mupirocin (mupA, ileS), gentamicin [aac(6’)-aph(2”)], vancomycin (vanA, vanB), 
linezolid (cfr), erythromycin (ermA, ermB, ermC, msrA), tetracycline (tetK, tetL, tetM, 
tetO, tetS) and fusidic acid (fusB, fusC, fusD). The primer pairs used to amplify the 
genes of interest as well as the conditions used for PCR amplification are listed in Table 
3.7. 
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Table 3.7: Primer pairs, their respective sequences and amplification conditions for the various resistant genes 
Resistant 
gene 
Primer name Primer sequence (5‟- 3‟) PCR condition References 
blaZ blaZ-F TACAACTGTAATATCGGAGGG 1 cycle for 5 min at 95ºC; 30 cycles 
of 1 min at 95ºC, 1 min at 55ºC, 1 
min at 72ºC; 1 cycle of 5 min at 
72ºC 
Vali et al., 2008 
blaZ-R AGGAGAATAAGCAACTATATCATC 
mupA Mup 1 CCCATGGCTTACCAGTTGA same as blaZ Ramsey et al., 1996 
Mup 2 CCATGGAGCACTATCCGAA 
ileS MupA TATATTATGCGATGGAAGGTTGG same as blaZ Anthony et al., 1999 
MupB AATAAAATCAGCTGGAAAGTGTTG 
aac6-
aph2 
aac(6)-aph(2)-1 TTGGGAAGATGAAGTTTTTAGA same as blaZ Martineau et al., 2000 
aac(6)-aph(2)-2 CCTTTACTCCAATAATTTGGCT 
vanA vanA F  CATGAATAGAATAAAAGTTGCAATA same as blaZ Tiwari and Sen, 2006 
vanA R  CCCCTTTAACGCTAATACGACGATCAA 
vanB vanB F GTGACAAACCGGAGGCGAGGA same as blaZ Tiwari and Sen, 2006 
vanB R CCGCCATCCTCCTGCAAAAAA 
cfr cfr-fw   TGAAGTATAAAGCAGGTTGGGAGTCA same as blaZ Kehrenberg and Schwarz, 
2006 cfr-fw   ACCATATAATTGACCACAAGCAGC  
ermA ermA-1 TATCTTATCGTTGAGAAGGGATT same as blaZ Martineau et al., 2000 
ermA-2 CTACACTTGGCTTAGGATGAAA 
ermB ermB-1 CTATCTGATTGTTGAAGAAGGATT same as blaZ Martineau et al., 2000 
ermB-2 GTTTACTCTTGGTTTAGGATGAAA 
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Table 3.7 (continue)    
Resistant 
gene 
Primer name Primer sequence (5‟- 3‟) PCR condition References 
ermC ermC-1 CTTGTTGATCACGATAATTTCC    same as blaZ Martineau et al., 2000 
ermC-2 ATCTTTTAGCAAACCCGTATTC 
msrA msrA-1 TCCAATCATTGCACAAAATC   same as blaZ Martineau et al., 2000 
msrA-2 AATTCCCTCTATTTGGTGGT 
tetK tetK -1 TCGATAGGAACAGCAGTA  same as blaZ Ng et al., 2001 
tetK -2 CAGCAGATCCTACTCCTT 
tetL tetM -1 GTGGACAAAGGTACAACGAG  same as blaZ Ng et al., 2001 
tetM- 2 CGGTAAAGTTCGTCACACAC 
tetM tet(L)-1 TCGTTAGCGTGCTGTCATTC same as blaZ Ng et al., 2001 
tet(L)-2 GTATCCCACCAATGTAGCCG 
tetO tet(O)-1 AACTTAGGCATTCTGGCTCAC  same as blaZ Ng et al., 2001 
 tet(O)-2 TCCCACTGTTCCATATCGTCA 
tetS tet(S)-1 CATAGACAAGCCGTTGACC same as blaZ Ng et al., 2001 
 tet(S)-2 ATGTTTTTGGAACGCCAGAG 
fusB fusB-1F TCATATAGATGACGATATTG same as blaZ Castanheira et al., 2010b 
fusB-1R ACAATGAATGCTATCTCGAC 
fusC fusC-1F GATATTGATATCTCGGACTT same as blaZ Castanheira et al., 2010b 
fusC-1R AGTTGACTTGATGAAGGTAT 
fusD fusD-1F TGCTTATAATTCGGTCAACG same as blaZ Castanheira et al., 2010b 
fusD-1R TGGTTACATAATGTGCTATC 
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PCR amplification for mupA, ileS, aac6’-aph2”, vanA, vanB, cfrA and msrA 
genes was performed in a final volume of 25 µl containing 5 µl DNA template 
(approximately 20 ng), 0.3 µM of each primer, 35 µM of each deoxynucleoside 
triphosphate, 1.4 mM MgCl2 and 0.5 U Taq DNA polymerase (Promega, Madison Wis., 
USA). PCR detection of blaZ, ermA, ermB and ermC genes was performed by using 
multiplex-PCR in a final volume of 25 µl containing 5 µl DNA template (approximately 
20 ng), 0.3 µM of each primer, 50 µM of each deoxynucleoside triphosphate, 1.8 mM 
MgCl2 and 1.0 U Taq DNA polymerase (Promega, Madison Wis., USA) whereas 
detection of tetracycline resistance gene (tetK, tetL, tetM, tetO, tetS) was performed by 
using multiplex-PCR in a final volume of 25 µl containing 5 µl DNA template 
(approximately 20 ng), 0.3 µM of each primer, 50 µM of each deoxynucleoside 
triphosphate, 1.8 mM MgCl2 and 1.0 U Taq DNA polymerase (Promega, Madison Wis., 
USA).  
Representative products were purified by using the PCR Mega-Quick Spin
TM
 
product purification kit (Intron, Biotechnology, Korea). Briefly, 100 µl of binding 
buffer was added into a 1.5 ml microcentrifuge tube containing the PCR-amplified 
product and mixed well. Meanwhile, a spin column was placed in a 2 ml collection 
tube. The suspension was transferred into the spin column and centrifuged for 1 min at 
10, 000 x g at room temperature. After centrifugation, the flow-through was discarded 
and 500 µl of washing buffer (containing ethanol) was added into the column and 
centrifuged for 1 min at 10 000 x g at room temperature. The column was washed again 
with washing buffer and the flow-though was discarded. In order to remove the residual 
buffer, centrifugation was repeated again for additional 1 min. 
The DNA bound to the column was eluted by addition of 40 µl of ddH2O onto 
the column and allowing it to stand for 1 min, and subjecting the tube with column to 
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centrifugation at 10, 000 x g for 1 min at room temperature. The column was discarded 
after centrifugation and the flow-through containing the desired PCR product was 
collected in the 1.5 ml micro-centrifuged tube. The extracted PCR product was kept in    
-20°C.  
The purified PCR products were outsource to a commercial company (1st Base 
Pte Ltd, Malaysia) for sequencing. Sequences obtained were aligned and compared with 
archived database sequences for gene identification using BLAST.  
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3.2.5 PCR detection of tetracycline and gentamicin resistance transposons 
Detection of tetracycline (Tn916, Tn5801) and gentamicin (Tn4001) transposon-
associated genes were performed by PCR amplification on genomic and plasmid DNA 
as template. The primers used for the detection of the transposon-associated genes, their 
sequences and amplification parameters are shown in Table 3.8. 
 
Table 3.8: Primer pairs, their respective sequences and amplification conditions for 
transposons associated integrases 
Transposon
-encoding 
gene 
Primer 
name 
Primer sequence 
(5‟- 3‟) 
PCR conditions Reference 
Tn916  327(Tn91
6-1) 
GCCATGACCT
ATCTTATA 
1 cycle for 5 min at 
95ºC; 30 cycles of 1 
min at 95ºC, 1 min at 
55ºC, 1 min at 72ºC; 
1 cycle of 5 min at 
72ºC 
de Vries et al., 
2009 
328 
(Tn916-2) 
CTAGATTGCG
TCCAA 
Tn5801 1811(Intc
w459-1) 
CCGATATTGA
GCCTATTGAT
GTG 
Same as Tn916 de Vries et al., 
2009 
1812(Intc
w459-2) 
GTCCATACGT
TCCTAAAGTC
GTC 
Tn4001 Primer 1 TGAAAAGCG
AAGAGATTC
AAAGC 
Same as Tn916 Kozitskaya et 
al,. 2004 
Primer 2 CTAAACCGT
GCATTTGTCT
TA 
 
PCR amplification was performed in a final volume of 25 µl containing 5 µl 
DNA template (approximately 20 ng), 0.4 µM of each primer, 35 µM of each 
deoxynucleoside triphosphate, 1.4 mM MgCl2 and 0.5 U Taq DNA polymerase 
(Promega, Madison, Wis., USA).  
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The amplification product was purified and outsource to a commercial company 
(1st Base Pte Ltd, Malaysia) for sequencing. Sequences obtained were aligned and 
compared with archived database sequences for gene identification using BLAST. 
 
 
 
3.2.6 Transfer of Antibiotic Resistance determinant by transformation. 
3.2.6.1 Preparation of electro-competent S. aureus cells 
Electro-competent S. aureus cells were prepared according to method described 
by The SunLab Homepage 
(http://sunlab.ustc.edu.cn/protocol/gene_deletion_in_SA.htm) with minor 
modifications. Briefly, one single colony of S. aureus ATCC29213 was inoculated into 
10 ml TSB and incubated at 37°C with vigorous shaking overnight. After that, 10 ml of 
the overnight grown culture was transferred to 100 ml TSB medium in a 500 ml flask 
and incubated at 37°C with vigorous shaking until an OD610 reading of about 0.4.  
The flask was transferred to an ice bath for 5 min following which the cultures 
were transferred into 50 ml polypropylene tubes, centrifuged at 2 500 x g at 4°C for 10 
min. The resulting supernatant was discarded, and the cell pellet was re-suspended in 10 
ml of 0.5 M sucrose and kept on ice for an additional 5 min. The cell was harvested at 2 
500 x g at 4°C for 5 min. The cell pellet was re-suspended in 10 ml of 0.5 M sucrose 
and kept on ice for an additional 5 min before being harvested at 2500 x g at 4°C for 5 
min.   
The cell pellet was again re-suspended in 1 ml of ice-cold 0. 5 M sucrose and the 
suspension was kept on ice for 15 min. The cell suspension was aliquoted into several 
pre-chilled microcentrifuged tubes (40 µl) on ice. The aliquots were ethanol-freeze (dip 
into ice-cool ethanol) and stored at 80°C or used immediately.   
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3.2.6.2 Preparation of electro-competent E. coli cells 
Electro-competent E. coli cells were prepared according to method described by 
Sambrook and Russel (2001). Briefly, one single colony of E. coli DH10β was 
inoculated into 10 ml of TSB medium and incubated at 37°C with vigorous shaking 
overnight. After that, 5 ml of the overnight grown culture was transferred to 100 ml of 
fresh TSB medium in a 500 ml flask. The flask was incubated at 37°C with vigorous 
shaking until an OD610 reading of about 0.4. The flask was transferred to an ice-bath for 
30 min following which the cultures were transferred into 50 ml polypropylene tubes, 
which were centrifuged at 2500 x g for 15 min at 4°C and the resulting supernatant was 
discarded. The cell pellet was then re-suspended in 100 ml of ice-cold sterile deonised 
water, and the cell was harvested at 2500 x g at 4°C for 20 min. Again, the cell pellet 
was re-suspended with 50 ml of ice-cold 10% glycerol to wash and harvested at 2500 x 
g for 20 min at 4°C. The cell pellet was then re-suspended in 2 ml of ice-cold 10% 
glycerol. 
The cells were again harvested by centrifugation at 2 500 x g for 20 min at 4°C. 
The supernatant was carefully removed from the tubes and 100 µl of ice-cold GYT 
[10% (v/v) glycerol; 0.125% (w/v) yeast extracts; 0.25% (w/v) tryptone] medium were 
added in. The cell suspensions were diluted to a concentration of 2 X 10
10
 to 3 X 10
10
 
cells/ml with ice-cold GYT medium. The cell suspension was aliquoted into several pre-
chilled microcentrifuge tubes (40 µl) of ice. The aliquots were ethanol-freeze and stored 
at 80°C or used immediately. 
 
 
3.2.6.3 Transformation of electro-competent S. aureus cells 
Frozen stocks of 40 µl of electro-competent S. aureus ATCC29213 cells were 
thawed at room temperature. After the electro-competent S. aureus, ATCC29213 cells 
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(blaZ, MSSA) reached room temperature, 10 µl of plasmid DNA (approximately 100 
pg/µl) was added into the cell solution and left at room temperature for 30 min. 
The electroporation apparatus (Biorad, USA) was set to deliver an electrical 
pulse of 50 µF capacitance, 2.5 kV and 200 Ω resistance. The cuvette was placed in the 
electroporater device, and the pulse button was press once. The electroporation cuvette 
was removed and 1 ml of SMMP broth (at room temperature) was added to the cuvette, 
and the cell was transferred to a 15 ml polypropylene tube and incubated at 37°C for an 
hour with gentle rotation.   
After an hour, serial dilutions (10
-1
 to 10
-4
) were carried out and 10 µl of the 
diluted electroporated cells were transferred onto TSB agar supplemented with either 50 
µg/ml erythromycin or 50 µg/ml tetracycline. The plates were inverted and incubated at 
37°C overnight, and a same volume of untransformed competent cells was plated on 
TSB agar plates with and without selective antibiotics to serve as negative controls.   
 
CFU/µg = CFU on plate X 1x10
6
 pg  X volume of transformants X dilution factor 
      pg of the         µg       volume plated 
      plasmid DNA 
  
 
3.2.7 PCR detection of chromosomal associated fusidic acid and rifampicin 
resistance gene 
PCR was used for the amplification of chromosomal associated fusidic acid 
(fusA and fusE) and rifampicin (rpoB) genes. The primers pairs used to amplify the 
genes of interest as well as the conditions used for PCR amplification is listed in Table 
3.9. 
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Table 3.9: Primer pairs, their respective sequences and amplification conditions for the 
fusA, fusE and rpoB genes 
Resistan
ce  gene 
Primer 
name 
Primer sequence (5‟- 3‟) PCR conditions References 
rpoB Reverse TCAACTTTACGATAT
GGTTC 
1 cycle for 5 min at 95ºC; 
30 cycles of 1 min at 
95ºC, 1 min at 53ºC, 1 
min at 72ºC; 1 cycle of 5 
min at  72ºC 
Mick et 
al., 2010 
Forward GTCGTTTACGTTCTG
TAGGTG 
fusA rpsU ATGGCTGGTACCAAC
AAAGCATTTGCTCAC
TA 
same as rpoB O‟Neill et 
al., 2007 
tufL GCTGTGAGCTCTGTT
TTACCATGGTCAACG
TG 
fusA fusA-F2 CTCGTAAYATCGGTA
TCATG 
same as rpoB Castanheir
a et al., 
2010b fusA-R2 GCATAGTGATCGAA
GTAC 
fusA FusA-F TTTACCCTGAGTGTG
TTCT  
same as rpoB Chen et 
al., 2010 
FusA-R TACATTTAAGCTCAC
CTTGT 
fusE fusE(rpl
F)-1F 
CCTAGTGACGTAACA
GTAAC 
same as rpoB Castanheir
a et al., 
2010b fusE(rpl
F)-1F 
CGGCGWACRTATTC
ACCTTG 
 
PCR amplification for rpoB and fusE genes was performed in a final volume of 
25 µl containing 5 µl DNA template (approximately 20 ng), 0.3 µM of each primer, 35 
µM of each deoxynucleoside triphosphate, 1.4 mM MgCl2 and 0.5 U Taq DNA 
polymerase (Promega, Madison Wis., USA).  
All amplified products were purified and out-source to a commercial company 
(1st Base Pte Ltd, Malaysia) for DNA sequencing. Nucleotide sequences of rpoB and 
fusA obtained were compared to the rpoB wild-type sequence from S. aureus (GenBank 
accession-number: X64172) and fusE sequence from S. aureus MW2 (GenBank 
accession-number: NC_003923.1) as previously described (Mick et al. 2010) using 
Mega 4 software (The Biodesign Institute, USA). 
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3.2.7.1 Primer design of fusA gene 
Initially, PCR detection of fusA gene was performed by using primers obtained 
from published protocols (O‟Neill et al., 2007; Castanheira et al., 2010a,b; Chen et al., 
2010) as shown in Table 3.9. However, despite repeated PCR tests, no amplified 
product was obtained. Hence, new primers were designed for the detection of fusA gene. 
Briefly, fusA sequence from S. aureus (GenBank accession-number: 
NC_003923.1, NC_007622.1 and NC_ 002745. 2 were retrieved from GenBank. Two 
pairs of primers [FusA1-F (5‟-CGGTATCATGGCTCACATTG-3‟), FusA1-R (5‟-
AGCTGAATCGTCTGCTTTCG-3‟), FusA3-F (5‟-CGAAAGCAGACGATTCAGCT-
3‟) and FusA1,2,3-R (5‟-GTACCGCGACCTTGA GTGTT-3‟] were designed based on 
the sequence using Primer 3 programme. The specificity of these primers was initially 
tested by using in-silico PCR programme.     
PCR amplification for fusA gene was performed in a final volume of 25 µl 
containing 5 µl DNA template (approximately 20 ng), 0.3 µM of each primer, 35 µM of 
each deoxynucleoside triphosphate, 1.4 mM MgCl2 and 0.5 U Taq DNA polymerase 
(Promega, Madison Wis., USA).  
All amplified products were purified by using the PCR Mega-Quick Spin
TM
 
product purification kit (Intron, Biotechnology, Korea) and out-source to a commercial 
company (1st Base Pte Ltd, Malaysia) for DNA sequencing. Nucleotide sequences of 
fusA obtained were compared to the fusA sequence from S. aureus MW2 (GenBank 
accession-number: NC_003923.1) as previously described (Mick et al. 2010) using 
Mega 4 software (The Biodesign Institute, USA). 
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3.2.8 Congo red agar (CRA) method for detection of biofilm formation 
phenotype 
Detection of slime production was done according to the protocol by Freeman et 
al. (1989). The media constituted of brain heart infusion agar (Oxoid Ltd., Basingtoke, 
Hamphsire UK) 52 g/l, Congo red stains 0.8 g/l and sucrose 50 g/l. Inoculated agar was 
incubated aerobically at 37°C for 24 hours. The biofilm positive strains produced black 
colour colonies whereas biofilm negative strains remained pink/red in colour.   
 
 
3.2.9 PCR detection of virulence genes 
PCR was used to detect 21 different virulence genes, including enterotoxins (sea 
to see, seg to sej, tst), exfoliative-toxins (eta, etb, etd), cytotoxin (pvl), adhesions (cna, 
hlg, ica, sdrE, efb, fnbA, fnbB). The primer pairs used to amplify the genes of interest as 
well as the conditions used for PCR amplification are listed in Table 3.10. 
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Table 3.10: Primer pairs, their respective sequences and amplification conditions for the various virulence genes 
Virulence 
gene 
Primer name Primer sequence (5‟- 3‟) PCR conditions References 
sea SEA-1 GAAAAAAGTCTGAATTGCAGGGAACA 1 cycle for 5 min at 95ºC; 30 cycles of 
1 min at 95ºC, 1 min at 55ºC, 1 min at 
72ºC; 1 cycle of 5 min at 72ºC 
Jarraud et al., 2002 
SEA-2 CAAATAAATCGTAATTAACCGAAGGTTC 
seb SEB-1  ATTCTATTAAGGACACTAAGTTAGGGA  same as sea Jarraud et al., 2002 
 SEB-2 ATCCCGTTTCATAAGGCGAGT   
sec MpSEC-1  GTAAAGTTACAGGTGGCAAAACTTG  same as sea Jarraud et al., 2002 
 MpSEC-2 CATATCATACCAAAAAGTATTGCCGT    
sed SED-1 GAATTAAGTAGTACCGCGCTAAATAATATG same as sea Jarraud et al., 2002 
sed SED-2 GCTGTATTTTTCCTCCGAGAGT same as sea Jarraud et al., 2002 
see SEE-1 CAAAGAAATGCTTTAAGCAATCTTAGGC same as sea Jarraud et al., 2002 
SEE-2 CACCTTACCGCCAAAGCTG 
seg SEG-1 AATTATGTGAATGCTCAACCCGATC  same as sea Jarraud et al., 2002 
SEG-2 AAACTTATATGGAACAAAAGGTACTAGTTC 
seh SEH-1  CAATCACATCATATGCGAAAGCAG  same as sea Jarraud et al., 2002 
SEH-2 CATCTACCCAAACATTAGCACC 
sei SEI-1  CTCAAGGTGATATTGGTGTAGG same as sea Jarraud et al., 2002 
SEI-2 AAAAAACTTACAGGCAGTCCATCTC 
sej MpSEJ-1 TAACCTCAGACATATATACTTCTTTAACG  same as sea Jarraud et al., 2002 
MpSEJ-2 AGTATCATAAAGTTGATTGTTTTCATGCAG 
tst TST-1 TTCACTATTTGTAAAAGTGTCAGACCCACT  same as sea Jarraud et al., 2002 
TST-2 TACTAATGAATTTTTTTATCGTAAGCCCTT 
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Table 3.10 (continue)    
Virulence 
gene 
Primer name Primer sequence (5‟- 3‟) PCR conditions References 
eta MpETA-1 ACTGTAGGAGCTAGTGCATTTGT  same as sea Jarraud et al., 2002 
MpETA-3 TGGATACTTTTGTCTATCTTTTTCATCAAC 
etb MpETB-1 CAGATAAAGAGCTTTATACACACATTAC same as sea Jarraud et al., 2002 
 MpETB-2 AGTGAACTTATCTTTCTATTGAAAAACACTC   
etd ET-14 AACTATCATGTATCAAGG same as sea Yamaguchiet al., 2002 
 ET-15 CAGAATTTCCCGACTCAG   
pvl luk-PV-1 ATCATTAGGTAAAATGTCTGGACATGATCCA same as sea Lina et al., 1999 
 luk-PV-2 GCATCAASTGTATTGGATAGCAAAAGC   
cna cna-F AGTGGTTACTAATACTG same as sea Kumar et al., 2009 
cna-R CAGGATAGATTGGTTTA 
hlg hlg-F GCCAATCCGTTATTAGAAAATGC same as sea Kumar et al., 2009 
hlg-R CCATAGACGTAGCAACGGAT 
ica ica-F  GATTATGTAATGTGCTTGGA same as sea Kumar et al., 2009 
ica-R ACTACTGCTGCGTTAATAAT 
sdrE sdrE-F AGTAAAATGTGTCAAAAGA same as sea Kumar et al., 2009 
sdrE-R TTGACTACCAGGCTATATC 
efb efb-1 AACATTAGCGGCAATAGG  same as sea Moore and Lindsay, 
2001 efb-2 ATTCGCTCTTGTAAGACC 
fnbA fnbA-1 GATACAAACCCAGGTGGTGG same as sea Arciola et al., 2005 
fnbA-2 TGTGCTTGACCATGCTCTTC 
fnbB fnbB-1 TGTGCTTGACCATGCTCTTC same as sea Arciola et al., 2005 
fnbB-2 AGTTGATGTCGCGCTGTATG 
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Four multiplex-PCR were performed for the identification of virulence genes, 
and this includes; 1) multiplex A for detection of sea, seb, sec, sed and see genes; 2) 
multiplex B for detection of seg, seh, sei and sej genes; 3) multiplex C for detection of 
efb, hlg and cna genes and 4) multiplex D for detection of eta, etb, etd and tst genes. All 
four multiplex-PCR were performed in a final volume of 25 µl containing 5 µl DNA 
template (approximately 20 ng), 0.3 µM of each primer, 35 µM of each 
deoxynucleoside triphosphate, 1.8 mM MgCl2 and 1.5 U Taq DNA polymerase 
(Promega, Madison Wis., USA).  
Meanwhile, monoplex PCR was used for detection of ica, sdrE, fnbA, fnbB and 
pvl genes in a final volume of 25 µl containing 5 µl DNA template (approximately 20 
ng), 0.3 µM of each primer, 35 µM of each deoxynucleoside triphosphate, 1.4 mM 
MgCl2 and 0.5 U Taq DNA polymerase (Promega, Madison Wis., USA).  
Representative products were purified and outsource to a commercial company 
(1st Base Pte Ltd Malaysia) for sequencing.. Sequences obtained were aligned and 
compared with online database sequences for gene identification using BLAST. 
 
 
3.2.10 agr grouping 
Multiplex-PCR was used for the subgrouping of agr types as described by Lina 
et al. (2003) with minor modifications. Briefly, the multiplex was performed in a final 
volume of 25 µl containing 5 µl DNA template (approximately 20 ng), 0.4 µM of each 
primer, 35 µM of each deoxynucleoside triphosphate, 1.4 mM MgCl2 and 0.5 U Taq 
DNA polymerase (Promega, Madison Wis., USA) and the cycling parameters are: 
initial denaturation for 5 min at 95°C, followed by 30 cycles of denaturation (95°C for 1 
min), annealing (53°C for 1 min), elongation (72°C for 1 min) and a final elongation for 
5 min at 72°C. The primers used for agr grouping are shown in Table 3.11. 
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Representative products were purified and outsource to a commercial company 
(1st Base Pte Ltd Malaysia) for sequencing. Sequences obtained were aligned and 
compared with archived database sequences for gene identification using BLAST. 
 
Table 3.11: Primers sequences and their respective size for agr grouping 
Primer 
name 
Primer sequence (5‟- 3‟) Product length 
agr1-4sa-1 ATGCACATGGTGCACATGC     
agr1sa-2   GTCACAAGTACTATAAGCTGCGAT 439 
agr2sa-2   TATTACTAATTGAAAAGTGCCATAGC   572 
agr3sa-3   GTAATGTAATAGCTTGTATAATAATACCCAG 321 
agr4sa-2 CGATAATGCCGTAATACCCG 657 
 
 
3.2.11 SCCmec typing and further sub-grouping of SCCmec type IV 
Multiplex-PCR was used for the sub-grouping of SCCmec types as described by 
Milheirico et al. (2007) with minor modifications. Briefly, multiplex was performed in a 
final volume of 50 µl containing 5 µl DNA template (approximately 20 ng), 0.3 – 1.0 
µM of each primer, 50 µM of each deoxynucleoside triphosphate, 2.25 mM MgCl2 and 
1.5 U Taq DNA polymerase (Promega, Madison Wis., USA) and the cycling parameters 
are: Initial denaturation for 6 min at 94°C, followed by 30 cycles of denaturation (94°C 
for 30 sec), annealing (53°C for 30 sec), elongation (72°C for 1 min) and a final 
elongation for 5 min at 72°C.  
All SCCmec type IV strains were further subgrouped to SCCmec type IVa to 
IVd by using primers as described by Hisata et al. (2005) and Okuma et al. (2002) and 
were listed in Table 3.12.  
Briefly, multiplex PCR was performed in a final volume of 25 µl containing 5 µl 
DNA template (approximately 20 ng), 0.4 µM of each primer, 50 µM of each 
deoxynucleoside triphosphate, 1.80 mM MgCl2 and 1.0 U Taq DNA polymerase 
(Promega, Madison Wis., USA) and the cycling parameters are: Initial denaturation for 
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5 min at 94°C, followed by 30 cycles of denaturation (94°C for 1 min), annealing (50°C 
for 1 min), elongation (72°C for 1 min) and a final elongation for 5 min at 72°C.  
Representative products were purified and outsource to a commercial company 
(1st Base Pte Ltd Malaysia) for sequencing. Sequences obtained were aligned and 
compared with archived database sequences for gene identification using BLAST. 
 
Table 3.12: Primers sequences and their respective size for SCCmec typing 
Primer name Primer sequence (5‟- 3‟) Product 
length (bp) 
References 
CIF2 F2         
CIF2 R2 
TTCGAGTTGCTGATGAAGAAGG 
ATTTACCACAAGGACTACCAGC 
495 Milheirico 
et al., 2007 
ccrC F2           
ccrC R2 
GTACTCGTTACAATGTTTGG 
ATAATGGCTTCATGCTTACC 
449 Milheirico 
et al., 2007 
RIF5 F10       
RIF5 R13 
TTCTTAAGTACACGCTGAATCG 
ATGGAGATGAATTACAAGGG 
414 Milheirico 
et al., 2007 
SCCmec V 
J1F SCCmec 
V J1 R 
TTCTCCATTCTTGTTCATCC 
AGAGACTACTGACTTAAGTGG 
377 Milheirico 
et al., 2007 
dcs F2               
dcs R1 
CATCCTATGATAGCTTGGTC 
CTAAATCATAGCCATGACCG 
342 Milheirico 
et al., 2007 
ccrB2 F2      
ccrB2 R2 
AGTTTCTCAGAATTCGAACG 
CCGATATAGAAWGGGTTAGC 
311 Milheirico 
et al., 2007 
kdp F1              
kdp R1 
AATCATCTGCCATTGGTGATGC 
CGAATGAAGTGAAAGAAAGTGG 
284 Milheirico 
et al., 2007 
SCCmec III J1 
F  SCCmec III 
J1 R 
CATTTGTGAAACACAGTACG 
GTTATTGAGACTCCTAAAGC 
243 Milheirico 
et al., 2007 
mecI P2          
mecI P3 
ATCAAGACTTGCATTCAGGC 
GCGGTTTCAATTCACTTGTC 
209 Milheirico 
et al., 2007 
mecA P4      
mecA P7 
TCCAGATTACAACTTCACCAGG 
CCACTTCATATCTTGTAACG 
162 Milheirico 
et al., 2007 
4a1  
4a2 
TTTGAATGCCCTCCATGAATAAA
AT   
AGAAAAGATAGAAGTTCGAAAGA 
458 Okuma et 
al., 2002 
4b1                   
4b2 
AGTACATTTTATCTTTGCGTA 
AGTCATCTTCAATATCGAGAAAG
TA  
994 Okuma et 
al., 2002 
4c1                   
4c2 
TCTATTCAATCGTTCTCGTATTT 
TCGTTGTCATTTAATTCTGAACT 
678 Hisata et 
al., 2005 
4d1                   
4d2 
TTTGAGAGTCCGTCATTATTTCTT 
AGAATGTGGTTATAAGATAGCTA 
1010 Hisata et 
al., 2005 
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3.2.12 DNA fingerprinting of S. aureus strains 
3.2.12.1 PCR-RFLP of coa gene 
PCR amplification of coa gene was performed as previously described by 
Hookey et al. (1998) using coa-F primer (5‟-ATAGAGATGCTGGTACAGG-3‟) and 
coa-R primer (5‟-GCTTCCGATTGTTCGATGC-3‟) with minor modification. Briefly, 
PCR was carried out in a final volume of 25 μL containing 0.4 μM of each primer pair 
(Operon Biotechnologies GmbH, Germany), 5 μL of DNA template (approximately 20 
ng), 35 μM of each deoxynucleoside triphosphate, 1.5 mM MgCl2 and 0.5 U Taq DNA 
polymerase (Promega, Madison, Wis., USA).  
The cycling parameters are: initial denaturation (94°C for 5 min) followed by 30 
cycles of denaturation (95°C for 1 min), annealing (56°C for 1 min), elongation (72°C 
for 3 min) and a final elongation (72°C for 5 min).  
The amplicon of coa was digested with AluI enzyme (Promega Madison Wis, 
USA) as described by Hookey et al. (1998). An aliquot of 10 µl of PCR product was 
incubated at 37°C for 2 hours with 5 U of AluI enzyme supplemented with 0.5 U BSA. 
The digested products were separated in 1.5% agarose gel at 90 V for 3 hours. Gels 
were photographed under UV light after staining with ethidium bromide (0.5 μg/ml). 
 
 
3.2.12.2 Pulsed-field Gel Electrophoresis (PFGE) 
PFGE was performed according to an established protocol (Murchan et al., 
2003) with minor modifications. Briefly, a single colony was streaked on Tryptone-Soy 
agar and incubated at 37°C for overnight. The next day, the cell culture was transferred 
to 2 ml of cell suspension buffer (CSB), and cell density was adjusted to OD610 = 1.8. 
An aliquot of 100 µl of standardized cell suspension buffer was then transferred to a 1.5 
ml micro-centrifuged tube and 15 µl of lysozyme (10 mg/ml stock solution) and 2.5 µl 
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of lysostaphin (1 mg/ml stock solution) were added to the suspension. The suspension 
was incubated at 37°C for 15 min and 1 µl of proteinase K (10 mg/ml stock solution) 
was added into the microcentrifuged tube. A total of 100 µl of 1% Seakem Gold agarose 
(Cambrex Bio Science Rockland, Inc, USA) were mixed with 100 µl of the cell-
standardized suspension to form plugs. The bacterial cells were lysed within the plugs 
with cell lysis buffer (50mM Tris; 50 mM EDTA [pH 8.0], 1% Sacrosine, 1 mg/ml 
proteinase K) and incubated at 54°C for 3 hours. The plug was then washed thoroughly 
with sterile deionised water (twice) and TE buffer (5 times). The plug can be used 
immediately or stored at 4°C. 
For restriction endonuclease digestion, 1.5 mm slices of the agarose plugs were 
incubated overnight with 10 U of SmaI enzyme supplemented with 1 U BSA at room 
temperature. As for the H9812 Salmonella Braenderup marker, 1.5 mm slice of the 
agarose plug was incubated overnight with XbaI enzyme supplemented with 1 U BSA at 
37°C. The plug was then loaded onto a 1.0% agarose gel (Sigma Type I, USA).  
The electrophoresis was performed on CHEF-Mapper (Bio-Rad, Hercules, CA) 
with 0.5 X TBE as running buffer using condition as follows: switch times 5 sec to 60 
sec for 22 hours and angle was set at 120° and electrophoresis was carried out at a 6.0 
V/cm gradient at a temperature of 14°C. 
After electrophoresis, the gel was stained in 300 ml of ethidium bromide            
(1 µg/ml) for 10 min and destained with 300 ml of 0.5X TBE buffer for 2 hours. The gel 
image was captured on a UV transilluminator using a gel documentation system. 
 
 
3.2.12.3 spa typing 
spa typing was performed on all MRSA strains as described by Harmsen et al. 
(2003) using primer 1095F (5‟-AGACGATCCTTCGGTGAGC-3‟) and 1517R (5‟-
GCTTTTGCAATGTCATTTACTG-3‟). Briefly, monoplex-PCR was performed in a 
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final volume of 25 µl containing 5 µl DNA template (approximately 20 ng), 0.3 µM of 
each primer, 35 µM of each deoxynucleoside triphosphate, 1.40 mM MgCl2 and 0.5 U 
Taq DNA polymerase (Promega, Madison Wis., USA) and the cycling parameters are: 
initial denaturation for 10 min at 95°C, followed by 30 cycles of denaturation (95°C for 
30 sec), annealing (60°C for 30 sec), elongation (72°C for 45 sec) and a final elongation 
for 10 min at 72°C.  
The amplicons of spa was purified by using commercial DNA purification kit 
(Intron Biotechnology, Korea) and sequenced to validate their identities. Nucleotide 
sequences of spa amplicons and cluster analysis were analyzed using BioNumerics 6.0 
software (Applied Maths, Belgium).   
 
 
3.2.12.4 Heteroduplex PCR for detection of MLST type ST239 and 
multilocus sequence typing (MLST) 
In order to save cost and time, heteroduplex PCR was performed on all the 
strains using two pairs of primers as described by Feil et al. (2008) for rapid detection 
of pandemic clone, ST239. PCR amplification of heteroduplex PCR was performed in a 
final volume of 25 µl containing 5 µl DNA template (approximately 20 ng), 0.4 µM of 
each primer, 35 µM of each deoxynucleoside triphosphate, 1.4 mM MgCl2 and 1.0 U 
Taq DNA polymerase (Promega, Madison Wis., USA).  
MLST was conducted on two representatives ST239 (detected by using 
heteroduplex PCR) and all non ST239 strains. The PCR amplification for MLST was 
typically performed in a final volume of 25 µl containing 5 µl DNA template 
(approximately 20 µg), 0.3 µM of each primer, 35 µM of each deoxynucleoside 
triphosphate, 1.4 mM MgCl2 and 0.5 U Taq DNA polymerase (Promega, Madison Wis., 
USA). The primer pairs used to amplify the seven S. aureus housekeeping genes of 
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interest are listed in Table 3.13 whereas cycling temperature for both heteroduplex PCR 
and MLST are: initial denaturation for 7 min at 95°C, followed by 30 cycles of 
denaturation (95°C for 1 min), annealing (55°C for 1 min), elongation (72°C for 1 min 
and 30 sec) and a final elongation for 6 min at 72°C.  
Amplification products were purified by using commercial purification kits 
(Intron, Biotechnology, Korea) and outsource to a commercial company (1st Base Pte 
Ltd, Malaysia) for sequencing. The nucleotides of each housekeeping gene were 
trimmed by using Mega4 software, and the allelic number and sequences' types (STs) 
were assigned using the S. aureus MLST database (http://saureus.mlst.net). 
The clustering of related STs (defined as clonal complexes, CCs) was analyzed 
with the BURST algorithm (http://eburst.mlst.net) and by using BioNumerics 6.0 
software (Applied Maths, Belgium). 
 
Table 3.13: Primers sequences and their respective size for MLST 
Primer name Primer sequence (5‟- 3‟) References 
arcC-Up TTGATTCACCAGCGCGTATTGTC Enright et al., 2000 
arcC-Dn AGGTATCTGCTTCAATCAGCG Enright et al., 2000 
aroE-Up ATCGGAAATCCTATTTCACATTC Enright et al., 2000 
aroE-Dn GGTGTTGTATTAATAACGATATC Enright et al., 2000 
glpF-Up CTAGGAACTGCAATCTTAATCC Enright et al., 2000 
glp-Dn TGGTAAAATCGCATGTCCAATTC Enright et al., 2000 
gmk-Up ATCGTTTTATCGGGACCATC Enright et al., 2000 
gmk-Dn TCATTAACTACAACGTAATCGTA Enright et al., 2000 
pta-Up GTTAAAATCGTATTACCTGAAGG Enright et al., 2000 
pta-Dn GACCCTTTTGTTGAAAAGCTTAA Enright et al., 2000 
tpi-Up TCGTTCATTCTGAACGTCGTGAA Enright et al., 2000 
tpi-Dn TTTGCACCTTCTAACAATTGTAC Enright et al., 2000 
yqiL-Up CAGCATACAGGACACCTATTGGC Enright et al., 2000 
yqil-Dn CGTTGAGGAATCGATACTGGAAC Enright et al., 2000 
SA031F TCGCACTCTCGTTGAACA Feil et al., 2008 
SA0317R AAATCCGCTTCGACAAACATT Feil et al., 2008 
SA2003F CACTTTAAATACTGACGAAAAT Feil et al., 2008 
SA2003R TTGAAAATTGATCATTCAGCAA Feil et al., 2008 
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3.2.12.5 mec-associated direct repeat unit (dru) typing 
mec-associated dru typing was performed on all MRSA strains as described by 
Goering et al. (2008) using primer dru-F (5‟-GTTAGCATATTACCTCTCCTTGC- 3‟) 
and dru-R (5‟-GCCGATTGTGCTTGATGAG-3‟). Briefly, a monoplex-PCR was 
performed in a final volume of 25 µl containing 5 µl DNA template (approximately 20 
ng), 0.3 µM of each primer, 35 µM of each deoxynucleoside triphosphate, 1.40 mM 
MgCl2 and 0.5 U Taq DNA polymerase (Promega, Madison Wis., USA) and the cycling 
parameters are: initial denaturation for 5 min at 95°C, followed by 30 cycles of 
denaturation (95°C for 1 min), annealing (53°C for 1 min), elongation (72°C for 1 min) 
and final elongation for 5 min at 72°C.  
The amplicons of dru was purified by using commercial DNA purification kit 
(Intron Biotechnology, Korea) and sequenced to validate their identities. Nucleotide 
sequences of dru amplicons and cluster analysis were analyzed using BioNumerics 6.0 
software (Applied Maths, Belgium).   
 
 
3.2.13. Fingerprint pattern analysis for PCR-RFLP of coa gene, PFGE spa and 
mec-associated dru typing 
 The banding patterns generated by PCR-RFLP of coa gene and PFGE were 
analyzed with BioNumerics 6.0 (Applied Maths, Kortrijk, Belgium). All the DNA 
fingerprints were assigned arbitrary designation and analyzed by defining similarity 
(Dice) coefficient F = 2nxy/(nx + ny) where nx = number of fragments for isolate X, ny = 
number of fragments for isolate Y, and nxy = number of shared fragments between 
isolates X and Y (Thong et al., 2007). Gel photos were converted into JPEG images 
prior to export into BioNumerics 6.0 for cluster analysis which was carried out based on 
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the unweighted pair group method with arithmetic averages (UPGMA) using the 
position tolerance of 0.15 (Fontana et al., 2003).  
Nucleotide sequences of spa, MLST and mec-associated dru typing were analyzed 
by BioNumerics 6.0 (Applied Maths, Kortrijk, Belgium). The cluster analysis settings 
for the minimum spanning tree (MST) was set to 25% duplicate extension, 25% 
duplicate creation, 50% gap extension cost, 250% gap creation cost, maximum 
duplication length of three repeats and bin grouping distance of 0.5%. Based on the 
interpretation scheme recommended by Shore et al. (2010), two strains are considered 
closely related if two spa or dru types are at a MST distance value of ≤ 3 
(corresponding to > 98.5% similarity). The distance between each node represents the 
similarity level between two entries, i.e two entries that had a similarity of between 99.5 
to 100%, had a distance of 0.  
 
 
3.2.15 Statistical Analysis 
Statistica software (version 8.0) was used for data analysis. Comparison of 
certain variables was determined by Fisher‟s exact test. The associations between 
different virulence factors or resistance genes were determined by Spearman's rank 
order correlation coefficient test. The P value < 0.05 (two-tailed) was taken as the level 
of significance for Fisher‟ exact test whereas R value was taken as the type of 
association between the variables. The breakpoints for the association of virulence 
factors are defined as follows: perfect association with R = 1, no association with R = 0 
and invert correlation with R = -1.   
The association of mutations and resistance level for erythromycin and fusidic 
acid was determined by Kruskal-Wallis test (where all the categories of mutation consist 
of at least 5 entries).    
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CHAPTER 4 
RESULTS 
 
4.1 Bacterial Strains 
 One hundred eighty-eight non-repeat MRSA strains from 184 individual patients 
and four staff nurse were selected in this study (52 from year 2003, 9 from year 2004, 
16 from year 2007 and 111 from year 2008). All MRSA strains that could be revived 
from stock cultures were included for analysis. The organisms were isolated from 
respiratory samples, such as nasal swabs (n = 43; 23%), sputum (n = 23; 12%) and 
nasopharyngeal secretion (n = 9; 5%)], tissue (n = 16; 8%), wound swabs (n = 34; 
18%), urine (n = 6; 3%), pus (n = 12; 6%), body fluids (n = 24; 13%), catheter tips (n = 
3; 2 %), bone (n = 4; 2%), blood (n = 13; 7%), chest tube “drainage” (n = 1; 1%) 
(Figure 4.1; Appendix 1). 
All strains were obtained from the following wards: orthopaedic (n=58), medical 
(n=46), surgical (n=34), intensive care unit (n=20), dialysis (n=8), paediatric (n=9), 
others (n=6), cardiac care unit (n=4), obstetrics and gynecology (n=2) and psychiatry 
(n=1) (Figure 4.2; Appendix 1).       
 
Figure 4.1 Distribution of the 188 MRSA strains by sources 
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Figure 4.2 Distribution of the 188 MRSA strains by location 
 
 
4.2 Antimicrobial Susceptibility Profiles 
 All MRSA strains were sensitive to vancomycin but resistant to oxacillin. Using 
the disk diffusion method, the resistant rates are as follows: erythromycin (95%); 
clindamycin (94%); ciprofloxacin (92%); gentamicin (83%); trimethoprim-
sulfamethoxazole (59%); tetracycline (50%); netilmicin (42%); fusidic acid (10%); 
mupirocin (5%); rifampicin (4%); linezolid (2%); and teicoplanin (1%) (Figure 4.3A; 
Table 4.1; Appendix 3).  
A total of 124 strains (66%) were multidrug-resistant (MDR) (resistant to more 
than three classes of antimicrobial agents). There was a significant increase in the rates 
of resistance towards trimethoprim-sulfamethoxazole (P < 0.01), netilmicin (P < 0.01) 
and tetracycline (P < 0.01) for 2008 strains compared with the 2003 strains (Table 4.2). 
There was no significant difference in the resistance rates in 2003 and 2008 for the 
following antimicrobials: erythromycin (96% in year 2003 and 2008), ciprofloxacin 
(96% in 2003 to 89% in 2008), gentamicin (90% in 2003 to 82% in 2008), rifampicin 
(6% in 2003 to 4% in 2008), fusidic acid (10% in 2003 to 12% in 2008), teicoplanin 
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(4% in 2003 to 0% in 2008), mupirocin (2% in 2003 and 4% in 2008), clindamycin 
(94% in 2003 to 96% in 2008) and linezolid (2% in 2003 to 1% in 2008) (P > 0.05). The 
resistance rates for erythromycin remained the same (Table 4.2).  
The MIC for oxacillin, erythromycin, ciprofloxacin and tetracycline ranged from 
4.0 to 512 µg/ml, 0.25 to 256 µg/ml, 0.5 to 512 µg/ml and 0.5 to 256 µg/ml, 
respectively (Figure 4.3B, C). The temporal changes in the MIC of four antimicrobials 
for MRSA are summarized in Table 4.3. There was a significant increase (P < 0.05) of 
high-level erythromycin (128 and 256 µg/ml), medium (16 µg/ml) to high-level 
tetracycline (256 µg/ml) and medium-level ciprofloxacin (64 µg/ml) resistant strains 
between year 2003 and 2008.   
Based on Spearman‟s rank correlation coefficient test, the correlation between 
erythromycin and ciprofloxacin resistance was observed (R = 0.607, P < 0.05). 
Similarly, correlations between erythromycin and tetracycline (R = 0.1922, P < 0.05), 
ciprofloxacin and tetracycline (R = 0.0795, P < 0.05) were also observed. The values 
indicate that tetracycline-resistant strains were most likely to show co-resistance 
towards ciprofloxacin and erythromycin. Similarly, these values also indicate that 
erythromycin-resistant strains were most likely to show co-resistance towards 
ciprofloxacin and tetracycline.  
Based on the D-zone test, 96% (170/178) and 3% (6/178) of the erythromycin-
resistant strains showed inducible clindamycin resistance and constitutive clindamycin 
resistance, respectively (Figure 4.3D, E). Two erythromycin resistant strains did not 
have any flattening of the clindamycin zone adjacent to the erythromycin disk. 
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Figure 4.3 (A) MRSA strain (MRSA0805-24) in a representative plate used for the disk 
diffusion Antibiotic Susceptibility Test, (B) Nineteen MRSA strains in a representative 
plate used for MIC for tetracycline using agar microdilution method, (C) MRSA strain 
(MRSA0809-32) in a representative plate used for MIC using E-test strips, (D) MRSA 
strain (MRSA0805-21) in a representative plate used for D-zone test indicating of 
inducible-clindamycin resistance and (E) MRSA strains (MRSA0805-15 and 
MRSA0701-15) in two representative plate used for D-zone test indicating of 
constitutive-clindamycin resistance. 
Abbreviations: MUP, mupirocin; SXT, trimethoprim-sulfamethoxazole; RF, rifampicin; 
FD, fusidic acid; NET, netilmicin; ERY, erythromycin; DA, clindamycin; CN, 
gentamicin; VA, vancomycin; CIP, ciprofloxacin; TE, tetracycline; LZD, linezolid; 
TEC, teicoplanin    
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Table 4.1: Antimicrobial resistance of MRSA strains tested for 14 antimicrobial agents 
Antimicrobial 
agents 
Number of strains (%) 
Sensitive  Intermediate Resistant 
Ciprofloxacin   10    (5)   6   (3)  172 (92) 
Clindamycin   11    (6)   0   (0)  177 (94) 
Erythromycin    9     (4)   1   (1)  178 (95) 
Fusidic  acid 166   (88)   4   (2)    18 (10) 
Gentamicin   30   (16)   2   (1)  156 (83) 
Linezolid 185   (98)   0   (0)      3   (2) 
Netilmicin   68   (36) 42   (22)    78 (42) 
Rifampicin 179   (95)   1   (1)      8  (4) 
Teicoplanin 179   (95)   7   (4)      2   (1) 
Tetracycline   80   (43) 13   (7)    95 (50) 
Trimethoprim-
sulfamethoxazole 
  77   (41)   0   (0)  111 (59) 
Vancomycin 188  (100)   0   (0)       0 (0) 
Mupirocin 178  (95%)   0   (0)     10 (5) 
 
 
Table 4.2: Resistance rates of Malaysian MRSA strains in year 2003 and 2008 
Year 2003  
n =52 (%)  
2008  
n =111 (%) 
Total (%) P value 
Antimicrobials     
Ciprofloxacin 50 (96)    99 (89) 149 (91) 0.23 
Clindamycin  49(94)  106 (96) 155 (95) 0.71 
Erythromycin 50 (96)  106 (96) 156 (96) 1.00 
Fusidic  acid   5 (10)    13 (12)     18(11) 0.79 
Gentamicin 47 (90)    91 (82)  138 (85) 0.24 
Linezolid   1   (2)      1 (1)       2 (1) 0.54 
Netilmicin 14 (27)    55 (50)   69 (42) P < 0.01 
Rifampicin    3 (6)      4 (4)      7  (4) 0.68 
Teicoplanin     2 (4)      0 (0)       2 (1) 0.10 
Tetracycline 10 (19)   71 (64)   81 (50) P < 0.01 
Trimethoprim-
sulfamethoxazole 
19 (37)   80 (72)   99 (61) P < 0.01 
Vancomycin     0 (0)      0 (0)      0 (0) 1.00 
Mupirocin     1 (2)      4 (4)      5 (3) 1.00 
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Table 4.3: MIC values of oxacillin, erythromycin, ciprofloxacin, tetracycline, rifampicin 
and fusidic acid-resistant MRSA strains  
Year MIC 2003-2004 
(n=61) 
2007-2008 
(n=127) 
Total (n=188) P value 
  n  n   
Antibiotic     
Oxacillin     4       6        11        17  0.79 
     8       5        12       17 1 
   16       3        13        16 0.27 
   32       2          2         4 0.59 
   64       5        10       15 1 
 128     10        24        34  0.83 
 256     29        50        79  0.34 
 512       1         5          6  0.67 
Total resistance     61 (100%)     127 (100%) 188 (100%) 1 
Ciproflox-
acin 
0.5      0          2         2 1 
1      2          7         9 0.75 
2      0          5         5 0.17 
     8      8         12        20 0.45 
  16      3         10        13  0.55 
   32      4           8        12  1 
   64    18         18        36  0.02* 
 128      5        12        17 1 
 256    21         46         67 0.87 
 512     -          7           7 0.09 
Total resistance    59 (97%) 113 (89%) 172 (91%) 0.09 
Erythrom-
ycin 
0.25      0          1         1 1 
0.5      2          6         8 1 
    4      0          1         1 1 
    8      4           2          6  0.08 
  16      0          5          5  0.17 
   32      4           9        13  1 
   64      13         19        32  0.30 
 128    14           9        23  0.003* 
 256    24        75       99  0.01* 
Total resistance    59 (97%)  119 (94%) 178 (95%) 0.50 
Tetracycli-
ne 
0.25      1       0       0 0.33 
 0.5      4       0       4 0.10 
     1      6     11     17 1 
     2    11     14      25 0.25 
     4    19     14      33 0.002* 
      8      3       9      12 0.75 
   16      6       30      36 0.01* 
  32      4      17       21 0.43 
   64      4      14       17 0.43 
 128      3        7      10  1 
 256      0      11      11 0.01* 
 Total    17 (28%)      78 (61%)   95 (51%) 0 
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Table 4.3 (continue)    
Year  2003-2004 2007-2008 Total  P value 
  n  n    
 MIC n=61 n=127 n=188  
Rifampicin  0.5    58   122   180 0.72 
      2      0       1       1 1 
      4      1       0       1 0.32 
      8      2       4       6 1 
 Total      3 (5%)       5 (4%)       8 (4%) 0.72 
Fusidic 
Acid 
  0.5     56    114    170 0.79 
      6      2        2        4 0.60 
   16      0         1        1 1 
   64      0        3         3 0.55 
   96      1        2        3 1 
 256      2        5        7 0.59 
 Total      5 (8%)      13 (10%)      18 (10%) 0.79 
Mupirocin    0.5    56     122    178 0.3 
      8      1         0        1 0.3 
    16      1         0        1 0.3 
    32      2         4        6 1 
 256      1          1        2 0.54 
 Total      5 (8%)         5(4%)      10 (5%) 0.3 
* Indicative more P < 0.05 
 
4.3. Prevalence of β-lactam, mupirocin, gentamicin, vancomycin, linezolid, 
erythromycin, tetracycline and fusidic acid resistance genes in MRSA strains 
 PCR amplification for the detection of resistance genes for erythromycin (ermA, 
ermB, ermC and msrA), tetracycline (tetK, tetL, tetM, tetO and tetS), β-lactams (blaZ), 
mupirocin (mupA and ileS2) and gentamicin [aac(6’)-aph(2”)] were carried out using 
genomic DNA isolated from erythromycin, tetracycline, oxacillin, mupirocin and 
gentamicin resistant strains.   
 All the oxacillin-resistant MRSA strains harboured blaZ gene. On the other 
hand, all mupirocin-resistant strains harboured ileS2 gene whereas all gentamicin-
resistant strains harboured aac(6’)-aph(2”) genes. Furthermore, all erythromycin-
resistant strains harboured either ermA, ermC or msrA genes while all tetracycline-
resistant strains harboured either tetK or tetM genes. Specifically, ermA, aac(6’)-
aph(2”), tetM, ermC, tetK, ileS2, msrA and mupA specific amplicons were detected in 
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157 (84%), 156 (83%), 92 (49%), 40 (21%), 39 (21%), 10 (5%), 4 (2%) and 2 (1%) 
strains respectively (Figure 4.4; Appendix 4-12). However, no amplicon was obtained 
with primers that were specific for the ermB, fusB, fusC, fusD, cfrA, vanA, vanB, tetL, 
tetO and tetS genes despite repeated attempts.  
 Based on Kruskal-Wallis test, no significant difference was found between level 
of erythromycin resistance for 2008 strains and the presence of different types of 
erythromycin-resistance genes (H = 5.29, df = 2, P = 0.071). 
PCR amplifications using plasmid DNA as templates were carried out in parallel 
with additional 16S rRNA primers to preclude chromosomal DNA contamination. The 
presence of 720 bp amplicon indicative of either chromosomal DNA contamination or 
the resistance gene was chromosomal-encoded. Initially, detection of ermA, ermC and 
blaZ genes were carried out by using multiplex PCR. As 720 bp amplicon was detected 
among the MRSA strains which was also tested positive for ermA, ermC and blaZ 
genes, therefore the detection of ermA, ermC and blaZ genes were carried out using 
monoplex PCR in order to determine which of the resistant genes were plasmid 
encoded. Results from monoplex PCR showed thal all blaZ (n=188) and ermC (n=40) 
genes were plasmid encoded whereas ermA (n=157) was chromosomal-encoded (Figure 
4.4B; Table 4.4).  
The subsequent PCR detection of tetM, tetK, msrA, ileS2 and mupA genes were 
carried out by using the same batch of plasmids DNA that were used to detected ermA, 
ermC and blaZ genes in order to eliminate the possibility of chromosomal 
contamination. Results showed that tetM (n=92), tetK (n=39), ileS2 (n=10) and mupA 
(n=2) genes were plasmid-borne as no 720 bp amplicon was presence in the PCR 
(Figure 4.4A, D; Tabe 4.4). msrA and aac(6’)-aph(2”) genes were associated with 
chromosome as 16S rRNA gene was detected along with msrA and aac(6’)-aph(2”) 
genes.  
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Sequencing of the PCR amplicons obtained (selected representatives from ermA, 
ermC, msrA, mupA, ileS2, tetK, tetM, aac(6’)-aph(2”) and blaZ amplified products) 
indicated complete identity to their respective sequences in the NCBI database 
(Appendix 4-12). 
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Figure 4.4 Representative agarose gels of PCR-amplified products using different 
specific primers for detection of various resistant genes for the MRSA strains. (A) tetM 
and tetK-specific primers with genomic and plasmid DNA as template; (B) ermC-
specific primer with genomic and plasmid DNA as template; (C) ermA, ermC and blaZ-
specific primers with genomic DNA as template; (D) aac(6’)-aph(2”)-specific primers 
with genomic DNA as template; (E) ileS2-specific primers with genomic and plasmid 
DNA as template; (F) mupA-specific primers with genomic DNA as template; (G) 
msrA-specific primers with genomic DNA as template. Sterile deonised water was used 
as PCR control.  
g:  genomic DNA; p: plasmid DNA 
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Table 4.4: Resistance genes detected in the 188 MRSA strains 
Strain No Resistance Gene 
Genomic DNA Plasmid DNA 
MRSA2 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA3 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA4 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA8 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0301-1 ermA, blaZ blaZ 
MRSA0301-28 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0302-4 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0304-16 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0305-10 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0305-18 ermA, blaZ,  aac(6’)-aph(2”) blaZ 
MRSA0305-23 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0306-10 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0306-14 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0306-15 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0306-18 blaZ blaZ 
MRSA0306-26 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0306-7 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-1 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-10 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-14 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-20 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-23 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-25 ermA, blaZ,  aac(6’)-aph(2”) blaZ 
MRSA0307-5 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0307-9 ermA, blaZ blaZ 
MRSA0308-1 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0308-10 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0308-22 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0308-23 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0308-24 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0308-28 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0309-10 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0309-11 ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0309-9 ermA, blaZ blaZ 
MRSA0310-19 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0310-23 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0310-26 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0310-9 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-1 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-21 ermA, tetk, tetM, blaZ tetk, tetM, blaZ 
MRSA0311-23 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-4 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-7 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-8 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0311-9 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-13 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-15 ermA, blaZ, aac(6’)-aph(2”) blaZ 
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Table 4.4 (continue)  
Strain No Resistance Gene  
 Genomic DNA Plasmid DNA 
MRSA0312-17 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-2 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-3 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-30 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0312-35 tetK, blaZ, ileS2 blaZ, ileS2 
MRSA0401-13 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0402-21 ermA, tetM, blaZ, ileS2 tetM, blaZ, ileS2 
MRSA0402-8 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”), 
ileS2 
ermC, tetM, blaZ, 
ileS2 
MRSA0403-20 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0405-20 ermA, ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0406-8 ermA, tetM, blaZ, aac(6’)-aph(2”), ileS2, 
mupA 
tetM, blaZ, ileS2, 
mupA 
MRSA0408-33 ermA, blaZ, aac(6’)-aph(2”), ileS2 blaZ,  ileS2  
MRSA0408-34 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0409-17 ermA, tetM, blaZ tetM, blaZ 
MRSA0701-15 ermA, ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0701-26 blaZ blaZ 
MRSA0703-8 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0704-15 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0704-18 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0704-20 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0704-3 ermA, tetM, blaZ, aac(6’)-aph(2”), ileS2 tetM, blaZ, ileS2 
MRSA0705-13 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0705-17 ermA, ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0705-7 blaZ,  aac(6’)-aph(2”) blaZ 
MRSA0705-8 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0707-17 blaZ blaZ 
MRSA0707-26 ermC, tetK, tetM, blaZ, aac(6’)-aph(2”) ermC, tetK, tetM, 
blaZ 
MRSA0708-1 ermC, blaZ ermC, blaZ 
MRSA0708-10 ermC, blaZ ermC, blaZ 
MRSA0709-22 ermC, blaZ ermC, blaZ 
MRSA0801-1 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0801-13 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0801-16 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0801-2 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0801-21 ermA, ermC, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0801-26 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0801-27 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”), 
ileS2, mupA 
ermC, tetM, blaZ, 
ileS2, mupA 
MRSA0801-30 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0801-4 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0801-9 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0802-14 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0802-19 blaZ blaZ 
MRSA0802-2 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0802-3 ermA, blaZ, aac(6’)-aph(2”) blaZ 
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Table 4.4 (continue)  
Strain No Resistance Gene  
 Genomic DNA Plasmid DNA 
MRSA0803-28 ermC, blaZ ermC, blaZ 
MRSA0803-29 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0803-30 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA003-35 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0804-1 ermC, blaZ ermC, blaZ 
MRSA0804-14 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0804-20 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0804-24 ermA, ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0805-1 ermC, blaZ ermC, blaZ 
MRSA0805-10 blaZ, aac(6’)-aph(2”) blaZ 
MRSA0805-11 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0805-15 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”), 
ileS2 
ermC, tetM, blaZ, 
ileS2 
MRSA0805-17 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0805-19 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0805-20 ermA, tetM, blaZ, aac(6’)-aph(2”), ileS2 tetM, blaZ, ileS2 
MRSA0805-21 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0805-22 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0805-23 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0805-24 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0805-3 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0805-4 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0805-5 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0805-6 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0805-9 ermC, blaZ ermC, blaZ 
MRSA0806-1 ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0806-11 blaZ blaZ 
MRSA0806-13 blaZ blaZ 
MRSA0806-14 msrA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0806-18 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0806-21 ermC, blaZ ermC, blaZ 
MRSA0806-22 ermA, tetK, blaZ, aac(6’)-aph(2”) tetK, blaZ 
MRSA0806-26 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0806-33 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0807-1 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0807-13 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0807-14 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0807-19 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0807-7 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0807-8 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0808-17 ermA, ermC, msrA, tetK, tetM, blaZ, 
aac(6’)-aph(2”), ileS2 
ermC, tetK, tetM, 
blaZ, ileS2 
MRSA0808-19 ermA, blaZ,  aac(6’)-aph(2”) blaZ 
MRSA0808-21 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0808-24 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0808-25 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0808-26 ermA, blaZ, aac(6’)-aph(2”) blaZ 
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Table 4.4 (continue)  
Strain No Resistance Gene  
 Genomic DNA Plasmid DNA 
MRSA0808-35 ermA, ermC, tetK, tetM, blaZ, aac(6’)-
aph(2”) 
ermC, tetK, tetM, 
blaZ 
MRSA0809-1 ermC, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0809-10 ermA, tetM, blaZ tetM, blaZ 
MRSA0809-14 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0809-15 ermA, tetK, blaZ, aac(6’)-aph(2”) tetK, blaZ 
MRSA0809-24 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0809-25 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0809-27 ermA, blaZ blaZ 
MRSA0809-30 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0809-32 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0809-33 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0809-36 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0809-38 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0810-10 ermC, blaZ ermC, blaZ 
MRSA0810-13 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0810-15 ermA, ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0810-16 ermC, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0810-17 ermA, ermC, blaZ ermC, blaZ 
MRSA0810-18 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0810-2 ermA, tetM, blaZ tetM, blaZ 
MRSA0810-22 ermC, blaZ ermC, blaZ 
MRSA0810-23 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0810-6 ermC, blaZ ermC, blaZ 
MRSA0810-7 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0810-9 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0811-10 ermA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0811-11 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0811-13 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0811-16 ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0811-2 ermA, blaZ  
MRSA0811-22 ermC, blaZ ermC, blaZ 
MRSA0811-24 ermA, msrA, blaZ, aac(6’)-aph(2”) blaZ 
MRSA0811-25 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0811-26 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0811-28 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0811-30 ermA, ermC, tetK, blaZ ermC, tetK, blaZ 
MRSA0811-5 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0811-8 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-1 ermC, blaZ ermC, blaZ 
MRSA0812-11 blaZ blaZ 
MRSA0812-15 ermA, tetM, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0812-17 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-2 ermC, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-22 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0812-23 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
MRSA0812-27 ermA, ermC, tetM, blaZ, aac(6’)-aph(2”) ermC, tetM, blaZ 
MRSA0812-30 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
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4.4 Determination of tetracycline and gentamicin transposon-associated genes 
by PCR 
 PCR amplification was carried out on genomic DNA isolated from all tetM-
positive tetracycline and gentamicin-resistant strains in order to determine if they are 
associated with tetracycline transposon-associated genes (Tn916 and Tn5801) and 
gentamicin transposon-associated genes (Tn4001), respectively.  
 The results showed that Tn5801-like int was detected in 78 tetM-positive strains, 
and no Tn916-like int was detected (Figure 4.5; Appendix 13). Fourteen tetM-positive 
strains (MRSA0310-23, MRSA0402-8, MRSA0409-17, MRSA0801-13, MRSA0806-
26, MRSA0809-14, MRSA0809-25, MRSA0811-11, MRSA0811-26, MRSA0811-5, 
MRSA0812-23, MRSA0812-27, MRSA0812-33 and MRSA0812-37) did not harbour 
Tn5801 and Tn916-like int. Similarly, no Tn4001-like transposon was detected among 
gentamicin and netilimicin-resistant strains.   
  
Table 4.4 (continue)  
Strain No Resistance Gene  
 Genomic DNA Plasmid DNA 
MRSA0812-31 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-33 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-35 ermA, tetK, tetM, blaZ, aac(6’)-aph(2”) tetK, tetM, blaZ 
MRSA0812-36 ermA, ermC, msrA, blaZ, aac(6’)-aph(2”) ermC, blaZ 
MRSA0812-37 ermA, tetM, blaZ, aac(6’)-aph(2”) tetM, blaZ 
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Figure 4.5 Representative agarose gel of PCR-amplified products using primers specific 
for Tn5801-like int for tetM-positive strains. Sterile deonised water was used as PCR 
control.  
 
 
4.5 Transferability of Antibiotic Resistance determinant by transformation 
 Transformation studies were carried out using plasmid DNA for a subset of 30 
randomly selected erythromycin and tetracycline-resistant MRSA strains that harboured 
the plasmids in order to investigate if erythromycin and tetracycline resistance 
determinants were transferable.  
 Although blaZ (penicillin resistance) was carried on plasmids, no selection of 
penicillin-resistance was carried out. This is because the marker used for selection, 
ATCC29213 is known to harbour blaZ gene.  
Plasmids (previously used for the PCR detection of plasmid associated 
resistance genes) extracted from the 30 MRSA strains were electroporated into MRSA 
ATCC29213 cells, and the transformants were initially selected on TSA plates 
supplemented with either tetracycline or erythromycin.  
Only six out of 30 erythromcyin-resistant MRSA strains could be transferred 
and no transfer of tetracycline resistance was observed (Figure 4.6). Further analysis 
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showed that all resultant transformants were resistant to erythromycin (MIC 50 - 256 
µg/ml) (Table 4.5).  
Subsequent antibiogram profiling of the transformants showed that all six 
transformants were sensitive to tetracycline and mupirocin.  
PCR amplifications showed that only ermC gene was successfully transferred 
into the recipient S. aureus ATCC29213 suggesting that this resistant determinant was 
likely plasmid-encoded. Digested plasmids of sizes ranging from 1.1 to 18.5 kb were 
detected in six transformants (Figure 4.7, Table 4.5). Identical EcoRI restriction profiles 
were obtained from two plasmids extracted from donor MRSA (MRSA0812-1 and 
MRSA0804-1) and their respective transformants (Figure 4.7). The other plasmids 
extracted from transformants were smaller than plasmids from the donors. All the 
transformants which carried ermC contained plasmids with sizes of ~2.5 to 2.7 kb. 
Although MRSA0801-27 also harboured ileS2, mupA and tetM genes, none of 
the resistant genes were successfully transferred. Similarly, no tetM or tetK genes were 
successfully transferred even though the MRSA0812-33 and MRSA0806-1 haboured 
tetracycline resistant genes.  
 p[p[  
 
 A    B 
Figure 4.6 Representative plate supplemented with 50 µg/ml erythromycin used for the 
transformation test (A) transformant MRSA0801-27 and (B) transformant MRSA0803-
28.  
  
Transformant 
TSA 
supplemented 
with 50 µg/ml 
erythromycin  
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Figure 4.7 Agarose gel of EcoRI-digested plasmids extracted from MRSA strains and its 
ATCC29213 transformants. 
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Table 4.5: Transformation efficiencies, the size of EcoR1 digested plasmid, resistant 
gene transfer and the MIC for the selected MRSA strains and their transformants 
Strains 
no 
Transfor
mation 
efficienc
y 
Size of 
plasmid in 
donor strains 
(kb) 
Size of 
plasmid in 
transformant 
(kb) 
Resistant 
gene 
detected in 
transformant 
MIC for Ery 
detected in 
transformant 
MRSA0
801-27 
2.3 X 10
8 
15.4, 11.5, 7.0, 
6.4, 5.2, 4.2, 
3.0, 2.5, 1.8 
15.5, 7.0, 6.2, 
5.2, 4.1, 3.3, 
2.5, 1.9 
ermC 128 µg/ml 
MRSA0
803-28 
2.4 X 10
8 
12.3, 8.4, 6.6, 
6.2, 4.5, 4.0, 
3.7, 3.1, 2.5, 
1.9, 1.1 
8.0, 6.7, 6.2, 
5.0, 4.5, 4.0, 
2.5, 1.9, 1.1 
ermC 64 µg/ml 
MRSA0
812-33 
2.5 X 10
9 
12.0, 8.2, 7.0, 
6.4, 4.7, 4.1, 
3.2, 2.8, 1.8 
8.2, 7.0, 6.4, 
5.2, 4.7, 2.7, 
2.1 
ermC 50 µg/ml 
MRSA0
812-1 
9.6 X 10
8 
18.5, 12.6, 
10.7, 8.6, 5.2, 
4.6, 4.1, 3.8, 
3.2, 2.5, 2.0, 
1.3, 1.0 
18.5, 12.6, 
10.7, 8.6, 5.2, 
4.6, 4.1, 3.8, 
3.2, 2.5, 2.0, 
1.3, 1.0 
ermC 128 µg/ml 
MRSA0
806-1 
3.0 X 10
6 
18.3, 14.7, 8.8, 
8.2, 6.9, 6.4, 
4.8, 4.2, 3.8, 
2.0, 2.5, 1.4 
8.1, 6.8, 6.4, 
5.2, 4.8, 4.2, 
3.0, 2.5, 1.4, 
1.1 
ermC 256 µg/ml 
MRSA0
804-1 
8 X 10
8 
17.8, 12.4. 8.5, 
5.8, 4.9, 4.1, 
3.8, 3.6, 3.3, 
2.5, 2.1 
17.8, 12.4. 8.5, 
5.8, 4.9, 4.1, 
3.8, 3.6, 3.3, 
2.5, 2.1 
ermC 256 µg/ml 
 
 
4.6 Fusidic acid and rifampicin resistance determinants  
4.6.1 fusA primers designed 
PCR detection of fusA gene was carried out by using primers as previously 
described (O‟Neill et al., 2007; McLaws et al., 2008; Castanheira et al., 2010a; Chen et 
al., 2010). Despite repeated PCR tests for fusA using the published primers, no 
amplification was obtained. Therefore, new fusA primers were designed in this study. 
In the fusA primer designed, fusA sequence from S. aureus (GenBank accession 
number NC_003923.1, NC_007622.1 and NC_002745.2) were retrieved from GenBank 
(http://www.ncbi.nlm.nih.gov/gene?term=fusA%20staphylococcus%20aureus). fusA 
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gene sequences (~2082bp) were aligned by using Mega4 programme (The Biodesign 
Institute, USA).  
Two pairs of primers (FusA1-F, FusA1-R, FusA3-F and FusA1,2,3-R) were 
designed based on the sequence using Primer 3 programme 
(http://frodo.wi.mit.edu/primer3). PCR amplification using primer pairs FusA-1F (5‟ 
CGG TAT CAT GGC TCA CAT TG-3‟) and FusA-1R (5‟-AGC TGA ATC GTC TGC 
TTT CG-3‟) produced amplicon size of 832 bp whereas PCR amplification using primer 
pairs FusA3-F (5‟-CGA AAG CAG ACG ATT CAG CT-3‟) and FusA1,2,3-R (5‟-GTA 
CCG CGA CCT TGA GTG TT-3‟) produced amplicon size of 1099 bp. In Primer 3 
programme, the primer GC was set from 50 - 60 while primer temperature ranged from 
57 - 63°C.  
Primers FusA1-F and FusA1,2,3-R can also be used together in order to obtain 
PCR amplicon with size of 1.9 kb. These primers were found to be 100% specific when 
tested by using in-silico PCR programme (http://insilico.ehu.es/PCR/).  
 
 
4.6.2 Detection of rifampicin and fusidic acid resistance determinants by PCR 
PCR amplification using rpoB primers gave amplicon with 432 bp in size 
whereas PCR amplification using FusA1 and Fus3A gave amplicons with size of 832 bp 
and 1099 bp, respectively. The PCR amplification using fusE primers gave amplicon 
with 505 bp in size (Figure 4.8).  
Six rifampicin-resistant MRSA strains presented mutational change 484Arg/His 
in the cluster I of rpoB gene (Appendix 14 - 37). Five of these strains had non-
synonymous change 517Glu/Gln in cluster II (Table 4.6). Amino acid alteration of 
477Ala/Asp was observed in MRSA03008-10 with MIC 4 µg/ml whereas mutational 
change 481His/Asn was observed in MRSA0809-1 with MIC 2 µg/ml. Silent mutation 
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Ala(GCG → GCT) at 325‟ present in all the rifampicin resistant-strains and silent 
mutation Gly(GGT→GGA) at 462‟ was exhibited by MRSA0308-23 (Table 4.6).     
 Amino acid alteration of 461Leu/Lys in fusA gene was common among the 
resistant strains (n = 7, 31.33%) with a high-level of fusidic acid resistance (MIC 256 
µg/ml). One strain (MRSA0812-33) which had high-level of resistance to fusidic acid 
(MIC 256 µg/ml) has multiple mutations at 461Leu/Lys, 596Cys/Trp, 602Glu/Lys and 
317Met/Trp. Amino acid alteration 461Leu/Ser was also observed in two strains 
(MRSA0801-26 and MRSA0805-17) with MIC 6 µg/ml. MRSA0805-17 also exhibit 
mutational change at 404Pro/Leu. Six other strains with MIC 64 - 96 µg/ml showed 
amino acid alteration at 67Ala/Thr (n = 1), 457His/Tyr (n = 2) and combination of 
67Ala/Thr and 457His/Tyr (n=3) (Table 4.6). No mutation was observed for fusA gene 
in 3 strains, each with MIC of 6 µg/ml and 16 µg/ml. Based on the Kruskal-Wallis test, 
there was a significant difference between the level of resistance with different types of 
mutations (H = 16.39, df = 2, P < 0.05) in fusA gene.  
A silent mutation, Val(GTC→GTT) at 553‟ was present in 12 fusidic acid-
resistant strains whereas silent mutation Leu(TTA→TTG) at 325‟ was present in two 
fusidic acid- resistant strains (MRSA0810-7 and MRSA0810-17). Two silent mutations, 
Pro(CCT→CCA) at 342‟ and Ala(GCT→GCG) at 325‟ were exhibited by MRSA0805-
1.  
Three fusidic acid-resistant strains (MRSA0302-4, MRSA0312-35 and 
MRSA0805-1) showed no mutations in fusA and fusE gene. Based on the Spearman‟s 
rank correlation coefficient test, invert correlation between rifampicin and fusidic acid 
resistance (R = -0.52046, P < 0.05) was observed. This indicates that strain with 
rifampicin resistance is most likely to be sensitive to fusidic acid.  
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 A      B 
 
 
 
C 
Figure 4.8 Representative agarose gels of PCR amplified products using genomic DNA 
as template for detection of chromosomal associated resistant genes with (A) detection 
of rpoB gene, (B) detection of fusA gene where capital A represent PCR amplified 
product using primer FUSA-1F and FUSA-1R whereas capital C represent PCR 
amplified product using primer FUSA-3F and FUSA1,2,3-R and (C) detection of fusE 
gene.  Sterile deonised water was used as PCR control. 
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Table 4.6: Characteristics of rifampicin- and fusidic acid-resistant MRSA strains 
Strain   Rifampicin Resistance Fusidic acid Resistance GenBank 
Accession 
No 
Nucleotide 
mutation 
Amino acid 
substitution  
Nucleotide 
mutation 
Amino acid 
substitution 
MRSA03
08-23 
CGT-CAT 
GAA-
CAA 
484Arg→ His 
517Glu→ Gln 
TTA-AAA 461Leu→ Lys JN597293, 
HQ914957 
MRSA03
10-26 
CGT-CAT 
GAA-
CAA 
484Arg→ His 
517Glu→ Gln 
TTA-AAA 461Leu→ Lys JN597294, 
HQ914958  
MRSA08
09-32 
CGT-CAT 
GAA-
CAA 
484Arg→ His 
517Glu→ Gln 
TTA-AAA 461Leu→ Lys JN597299, 
HQ914961 
MRSA08
11-25 
CGT-CAT 484Arg→ His TTA-AAA 461Leu→ Lys JN597304, 
HQ914962 
MRSA08
12-33 
CGT-CAT 
GAA-
CAA 
484Arg→ His 
517Glu→ Gln 
TTA-AAA 
TGT-TGG 
GAA-AAA 
ATG-TGG 
461Leu→ Lys 
596Cys→ Trp 
602Glu→Lys 
317Met→Trp 
JN597305, 
HQ914963 
MRSA07
05-13 
CGT-CAT 
GAA-
CAA 
484Arg→ His 
517Glu→ Gln 
- - HQ914959 
MRSA03
08-10 
GCT-GAT 477Ala→ Asp - - HQ914953 
MRSA08
09-1 
CAT-AAT 481His→Asn - - HQ914960 
MRSA08
05-15 
- - TTA-AAA 461Leu→ Lys JN597296 
MRSA08
12-30 
- - TTA-AAA 461Leu→ Lys JN597303 
MRSA08
10-6 
- - GCA-ACA 67Ala→Thr JN597306 
MRSA08
10-10 
- - GCA-ACA 
CAC-TAC 
67Ala→Thr 
457His→Tyr 
JN597301 
MRSA03
07-23 
- - CAC-TAC 457His→Tyr JN597292 
MRSA08
10-7 
- - GCA-ACA 
CAC-TAC 
67Ala→Thr 
457His→Tyr 
JN597300 
MRSA08
07-8 
- - CAC-TAC 457His→Tyr JN597298 
MRSA08
10-17 
- - GCA-ACA 
CAC-TAC 
67Ala→Thr 
457His→Tyr 
JN597302 
 
MRSA08
05-17 
- - TTA-TCA 
CCA-CTA 
461Leu→Ser 
404Pro→Leu 
JN597297 
 
MRSA08
01-26 
- - TTA-TCA 461Leu→Ser JN597295 
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4.7 Congo red agar (CRA) method for detection of biofilm formation 
phenotype 
Using Congo red agar, biofilm formation bacteria formed black colour colonies 
whereas non-biofilm formation bacteria will develop red colour colonies. One hundred 
forty-three of 188 MRSA strains tested (76%) produced black colour colonies on congo 
red agar indicative of biofilm formation (Figure 4.9A; Table 4.7). The other 45 of 188 
MRSA strains (24%) produced smooth and red colonies indicative of non-biofilm 
formations (Figure 4.9B, Table 4.7).  
    
  A    B 
Figure 4.9 MRSA strain in two representative plate used for detection of biofilm 
formation with congo red agar (A) Biofilm producer and (B) non biofilm producer. 
 
 
4.8 Prevalence of virulence genes in MRSA strains  
All MRSA strains were screened for the presence of adhesions (cna, hlg, ica, 
sdrE, efb, fnbA and fnbB), enterotoxins (sea to see, seg to sej, tst) and exfoliative-toxins 
(eta, etb and etd) genes.  
Majority of the strains were positive for the adhesion genes such as extracellular 
fibrinogen binding protein (efb) (96%), fibrinogen binding protein (fnbA) (96%), 
intracellular adhesion (ica) (78%) while hemolysin (hlg) and putative adhesin (sdrE) 
Red colour 
colony 
indicative of 
non-slime 
production 
Presence of 
black colour 
colony changed 
CRA agar from 
red colour to 
black colour 
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were amplified in 59% and 27%, respectively (Figure 4.10). All biofilm formation 
MRSA strains harboured ica gene. No collagen adhesin (cna) gene was detected. Based 
on Spearman‟s rank correlation coefficient test, correlation between efb and fnb (R=1, P 
< 0.05), hlg and ica (R= 0.326, P < 0.05) were observed.   
A total of 101 strains were tested positive for at least one type of staphylococcal 
enterotoxin (SEs) while one strain was positive for exfoliative toxin (etd). No 
enterotoxins (seb, sed, see and seh) or exfoliative toxins (eta, etb) gene was detected. 
One strain (MRSA0805-10) harboured three SEs. Two strains harboured three toxin 
genes simultaneously whereas 30 strains harboured two toxin genes (Table 4.7, 4.8). 
The distribution of virulence genes is summarized in Table 4.8 (Appendix 38 - 47). 
The occurrence of SEs and exfoliative genes had significantly increased between 
year 2003 and 2008 (P = 0.001). There was a significant increase in the prevalence of 
virulence genes, sea (P = 0.003), sec (P = 0.006) and ica (P = 0.010) in 2008 strains 
compared with 2003 strains. However, no significant difference in the prevalence of 
virulence genes in 2003 and 2008 strains for the following genes: efb, fnbA, hlg, sdrE, 
seg, sei, etd and tst.  
sea and sec genes were detected in 17.5% and 6.9% MRSA strains, respectively 
and these strains were isolated from invasive samples (tissue, wound, blood, bone and 
pus). On the other hand, eight (67%) and ten (71%) of MRSA strains isolated from 
colonization samples (sputum and nasal swabs) were tested positive for seg and sei 
genes, respectively.   
Based on Spearman‟s rank correlation coefficient test, correlation between 
intercellular adhesion (ica) and SEs (R = 0.046, P < 0.05), hemolysin (hlg) and SEs (R 
= 0.007, P < 0.05) were observed.   
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Figure 4.10 Representative agarose gels of PCR amplified products using primers 
specific for (A) ica, (B) hlg and efb, (C) sdrE, (D) fnbA, (E) sea and sec, (F) seg, (G) 
etd, (H) tst and (I) sei genes. Sterile deonised water was used as PCR control.   
 
Table 4.7: Virulence genes detected in the 188 MRSA strains 
Strain No Virulence gene Biofilm formation 
on congo red agar 
MRSA2 efb, fnbA, ica Black  
MRSA3 efb, fnbA, ica, sdrE Black 
MRSA4 efb, fnbA Red 
MRSA8 efb, fnbA, ica, hlg Black 
MRSA0301-1 efb, fnbA Red 
MRSA0301-28 efb, fnbA, hlg Red 
MRSA0302-4 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0304-16 efb, fnbA Red 
MRSA0305-10 efb, fnbA, ica, hlg Black 
MRSA0305-18 efb, fnbA, ica, hlg, sea Black 
MRSA0305-23 efb, fnbA, ica, sec Black 
MRSA0306-10 efb, fnbA, hlg, sdrE Red 
MRSA0306-14 efb, fnbA Red 
MRSA0306-15 efb, fnbA, ica, hlg Black 
MRSA0306-18 efb, fnbA, ica, hlg, sea, seg Black 
MRSA0306-26 efb, fnbA, ica, hlg, sea Black 
MRSA0306-7 efb, fnbA, ica, hlg, sea Black 
MRSA0307-1 efb, fnbA, ica, hlg, sdrE Black 
MRSA0307-10 efb, fnbA Red 
MRSA0307-14 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0307-20 efb, fnbA Red 
MRSA0307-23 efb, fnbA, sdrE Red 
MRSA0307-25 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0307-5 efb, fnbA, ica, hlg Black 
MRSA0307-9 efb, fnbA Red 
MRSA0308-1 efb, fnbA, ica Black 
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Table 4.7 (continue)  
Strain No Virulence gene Biofilm formation 
on congo red agar 
MRSA0308-10 efb, fnbA, ica, hlg Black 
MRSA0308-22 efb, fnbA, ica, hlg Black 
MRSA0308-23 efb, fnbA, ica, hlg Black 
MRSA0308-24 efb, fnbA, ica, sea Black 
MRSA0308-28 efb, fnbA, hlg Red 
MRSA0309-10 efb, fnbA, ica, hlg, sec Black 
MRSA0309-11 efb, fnbA, ica, hlg Black 
MRSA0309-9 efb, fnbA, sec Red 
MRSA0310-19 efb, fnbA, hlg, sea Red 
MRSA0310-23 efb, fnbA Red 
MRSA0310-26 efb, fnbA, sec Red 
MRSA0310-9 efb, fnbA, ica, hlg Black 
MRSA0311-1 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0311-21 efb, fnbA, hlg Red 
MRSA0311-23 efb, fnbA, ica, hlg, sea Black 
MRSA0311-4 ica, sdrE Black 
MRSA0311-7 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0311-8 efb, fnbA, ica, hlg Black 
MRSA0311-9 efb, fnbA, sea Red 
MRSA0312-13 efb, fnbA, ica, hlg, sdrE Black 
MRSA0312-15 efb, fnbA, sea Red 
MRSA0312-17 efb, fnbA, sea Red 
MRSA0312-2 efb, fnbA Red 
MRSA0312-3 efb, fnbA, ica, hlg, sdrE Black 
MRSA0312-30 efb, fnbA, ica, hlg Black 
MRSA0312-35 - Red 
MRSA0401-13 efb, fnbA, ica Black 
MRSA0402-21 efb, fnbA, sea Red 
MRSA0402-8 efb, fnbA, sea Red 
MRSA0403-20 efb, fnbA, ica, hlg Black 
MRSA0405-20 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0406-8 efb, fnbA, ica Black 
MRSA0408-33 efb, fnbA, ica Black 
MRSA0408-34 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0409-17 efb, fnbA Red 
MRSA0701-15 efb, fnbA, ica, hlg, sdrE, sea, seg Black 
MRSA0701-26 efb, fnbA, ica, sdrE, sea Black 
MRSA0703-8 efb, fnbA, ica Black 
MRSA0704-15 efb, fnbA, ica, hlg, sea Black 
MRSA0704-18 efb, fnbA, ica Black 
MRSA0704-20 efb, fnbA, ica, sea Black 
MRSA0704-3 efb, fnbA, ica, sdrE, sea Black 
MRSA0705-13 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0705-17 ica, hlg, sdrE, sec, seg Black 
MRSA0705-7 ica, hlg, sdrE, seg Black 
MRSA0705-8 efb, fnbA, ica, sea Black 
MRSA0707-17 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0707-26 efb, fnbA, ica, sdrE, sea Black 
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Table 4.7 (continue)  
Strain No Virulence gene Biofilm formation 
on congo red agar 
MRSA0708-1 ica, hlg, sec, seg Black 
MRSA0708-10 ica, hlg, sdrE, sec, seg Black 
MRSA0709-22 ica, hlg, sdrE, sei Black 
MRSA0801-1 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0801-13 efb, fnbA, sea Red 
MRSA0801-16 efb, fnbA, ica, hlg Black 
MRSA0801-2 efb, fnbA, ica Black 
MRSA0801-21 efb, fnbA, ica, hlg, sdrE, sec Black 
MRSA0801-26 efb, fnbA, ica, sdrE, sea, sec Black 
MRSA0801-27 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0801-30 efb, fnbA, ica, hlg Black 
MRSA0801-4 efb, fnbA, ica, hlg Black 
MRSA0801-9 efb, fnbA, ica, sdrE Black 
MRSA0802-14 efb, fnbA, ica Black 
MRSA0802-19 efb, fnbA, ica, sdrE, tst Black 
MRSA0802-2 efb, fnbA, ica, hlg Black 
MRSA0802-3 efb, fnbA, ica, hlg Black 
MRSA0803-28 efb, fnbA, ica, sec, sei Black 
MRSA0803-29 efb, fnbA, ica Black 
MRSA0803-30 efb, fnbA, ica, hlg, sdrE Black 
MRSA003-35 efb, fnbA, ica, hlg Black 
MRSA0804-1 efb, fnbA, ica, hlg, sdrE, sec, sei Black 
MRSA0804-14 efb, fnbA, ica, sea Black 
MRSA0804-20 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0804-24 efb, fnbA, ica, hlg, sea Black 
MRSA0805-1 efb, fnbA, ica, hlg, sdrE, sei Black 
MRSA0805-10 efb, fnbA, hlg, sec, seg, sei Red 
MRSA0805-11 efb, fnbA, ica, hlg, sdrE Black 
MRSA0805-15 efb, fnbA, ica Black 
MRSA0805-17 efb, fnbA, ica, hlg Black 
MRSA0805-19 efb, fnbA, ica, sea Black 
MRSA0805-20 efb, fnbA, ica, hlg, sdrE, sec Black 
MRSA0805-21 efb, fnbA, ica, hlg Black 
MRSA0805-22 efb, fnbA Red 
MRSA0805-23 efb, fnbA, ica, hlg Black 
MRSA0805-24 efb, fnbA, ica Black 
MRSA0805-3 efb, fnbA, ica, hlg Black 
MRSA0805-4 efb, fnbA, sea, sec Red 
MRSA0805-5 efb, fnbA, ica, sea Black 
MRSA0805-6 efb, fnbA, ica, hlg Black 
MRSA0805-9 efb, fnbA, ica, hlg, sea, sec, sei Black 
MRSA0806-1 efb, fnbA, ica, hlg, sdrE, sea, sec Black 
MRSA0806-11 efb, fnbA, ica, hlg, sdrE, sea, sec Black 
MRSA0806-13 efb, fnbA, ica, hlg, sdrE, etd Black 
MRSA0806-14 efb, fnbA, ica, hlg, sdrE, seg Black 
MRSA0806-18 efb, fnbA, ica, hlg Black 
MRSA0806-21 efb, fnbA, ica, hlg, seg Black 
MRSA0806-22 efb, fnbA, ica, hlg Black 
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Table 4.7 (continue)  
Strain No Virulence gene Biofilm formation 
on congo red agar 
MRSA0806-26 efb, fnbA,hlg Red 
MRSA0806-33 efb, fnbA, ica, hlg, sea Black 
MRSA0807-1 efb, fnbA, ica, hlg, sea Black 
MRSA0807-13 efb, fnbA, ica Black 
MRSA0807-14 efb, fnbA, sdrE, sea Red 
MRSA0807-19 efb, fnbA, ica, sei Black 
MRSA0807-7 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0807-8 efb, fnbA, ica, hlg, sea Black 
MRSA0808-17 efb, fnbA, ica, hlg, sea, sei Black 
MRSA0808-19 ica, sea Black 
MRSA0808-21 efb, fnbA, hlg, sea Red 
MRSA0808-24 efb, fnbA, ica, sdrE, sea Black 
MRSA0808-25 efb, fnbA, ica, sdrE Black 
MRSA0808-26 efb, fnbA, ica, hlg, sea Black 
MRSA0808-35 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0809-1 efb, fnbA, ica, sea Black 
MRSA0809-10 efb, fnbA, ica, hlg Black 
MRSA0809-14 efb, fnbA Red 
MRSA0809-15 efb, fnbA, hlg, sea Red 
MRSA0809-24 efb, fnbA, ica, sea, sec Black 
MRSA0809-25 efb, fnbA, ica, hlg Black 
MRSA0809-27 efb, fnbA, hlg Red 
MRSA0809-30 efb, fnbA, ica, hlg Black 
MRSA0809-32 efb, fnbA, hlg Red 
MRSA0809-33 efb, fnbA, ica, hlg, sea Black 
MRSA0809-36 efb, fnbA, sea Red 
MRSA0809-38 efb, fnbA, ica, hlg, sea Black 
MRSA0810-10 efb, fnbA, ica, hlg, sec, sei Black 
MRSA0810-13 efb, fnbA, ica, sea Black 
MRSA0810-15 efb, fnbA, ica, hlg, sea Black 
MRSA0810-16 efb, fnbA, ica, sdrE, sec Black 
MRSA0810-17 efb, fnbA, ica, hlg, sec, sei Black 
MRSA0810-18 efb, fnbA, ica, hlg Black 
MRSA0810-2 efb, fnbA, sea, sei Red 
MRSA0810-22 efb, fnbA, ica, hlg, sec, sei Black 
MRSA0810-23 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0810-6 efb, fnbA, sec Red 
MRSA0810-7 efb, fnbA, ica, sea Black 
MRSA0810-9 efb, fnbA, ica, hlg, sdrE Black 
MRSA0811-10 efb, fnbA, ica Black 
MRSA0811-11 efb, fnbA, ica, hlg, sea, sec Black 
MRSA0811-13 efb, fnbA, ica, hlg Black 
MRSA0811-16 efb, fnbA, sec, seg Red 
MRSA0811-2 efb, fnbA, ica, hlg Black 
MRSA0811-22 efb, fnbA, ica, hlg, sec, sei Black 
MRSA0811-24 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0811-25 efb, fnbA, ica, sea, sec Black 
MRSA0811-26 efb, fnbA, ica, hlg Black 
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Table 4.8: Prevalence of genes encoding virulence determinants in Malaysian MRSA 
strains in 2003, 2004, 2007 and 2008 
Gene  No of strains  P value Gene combination No of strains 
2003 to 
2004 
2007 to 
2008 
2003 to 
2004 
2007 to 
2008 
sea 19 54 0.152 sec + seg + sei   1 
sec 4 32 0.003 sea + sec + sei  1 
seg 1 11 0.107 sea + sec   14 
sei 0 14 0.006 sec + sei  7 
etd 0 1 1.000 sec + seg  5 
tst 0 1 1.000 sea + sei  2 
efb 59 121 1.000 sea + seg   1 1 
fnbA 59 121 1.000 sea 18 36 
hlg 34 75 0.753 sec   3 4 
ica 39 104 0.010 seg   4 
sdrE 14 37 0.484 sei  3 
    etd  1 
    tst  1 
    Total    22 80 
 
  
Table 4.7 (continue)  
Strain No Virulence gene Biofilm formation 
on congo red agar 
MRSA0811-28 efb, fnbA, ica, hlg Black 
MRSA0811-30 efb, fnbA, ica, sdrE, seg Black 
MRSA0811-5 efb, fnbA Red 
MRSA0811-8 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0812-1 efb, fnbA, ica, hlg Black 
MRSA0812-11 efb, fnbA, ica, hlg, sdrE, sea Black 
MRSA0812-15 efb, fnbA, ica, sea Black 
MRSA0812-17 efb, fnbA, ica, sdrE Black 
MRSA0812-2 efb, fnbA, ica, hlg Black 
MRSA0812-22 efb, fnbA, ica, hlg, sdrE Black 
MRSA0812-23 efb, fnbA, ica, sdrE, sec, sei Black 
MRSA0812-27 efb, fnbA, sea, sec Red 
MRSA0812-30 efb, fnbA, ica Black 
MRSA0812-31 efb, fnbA, hlg, sdrE Red 
MRSA0812-33 efb, fnbA, ica Black 
MRSA0812-35 efb, fnbA Red 
MRSA0812-36 efb, fnbA, sec, seg Red 
MRSA0812-37 efb, fnbA, ica, sea, sec Black 
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4.9 Prevalence of pvl gene in MRSA strains 
 PCR amplification was carried out on genomic DNA isolated from the 188 
MRSA strains to determine if pvl gene was present among the strains. pvl gene was 
detected from five MRSA strains (2 from year 2007 and 3 from year 2008) (Figure 
4.11; Appendix 4.8) and these strains were isolated from three invasive samples (2 
wound and 1 tissue) and two colonization samples (1 tracheal secretion and 1 nasal 
swabs). There was no significant difference in the prevalence of pvl gene in 2003 and 
2008 strains (P > 0.05).  
 
 
 
Figure 4.11 Representative agarose gel of PCR amplified product using primers specific 
for pvl gene. Sterile deionised water water used as PCR control. 
 
 
4.10 agr grouping of MRSA strains 
Three agr genotypes were observed among the MRSA strains: agr type I (97%; 
51 strains from 2003, 9 from 2004, 15 from 2007 and 108 from 2008), agr type II 
(1.6%; 1 from 2007 and 2 from 2008) and agr type III (0.5%; 1 from year 2008) (Figure 
4.12; Table 4.10; Appendix 49-51). No agr type IV was observed. One strain 
(MRSA0312-35) did not belong to any agr group. Moreover, this MRSA0312-35 also 
did not harbour any virulence gene. 
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Figure 4.12 Representative agarose gel of PCR amplified products using primers 
specific for agr grouping for MRSA strains. Sterile deonised water was used as PCR 
control. 
 
 
4.11 SCCmec types 
Three SCCmec types were observed: SCCmec type III (86%, n=162), SCCmec 
type IV (13%, n=25) and SCCmec type V (1%, n=1) (Figure 4.13; Table 4.10). Thirteen 
SCCmec type IV isolates were further subtyped as SCCmec type IVa (Figure 4.14). The 
subsequent 12 SCCmec type IV isolates could not be furthered subgrouped using the 
available primers used in this study.  
SCCmec type III was observed among MRSA strains isolated from year 2003, 
2004, 2007 and 2008 while SCCmec type IV was observed among MRSA strains 
isolated from year 2007 to 2008. The only SCCmec type V MRSA strain was isolated in 
year 2008.  
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Figure 4.13 Representative agarose gel of PCR-amplified products for SCCmec typing. 
Sterile deionised water was used as PCR control.  
 
 
 
 
Figure 4.14 Representative agarose gel of PCR-amplified products for SCCmec IVa. 
JCSC4744 was used as positive control while sterile deionised water was used as PCR 
control.  
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4.12 Genomic Diversity of S. aureus strains 
4.12.1 Genotypes of MRSA based on PCR-RFLP of coa gene 
Digestion of coa positive PCR amplicons with AluI enzyme yielded 47 different 
restriction profiles (F = 0.24 - 1.0) (Figure 4.15 – 4.16; Table 4.10). Four strains 
(MRSA0312-35, MRSA0803-29, MRSA0707-26 and MRSA0802-14) could not be 
typed by coa-RFLP typing despite, repeated attempts. Seventy two MRSA strains with 
coa-RFLP profiles C12 to C14 were found to be clonally related as they shared more 
than 80% similarity. Among them, 37 strains shared identical coa-RFLP profiles (coa-
RFLP profile C12), even though they were cultured from different occasions and 
sources (Figure 4.16). MRSA strains with coa-RFLP profile C12 were cultured from 
both invasive (n=17; including bone, tissue, blood, pus) and colonization samples 
(n=20; including nasal swabs, tracheal secretions; nasopharyngeal secretion; sputum) 
samples obtained from different patients wards.       
Ten MRSA strains (MRSA0309-11, MRSA0310-9, MRSA0311-7, MRSA0312-
15, MRSA0402-21, MRSA0405-20, MRSA0801-30, MRSA0809-10, MRSA0810-18 
and MRSA0810-7) which were isolated from three different years (year 2003, 2004 and 
2008) shared similar coa-RFLP profiles, C21.  
 Two MRSA strains (MRSA2 and MRSA8) obtained from two staff nurses 
shared identical coa-RFLP profiles (C13) with 31 clinical MRSA strains, although they 
were cultured from different sources (tracheal secretions, slough, pus, blood, wound 
swab, urine, tip, sputum) and time period (year 2003, 2004, 2007 and 2008).  
 One MRSA strain, MRSA0805-10 which harboured three enterotoxin genes 
(sec, seg and sei) was found to be clonally related to four other strains, MRSA0704-15, 
MRSA0705-8, MRSA0807-13 and MRSA0811-25 (coa-RFLP profile, C8) as they 
shared 90.9% similarity in their coa-RFLP profiles (Figure 4.16). Three out of four 
MRSA strains with C8, coa-RFLP profiles (MRSA0704-15, MRSA0705-8 and 
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MRSA0811-25) harboured sea enterotoxin genes even though they were cultured from 
different sources (nasal swabs, blood and tips) and occasion (year 2007 and 2008).  
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Figure 4.15 Three representative agarose gels of PCR-RFLP of coa gene for MRSA 
strains. PCR-RFLP profiles are indicates in the brackets.  
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Figure 4.16 Dendrogram of PCR-RFLP of coa gene of MRSA strains. The dotted 
vertical line indicates 80% similarity level.  
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4.12.2 Genotypes of MRSA based on Pulsed-field Gel Electrophoresis (PFGE) 
 Genomic DNA from the 188 MRSA strains were digested with SmaI and this 
resulted in 85 distinct pulsed-field profiles (PFPs; F = 0.57-1.0) comprising of 10 – 18 
restriction fragments that ranged in size from approximately 23 Kb to 755 Kb (Figure 
4.17 and Table 4.10). 
Based on 80% similarity, nine clusters were observed, namely Cluster 1 to 
Cluster 9. Cluster 1 consists of 48 MRSA strains; Cluster 2 consists of 11 strains; 
Cluster 3 consists of 46 strains; Cluster 4 consists of 30 strains; Cluster 5, 6 and 9 
consists of 5 strains; and Cluster 7 and 8 consists of 9 strains. Twenty MRSA strains 
were not grouped under any clusters (Figure 4.18).   
MRSA strains within Clusters 1, 5 and 7 were isolated from three different years 
including year 2003, 2007 and 2008 while MRSA strains from Cluster 3 and 4 were 
isolated from year 2003, 2004 and 2008. Cluster 6 consists of MRSA strains from year 
2003 and 2008 whereas Cluster 8 consists of MRSA strains isolated from year 2007 to 
2008. Finally, Cluster 2 consists of MRSA strains isolated from year 2003, 2004, 2007 
and 2008 while Cluster 9 consists of MRSA strains from year 2008. All the MRSA 
strains from Cluster 1 to Cluster 7 shared a common band with size of 28 kB.  
Thirty-six MRSA from year 2003, 2007 and 2008 shared similar PFGE profile; 
SM7 even though they were cultured from different sources such as nasal swabs, 
tissues, urine, wound, tracheal secretions, chest tube, sputum, tips, nasopharyngeal 
secretions and pus. Interestingly, the only coa-negative MRSA strain (MRSA0312-35) 
was also found to exhibit the same PFGE profile; SM7.   
Furthermore, some MRSA strains with PFGE profile SM7 were also found to 
harbour different types of virulence genes with five harboured sea and sec enterotoxin 
genes together whereas one strain harboured sea and pvl toxin's genes. Eight other 
strains with PFGE profile; SM7 harboured sea gene whereas two harboured sec gene. 
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The remaining 20 MRSA strains with this similar PFGE profile; SM7 did not harbour 
any virulence gene. All MRSA strains with PFGE profile; SM7 was resistant to 
erythromycin and oxacillin. Except for MRSA0301-28 and MRSA0805-22 which of 
SCCmec type IV, all the others 34 MRSA strains with PFGE profile SM7 belong to 
SCCmec type III. 
On the other hand, 21 MRSA strains (MRSA0306-15, MRSA0306-7, 
MRSA0307-1, MRSA0307-14, MRSA0307-20, MRSA0307-23, MRSA0308-1, 
MRSA0308-22, MRSA0309-11, MRSA0310-9, MRSA0311-23, MRSA0311-7, 
MRSA0311-9, MRSA0312-2, MRSA0312-3. MRSA0802-2, MRSA0802-3, 
MRSA0809-10, MRSA0809-27, MRSA0810-18 and MRSA0810-2) were 
indistinguishable by PFGE, although they were isolated from year 2003 and 2008. 
Similar to PFGE profile SM7, these 21 MRSA strains with PFGE profile SM17 were 
also being cultured from different sources such as pus, wound swabs, tracheal 
secretions, blood, tissue, slough and nasal swab). 
On the other hand, 15 out of 25 SCCmec type IV strains with PFGE profiles 
SM73 to SM78 and SM80 to SM85 were grouped together, and they shared 73.4% 
similarity. Among them, eight MRSA strains with PFGE profiles SM73 to SM78 were 
found to be clonally related to one SCCmec type III strain (MRSA0802-19).   
The MRSA strain (MRSA0805-10) which harboured three enterotoxin genes 
(sec, seg and sei) shared the same pulsed-field profiles, SM21 with 16 MRSA strains 
isolated from year 2003 and 2008. These 17 MRSA strains were also being isolated 
from different sources including nasal swabs, pus, blood, tracheal secretions, wound 
swabs, urine and sputum.  
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Figure 4.17 Representative pulsed-field gels of SmaI-digested genomic DNA from 
MRSA strains. PFGE profiles are indicates in brackets. Salmonella Braenderup H9812 
was used as DNA marker. 
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Figure 4.18 Dendrogram of PFGE of MRSA strains. The dotted vertical line indicates 
80% similarity level.  
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4.12.3 Genotypes of MRSA based on spa types 
 
 PCR amplification of spa gene using primers 1095F and 1517R gave amplicons 
that ranged from 300 bp to 600 bp (Figure 4.19). Sequence analysis of spa amplicons 
from 188 MRSA strains gave 17 distinct spa types. One novel spa type (t6405) was 
detected, and deposited to ridom spa server (http://www.spaserver.ridom.de/) 
(Appendix 52). This t6405 spa type was only present among MRSA strains from year 
2008. The most frequent spa type was t037 (66.50%). Repeats among other spa types 
varied from one strain (t002, t363, t458, t657, t860, t1544, t2029, t4150 and t4152), two 
strains (t1107), three strains (t1378), four strains (t304, t4184 and t6405), 12 strains 
(t032) and finally to 25 strains (t421) (Table 4.10 – 4.11). The discriminatory power of 
spa typing was 0.53.  
 Three spa types t037 (n=50), t421 (n=1) and t1544 (n=1) were present among 
strains isolated in year 2003 while five spa types (t304, t4184, t002, t860 and t032) 
were introduced in year 2007 and another nine spa types (t1378, t6405, t4150, t1107, 
t458, t4152, t657, t2029 and t363) emerged in year 2008.  
 The minimum spanning tree shows two spa clonal complexes (spaCC) 
arbitrarily named spaCC1 and spaCC2 (Figure 4.20). Strains which shared more than 
98.5% similarity were grouped in the same spa clonal complex (spaCC). spaCC1 
comprised of 156 strains from five spa types (t037, t6405, t421, t363 and t2029) (Figure 
4.20). Among them, 56% (88/156) were from year 2008. spaCC2 contains 19 strains 
from three spa types (t4184, t1378 and t032). The other 9 spa types (t860, t4150, t1544, 
t458, t1107, t002, t657, t304 and t4152) were not grouped in any spa clonal complexes 
as they only shared 87.1% similarity.   
 All MRSA within spaCC2 belongs to SCCmec type IV. Similarly, strains from 
spa type t002, t1107 and t304 were also from SCCmec type IV. Among them, spa type 
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t002 and t1107 were sharing 95.5% similarity All SCCmec type IV strains with spa 
types t4184, t1378, t032, t002, t1107 and t304 only shared 92.2% similarity.  
 On the other hand, most of the MRSA strains with same spa types were often 
cultured from different types of samples. For examples, the MRSA strains with spa type 
t421 were isolated from nasal swabs, blood, wound swabs, tissues, tracheal secretions, 
urine, sputum and pus whereas MRSA strains with spa type t032 were isolated from 
tracheal secretions, nasal swabs, pus and wound swabs.  
  
 
                        
 
Figure 4.19 Representative agarose gel of spa typing for MRSA strains. Sterile deonised 
water was used as PCR control. 
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Figure 4.20 Minimal spanning tree analyses for the spa types of 188 MRSA strains. 
Clusters of related spa types were arbitrarily assigned clonal complexes (spaCC1-2). 
The sizes of node indicate the number of strains of each MLST types.  
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4.12.4 Genotypes of MRSA based on Multilocus-sequence typing (MLST) of seven 
housekeeping genes 
 All 188 MRSA strains were screened for the pandemic ST239 lineage. Out of 
the 188 MRSA strains, 157 (51 from 2003, all 2004 strains, 8 from 2007 and 89 from 
2008) produced both DNA bands (220 bp and 480 bp), as determined via the 
heteroduplex PCR (Figure 4.21). This indicates that presence of ST239 lineage (CC8) 
and this was later confirmed by MLST.   
 PCR amplification of the seven house-keeping genes (arcC, aroE, gmk, glpF, 
yqil, tpi and pta) resulted in amplicons around 500 bp (Figure 4.22). Sequence analysis 
by using online MLST.net revealed ten different multilocus sequence types including 
ST22 (CC22) (n = 19), ST6 (CC6) (n = 4), ST20 (CC20) (n=1), ST5 (CC5) (n = 1), 
ST573 (CC1) (n = 1), ST80 (CC80) (n = 1), ST241 (CC8) (n = 1), ST772 (n = 1) (CC1), 
ST1178 (n = 2) (CC5) and ST239 (CC8) (Figure 4.22, Table 4.9 - 4.11;Appendix 53-
54).  
   ST239 and ST20 were present since 2003 whereas ST5, ST6 and ST22 were 
introduced in year 2007. The other MLST types (ST80, ST573, ST241, ST1178 and 
ST772) were only present in year 2008.  
 A minimum spanning tree based on the degree of similarity between seven 
housekeeping genes of MRSA strains was generated (Figure 4.23). The analysis showed 
that MLST types ST239 and ST241 were closely related with only one MST distance 
away as they shared six alleles including arcC, aroE, glpF, gmk, pta and tpi. Similarly, 
both ST772 and ST573 were also closely related with only one allele difference (pta).  
 There are two allelic differences between ST5 and ST1178 as they shared five 
similar alleles including arcC, glpF, gmk, pta and yqil. Similarly, this ST5 was also 
found to share five alleles with ST6 and the only two different alleles were arcC and 
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yqiL. All the MRSA strains from these three MLST types (ST5, ST6 and ST1178) were 
of SCCmec type IV.  
 On the other hand, most of the MRSA strains with same MLST types were often 
cultured from different types of samples. For examples, the MRSA strains with MLST 
type ST6 were isolated from wound swabs, nasopharygeal secretions and tracheal 
secretions whereas MRSA strains with spa type t032 were isolated from tracheal 
secretions, nasal swabs, pus and wound swabs.  
 
  
 
Figure 4.21 Representative agarose gel of PCR amplified products using primers 
specific for ST8, ST30 and ST239. Sterile deonised water was used as PCR control.  
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Figure 4.22 Representative agarose gel of PCR amplified products using primers 
specific for seven housekeeping gene (gmk, pta, tpi, glpF, aroE, arccC and yqil) in 
MRSA using genomic DNA as template. The labeling of strains is indicated in the gel 
photo.    
 
Table 4.9: Allelic profiles of different MLST types 
ST No of 
MRSA 
strains 
Allelic profile (allele no) 
arcC aroE glpF gmk pta  tpi yqiL 
5 4 1 4 1 4 12 1 10 
6 1 12 4 1 4 12 1 3 
20 1 4 9 1 8 1 10 1 
22 19 7 6 1 5 8 8 6 
80 1 1 3 1 14 11 51 10 
239 157 2 3 1 1 4 4 3 
241 1 2 3 1 1 4 4 30 
573 1 1 1 1 1 12 1 1 
772 1 1 1 1 1 22 1 1 
1178 2 1 181 1 4 12 10 10 
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Figure 4.23 Minimum spanning tree analyses for the MLST types of 188 MRSA strains. 
Each sequence type is represented by a node. The distance between each node 
represents the number of allelic differents. The sizes of node indicate the number of 
strains of each MLST types.  
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4.12.5 Genotypes of MRSA based on mec-associated direct repeat unit (dru) types 
PCR amplification of mec gene was performed by using primers as described 
earlier by Goering et al. (2008) resulted in mec amplicon that ranged from 800 bp to 
1000 bp (Figure 4.24).  
Sequence analysis of mec-associated direct repeat unit (dru) in 188 strains gave 
30 distinct dru types. Eighteen novel dru types (dt13l, dt13m, dt11al, dt15l, dt15m, 
dt7v, dt13n, dt15n, dt10aw, dt13ao, dt11am, dt13p, dt11an, dt13q, dt10ax, dt12j, dt12k 
and dt14h) were detected (Appendix 55). The information of these novel sequences has 
been deposited in www.dru-typing.org. 
 The predominant dru type was dt13d (n=57, 30.32%). Repeats among other dru 
types varied from one strain (dt12k, dt12j, dt11an, dt2c, dt13p, dt7l, dt10aw, dt15n, 
dt13i, dt15l, dt15m, and dt14h), two strains (dt13l, dt13m, dt7v, dt10ax, and dt11am), 
three strains (dt11c, dt13ao, dt10ao and dt13q), four strains (dt13f), five strains (dt9w, 
dt13n, 11al and dt13j), six strains (dt14c), 32 strains (dt10a) and 35 strains (dt13g) 
(Table 4.10 - 4.11). The discriminatory power of mec-associated dru typing was 0.85. 
 A minimum spanning tree based on the degree of similarity between dru repeats 
successions of MRSA strains was generated (Figure 4.25). The analysis showed four 
dru clonal complexes (druCC) arbitrarily named druCC1 to druCC4 (Figure 4.25). 
druCC1 consists of strains from dru types dt13d, dt13j, dt13g, dt13n, dt13ao, dt13p, 
dt13m, dt13f and dt13i, whereas druCC2 consists of strains from dru types dt15n, dt15l 
and dt15m (Figure 4.25). dt9w and dt10ax were grouped in druCC3 and dt11al and 
dt13q were grouped in druCC4 (Figure 4.25). Fourteen dru types (dt11an, dt12j, dt14h, 
dt12k, dt14c, dt11am, dt7v, dt13l, dt7l, dt2c, dt10ao, dt11c, dt10a and dt10aw) were not 
grouped in any dru clonal complexes as they only shared 91.6% similarity.  
 Twenty-three different dru types (dt11an, dt12j, dt12k, dt15n, dt15l, dt15m, 
dt9w, dt10ax, dt11am, dt13l, dt11al, dt13q, dt14h, dt14c, dt13j, dt13g, dt13n, dt13ao, 
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dt13p, dt13m, dt13f, dt13i and dt13d) including all strains within dru clonal complexes 
druCC1 to druCC4 were found to share 95% similarity.  
 MRSA strains from dru type dt13d were cultures from different years (2003, 
2004, 2007 and 2008) and sources such as nasal swabs, wound swabs, tissue, urine, 
nasopharygeal secretions, pus, tracheal secretions, blood, sputum, shoulder swab and 
bone.  
 On the other hand, MRSA strains from dru type dt10a were isolated from three 
different years (2003, 2007 and 2008) and from different specimens including wound 
swabs, sputum, tracheal secretions, nasopharygeal secretions, nasal swabs, pus and 
blood.  
 Twenty-one out of 32 MRSA strains with dru type dt10a belong to SCCmec type 
IV. The remaining four SCCmec type IV strains were from dru type dt13ao (2 strains), 
dt10aw (1 strain), and dt13d (one strain).   
  
 
 
Figure 4.24 Representative agarose gel of mec-associated dru typing for MRSA strains. 
Sterile deonised water was used as PCR control. 
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Figure 4.25 Minimal spanning tree analyses for the dru types of 188 MRSA strains. 
Clusters of related dru types were arbitrarily assigned clonal complexes (druCC1-4). 
Each sequence type is represented by a node. The sizes of node indicate the number of 
strains of each dru types.  
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Table 4.10: SCCmec and agr, spa, MLST and dru types, coa-RFLP and PFGE profiles 
of the 188 MRSA strains.  
 
Strain No SCCme
c type 
agr 
typ
e 
spa 
type 
MLST 
type 
dru 
type 
coa-
RFLP 
profile 
Sma1- 
PFGE 
profile 
MRSA2 III I t037 ST239 dt13d C13 SM7 
MRSA3 III I t037 ST239 dt13d C30 SM40 
MRSA4 III I t037 ST239 dt13d C32 SM55 
MRSA8 III I t037 ST239 dt14h C13 SM15 
MRSA0301-1 III I t037 ST239 dt13d C12 SM68 
MRSA0301-28 III I t037 ST239 dt13d C12 SM7 
MRSA0302-4 III I t037 ST239 dt14c C12 SM51 
MRSA0304-16 III I t037 ST239 dt13d C12 SM13 
MRSA0305-10 III I t037 ST239 dt13d C30 SM7 
MRSA0305-18 III I t037 ST239 dt13i C12 SM64 
MRSA0305-23 III I t037 ST239 dt13l C13 SM6 
MRSA0306-10 III I t037 ST239 dt13d C18 SM14 
MRSA0306-14 III I t037 ST239 dt13g C12 SM22 
MRSA0306-15 III I t037 ST239 dt13d C13 SM17 
MRSA0306-18 III I t1544 ST20 dt14c C20 SM23 
MRSA0306-26 III I t037 ST239 dt13g C14 SM7 
MRSA0306-7 III I t037 ST239 dt13d C13 SM17 
MRSA0307-1 III I t037 ST239 dt9w C19 SM17 
MRSA0307-10 III I t037 ST239 dt13m C12 SM66 
MRSA0307-14 III I t037 ST239 dt13d C12 SM17 
MRSA0307-20 III I t037 ST239 dt10a C13 SM17 
MRSA0307-23 III I t037 ST239 dt10a C12 SM17 
MRSA0307-25 III I t037 ST239 dt13g C12 SM63 
MRSA0307-5 III I t037 ST239 dt11al C13 SM38 
MRSA0307-9 III I t421 ST239 dt13d C10 SM21 
MRSA0308-1 III I t037 ST239 dt13d C30 SM17 
MRSA0308-10 III I t037 ST239 dt14c C12 SM1 
MRSA0308-22 III I t037 ST239 dt13d C13 SM17 
MRSA0308-23 III I t037 ST239 dt15l C12 SM32 
MRSA0308-24 III I t037 ST239 dt13g C26 SM30 
MRSA0308-28 III I t037 ST239 dt13d C30 SM60 
MRSA0309-10 III I t037 ST239 dt13g C23 SM7 
MRSA0309-11 III I t037 ST239 dt13g C21 SM17 
MRSA0309-9 III I t037 ST239 dt13d C30 SM28 
MRSA0310-19 III I t037 ST239 dt13d C13 SM30 
MRSA0310-23 III I t037 ST239 dt13d C15 SM8 
MRSA0310-26 III I t037 ST239 dt15m C30 SM36 
MRSA0310-9 III I t037 ST239 dt9w C21 SM17 
MRSA0311-1 III I t037 ST239 dt13m C11 SM66 
MRSA0311-21 III I t037 ST239 dt13d C12 SM42 
MRSA0311-23 III I t037 ST239 dt13d C24 SM17 
MRSA0311-4 III I t037 ST239 dt11al C30 SM21 
MRSA0311-7 III I t037 ST239 dt13d C21 SM17 
MRSA0311-8 III I t037 ST239 dt10a C13 SM21 
MRSA0311-9 III I t037 ST239 dt13d C12 SM17 
MRSA0312-13 III I t037 ST239 dt13d C12 SM47 
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Table 4.10 (continue)       
Strain No SCCme
c type 
agr 
typ
e 
spa 
type 
MLST 
type 
dru 
type 
coa-
RFLP 
profile 
Sma1- 
PFGE 
profile 
MRSA0312-15 III I t037 ST239 dt11al C21 SM21 
MRSA0312-17 III I t037 ST239 dt11al C13 SM7 
MRSA0312-2 III I t037 ST239 dt9w C13 SM17 
MRSA0312-3 III I t037 ST239 dt13d C13 SM17 
MRSA0312-30 III I t037 ST239 dt11c C6 SM19 
MRSA0312-35 III ND t037 ST239 dt13l ND SM7 
MRSA0401-13 III I t037 ST239 dt13d C12 SM29 
MRSA0402-21 III I t037 ST239 dt7v C21 SM26 
MRSA0402-8 III I t037 ST239 dt13d C19 SM10 
MRSA0403-20 III I t037 ST239 dt11al C12 SM12 
MRSA0405-20 III I t421 ST239 dt13d C21 SM20 
MRSA0406-8 III I t037 ST239 dt13d C12 SM64 
MRSA0408-33 III I t037 ST239 dt7v C13 SM67 
MRSA0408-34 III I t037 ST239 dt13n C15 SM33 
MRSA0409-17 III I t037 ST239 dt13d C11 SM27 
MRSA0701-15 IV II t002 ST5 dt10a C4 SM56 
MRSA0701-26 IV I t304 ST6 dt10a C38 SM46 
MRSA0703-8 III I t421 ST239 dt13d C30 SM7 
MRSA0704-15 III I t037 ST239 dt13ao C8 SM11 
MRSA0704-18 III I t860 ST239 dt13d C30 SM69 
MRSA0704-20 III I t421 ST239 dt13d C30 SM62 
MRSA0704-3 III I t037 ST239 dt13d C13 SM61 
MRSA0705-13 III I t037 ST239 dt15n C24 SM70 
MRSA0705-17 IV I t032 ST22 dt10a C41 SM75 
MRSA0705-7 IV I t032 ST22 dt10aw C43 SM84 
MRSA0705-8 III I t421 ST239 dt13ao C8 SM65 
MRSA0707-17 IV I t304 ST6 dt10a C30 SM44 
MRSA0707-26 III I t037 ST239 dt13a ND SM59 
MRSA0708-1 IV I t4184 ST22 dt13d C44 SM71 
MRSA0708-10 IV I t032 ST22 dt10a C33 SM73 
MRSA0709-22 IV I t032 ST22 dt10a C39 SM54 
MRSA0801-1 III I t037 ST239 dt11am C7 SM24 
MRSA0801-13 III I t421 ST239 dt13d C13 SM39 
MRSA0801-16 III I t6405 ST239 dt13j C30 SM13 
MRSA0801-2 III I t037 ST239 dt13g C12 SM36 
MRSA0801-21 IV I t037 ST22 dt10a C33 SM83 
MRSA0801-26 III I t037 ST239 dt13d C12 SM7 
MRSA0801-27 III I t421 ST239 dt13f C7 SM41 
MRSA0801-30 III I t037 ST239 dt13f C21 SM18 
MRSA0801-4 III I t037 ST239 dt13g C10 SM36 
MRSA0801-9 III I t037 ST239 dt13d C30 SM7 
MRSA0802-14 III I t037 ST239 dt13p ND SM1 
MRSA0802-19 III I t037 ST239 dt10a C43 SM79 
MRSA0802-2 III I t6405 ST239 dt13j C22 SM17 
MRSA0802-3 III I t6405 ST239 dt13j C39 SM17 
MRSA0803-28 IV I t4184 ST22 dt10a C36 SM80 
MRSA0803-29 III I t037 ST239 dt14c ND SM4 
MRSA0803-30 III I t037 ST239 dt14c C12 SM3 
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Table 4.10 (continue)       
Strain No SCCme
c type 
agr 
typ
e 
spa 
type 
MLST 
type 
dru 
type 
coa-
RFLP 
profile 
Sma1- 
PFGE 
profile 
MRSA0803-35 III I t421 ST239 dt13d C28 SM21 
MRSA0804-1 IV I t4184 ST22 dt10a C45 SM74 
MRSA0804-14 III I t037 ST239 dt13d C30 SM35 
MRSA0804-20 III I t421 ST239 dt13j C30 SM21 
MRSA0804-24 III I t037 ST239 dt13d C15 SM16 
MRSA0805-1 IV I t1107 ST1178 dt13ao C5 SM57 
MRSA0805-10 IV I t1107 ST1178 dt13ao C9 SM21 
MRSA0805-11 III I t037 ST239 dt13g C12 SM40 
MRSA0805-15 III I t363 ST241 dt7l C47 SM5 
MRSA0805-17 III I t037 ST239 dt13d C12 SM2 
MRSA0805-19 III I t037 ST239 dt13g C12 SM36 
MRSA0805-20 III I t6405 ST239 dt11an C13 SM21 
MRSA0805-21 III I t4152 ST239 dt13g C13 SM7 
MRSA0805-22 III I t037 ST239 dt14c C12 SM7 
MRSA0805-23 III I t037 ST239 dt13g C17 SM28 
MRSA0805-24 III I t037 ST239 dt13ao C30 SM4 
MRSA0805-3 III I t037 ST239 dt13g C13 SM7 
MRSA0805-4 III I t037 ST239 dt13d C30 SM7 
MRSA0805-5 III I t037 ST239 dt13d C16 SM15 
MRSA0805-6 III I t037 ST239 dt13j C12 SM18 
MRSA0805-9 IV I t032 ST22 dt10a C3 SM77 
MRSA0806-1 III I t421 ST239 dt13f C10 SM21 
MRSA0806-11 IV I t304 ST6 dt10a C40 SM48 
MRSA0806-13 III III t037 ST80 dt10a C5 SM36 
MRSA0806-14 III II t458 ST573 dt2c C1 SM58 
MRSA0806-18 III I t037 ST239 dt11am C12 SM37 
MRSA0806-21 IV I t4184 ST22 dt10a C35 SM78 
MRSA0806-22 III I t037 ST239 dt13g C12 SM36 
MRSA0806-26 III I t037 ST239 dt13g C12 SM7 
MRSA0806-33 III I t037 ST239 dt13d C2 SM7 
MRSA0807-1 III I t037 ST239 dt10a C13 SM36 
MRSA0807-13 III I t037 ST239 dt13g C8 SM52 
MRSA0807-14 III I t421 ST239 dt13n C12 SM21 
MRSA0807-19 III I t037 ST239 dt13d C31 SM7 
MRSA0807-7 III I t421 ST239 dt13q C12 SM7 
MRSA0807-8 III I t037 ST239 dt13q C13 SM7 
MRSA0808-17 III I t421 ST239 dt13f C2 SM21 
MRSA0808-19 III I t421 ST239 dt13g C30 SM7 
MRSA0808-21 III I t037 ST239 dt13g C13 SM36 
MRSA0808-24 III I t421 ST239 dt13d C15 SM16 
MRSA0808-25 III I t037 ST239 dt13g C30 SM36 
MRSA0808-26 III I t421 ST239 dt13d C30 SM21 
MRSA0808-35 III I t037 ST239 dt13q C13 SM16 
MRSA0809-1 III I t037 ST239 dt11c C12 SM59 
MRSA0809-10 III I t037 ST239 dt13g C21 SM17 
MRSA0809-14 III I t421 ST239 dt10ax C46 SM43 
MRSA0809-15 III I t037 ST239 dt13d C13 SM34 
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Table 4.10 (continue)       
Strain No SCCme
c type 
agr 
typ
e 
spa 
type 
MLST 
type 
dru 
type 
coa-
RFLP 
profile 
Sma1- 
PFGE 
profile 
MRSA0809-24 III I t037 ST239 dt13d C13 SM25 
MRSA0809-25 III I t4150 ST239 dt13d C30 SM7 
MRSA0809-27 III I t037 ST239 dt13d C30 SM17 
MRSA0809-30 III I t421 ST239 dt10ax C13 SM40 
MRSA0809-32 III I t037 ST239 dt12j C15 SM49 
MRSA0809-33 III I t037 ST239 dt13g C12 SM7 
MRSA0809-36 III I t421 ST239 dt13n C12 SM21 
MRSA0809-38 III I t037 ST239 dt13g C12 SM72 
MRSA0810-10 IV I t1378 ST22 dt10a C36 SM82 
MRSA0810-13 III I t037 ST239 dt13d C7 SM1 
MRSA0810-15 III I t421 ST239 dt13d C13 SM21 
MRSA0810-16 III I t037 ST239 dt13n C12 SM40 
MRSA0810-17 IV I t1378 ST22 dt10a C25 SM81 
MRSA0810-18 III I t421 ST239 dt13d C21 SM17 
MRSA0810-2 III I t037 ST239 dt13g C30 SM17 
MRSA0810-22 IV I t032 ST22 dt10a C35 SM83 
MRSA0810-23 III I t037 ST239 dt13g C13 SM7 
MRSA0810-6 III I t1378 ST22 dt10a C37 SM50 
MRSA0810-7 III I t421 ST239 dt13d C21 SM21 
MRSA0810-9 III I t421 ST239 dt13d C13 SM7 
MRSA0811-10 III I t037 ST239 dt13d C30 SM7 
MRSA0811-11 III I t037 ST239 dt13d C19 SM21 
MRSA0811-13 III I t037 ST239 dt13g C30 SM31 
MRSA0811-16 III I t032 ST22 dt10a C30 SM7 
MRSA0811-2 III I t037 ST239 dt13d C29 SM21 
MRSA0811-22 IV I t032 ST22 dt10a C42 SM76 
MRSA0811-24 III I t037 ST239 dt13g C30 SM7 
MRSA0811-25 III I t037 ST239 dt13g C8 SM9 
MRSA0811-26 III I t037 ST239 dt13g C13 SM7 
MRSA0811-28 III I t037 ST239 dt13g C27 SM7 
MRSA0811-30 IV I t032 ST22 dt10a C34 SM85 
MRSA0811-5 III I t037 ST239 dt9w C30 SM4 
MRSA0811-8 III I t037 ST239 dt10a C13 SM7 
MRSA0812-1 IV I t032 ST22 dt10a C40 SM74 
MRSA0812-11 III I t304 ST6 dt10a C35 SM45 
MRSA0812-15 III I t037 ST239 dt13g C13 SM7 
MRSA0812-17 III I t037 ST239 dt13g C12 SM36 
MRSA0812-2 III I t037 ST239 dt11c C30 SM59 
MRSA0812-22 III I t037 ST239 dt13g C13 SM7 
MRSA0812-23 IV I t032 ST22 dt10a C40 SM74 
MRSA0812-27 III I t037 ST239 dt13g C30 SM7 
MRSA0812-30 III I t2029 ST239 dt12k C13 SM49 
MRSA0812-31 III I t037 ST239 dt13g C30 SM7 
MRSA0812-33 III I t037 ST239 dt10a C36 SM49 
MRSA0812-35 III I t037 ST239 dt13g C30 SM7 
MRSA0812-36 V II t657 ST772 dt10ao C1 SM53 
MRSA0812-37 III I t037 ST239 dt9w C30 SM7 
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4.13 Genomic changes of MRSA based on three different sequence typing 
methods. 
4.13.1 Genomic changes of MRSA based on spa typing 
 Three spa types (i.e. t037, t1544 and t421) were detected in year 2003. Five spa 
types (t032, t4184, t002, t304 and t860) were introduced in UMMC in year 2007 and 
nine spa types (t1378, t6405, t4150, t1107, t458, t4152, t657, t363 and t2029) were only 
found in 2008 strains (Figure 4.26; Table 4.11).  
 t037 was found to be closely related with spa type (t421) with differences in 
only one mutation and both spa types shared the same MLST type ST239, even though 
they were obtained from four years apart. 
 Five spa types (t4184, t032, t1378, t002 and t6405) which were introduced 
between year 2007 and 2008 were related with spa type t037 with differences of five to 
25 mutations (Figure 4.26). spa type t304 was also related with spa t037 with 
differences of nine mutations (Figure 4.26).  
 On the other hand, eight spa types (t4150, t1107, t458, t4152, t657, t860, t2029 
and t363) which were also being introduced in year 2007 to 2008 were related with spa 
type 421 with differences of three to 12 mutations (Figure 4.26). All eight spa types 
which were introduced in year 2007 to 2008 was isolated from tissue, wound swab, 
nasopharyngeal secretions, nasal swab, sputum and tracheal secretions obtained from 
patients who stayed in orthopaedic, paediatric and medical wards. Strain with spa type 
t421 was isolated from nasal swab, blood, wound swabs, tissue, tracheal secretions, 
urine, sputum, pus obtained from patients who stayed in CICU, medical, surgical, ICU, 
dialysis, orthopaedic, dialysis, gynecology and obstetrics.   
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Figure 4.26 Maximum Parsimony Tree derived from spa types of MRSA strains in 
2003-04 and 2007-08 from UMMC, Malaysia. The clustering was performed by using 
the BioNumerics 6.0. The numerals on the line indicate the genetic distance between 
each spa types. The sizes of node indicate the number of strains of each spa types.  
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4.13.2 Genomic changes of MRSA based on MLST 
Two MLST types (i.e. ST20 and ST239) were detected in year 2003. Three 
MLST types (ST5, ST6 and ST22) were introduced in UMMC in year 2007 and five 
MLST types (ST80, ST241, ST573, ST772 and ST1178) were only found in 2008 
strains (Figure 4.27; Table 4.11).  
MLST type ST241 which was present in year 2008 was found to be closely 
related with MLST type ST239 that was present since year 2003. Both MLST types 
shared six similar allele including arcC, aroE, glpF, gmk, pta and tpi. 
Seven other MLST types including ST22, ST573, ST772, ST6, ST5, ST1178 
and ST80 which were introduced between year 2007 and 2008 was found to be related 
with MLST type, ST239 with differences of six to 11 mutations (Figure 4.27). It was 
noted that ST772 which was also SCCmec type V was closely related with ST572 with 
difference of one mutation. 
  ST1178 was found to be related with ST5 (from clonal complex CC5) with 
differences of two mutations (Figure 4.27). ST1178 was introduced in May 2008, 14 
months after ST5 was introduced (Jan, 2007) 
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Figure 4.27 Maximum Parsimony Tree derived from MLST types of MRSA strains in 
2003-04 and 2007-08 from UMMC, Malaysia. The clustering was performed by using 
the BioNumerics 6.0. The numerals on the line indicate the genetic distance between 
each MLST types. The sizes of node indicate the number of strains of each MLST 
types.  
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4.13.3  Genomic changes in MRSA based on mec-associated dru typing 
 Thirteen dru types (i.e. dt9w, dt13i, dt13m, dt13g, dt13d, dt13l, dt15m, dt15l, 
dt14h, dt14c, dt11al, dt10a and dt11c) were detected in year 2003. Two dru types 
(dt13n and dt7v) were introduced in UMMC in year 2004, three dru types (dt10aw, 
dt15n and dt13ao) in year 2007 and 12 dru types (dt11am, dt12k, dt13q, dt13j, dt13p, 
dt13f, dt11an, dt10ax, dt12j, dt7l, dt10ao and dt2c) were only found in 2008 strains 
(Figure 4.28; Table 4.11).   
 dt13d was found to be closely related with eight other dt types (i.e dt13f, dt13ao, 
dt13m, dt13i, dt13g, dt13n, dt13j and dt13p) with differences in only one mutation and 
all nine dru types shared the same MLST type ST239, even though they were obtained 
four years apart. These eight dru types (dt13f, dt13ao, dt13m, dt13i, dt13g, dt13n, dt13j 
and 13p) were closely related to dt13d as there is only one MST distance away from 
dt13d (shared more than 98.5%) similarity.   
 dt10a which consists of strains from three different years (2003, 2007 and 2008) 
belong to five different MLST types, including ST5, ST6, ST22, ST80 and ST239. 
dt10aw was closely related to dt10a with only three mutations differences.  
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Figure 4.28 Maximum Parsimony Tree derived from dru types of MRSA strains in 
2003-04 and 2007-08 from UMMC, Malaysia. The clustering was performed by using 
the BioNumerics 6.0. The numerals on the line indicate the genetic distance between 
each dru types. The sizes of node indicate the number of strains of each dru types.  
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Table 4.11: Summary of MLST, dru and spa types among 188 MRSA strains 
Sequence 
typing 
Year Cluster 
complexes 
Total 
2003 2004 2007 2008 
spa type       
t037 50 8 4 63 SpaCC1 125 
t1544 1 - - - ND 1 
t421 1 1 3 20 SpaCC1 25 
t002 - - 1 - ND 1 
t304 - - 2 2 ND 4 
t4184 - - 1 3 SpaCC2 4 
t032 - - 4 8 SpaCC2 12 
t1378 - - - 3 SpaCC2 3 
t6405 - - - 4 SpaCC1 4 
t4150 - - - 1 ND 1 
t1107 - - - 2 ND 2 
t458 - - - 1 ND 1 
t4152 - - - 1 ND 1 
t657 - - - 1 ND 1 
t2029 - - - 1 SpaCC1 1 
t860 - - 1 - ND 1 
t363 - - - 1 SpaCC1 1 
MLST 
type 
      
ST239 51 9 8 89 CC8 157 
ST20 1 - - - CC20 1 
ST5 - - 1 - CC5 1 
ST6 - - 2 2 CC6 4 
ST22 - - 5 14 CC22 19 
ST772 - - - 1 CC1 1 
ST1178 - - - 2 CC5 2 
ST573 - - - 1 CC1 1 
ST80 - - - 1 CC80 1 
ST241 - - - 1 CC8 1 
dru type     ND  
dt2c - - - 1 ND 1 
dt7l - - - 1 ND 1 
dt7v - 2 - - ND 2 
dt9w 3 - - 2 druCC3 5 
dt10a 3 - 8 21 ND 32 
dt10ao - - - 3 ND 3 
dt10aw - - 1 - ND 1 
dt10ax - - - 2 druCC3 2 
dt11al 4 1 - - druCC4 5 
dt11am - - - 2 ND 2 
dt11an - - - 1 ND 1 
dt11c 1 - - 2 ND 3 
dt12j - - - 1 ND 1 
dt12k - - - 1 ND 1 
dt13d 24 5 4 24 druCC1 57 
dt13g 6   29 druCC1 35 
dt13f    4 druCC1 4 
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Table 4.11 (continued)   
Sequence 
typing 
Year    Cluster 
complexes 
Total 
 2003 2004 2007 2008   
dt13i 1    druCC1 1 
dt13j    5 druCC1 5 
dt13l 2    ND 2 
dt13m 2    druCC1 2 
dt13n  1  4 druCC1 5 
dt13ao   2 1 druCC1 3 
dt13p    1 druCC1 1 
dt13q    3 druCC4 3 
dt14c 3   3 ND 6 
dt14h 1    ND 1 
dt15l 1    druCC2 1 
dt15m 1    druCC2 1 
dt15n   1  druCC2 1 
 
 
4.13.4 Clonal evolution of Malaysian MRSA from year 2003, 2004, 2007 and 2008  
Although MRSA clone ST239 remained as the predominant clone in UMMC 
over the years (51/52 in year 2003 and 89/111 in year 2008), the combined analysis by 
MLST-spa types showed genotypic changes of MRSA clones ST239-t037 and ST239-
t421 between year 2003 and 2008 where (i) the predominant ST239-t037 clone in year 
2003 (96%) has decreased in year 2008 (56.8%) while (ii) the ST239-t421 (1.9% in year 
2003) has increased in year 2008 (18.0%). It is observed that ST239-t421 clone (from 
year 2003) that was from ICU might have spread to other wards; i.e medical, dialysis, 
surgical and orthopaedic in year 2008. Both ST239-t037 and ST239-t421 clones cover 
98.0% of strains from year 2003 and 79.8% of strains from year 2008.   
Four new MLST-spa clones (ST22-t032, ST5-t002, ST6-t304, ST22-t4184) 
were introduced in year 2007 and another four MLST-spa clones (ST241-t363, ST80-
t037, ST573-t1378) in year 2008. All four MLST-spa clones which were introduced in 
year 2007 was cultured from medical and surgical wards whereas newly introduced 
clones in year 2008 was cultured from orthopaedic, dialysis and medical wards.  
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Further combined analysis by MLST-spa-dru can increase the discriminatory 
power in subtyping of the MRSA strains. Forty-seven different MRSA clones were 
present in UMMC over the study period (2003, 2004, 2007 and 2008) where (i) ST239-
t037-dt13d clone in year 2003 (44.2%) and decreased in year 2008 (13.5%), (ii) ST239-
t037-dt14h, ST239-t037-dt13i, ST239-t037-dt13l, ST239-t037-dt13m, ST239-t037-
dt15l, ST239-t037-dt15m, ST20-t1544-dt14c clones that only present in year 2003 
(17.4%), (iii) ST239-t421-dt13d introduced in year 2003 and slightly increased in year 
2008 (7.2%), (iv) the ST239-t037-dt13g clone in year 2003 (11.5%) that were culture 
from orthopaedic and ICU wards had spread to six others wards including orthopaedic, 
ICU, surgical, medical, cardiac care unit and pediatric and become more dominant in 
year 2008 (23.4%), (v) ST22-t032-dt10a, ST22-t4184-dt10a, ST6-t304-dt10a, ST239-
t037-dt13ao clones introduced in year 2007 and existed at low prevalence in year 2008, 
(vi) ST239-t037-dt13n and ST239-t037-dt7v clones introduced in year 2004 (vii) ST5-
t002-dt10a, ST22-t4184-dt10a, ST239-t860-dt13d, ST239-t037-dt15n, ST22-t032-
dt10aw and ST239-t421-dt13ao clones introduced in year 2007 and (viii) 23 new clones 
introduced in year 2008 and they were cultured from five different wards including 
dialysis, medical, orthopaedic, surgical and ICU (Figure 4.29).   
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Figure 4.29 Distribution of different MLST-spa-dru types of MRSA strains from year 
2003, 2004, 2007 and 2008 in the UMMC, Kuala Lumpur, Malaysia.  
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CHAPTER 5 
DISCUSSION 
 
5.1 Antibiograms of MRSA strains from a Malaysian hospital 
Infections caused by MRSA continue to be a problem in Malaysian hospitals. 
Although several studies have documented the antimicrobial resistance trends of MRSA 
in other countries (Udo et al., 2006; Klein et al., 2007), reports comparing resistance 
trends between two periods of time in Malaysia are scanty. This study shows the 
antimicrobial resistance trends of MRSA isolated in UMMC between year 2003 to 2004 
and 2007 to 2008.   
 All the 188 MRSA strains obtained from UMMC remain susceptible to 
vancomycin. This is concordant with previous reports (Rohani et al., 2000; Neela et al., 
2008; Al-Talib et al., 2010) from Malaysia. This information is relevant and important 
as vancomycin is known to be one of the few remaining antibiotics left for the treatment 
of MRSA infections (Ahmad et al., 2010).  
Elsewhere, vancomycin-resistant S. aureus (VRSA) has been reported in-
hospital settings in Japan (Hiramatsu, 2001) and India (Saha et al., 2008). Similarly, 
presence of MRSA strains with reduced susceptibility to vancomycin and vancomycin-
intermediate S. aureus (VISA) have also been reported in other Asia countries such as 
Thailand (Trakulsomboon et al., 2001), Singapore (Fong et al., 2009), Japan (Song et 
al., 2004), Korea (Kim et al., 2000), Vietnam (Song et al., 2004), Taiwan (Hsueh et al., 
2010) and Philippines (Song et al., 2004).   
Although MRSA strains in Malaysia are still susceptible to vancomycin, report 
on vancomycin treatment failure in vancomycin-susceptible MRSA strains has been 
reported in Malaysia (Norazah et al., 2009). Furthermore, Ahmad et al. (2010) also 
reported of an increase of vancomycin MIC values among MRSA strains in Malaysia. 
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Therefore, the use of vancomycin for treatment of MRSA should be treated with 
cautions in order to avoid the emergence of VISA or VRSA in Malaysia and to 
minimize the occurrence of treatment failure.  
 On the other hand, Neela et al. (2008) reported that linezolid and teicoplanin 
were highly effective against MRSA infection, and in this study a majority of the 
MRSA strains remained sensitive to both linezolid and teicoplanin. Linezolid is known 
to be effective against MRSA strains with reduced susceptibility to vancomycin 
(Yanagihara et al., 2002). As teicoplanin is one of the glycopeptides antibiotics 
(Matthews et al., 2007), it is not suitable to be used to treat MRSA infectious with 
decreased susceptibility of vancomycin.   
The rifampicin-resistance rate for MRSA was lower than the 5% rate previously 
reported by Norazah et al. (2002), 15.6% (5 out of 32 MRSA isolates) by Neela et al. 
(2008) and 12.1% from the 2008 Malaysian National Surveillance on Antibiotic 
Resistance Report (Ministry of Health Malaysia, 2008). Similarly, MRSA rifampicin-
resistance rate in Malaysia (12.1% reported in 2008 Malaysian National Surveillance of 
Antibiotic Resistance Report) is relatively lower when compared to earlier studies 
reported in South Africa between year 2001-2003 (Shittu and Lin, 2006) and Italy 
between year 2000-2007 (Campanile et al., 2009). The low rifampicin resistance rate 
reported in UMMC might possibility due to limited usage of this drug in the hospital. 
Furthermore, rifampicin is often used along with fusidic acid or vancomycin and 
gentamicin or cloxacillin and gentamicin to treat infections due to MRSA in order to 
minimize the development of rifampicin-resistant MRSA (Norazah et al., 2002; 
National Antibiotic Report Malaysia, 2008).   
Tetracycline-resistant MRSA had significantly increased over the six-year 
periods (P < 0.01), possibility because of an increased usage of tetracycline or 
doxycyline in the hospital (unpublished hospital records). Thong et al. (2009) reported 
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tetracycline-resistance rate of MRSA at 32% in year 2003. The increase in tetracycline-
resistance rate has also been reported in another Malaysian hospital (Neela et al., 2008).  
There was a significant increase in resistance rates towards trimethoprim-
sulfamethoxazole from year 2003 to 2008. This was probably due to an increased usage 
of trimethoprim-sulfamethoxazole in the hospital (unpublished hospital records). 
Similar high resistance rates of trimethoprim-sulfamethoxazole were reported by Neela 
et al. (2008) (75%) and Thong et al. (2009) (73%).  
There was a sharp increase in netilmicin-resistance rates between year 2003 and 
2008. Thong et al. (2009) reported an increase in netilmicin-resistance rate from 16% in 
2003 to 41% in year 2004. However, netilmicin-resistance rates (42%) noted in this 
study was lower when compared to the 68.7% from year 2006 - 2007 reported by Neela 
et al. (2008).   
The resistance rates of clindamycin had increased slightly from 94% (in year 
2003) to 96% (in year 2008) over six years. This was much higher than that previously 
reported in Malaysia by Neela et al. (2008) (0%), Ahmad et al. (2009) (0%) and Al-
Talib et al. (2010) (6%). Similarly, the mupirocin-resistance rate was relatively higher 
than 1.25% reported in Malaysia (Norazah et al., 2001) and 2% reported in United 
States (Wolk et al., 2009). Although the mupirocin-resistance rate in UMMC had 
increased (5% in year 2008) over the years, this antibiotic is still of limited use in 
UMMC as it is only recommended for outpatients and not for in-patients (Lim et al., 
2010). This antibiotic was also being used for the treatment of MRSA colonization in 
medical staff for a period of five days and then re-tested on the seventh day to ensure 
clearance of MRSA (Lim et al., 2010).   
On the other hand, the rates of resistance to erythromycin reported in this study 
remained high (96%) in year 2003 and 2008. This is concordant with previously 
reported erythromycin-resistance rates from 81.2 - 96.0% (Neela et al., 2008; Ahmad et 
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al., 2009; Thong et al., 2009). Sam et al. (2008) reported that MRSA from UMMC is 
often resistant to erythromycin, gentamicin and ciprofloxacin. Similar observation was 
reported here as most of the MRSA strains isolated from year 2003, 2004, 2007 and 
2008 from UMMC were also resistant to erythromycin, gentamicin and ciprofloxacin.   
 Besides, the significant increase of high-level tetracycline (MIC (≥ 256 µg/ml) 
and erythromycin (MIC (≥ 128 µg/ml) resistant strains between year 2003 and 2008 
along with the co-resistance between erythromycin, ciprofloxacin and tetracycline is 
worrisome because choices of antimicrobial agents for treatment of life-threatening 
cases will be limited as use of tetracycline, ciprofloxacin and erythromycin is still 
common in Malaysian hospitals for treatment of respiratory tract and other nosocomial 
infections (National Antibiotic Guideline Malaysia, 2008).    
Both inducible and constitutive macrolide, lincosamide and streptogramin 
(MLSB) phenotypes were observed among erythromycin-resistant strains with the 
majority (96%) showing inducible macrolide, lincosamide and streptogramin (i-MLSB) 
phenotype. The prevalence of i-MLSB isolates (92%) was much higher when compared 
to 63% reported in Korea (in 2004) (Lim et al., 2006).   
 
 
5.2 β-lactam, mupirocin, gentamicin, vancomycin, linezolid, erythromycin, 
tetracycline and fusidic acid resistance genotypes in MRSA strains 
Genotypic detection of β-lactam resistance genes indicated that all MRSA 
harboured blaZ gene. This is not surprising as penicillin resistance is due to the 
production of β-lactamases, which is encoded by blaZ gene (Olsen et al., 2006; Vali et 
al., 2008). A similar result was reported by Vali et al. (2008) as 97.5% (n=117) where 
their MRSA strains also harboured the blaZ gene.         
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On the other hand, genotypic detection of resistance genes also pointed out that 
erythromycin, tetracycline, gentamicin and mupirocin resistance were always attributed 
to the presence of resistance genes. The most prevalent resistance gene reported in 
erythromycin-resistant strains was ermA (85%) followed by ermC (21%) and msrA 
(2%). Similar observation was reported by Sekiguchi et al. (2004) where all their 
erythromycin-resistant strains harboured ermA gene. However, this differs from the 
report by Spiliopoulou et al. (2004) and Schmitz et al. (2000) where most of their 
erythromycin-resistant strains harboured ermC gene. In addition, the presence of 
different erythromycin resistance genes (ermA, ermC and msrA) were not directly 
related to higher MIC values (based on Kruskal-Wallis test). For example, 31% of 
erythromycin-resistant strains that harboured ermA or ermC gene was associated with 
MIC 8 - 64 µg/ml. This is concordant with the previous report by Sekiguchi et al. 
(2004) as all their ermA-positive strains were associated with low-level of erythromycin 
resistance (MIC > 4 µg/ml). Chavez-Bueno et al. (2005) reported that all the non-
inducible MRSA strains harboured msrA gene, and a similar observation was reported 
here as all four msrA-positive strains showed negative results in the D-zone test 
(indication of non-inducible MRSA strains.    
A majority of tetracycline-resistant strains harboured tetM (97%) followed by 
tetK (41%) gene. This is in-contrast to reports by Jones et al. (2006) and El-Mahdy et 
al. (2010) where tetK gene was the predominant gene in tetracycline-resistant strains. 
Spearman's rank correlation tests showed that a strain which harboured tetK gene also 
harboured tetM gene. This is in agreement with Schmitz et al. (2001) as their MRSA 
strain also harbours both tetK and tetM. Schmitz et al. (2001) also reported that strains 
with both tetK and tetM genes often display higher MIC values than strains containing a 
single gene. In contrast, this study showed the combination of tetK and tetM genes did 
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not display higher MIC values as over 78% of the strains that harboured both tetK and 
tetM together were associated with MIC value of 16 - 64 µg/ml. 
All ten mupirocin-resistant strains harboured ileS2 gene with two MRSA strains 
(MRSA0406-8 and MRSA0801-27) that display higher MIC of 256 µg/ml harboured 
additional mupA gene. This is in-contrast with the earlier reports by Yun et al. (2003) 
and Perez-Roth et al. (2006) which showed that presence of ileS2 gene was associated 
with high-level mupirocin resistance. The association of ileS2 gene with low mupirocin-
resistance in UMMC strains could possibly due to lack of ileS2 gene expression among 
the bacterial colonies as similar observation have been reported earlier by Anthony et al. 
(1999).   
aac(6’)-aph(2”) gene that encodes for enzyme AAC(6‟)/APH(2”) which 
inactivates a broad range of aminoglycoside, including gentamicin and netilmicin 
(Rouch et al., 1987; Hodel-Christian et al., 1991; Martineau et al., 2000;) was detected 
among all gentamicin- and netilmicin-resistant strains in this study. This showed a 
correlation between the presence of aac(6’)-aph(2”) gene with gentamicin-resistance, 
and similar observation was also being reported by Martineau et al. (2000).     
No glycopeptides (vancomycin and teicoplanin) and linezolid resistance genes 
were detected in any of the MRSA strains. The absence of genes encoding for 
glycopeptides and linezolid resistance is important as these antimicrobial agents are the 
drug of choice to treat patients with MRSA infections (National Antibiotic Guideline 
Malaysia, 2008).  
Although fusidic acid resistance is often associated with the presence of 
acquired-fusidic acid resistance genes (fusB, fusC or fusD) or mutation in fusA gene 
(Lannergard et al., 2009), no fusB, fusC or fusD gene was detected among fusidic acid-
resistant strains in this study despite repeated experiments were carried out by using 
three different sets of published primers. Absence of fusB and fusC genes among fusidic 
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acid-resistant strain is uncommon as previous reports in Taiwan showed that 73.5% of 
fusidic acid-resistant strains harboured fusC gene (Chen et al., 2011) and more than 
10% of fusidic acid resistant-strains in 13 European countries harboured either fusB or 
fusC gene (Castanheira et al., 2010b). Fusidic acid-resistant strains reported in this 
study might be different from those in different countries as none of these strains 
harboured fusB, fusC or fusD gene. The reduced-susceptibility of fusidic acid in UMMC 
could be due to mutational change in fusA or fusE genes.  
 
 
5.3 Detection of tetracycline and gentamicin transposon-associated genes  
 Tn5801-like integrase was detected in majority (85%) of the tetM-positive 
strains suggesting that tetM gene is located on Tn5801-like conjugative transposons. 
The other tetM gene (15%) could be located on other transposon such as Tn1545. 
Association between tetM gene and Tn1545 has been reported in other gram positive 
bacterium including Listeria monocytogenes, Enterococcus sp and Streptococcus 
pneumoniae (Bertrand et al., 2005; Agerso et al., 2006; Varaldo et al., 2009). In 
addition, Doucet-populaire et al. (1991) have indicated the transfer of conjugative 
transposon Tn1545 from E. faecalis to L. monocytogenes.  
  Although Chow et al. (2007) reported that high-level gentamicin resistance is 
mediated by a Tn4001-like transposon, none of the gentamicin-resistant strains from 
this study harboured Tn4001-like transposon. The gentamicin-resistant strains from 
UMMC could be mediated by other transposons such as Tn5281. This Tn5281 
transposon is known as the main distributor of aac(6’)-aph(2”) gene among E. faecalis 
strains in Tehran hospitals (Feizabadi et al., 2008).  
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5.4 Transferability of erythromycin and tetracycline resistance determinants 
by transformation 
 Transformation experiments were carried out to determine if erythromycin and 
tetracycline phenotype could be transmissible to other S. aureus strains. The recipient 
strain used in this study was S. aureus ATCC29213, which harboured blaZ gene 
(resistant to penicillin).   
 The result from transformation experiments yielded success in six out of 30 
MRSA strains where only erythromycin-resistance phenotype was transferable, and no 
tetracycline-resistance phenotype was transferred. Further analysis showed that only 
ermC was transmissible.  
Although Monecke et al. (2009) reported that tetK gene was plasmid-borne and 
transmissible; none of the tetK gene was transferable in this study. Similarly, no tetM 
gene was transferable. Discrepancy observed might be due to the inherent property of 
the recipient S. aureus ATCC29213 as Schenk and Laddaga (1992) reported that this 
strain ATCC29213 has lower transformation efficiency when compared to another 
recipient strain, RN4220.     
  Size of plasmid carrying ermC gene reported in this study was similar to the 
plasmid size (2.5 kb) reported by Westh et al. (1995). Based on the EcoR1 restriction 
profiles obtained, size of plasmids that were isolated from the transformants (~ 1.1 – 
18.5 kB) was slightly smaller than its donor (~ 1.4 – 18.5 kB). This was because the 
donor strains harboured more than a single type of plasmids.     
 
 
5.5  Mutations analysis of rpoB (rifampicin) and fusA (fusidic acid) resistance 
determinants 
 All rifampicin and fusidic acid-resistant strains were subjected for mutational 
analysis. The mutation identification and analysis of the rifampicin resistance was based 
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on the published cluster I (amino acid number 462 – 488) and II (amino acid number 
515 – 530) of rpoB gene (Mick et al., 2010) whereas mutation analysis of fusidic acid 
resistance was based on fusA and fusE genes (Castanheira et al., 2010a, b). 
Wichelhaus et al. (2002) reported that the presence of mutational change 
484Arg/His or 477Ala/Asp in rpoB gene is capable of conferring high-level rifampicin 
resistance (MIC 256 µg/ml). However, in this study, the presence of the same 
mutational change was associated with MIC of 4 - 8 µg/ml. Mutational change 
517Glu/Gln in five Malaysian MRSA strains with MIC 8 µg/ml is new and has not been 
reported elsewhere. Although Wichelhaus et al. (2002) reported that double mutations 
in rpoB gene can cause high resistance in rifampicin, this study showed that the double 
mutations in rpoB gene of five MRSA strains resulted in rifampicin resistance at MIC 8 
µg/ml.         
This study indicated that different types of mutations in fusA gene were 
associated with different levels of resistance (based on Kruskal-Wallis Test) in fusidic 
acid. For example, seven MRSA strains with high-level fusidic acid-resistance (MIC 
256 µg/ml) were associated with mutational change 461Leu/Lys in fusA gene while 
non-synonymous change 461Leu/Ser in fusA gene confers to low-level resistance (MIC 
4-8 µg/ml). Besier et al. (2003) and Canstanheira et al. (2010b) also showed that 
substitution of 461Leu/Lys in fusA gene is often linked to higher fusidic acid resistance 
(MIC 256 µg/ml) when compared to other alterations (461Leu/Ser) at the same amino 
acid 461‟. 
 Besier et al. (2005) reported that mutation change 67Ala/Thr in fusA gene did 
not contribute to fusidic acid resistance, and that mutational change 67Ala/Thr is unable 
to compensate for the fitness loss due to resistance-mediating amino acid. However in 
this study, the presence of similar mutational change (67Ala/Thr) in fusA gene was 
associated with MIC values from 64 to 96 µg/ml.  
151 
 
 One strain (MRSA0812-33) which had high-level resistance to fusidic acid 
(MIC 256µg/ml) has multiple mutations at 461Leu/Lys, 596Cys/Trp, 602Glu/Lys and 
317Met/Trp. The role of three novels mutational change (317Met/Trp, 596Cys/Trp and 
602Glu/Lys) remain unknown as mutational change 461Leu/Lys itself is associated 
with high-level of fusidic acid resistance. 
The absence of fusE mutation is not surprising as this mutational change in fusE 
gene is rare and was only reported in one strain from Ireland (Castanheira et al., 2010b).   
Three fusidic acid-resistant strains (MRSA0302-4, MRSA0312-35 and 
MRSA0805-1) that were tested negative for the presence of acquired fusidic acid 
resistance genes that is fusB, fusC and fusD also showed no mutation in fusA and fusE 
genes. Similar observation was reported by Castanheira et al. (2010a) as mutational 
change was only seen in one out of five U.S isolates that did not carry acquired fusidic 
acid resistance genes.  
Spearman's rank correlation tests showed that rifampicin-resistant strains were 
mostly sensitive to fusidic acid. This is in agreement with Chen et al. (2011)
 
where 
majority of their fusidic acid resistant-strains were sensitive to rifampicin (MIC 0.5 
µg/ml). This is important as combination therapy of rifampicin and fusidic acid with or 
without linezolid are used to treat patients with serious infections caused by MRSA with 
reduced vancomycin susceptibility (Howden et al., 2004).   
 
 
5.6 Biofilm formation phenotype by congo red agar (CRA) 
One hundred forty-three MRSA strains were categorized as biofilm formation 
bacteria using congo red agar (CRA) methods designed by Freeman et al. (1989). 
Detection of biofilm formation bacteria based on phenotypic method is important as 
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formation of biofilm itself is an example of the phenotypic changes in S. aureus (Khan 
et al., 2011). 
The present study showed that invasive MRSA strains (80%) are often 
associated with biofilm formation when compared to colonization MRSA strains (75%). 
This is a cause of concern as the ability of S.aureus to form biofilm played an essential 
role in the virulence of the bacterium leading to the development of device-related 
infections (El-Din et al., 2011).   
There is no correlation between biofilm formation and antimicrobial resistance 
(P > 0.05).  
 
 
5.7 Virulence genes determinants by PCR 
 In this study, the majority of the strains were positive for the adhesion genes 
such as extracellular fibrinogen binding protein (efb) (96%), fibrinogen binding protein 
(fnbA) (96%), intracellular adhesion (ica) (78%) while hemolysin (hlg) and putative 
adhesin (sdrE) were amplified in 59% and 27%, respectively. Further analysis by using 
Spearman‟s rank correlation showed that all efb positive strains were tested positive for 
fnbA gene. Similarly, correlation between hlg and ica gene was observed. This is 
important as both efb and fnb genes are involved in the adherence of S. aureus strains to 
the host tissue (Ferry et al., 2005). ica gene is involved in the biofilm formation 
whereas hlg  promotes host cell lysis, which results in injury of the alveolar-capillary 
barrier in the host cell (Ferry et al., 2005). 
Overall, 54% of the MRSA strains harboured at least one type of enterotoxins 
(SEs) gene. The percentage of 2007 and 2008 strains harbouring SEs (62%) were higher 
when compared to 2003 and 2004 strains (36%) but lower when compared to a study 
done by Ghaznavi-Rad et al. (2010). The increase in the number of strains bearing SEs 
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genes could be caused by horizontal gene transfer between the strains as SEs genes are 
known to be carried by mobile genetic elements such as plasmids, pathogenicity islands, 
SCCmec and prophages (Hu et al., 2008). This is a cause for concern as SEs genes are 
often associated with food borne poisoning, toxin shock syndrome and other toxin 
mediated disease (Ferry et al., 2005; Ortega et al., 2010).     
sea gene was the most common SEs gene present among the MRSA strains 
(31% of 2003 to 2004 strains and 43% of 2007 to 2008 strains). This concurred with the 
reports by Ghaznavi-Rad et al. (2010) in another tertiary hospital in Kuala Lumpur and 
Pourmand et al. (2009) in Tehran, Iran. However, this differed from the report by Sauer 
et al. (2008) as MRSA harbouring seg and sej genes was common in a University 
Hospital located in Czech Republic. In this study, 39% of MRSA strains isolated from 
invasive samples (tissue, wound, pus, blood and bone) and lower respiratory samples 
(tracheal secretion, nasopharyngeal secretion and sputum) were tested positive for sea 
gene. The incidence of sea (39%) and sec (19%) genes detected in this study was much 
higher than the result reported by Sauer et al. (2008). The frequency of sea gene 
reported in this study was also higher than 36.5% reported by Ghasemzadeh-
Moghaddam et al. (2011). Similarly, the frequency of sea (30%) and sec (16%) gene 
obtained from nasal swabs was also higher when compared to study reported by Collery 
et al. (2008). However, it is lower when compared to study reported by Wang et al. 
(2010) where they showed that strains bearing sea were found to be associated with 
lower respiratory infections. Hu et al. (2008) indicated that sec and tst genes were 
associated with mobile genetic element type I vSa4. This study shows that the presence 
of sea gene was mainly associated with infections such as bloodstream infections, soft-
tissue infections, bone infections and lower respiratory infections.         
Although both seg and sei genes are located in the same operon, only one strain 
(MRSA0805-10) harboured sec, seg and sei genes. Similarly, the Spearman correlation 
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test showed that strains with seg gene most likely do not harbour sei gene (R= -0.923, P 
< 0.05). This concurred with the result reported by Collery et al. (2008). However, it 
differs from the observation shown by Sauer et al. (2008) where they indicated that seg 
virulence determinant was always associated with the sei gene.  
Exfoliative toxin (encoded by etd) that can cause an inflammatory response of 
the skin was detected in MRSA0806-13 strain, and this strain belonged to agr type III. 
In contrast to the finding of Ghasemzadeh-Moghaddam et al. (2011) on SEB and ETA 
production among Malaysian S. aureus strains, no strain in this study possessed eta, etb 
and seb genes. Both eta and etb are important for superficial skin infections such as 
bullous impetigo (Mertz et al., 2007) whereas seb gene is often associated with food 
poisoning (Ferry et al. 2005; Ortega et al. 2010).   
In this study, the number of MRSA strains (27%) harbouring sdrE genes was 
lower than the 89.5% reported in Netherland by Sabat et al. (2006). This is not 
surprising as the strains might harbour other sdr genes such as sdrC or sdrD. Eighteen 
invasive (22%) strains harboured sdrE gene. This is lower than the 56% reported earlier 
by Peacock et al. (2002). Although Sabat et al. (2006) reported that the absence of sdrE 
and sdrD gene in S. aureus will result in decreased potential in infecting bone, the result 
from this study showed that indigenous S. aureus in this tertiary hospital can cause bone 
infections even without the presence of sdrE gene. This infection could have involved 
other alleles of the sdr gene.  
Fifty (27%) invasive strains were found to harbour hemolysin gene (hlg). This is 
not surprising as the previous report by Peacock et al. (2002) indicated that virulence 
factors such as fnbA, cna, sdrE, hlg, sej, eta and ica were significantly more common in 
invasive strains, and they contributed independently to virulence.         
Fifty four (29%) of the invasive strains (blood, bone, pus, wound and tissue) 
were tested positive for ica gene. This ica gene plays an important role in the biofilm 
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formation (Martin-Lopez et al., 2002). Significance increase in the occurrence of ica, 
sec and sei genes among 2008 strains when compared to 2003 strains was observed. 
Furthermore, Spearman's rank correlation tests also showed that MRSA strains with ica 
and hlg genes showed a higher virulence potential as these strains also harboured SEs, 
exfoliative toxin and tst gene. This is a cause for concern as the biofilm associated 
bacteria is normally resistant to host immune systems and antimicrobial, and the 
presence of SEs will further weaken the host immune systems (Plata et al., 2009). SEs 
is associated with food poisoning whereas tst is the gene responsible for the toxic shock 
syndrome (Plata et al., 2009). The presence of ica and SEs genes will often complicate 
treatment. 
  There is no correlation (P > 0.05) between toxin genes profiles with 
antimicrobial resistance as strains with identical virulotypes frequently harboured 
different types of resistance genes.  
 
5.8 Distribution of pvl genotypes among Malaysian MRSA strains 
PVL toxin (encoded by pvl gene) that causes necrotic suppurative skin lesions 
(Hussain et al., 2007) was detected in five MRSA strains (2 in year 2007 and 3 in year 
2008) cultured from wounds, tissue, tracheal secretion and nasal swabs. Among the five 
PVL positive strains, three were from invasive strains whereas two were from 
colonization strains. The prevalence of pvl gene among MRSA strains in this tertiary 
hospital (2.9% of invasive strains and 2.4% of colonization strains) were lower than 5% 
of invasive strains and 4.5% of carriage strains reported by Neela et al. (2008). 
However, the prevalence of pvl gene reported in this study was higher than 2% rate 
reported in ICU of 14 medial centres (2 University Hospital and 12 referral hospitals) 
located in The Netherland (Rijnders et al., 2009).  
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5.9 Distribution of agr types among Malaysian MRSA strains  
In this study, the majority of the strains were of agr type I. This is consistent 
with previous reports by Peerayeh et al. (2009) and Ghasemzadeh-Moghaddam et al. 
(2011). Although Collery et al. (2008) reported that strains possessing tst gene are often 
associated with agr type III, only tst positive strain (MRSA0802-19) was associated 
with agr type I.   
Both MRSA strains (MRSA0701-15 and MRSA0806-14) that were associated 
with agr type II harboured seg gene, and this differed from the result reported by Afroz 
et al. (2008) as their agr type II-MRSA strains harboured pvl gene.   
 Afroz et al. (2008) indicated that pvl positive strains were grouped into agr type 
II or III, however all the pvl positive MRSA strains in this study were associated with 
agr type I.  
 
 
5.10 Distribution of SCCmec types among Malaysian MRSA strains  
 The predominant SCCmec type in this study was SCCmec type III (87%), and 
this SCCmec type III is also common in other Malaysian hospitals (Ahmad et al., 2009; 
Ghaznavi-Rad et al., 2010) as well as in other Asia countries, including Singapore, 
Thailand, Indonesia and Taiwan (Chongtrakool et al., 2006; Wang et al., 2007). In 
contrast, the predominant SCCmec types in Korea and Japan was SCCmec type II (Ko 
et al., 2005; Chongtrakool et al., 2006). The presence of different predominant SCCmec 
type in Malaysia when compared to Korea and Japan could possibly due to the presence 
of different endemic MRSA clones in these countries. The predominant MRSA clone in 
Malaysia was associated with SCCmec type III (ST239-III-t037) while the predominant 
MRSA clone in Korea and Japan was associated with SCCmec type II (ST5-II-t002) 
(Ghaznavi-Rad et al., 2010; Song et al., 2011). 
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All the 25 SCCmec type IV strains in this study were associated with HA-
MRSA. Similar observation was reported in Malaysia by Ahmad et al. (2009) as 11 out 
of 20 SCCmec type IV MRSA strains were associated with HA-MRSA. The presence of 
SCCmec type IV HA-MRSA has also been previously reported in Denmark (Faria et al., 
2005).  
Besides, all SCCmec type IV isolates were susceptible to rifampicin, mupirocin, 
teicoplanin and vancomycin. This is in agreement with a previous report by Ahmad et 
al. (2009) that SCCmec type IV isolates are susceptible to four or more non β-lactam 
antibiotics. Similarly, D‟Souza et al. (2010) also reported that 83% of their SCCmec 
type IV strains from India were susceptible to many classes of antimicrobials agents. 
Six out of 25 ST22 SCCmec type IV MRSA strains reported here were resistant to 
gentamicin. This differs from reports of Ahmad et al. (2009) (Malaysia) and Conceição 
et al. (2010) (Atlantic Azores island) where the ST22 strains were sensitive to 
gentamicin and tetracycline.     
 
 
5.11 Genomic Diversity of MRSA based on PCR-RFLP of coa, PFGE, spa, 
MLST and mec-associated dru types 
 Genotyping by PCR-RFLP of coa gene using AluI enzyme and PFGE using 
SmaI enzyme showed that most of the MRSA strains were genetically related (shared 
more than 80% similarity) although they were cultured from different sources and 
different time periods. This is because all the MRSA strains used in this study were 
isolated from the same hospital, UMMC in a different time period (year 2003, 2004, 
2007 and 2008). Norazah et al. (2003) reported that a majority of the MRSA strains 
isolated from eight tertiary hospitals in Malaysia from year 1997 until 1999 were 
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associated with three major PFGE patterns, indicating that a few predominant MRSA 
clones were circulating in Malaysian hospitals.  
 Four strains (MRSA0312-35, MRSA0803-29, MRSA0707-26 and MRSA0802-
14) could not be typed by coa-RFLP typing despite, repeated attempts. Similar 
observation was reported by Sanjiv et al. (2008) as one out of 21 S. aureus strains 
studied did not produce any coa gene. Identical profiles were obtained in separate 
experiments using the same set of strains indicating that this subtyping method is 
reproducible. 
 Some of the MRSA strains (MRSA0305-10, MRSA0703-8, MRSA0801-9, 
MRSA0805-4, MRSA0808-19, MRSA0809-25, MRSA0811-10, MRSA0811-16, 
MRSA0811-24, MRSA0812-27, MRSA0812-31, MRSA0812-35 and MRSA0812-37) 
obtained from year 2003 and 2007 also shared similar coa-RFLP pattern (C13) and 
PFGE profile (SM7) with MRSA strains obtained from year 2008. This indicates the 
persistence of particular coa-RFLP and PFGE profiles in UMMC.  
Some MRSA strains which were clonally related by PFGE (shared more than 
80% similarity) harboured different types of enterotoxin genes. Similarly, some of the 
MRSA strains which were clonally related by coa-RFLP (shared more than 80% 
similarity) were also harboured different types of enterotoxin genes. This indicated that 
MRSA strains are able to acquire or lose enterotoxin genes as these genes are likely 
located on mobile genetic elements such as pathogenicity islands, plasmids and 
prophages (Hu et al., 2008).                
 Most of the PFGE clonally related strains (shared more than 80% similarity) 
shared very similar resistotypes. For example; all the strains from Cluster 1 of PFGE 
were resistant to erythromycin and gentamicin. Thirty-nine out of 48 MRSA strains 
from this Cluster 1 were resistant to ciprofloxacin, and 32 MRSA strains were also 
resistant to tetracycline and trimethoprim-sulfamethoxazole. In another example, all five 
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MRSA strains from Cluster 5 were resistant to oxacillin with one MRSA strain 
(MRSA0312-13) also resistant to erythromycin and gentamicin. This suggests that 
several clones (bacterial isolates that have been cultured independently from different 
time and sources but shared similar pulsed-field profiles) (van Belkum et al., 2007) of 
MRSA strains were circulating in this tertiary hospital during the study period. Some 
other MRSA strains from year 2007 and 2008 (MRSA0703-8, MRSA0805-21, 
MRSA0805-4, MRSA0812-22, MRSA0812-31 and MRSA0812-37) also shared similar 
resistotypes (resistant to oxacillin, erythromycin, gentamicin, ciprofloxacin, 
tetracycline, netilmicin and trimethoprim-sulfamethoxazole) as well as PFGE profiles 
(SM7) and this further implies the persistence of this clone within the hospital 
environment. MRSA strains with PFGE profile SM17 which were cultured from year 
2003 and 2008 but from different wards further supports the notion of the circulation of 
a particular clone in the hospital.   
  Although PCR-RFLP of coa gene has been described as an excellent tool for 
rapid, reliable and in-expensive subtyping method for MRSA during outbreak and 
known to provide a reasonable result for subtyping of epidemiological un-related strains 
(Stranden et al., 2003; Himabindu et al., 2009), PFGE was found to be more 
discriminative than PCR-RFLP of coa gene in subtyping Malaysian MRSA strains. 
PFGE can differentiate strains, which are indistinguishable by PCR-RFLP of coa gene. 
In addition, PFGE showed higher reproducibility rate than PCR-RFLP of coa gene and 
able to subtype strains, which cannot by type by PCR-RFLP of coa gene. 
Further analysis was carried out by using sequence based-typing such as spa 
typing, MLST and mec-associated dru typing. The cluster analysis based on spa types 
showed that most of the MRSA strains (98.5%) were closely related, grouped in spa 
CC1 and they shared the same spa-repeat succession (02-25-17) while cluster analysis 
160 
 
based on dru types indicated that over 60.1% of the MRSA strains studied were closely 
related with two dru types, dt13d and dt13g being the predominant clones.  
 Both spa and dru typing results concurred with the result from PCR-RFLP of 
coa gene as majority of the MRSA strains which were clonally related (share more than 
80% similarity) were from spa types t037 and t421 and dru types within the druCC1. 
Similarly, majority of the MRSA which were found to be clonally related by PFGE 
were also from spa type t037, t421, t6405, t363 and t2029 and dru types dt13d, dt13g, 
dt13n, dt13j, dt13ao, dt13p, dt13m, dt13f, dt13i.  
 In addition, 15 SCCmec type IV strains (with PFGE profiles SM73 - SM78 and 
ST80 - SM85) which were grouped to together with 73.4% similarity in PFGE were 
closely related by spa typing (shared 98.5% similarity) as they were from spa types 
t032, t1378 and t4184 and dru type dt10a. However, these 15 strains only shared 40.4% 
similarity in PCR-RFLP of coa gene with coa-RFLP profiles C3, C25, C33 to C36 and 
C40 to C43. This indicates that PFGE is an useful subtyping tool for determining 
SCCmec type IV strains. 
 Over 66.5% of the strains studied were of spa type t037, and it was present in 
year 2003, 2004, 2007 and 2008. This implies the persistence of these spa types within 
the hospital environment. In addition, Ghaznavi-Rad et al. (2009) also reported that 
over 90% of MRSA strains isolated between year 2007 and 2008 in another tertiary 
hospital (HKL) in Malaysia belonged to a single spa type t037. This indicates that spa 
type t037 could be the predominant spa type among Malaysian MRSA strains.  
 Two spa types (t6405 and t4150) which were introduced in 2008 were unique in 
Malaysia and have not been reported in other places (Ghaznavi-Rad et al., 2010; Lim et 
al., 2010). spa types t860, t4152 and t2029 which were also introduced in 2007 or 2008 
were new in Malaysia even though they have previously been reported in Portugal, 
Sweden and Austria, respectively (Amorim et al., 2007; Ridom spa server).  
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Ghaznavi-Rad et al. (2011) reported the occurrence of six dru types (dt10a, 
dt14c, dt13d, dt13i, dt9w and dt13g) among strains from a tertiary hospital (HKL) in 
Malaysia during 2007 - 2008. However, this study indicated that these six dru types 
might have disseminated in Malaysia earlier than expected as these six dru types were 
detected in MRSA strains in UMMC since year 2003. 
 The 36 MRSA strains which were indistinguishable by PFGE (PFGE profile 
SM7) were differentiated into eight different dru types (dt13d, dt13g, dt11al, dt13l, 
dt14c, dt13q, dt10a and dt9w) and five different spa types (t037, t421, t4152, t4150 and 
t032). Besides, 21 MRSA strains which were indistinguishable by PFGE (PFGE profile 
SM17) were further differentiated into five dru types (dt13d, dt92, dt10a, dt13g and 
dt13j) and three spa types (t037, t421 and t6405). This indicated that both spa and dru 
typing were more discriminative than PFGE in subtyping MRSA strains from this 
tertiary hospital.  
  MLST analysis also showed that the majority (157/188; 83.5%) of MRSA 
belongs to the pandemic clone MLST type ST239. This indicates that ST239 was the 
predominant clone in UMMC, and similar results were reported in other tertiary 
hospitals in Malaysia (Ghaznavi-Rad et al., 2010), China (Xu et al., 2009), Germany 
(Wisplinghoff et al., 2005) and Russia (Baranovich et al., 2009). This 
Brazilian/Hungarian MRSA clone has advantageous genetic properties that enhance the 
ability of biofilm formation as well as the ability to adhere and invade human airway 
cells (Amaral et al., 2005). Similar observation was indicated in this study as over 77% 
of the biofilm-producer strains were from the pandemic clone ST239.  
 Both ST239 and ST241 are known to be evolved from ST8, within clonal 
complex 8 and they differed by a single-point mutation in the yqil locus. Although 
MLST ST241 is new in Malaysia, this genotype has been reported earlier in Germany 
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(Deurenburg et al., 2006) and India (Gadepalli et al., 2009). In this study, ST241 was 
also found to be associated with spa type t363.         
 The ST5 clone which was introduced in year 2007 was characterized by spa type 
t002, dru type dt10a and SCCmec type IV. The presence of ST5 with SCCmec type IV 
was also reported by Aires-de-Sousa et al. (2008) in Portugal. However, this MRSA 
ST5 which is also known as Rhinne Hesse epidemic strain is also associated with 
SCCmec type II and has been reported in German, Korean and Japan (Ko et al., 2005; 
Monecke et al., 2009). 
 ST573 clone reported in year 2008 is a single-locus variant of ST1 with a single-
point mutation in the pta locus. Similarly, this clone was also related to another MRSA 
clone (ST188) reported in year 2007-2008 from another tertiary hospital (HKL) 
(Ghaznavi-Rad et al., 2010, 2011). Both clones were from the same clonal cluster, CC1 
and they differed by three-point mutations in the arcc, gmk and pta locus.  
 Even though most of the strains in this study were closely related by MLST, 
some of the strains have greater diversity than MRSA strains isolated from another 
tertiary hospital in Malaysia. Seven clonal clusters, which are CC5 (ST5 and ST1178), 
CC6 (ST6), CC8 (ST239, ST241), CC1 (ST573 and ST772), CC20 (ST20), CC22 
(ST22), CC80 (ST80) were observed among UMMC strains when compared to only 
four clonal clusters [CC1 (ST1 and ST188), CC7 (ST7), CC8 (ST239 and ST1283) and 
CC22 (ST22)] reported in another tertiary hospital (Hospital Kuala Lumpur) (Ghaznavi-
Rad et al. 2010, 2011).  
 Among the ten major clones of MRSA (ST5, ST8, ST22, ST25, ST36, ST45, 
ST228, ST239, ST247 and ST250) reported worldwide (Deurenburg and Stobberigh, 
2008), three MRSA clones (ST5, ST22 and ST239) were present in this hospital and 
other tertiary hospitals in Malaysia (Ahmad et al., 2009; Ghaznavi-Rad et al., 2010). 
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Ahmad et al. (2009) reported the presence of the Berlin clone (ST45-SCCmec type IV) 
among HA-MRSA between year 2006 and 2008 from Malaysian hospitals. 
 The higher resolution and greater discriminatory ability of spa and mec-
associated dru typing methods could further differentiate ST239 clone into seven spa 
types (t037, t421, t6405, t4150, t4152, t2029 and t860) and 26 different dru types. In 
another study, Ghaznavi-Rad et al. (2011) also showed that mec-associated dru typing 
is useful to enhance the epidemiological discrimination of ST239. This suggest that 
combination of spa and mec-associated dru typing together might be useful in subtyping 
MRSA as both spa and mec-associated dru typing are more rapid, less laborious and 
relatively cheaper than MLST.  
 
 
5.12 Evolutionary changes in MRSA based on spa typing, MLST and mec-
associated dru typing 
 In this study, three different typing methods (spa typing, MLST and mec-
associated dru typing) were used for the evolutionary study of MRSA strains isolated 
from four different years (2003, 2004, 2007 and 2008).  
 Maximum parsimony tree based on spa typing indicated that three spa types 
(t037, t421 and t1544) were detected since year 2003 with spa types‟ t037 and t421 
associated with ST239 whereas spa type t1544 was associated with ST20. Five spa 
types (t032, t4184, t002, t304 and t860) were introduced in year 2007 with spa types‟ 
t032 and t4184 associated with ST22, spa type t002 associated with ST5, spa type t304 
associated with ST6 and spa type t860 associated with ST239. Nine other spa types 
(t1378, t6405, t4150, t1107, t458, t4152, t657, t2029 and t363) were introduced in year 
2008. Among the nine spa types, four spa types (t6405, t4150, t4152 and t2029) were 
associated with ST239.  
164 
 
 The present data based on the maximum parsimony tree derived from spa types 
indicated that spa types t6405, t304, t002, t4184, t1378 and t032 might have originated 
from spa type t037 with 5 - 25 mutations differences whereas spa types‟ t4150, t1107, 
t458, t4152, t657, t860, t2029 and t363 might have originated from spa type t421 with 3 
– 10 mutations differences. The data showed that 22 to 25 mutations and 3 - 4 
generations gaps are required for spa type t1378, t032 and t4184 which are associated 
with ST22 (CC22) to evolve from t037 which were associated with ST239 (CC8).  
 Although both spa types t002 and t1107 were associated with MLST CC5, spa 
type t002 evolved from spa type t037 (MLST CC8) by 10 mutations whereas t1107 
evolved from spa type t421 (MLST CC8) by 8 mutations and both t002 and t1107 were 
differed by 19 mutations. This indicates that spa typing has higher discriminatory power 
than MLST. In addition, spa typing is also reported to have discriminatory power lies 
between PFGE and MLST (Malachowa et al., 2005).  
 On the other hand, the maximum parsimony tree derived from MLST showed 
that ST241 was evolved from ST239 by one mutation. This is expected as both ST239 
and ST241 were originated from ST8 (CC8) and they shared six similar alleles 
including arcC, gmk, glpF, aroE, pta and tpi. ST772 was evolved from ST573 by one 
mutation different in pta locus.  
 It is noted that ST22 from clonal cluster C22 was evolved from ST239 (CC8) 
with one generation gap and seven mutations differences. ST6 (CC6) which was 
detected in year 2007 was evolved from ST239 (CC8) by three generation gaps and six 
mutations differences. The ST5 (CC5) which was detected in year 2007 evolved from 
ST239 (CC8) with 6 mutations differences and four generation gaps and ST1178 (CC5) 
(detected in year 2008) was evolved from ST5 with differences in two mutations in 
aroE and tpi locus.  
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Even though MLST is proven as an excellent method to study molecular 
evolution in MRSA, the present data support that mec-associated dru typing has a 
greater discriminatory ability than MLST for the analysis of highly clonal MRSA 
strains such as ST239. The present data based on the maximum parsimony tree 
indicated that 13 different dru types were detected since year 2003, and they were 
associated with ST239. Ten dru types (dt11am, dt15n, dt13q, dt13p, dt13j, dt13n, dt13f, 
dt13ao, dt12j, dt7v) which are associated with ST239 and spa type t037 have been 
introduced in year 2004, 2007 and 2008 with five dru types (dt13ao, dt13f, dt13p, dt13j 
and dt13n) evolved from dt13d by one mutation suggesting that some strains from these 
dru types might have originated from dt13d. The other five dru types (dt11am, dt15n, 
dt13q, dt12j and dt7v) were evolved from dt13d by 4 – 13 mutation differences and 1 – 
5 generation gaps.  
dru type dt10ax which is associated with spa type t421 and MLST ST239 was 
evolved from dru type dt13d with 6 mutations differences and 2 generation gaps. The 
dru type 11an which is associated with spa type t6405 and MLST ST239 was evolved 
from dru type dt13d with 5 mutations differences and 1 generation gap. On the other 
hand, dt10aw which is associated with ST22 might have evolved from dt10 with only 
three mutation differences.  
 However, mec-associated dru typing method cannot be applied on MSSA 
strains as they lack mecA gene. Another disadvantage of this mec-associated dru typing 
was it is unable to differentiate different lineages as dt10a consists of MRSA strains 
from five different lineages (CC5, CC6, CC8, CC22 and CC80). Therefore, mec-
associated dru typing should be used in combination with another sequence typing 
method (i.e spa typing) to characterize MRSA strains.  
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5.13 Clonal evolution of Malaysian MRSA from year 2003, 2004, 2007 and 2008 
 This study demonstrated that the predominant ST239-t037 had decreased from 
96% in 2003 to 56.8% in 2008 whereas a slight increase in the prevalence of ST239-
t421 from 1.9% in 2003 to 18.0% in 2008. It is observed that ST239-t421 clone (from 
2003) that was from ICU might have spread to other wards; i.e medical, dialysis, 
surgical and orthopaedic in 2008 suggesting changes of MRSA clones in UMMC during 
the study period.  
 Further combined analysis with MLST-spa-dru typing demonstrated that the 
prevalence rate of ST239-t037-dt13d had decreased from 44.2% in 2003 to 13.5% in 
2008 and was replaced by MLST239-t037-dt13g and other new emerging of MRSA 
clones that accounted for 68.5% of MRSA strains in 2008. ST239-t037-dt13g could 
easily be transmitted in this hospital as they have spread from two wards (in 2003) to 
six different wards (in 2008). This dt13g which was cultured from wound and blood 
samples (in 2003) and infected tissue, wound, pus and bone as well as colonized 
respiratory tract (nasal swabs, sputum, nasopharyngeal secretion) and catheter tips in 
year 2008. This further suggests the changes of MRSA clones in UMMC over the study 
periods. 
Both ST239-t037-dt13d and ST239-t421-dt13d might have a stronger survival 
advantage when compared to ST239-t037-dt13l, ST239-t037-dt13m, ST239-t037-dt14h, 
ST239-t037-dt13i, ST20-t1544-dt14c, ST239-t037-dt15l and ST239-t037-dt15m as they 
were present throughout the study periods.  
 
 
5.14 Limitation of the study 
 The limitations of this study were the number of MRSA strains in the different 
study periods (2003, 2004, 2007 and 2008) varied and there were no MRSA strains 
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from year 2005 and 2006 included in the analysis. This was mainly due to lack of 
proper storage maintenance of the bacterial stock cultures in the hospital as MRSA 
strains from the earlier years (2003 to 2007) were kept in stab cultures, which could not 
be kept for a longer period of time. Unlike the earlier years, MRSA strains from year 
2008 onwards were kept in glycerol stock at - 85°C and they could be revived.     
 There are no positive controls available for the detection of ermB, tetL, tetO, 
tetS, cfrA, fusB, fusC, fusD, vanA and vanB resistance genes; Tn916 and Tn4001 
transposon-associated genes; cna, fnbB, seb, sed, see, seh, sej, eta and etb virulence 
genes and agr type IV. Therefore, negative results should be treated with caution.  
 
 
5.15 Consideration for future study 
One fusidic acid-resistant MRSA strain (MRSA0812-33) which had multiple 
mutations, including three novel substitution (317Met/Trp, 596Cys/Trp and 
602Glu/Lys) exhibited high levels of fusidic acid resistance (MIC 256 µg/ml). The role 
of this three newly found mutational change in fusA is unknown and needs further 
investigation as mutational change 461Leu/Lys alone is capable of conferring high level 
of fusidic acid resistance.  
On the other hand, this study also addressed several items which required more 
precise research in the future. Clinical information of persons with community-acquired 
MRSA should be collected in order to compare the association of CA-MRSA and HA-
MRSA in Malaysia. In addition, comparison between coagulase-negative 
Staphylococcus and MRSA in Malaysia should be studied in more detail. 
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CHAPTER 6 
CONCLUSIONS 
 
 The objectives of this study were to investigate the antimicrobial susceptibility 
patterns of 14 commonly used antibiotics in this tertiary hospital, the presence of 
selected plasmid-mediated erythromycin, tetracycline, mupirocin and β-lacam resistance 
genes and the transmissibility of the erythromycin and tetracycline phenotypes as well 
as the chromosomal mutations involved in rifampicin and fusidic acid resistance; the 
prevalence of virulence gene and agr grouping of MRSA strains; genomic relatedness 
of MRSA strains by SCCmec typing, PCR-RFLP of coa gene, pulsed-field gel 
electrophoresis (PFGE), multilocus sequence typing (MLST), mec-associated dru 
typing and spa typing as well as the evolution of MRSA strains in 2003, 2004, 2007 and 
2008.  
An increase of the tetracycline and netilmicin resistance rates and occurrence of 
multidrug-resistant (MDR) strains from year 2008 when compared to year 2003 were 
observed. The antibiotic resistance rates and the occurrence of MDR strains were also 
higher when compared to a previous UMMC report (Thong et al., 2009). Moreover, the 
erythromycin, clindamycin, gentamicin and ciprofloxacin resistance rates remain high 
over a six-year period. Tetracycline-resistant strains often show co-resistance towards 
ciprofloxacin and erythromycin. Vancomycin remains the most active agent „in-vitro‟ 
against S. aureus infection followed by linezolid and teicoplanin. 
Erythromycin, tetracycline, gentamicin and mupirocin resistance is always 
attributed to the presence of resistance genes.  The ermA and tetM were the predominant 
genes detected in erythromycin- and tetracycline-resistant strains, respectively whereas 
ileS2 gene was the most frequent gene detected in mupirocin-resistant strains. The 
presence of ermA, ermC and msrA genes were associated with erythromycin resistance 
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whereas presence of tetK and tetM genes were associated with tetracycline resistance 
among Malaysian MRSA strains. The presence of ileS2 and mupA genes were 
responsible for mupirocin resistance while the presence of aac(6’)-aph(2”) gene was 
responsible for aminoglycoside (gentamicin and netilmicin) resistance among 
Malaysian MRSA strains.   
Associations of resistance genes (ermC, tetM and tetK) with mobile genetic 
elements such as transposons possibly enhance the spread of resistant traits in MRSA.  
Transmissibility of the erythromycin phenotype in MRSA strains was demonstrated in 
the transformation experiments carried out. Results indicated that ermA gene was 
plasmid-encoded thereby increasing their mobility and transmissibility.  
 Different amino acid alterations are responsible for rifampicin and fusidic acid 
resistance among Malaysian MRSA strains. The presence of double mutation in rpoB 
gene often involved in high-rifampicin resistance (MIC 8 µg/ml) while amino acid 
alteration at 461Leu/Lys often linked with high-fusidic acid resistance (MIC 256 
µg/ml). 
Increase of MRSA strains with toxin genes over the six-years period signal the 
potential loss of the usage of antimicrobial agents in treating MRSA infections as 
MRSA strain with virulence factors is normally resistant to host immune systems and 
other antimicrobial agents. agr type I and SCCmec type III remained as the predominant 
agr and SCCmec type among MRSA strains in UMMC. The pvl gene was more 
common among invasive strains than colonization strains  
 DNA fingerprinting carried out using gel-based fingerprinting methods (PCR-
RFLP of coa gene and PFGE) and sequence typing methods (MLST, spa and mec-
associated dru typing) showed that MRSA strains in this tertiary hospital were 
genetically related. The MDR MRSA clinical isolates from UMMC were mostly 
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genetically related, suggesting that few predominant clones of the species are involved 
in infection.  
 MLST type ST239 and spa type t037 are the predominant MRSA clone in this 
tertiary hospital in Malaysia. Moreover, 23 different dru types were associated with 
ST239-t037 with ten dru types being introduced in later years suggesting that they 
might have evolved from dt13d and dt15n might also be possibly evolved from dt15l.  
The combined analysis by MLST-spa-dru types indicated the changes of MRSA 
clones at UMMC in Malaysia where ST239-t037-dt13d and other MRSA clones in 2003 
were replaced by ST239-t037-dt13g and other new emerging spa and dru types. 
 Correlation between DNA profiles and resistotypes was observed. Isolates with 
indistinguishable PFGE profiles often have similar antibiotic susceptibility patterns 
even though there are variations in certain antibiograms in distinct clones of MRSA.   
On the other hand, no direct correlation between DNA profiles and virulotypes 
were observed as strains with identical DNA profiles frequently belonged to different 
virulotypes. This was not surprising as majority of the virulence determinants were 
found to be encoded on transmissible mobile elements and their acquisition would, at 
most, lead to minimal changes in the genetic profiles of the recipient strains.  
 The data from this current study may act as reference for monitoring mupirocin, 
rifampicin, fusidic acid and the prevalence of virulence among Malaysian MRSA 
strains over extended time periods. Furthermore, the data in this study underline the 
necessity of surveillance typing in order to control MRSA strains in this hospital.   
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APPENDIX 1 
Bacterial Strains Information 
Strains Specimen Ward Isolated Year 
MRSA2 Nasal swab Orthopaedic 2003 
MRSA3 Nasal swab Orthopaedic 2003 
MRSA4 Nasal swab Orthopaedic 2003 
MRSA8 Nasal swab Orthopaedic 2003 
MRSA0301-1 Wound swab Orthopaedic 2003 
MRSA0301-28 Tissue Orthopaedic 2003 
MRSA0302-4 Tissue Orthopaedic 2003 
MRSA0304-16 Nasal swab ICU 2003 
MRSA0305-10 Urine Orthopaedic 2003 
MRSA0305-18 Nasal swab Orthopaedic 2003 
MRSA0305-23 Nasal swab Orthopaedic 2003 
MRSA0306-10 Nasophargeal secretion Paediatric 2003 
MRSA0306-14 Bone Orthopaedic 2003 
MRSA0306-15 Pus Medical 2003 
MRSA0306-18 Bone Orthopaedic 2003 
MRSA0306-26 Wound swab Orthopaedic 2003 
MRSA0306-7 Wound swab Orthopaedic 2003 
MRSA0307-1 Wound swab Orthopaedic 2003 
MRSA0307-10 Nasophargeal secretion Obstetric and gynaecology 2003 
MRSA0307-14 Wound swab ICU 2003 
MRSA0307-20 Wound swab Orthopaedic 2003 
MRSA0307-23 Wound swab Orthopaedic 2003 
MRSA0307-25 Body fluid Orthopaedic 2003 
MRSA0307-5 Wound swab Orthopaedic 2003 
MRSA0307-9 Nasal swab CICU 2003 
MRSA0308-1 Tracheal secretion Surgical 2003 
MRSA0308-10 Tissue Orthopaedic 2003 
MRSA0308-22 Blood ICU 2003 
MRSA0308-23 Blood ICU 2003 
MRSA0308-24 Blood ICU 2003 
MRSA0308-28 Nasal swab Orthopaedic 2003 
MRSA0309-10 Tissue Orthopaedic 2003 
MRSA0309-11 Nasal swab ICU 2003 
MRSA0309-9 Nasal swab Paediatric 2003 
MRSA0310-19 Wound swab Orthopaedic 2003 
MRSA0310-23 Wound swab Orthopaedic 2003 
MRSA0310-26 Tracheal secretion ICU 2003 
MRSA0310-9 Wound swab Orthopaedic 2003 
MRSA0311-1 Tracheal secretion ICU 2003 
MRSA0311-21 Sputum Orthopaedic 2003 
MRSA0311-23 Tracheal secretion ICU 2003 
MRSA0311-4 Pus Surgical 2003 
MRSA0311-7 Tissue Orthopaedic 2003 
MRSA0311-8 Wound swab Orthopaedic 2003 
MRSA0311-9 Wound swab Orthopaedic 2003 
MRSA0312-13 Pus Medical 2003 
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(continue)    
Strain No Specimen Ward isolated Year 
MRSA0312-15 Blood Medical 2003 
MRSA0312-17 Tracheal secretion Surgical 2003 
MRSA0312-2 Slough Orthopaedic 2003 
MRSA0312-3 Pus Other 2003 
MRSA0312-30 Tissue Orthopaedic 2003 
MRSA0312-35 Chest tube Surgical 2003 
MRSA0401-13 Wound swab Orthopaedic  2004 
MRSA0402-21 Nasophargeal secretion Paediatric 2004 
MRSA0402-8 Tracheal secretion ICU 2004 
MRSA0403-20 Sputum Dialysis 2004 
MRSA0405-20 Blood Medical  2004 
MRSA0406-8 Blood Other 2004 
MRSA0408-33 Blood Dialysis 2004 
MRSA0408-34 Wound swab Surgical 2004 
MRSA0409-17 Shoulder swab Surgical 2004 
MRSA0701-15 Sputum Medical 2007 
MRSA0701-26 Wound swab Surgical 2007 
MRSA0703-8 Wound swab Surgical 2007 
MRSA0704-15 Nasal swab Orthopaedic 2007 
MRSA0704-18 Wound swab Orthopaedic 2007 
MRSA0704-20 Blood CICU 2007 
MRSA0704-3 Wound swab ICU 2007 
MRSA0705-13 Blood Medical  2007 
MRSA0705-17 Tracheal secretion Medical 2007 
MRSA0705-7 Tracheal secretion Medical 2007 
MRSA0705-8 Blood Dialysis 2007 
MRSA0707-17 Nasophargeal secretion Paediatric 2007 
MRSA0707-26 Nasal swab Medical  2007 
MRSA0708-1 Nasal swab Surgical 2007 
MRSA0708-10 Tracheal secretion Medical 2007 
MRSA0709-22 Tracheal secretion Medical 2007 
MRSA0801-1 Wound swab Medical 2008 
MRSA0801-13 Blood Medical 2008 
MRSA0801-16 Sputum Mecial 2008 
MRSA0801-2 Wound swab Surgical 2008 
MRSA0801-21 Pus Surgical 2008 
MRSA0801-26 Tracheal secretion Orthopaedic 2008 
MRSA0801-27 Tissue ICU 2008 
MRSA0801-30 Bone Orthopaedic 2008 
MRSA0801-4 Tracheal secretion Medical 2008 
MRSA0801-9 Sputum Medical 2008 
MRSA0802-14 Nasal swab Orthopaedic 2008 
MRSA0802-19 Nasopharygeal secretion Paediatric 2008 
MRSA0802-2 Nasal swab Orthopaedic 2008 
MRSA0802-3 Wound swab Surgical 2008 
MRSA0803-28 Nasal swab ICU 2008 
MRSA0803-29 Sputum Surgical 2008 
MRSA0803-30 Tissue Orthopaedic 2008 
MRSA003-35 Tracheal secretion Orthopaedic 2008 
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(continue)    
Strain No Specimen Ward isolated  
MRSA0804-1 Nasal swab Cardiac care unit 2008 
MRSA0804-14 Nasal swab Orthopaedic 2008 
MRSA0804-20 Nasal swab Medical 2008 
MRSA0804-24 Tissue Medical 2008 
MRSA0805-1 Nasopharygeal secretion Paediatric 2008 
MRSA0805-10 Wound swab Orthopaedic 2008 
MRSA0805-11 Nasal swab Cardiac care unit 2008 
MRSA0805-15 Tissue Orthopaedic 2008 
MRSA0805-17 Sputum Medical 2008 
MRSA0805-19 Pus Orthopaedic 2008 
MRSA0805-20 Urine Orthopaedic 2008 
MRSA0805-21 Tip Medical 2008 
MRSA0805-22 Tracheal secretion Medical 2008 
MRSA0805-23 Tracheal secretion Cardiac care unit 2008 
MRSA0805-24 Wound swab Medical 2008 
MRSA0805-3 Nasal swab Surgical 2008 
MRSA0805-4 Sputum Dialysis 2008 
MRSA0805-5 Urine Surgical 2008 
MRSA0805-6 Nasal swab Orthopaedic 2008 
MRSA0805-9 Pus Psychiatry 2008 
MRSA0806-1 Blood Dialysis 2008 
MRSA0806-11 Wound swab Medical 2008 
MRSA0806-13 Nasal swab Dialysis 2008 
MRSA0806-14 Nasal swab Orthopaedic 2008 
MRSA0806-18 Nasal swab Orthopaedic 2008 
MRSA0806-21 Blood Surgical 2008 
MRSA0806-22 Nasal swab ICU 2008 
MRSA0806-26 Nasal swab Surgical  2008 
MRSA0806-33 Nasopharygeal secretion Paediatric 2008 
MRSA0807-1 Nasal swab Orthopaedic 2008 
MRSA0807-13 Nasal Swab Surgical 2008 
MRSA0807-14 Urine Surgical 2008 
MRSA0807-19 Tracheal secretion Other 2008 
MRSA0807-7 Nasal swab Surgical 2008 
MRSA0807-8 Nasal swab Surgical  2008 
MRSA0808-17 Sputum Medical 2008 
MRSA0808-19 Wound swab Orthopaedic 2008 
MRSA0808-21 Bone Orthopaedic 2008 
MRSA0808-24 Wound swab Obstetric and gynaecology 2008 
MRSA0808-25 Tip Neurosurgical 2008 
MRSA0808-26 Nasal swab CICU 2008 
MRSA0808-35 Wound swab Surgical 2008 
MRSA0809-1 Graft Surgical 2008 
MRSA0809-10 Sputum Medical 2008 
MRSA0809-14 Tracheal secretion Medical 2008 
MRSA0809-15 Tracheal secretion Medical 2008 
MRSA0809-24 Tracheal secretion Medical 2008 
MRSA0809-25 Sputum Dialysis 2008 
MRSA0809-27 Nasal swab Medical 2008 
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(continue)    
Strain No Resistance profiles   
MRSA0809-30 Sputum Medical 2008 
MRSA0809-32 Pus Dialysis 2008 
MRSA0809-33 Tissue Medical 2008 
MRSA0809-36 Urine Medical 2008 
MRSA0809-38 Tracheal secretion Surgical 2008 
MRSA0810-10 Tracheal secretion Medical 2008 
MRSA0810-13 Wound swab Dialysis 2008 
MRSA0810-15 Sputum Surgical 2008 
MRSA0810-16 Tracheal secretion Medical 2008 
MRSA0810-17 Sputum Medical 2008 
MRSA0810-18 Nasal swab Orthopaedic 2008 
MRSA0810-2 Nasal swab Medical 2008 
MRSA0810-22 Nasal swab Medical  2008 
MRSA0810-23 Tracheal secretion Medical 2008 
MRSA0810-6 Sputum Medical 2008 
MRSA0810-7 Pus Medical 2008 
MRSA0810-9 Pus Orthopaedic 2008 
MRSA0811-10 Urine Surgical 2008 
MRSA0811-11 Sputum Orthopaedic 2008 
MRSA0811-13 Nasopharygeal secretion Medical 2008 
MRSA0811-16 Nasal swab Medical 2008 
MRSA0811-2 Sputum Surgical 2008 
MRSA0811-22 Nasal swab Cardiac care unit 2008 
MRSA0811-24 Nasal swab Medical 2008 
MRSA0811-25 Tip Surgical 2008 
MRSA0811-26 Tracheal secretion Surgical  2008 
MRSA0811-28 Nasal swab Surgical 2008 
MRSA0811-30 Wound swab Orthopaedic 2008 
MRSA0811-5 Tracheal secretion ICU 2008 
MRSA0811-8 Pus Surgical 2008 
MRSA0812-1 Nasal swab Orthopaedic 2008 
MRSA0812-11 Tracheal secretion Surgical 2008 
MRSA0812-15 Sputum Medical 2008 
MRSA0812-17 Nasopharygeal secretion Paediatric 2008 
MRSA0812-2 Nasal swab Orthopaedic 2008 
MRSA0812-22 Sputum Surgical 2008 
MRSA0812-23 Sputum Medical 2008 
MRSA0812-27 Wound swab Orthopaedic 2008 
MRSA0812-30 Tracheal secretion Medical 2008 
MRSA0812-31 Sputum Medical 2008 
MRSA0812-33 Tracheal secretion ICU 2008 
MRSA0812-35 Pus Medical 2008 
MRSA0812-36 Tissue ICU 2008 
MRSA0812-37 Tissue Orthopaedic 2008 
202 
 
APPENDIX 2 
Media, buffers and solution 
 
All media and solutions were prepared with distilled or deionised water. Most of the 
media were sterilized by autoclaving at 15 psi at 121°C for 20 minutes, unless otherwise 
stated. 
 
1. Tryptone soy agar (Oxoid Ltd, UK) 
Tryptone soy agar       16.0 g 
Distilled water up to 400 ml.  
2. Tryptone Soy broth (Oxoid Ltd, UK) 
Tryptone soy broth       12.0 g 
Distilled water up to 100 ml 
3. Luria-bertani (LB) agar 
Tryptone (Oxoid Ltd, UK)     4.0 g 
Yeast extracts (Oxoid Ltd, UK)     2.0 g 
Sodium chloride (Merk, USA)     2.0 g 
Bacteriological agar (Oxoid Ltd, UK)    6.0 g 
Distilled water up to 400 ml 
4. Luria-bertani (LB) broth 
Sodium chloride (Merck, USA)     1.0 g 
Yeast extract (Oxoid Ltd, UK)     1.0 g 
Tryptone (Oxoid Ltd, UK)     2.0 g 
Distilled water up to 200 ml 
5. Mannitol salt agar (Oxoid Ltd, UK) 
Mannitol salt agar      44.0 g 
Distilled water up to 400 ml 
6. Meuller-hinton agar (BD-BBL, USA) 
Meuller-hinton II agar      15.2 g 
Distilled water up to 400 ml 
7. Brain-heart Infusion agar (Oxoid Ltd, UK) 
Brain-heart infusion agar      20.8 g 
Distilled water up to 400 ml 
8. 50% glycerol 
Ultrapure glycerol (Invitrogen, USA)    25 ml 
Distilled water up to 50 ml 
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9. 0.85% Sodium chloride 
Sodium chloride (Merck, USA)     3.2 g 
Distilled water up to 400 ml 
10. Lysozyme (10 mg/ml) 
Lysozyme (Sigma, USA)     0.01 g 
Sterile deonised water up to 1 ml and filter sterilized 
11. Lysostaphin (1 mg/ml) 
Lysostaphin (Sigma, USA)     0.001 g 
Sterile deonised water up to 1 ml 
12. 1M Tris, pH 8.0 (molecular weight = 121.44 g) 
Trizma base (Sigma, USA)     48.45 g 
Deonised water up to 360 ml 
The pH of the solution was adjusted to 8.0 by adding concentrated HCl and top up 
with deonised water up to 400 ml.  
13. 0.5M Ethylenediaminetetraacetic acid, pH 8.0 (molecular weight = 372.44) 
Ethylenediaminetetraacetic acid (EDTA) (Invitrogen, USA) 74.4 g 
Deonised water up to 360 ml 
The pH of the solution was adjusted to 8.0 by adding NaOH and top up with 
deonised water up to 400 ml.  
14. Solution I (TES) (10mM Tris, 1 mM EDTA and 0.1mM NaCl, pH8.0) 
1M Tris, pH 8.0       4 ml   
0.5M EDTA pH 8.0      0.8 ml 
Sodium chloride (molecular weight = 58.44 g)   23.38 g 
Sterile deonised water up to 400 ml 
15. 10% Sodium dodecyle supphate (SDS) 
Sodium dodecyle sulphate (Invitrogen, USA)   10 g 
Sterile deonised water up to 100 ml. Do not autoclave. 
16. 10N NaOH  
NaOH (Sigma, USA) (molecular weight = 40 g)  40 g 
Sterile deonised water up to 100 ml and do not autoclave.    
17. Solution II (1% SDS, 0.2N NaOH) 
10% SDS        1 ml 
10N NaOH       0.2 ml 
Sterile deonised water up to 10 ml and used immediately. 
18. 70% ethanol 
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Ultrapure ethanol (Sigma, USA)     70 ml 
Sterile deonised water      30 ml 
19. 0.5M sucrose  
Sucrose (molecular weight = 342.30 g) (BDH, USA)  17.12 g 
Sterile deonised water up to 100 ml and filter sterilized. 
20. 10% Glycerol 
Ultrapure glycerol (Invitrogen, USA)    10 ml 
Sterile deonised water up to 100 ml 
21. GYT Medium 
Glycerol (Invitrogen, USA)     10 ml 
Yeast extract (Oxoid Ltd, UK)     0.125 g 
Tryptone (Oxoid Ltd, UK)     0.125 g 
Deonised water up to 100 ml 
22. 0.2 M sodium hydrogen maleate 
Maleic acid (Sigma, USA)     13.7 g 
NaOH (Sigma, USA)      4.0 g 
Deonised water up to 500 ml 
23. Pennasay broth 
Antibiotic Medium 3 (BD, USA)    17.5 g 
Deonised water up to 250 ml 
24. 2X SMM broth 
0.2 M sodium hydrogen maleate     25 ml 
0.1 N NaOH       40 ml 
pH adjusted to 6.5 before addition of 
1M MgCl2 (Promega Ltd, USA)     5 ml 
Sucrose (Sigma, USA)      42.7g 
Sterile deonsed water to 125 ml and filter sterilzed 
25. SMMP broth (pH 7.0) 
2 X SMM        55 ml 
4 X Pennasay broth      40 ml 
10% (w/v) bovine albumin (Sigma, USA)   5 ml 
pH adjusted to 7.0 and filter sterilized 
26. Congo red agar 
Congo red (WR Prolabo, France)    0.2 g 
Sucrose (Sigma, USA)      10 g 
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27. Tris-EDTA (TE) buffer (10mM Tris : 1mM EDTA, pH8.0) 
1 M Tris, pH 8.0        10 ml 
0.5 M EDTA, pH 8.0       2 ml 
Deionised water to 1000 ml. 
28. Proteinase K (10.0mg/ml) 
Proteinase K (Promega, USA)     100 mg 
Sterile deionised water to 10.0ml 
29. 1.0% Seakem gold agarose 
Seakem gold agarose (Cambrex Bio-Science, Rockland USA)  0.1g 
TE buffer        10 ml 
Swirl gently to disperse agarose and microwave for 30 seconds. Mix gently and 
repeat for 10-second interval until the agarose is completely dissolved. 
30. Cell suspension buffer (100.0mM Tris, 100mM EDTA, pH8.0) 
1 M Tris, pH 8.0        10 ml 
0.5 M EDTA, pH 8.0       20 ml 
Deionised water to 100 ml 
31. 10% Sarcosyl (N-Lauryl-Sarcosine [Molecular weight = 293.39g] 
Sodium N-lauroyl-sarcosinate Solution (Fluka, USA)  10 ml 
Deionised water to 100 ml 
32. Cell lysis buffer (50mM Tris, 50mM EDTA, pH8.0 + 1.0% Sarcosine) 
1.0M Tris, pH 8.0       25 ml 
0.5M EDTA, pH 8.0      50 ml 
10% Sarcosyl        50 ml 
Deionised water to 500 ml 
33.  Pre-Restriction buffer (per plug slice) 
10 X RE Buffer (Promega, USA)    10 l 
BSA (Promega, USA)      1 l 
Deionised water        89 ml 
34. Restriction buffer mixture (per plug slice) 
10 X RE buffer (Promega, USA)    10 µl 
Enzyme (Promega, USA)     2 µl 
BSA (Promega, USA)      1 µl 
Deionised water        87 µl 
35. 10X Tris-Borate EDTA Buffer (TBE), pH8.3 
Trizma-base (Sigma, USA)     121.1 g 
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Othoboric Acid (Merck, USA)      61.8 g 
EDTA (Ultra Pure Grade) (Invitrogen, USA)    0.745 g 
Deionised water to 1000 ml 
The pH of the stock solution was adjusted pH to 8.3 and autoclaved. It was then 
diluted to 0.5X for routine use. 
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APPENDIX 3  
Antimicrobial resistance profiles of the 188 MRSA strains 
Strains Resistance profiles 
MRSA2 ERY, GEN, CIP, TET, OXA, SXT 
MRSA3 ERY, GEN, CIP, OXA, SXT 
MRSA4 ERY, GEN, CIP, OXA, SXT 
MRSA8 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0301-1 ERY, CIP, OXA, SXT 
MRSA0301-28 ERY, GEN,CIP. TET, OXA, SXT 
MRSA0302-4 ERY, GEN, RD, CIP, NET, FD, OXA, SXT 
MRSA0304-16 ERY, GEN, LZD, CIP, OXA 
MRSA0305-10 ERY, GEN, NET, OXA 
MRSA0305-18 ERY, GEN, OXA, SXT 
MRSA0305-23 ERY, GEN, DA, CIP, TET, OXA, SXT 
MRSA0306-10 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0306-14 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0306-15 ERY, GEN, CIP, OXA 
MRSA0306-18 OXA 
MRSA0306-26 ERY, GEN, CIP, NET, OXA 
MRSA0306-7 ERY, GEN, CIP, OXA, SXT 
MRSA0307-1 ERY, GEN, CIP, NET, OXA 
MRSA0307-10 ERY, GEN, CIP, NET, OXA 
MRSA0307-14 ERY, GEN, CIP, OXA 
MRSA0307-20 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0307-23 ERY, GEN, CIP, FD, OXA 
MRSA0307-25 ERY, GEN, CIP, OXA, SXT 
MRSA0307-5 ERY, GEN, CIP, NET, OXA 
MRSA0307-9 ERY, CIP, OXA 
MRSA0308-1 ERY, GEN, CIP, OXA 
MRSA0308-10 ERY GEN, RD, CIP, TET, OXA, SXT 
MRSA0308-22 ERY, GEN, CIP, OXA 
MRSA0308-23 ERY, GEN, RF, CIP, TE, FD, OXA, SXT 
MRSA0308-24 ERY, GEN, CIP, OXA 
MRSA0308-28 ERY, GEN, CIP, OXA, SXT 
MRSA0309-10 ERY, GEN, CIP, OXA, SXT 
MRSA0309-11 ERY, GEN, CIP, OXA 
MRSA0309-9 ERY, GEN, CIP, NET, OXA 
MRSA0310-19 ERY, GEN, CIP, OXA 
MRSA0310-23 ERY, GEN, DA, CIP, NET, TET, OXA, SXT 
MRSA0310-26 ERY, GEN, RD, CIP, NET, FD, OXA 
MRSA0310-9 ERY, GEN, CIP, OXA 
MRSA0311-1 ERY, GEN, CIP, OXA 
MRSA0311-21 ERY, CIP, TET, OXA, SXT 
MRSA0311-23 ERY, GEN, TEC, CIP, OXA, SXT 
MRSA0311-4 ERY, GEN, CIP, NET, OXA 
MRSA0311-7 ERY, GEN, CIP, OXA 
MRSA0311-8 ERY, GEN, CIP, OXA 
MRSA0311-9 ERY, GEN, CIP, OXA 
MRSA0312-13 ERY, GEN, OXA 
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(continue)  
Strain No Resistance profiles 
MRSA0312-15 ERY, GEN, CIP, OXA 
MRSA0312-17 ERY, GEN, CIP, NET, OXA 
MRSA0312-2 ERY, GEN, CIP, OXA 
MRSA0312-3 ERY, GEN 
MRSA0312-30 ERY, GEN, CIP, OXA 
MRSA0312-35 MUP, TEC, TET, FD, OXA 
MRSA0401-13 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0402-21 ERY, LZD, MUP, DA, CIP, TET, OXA, SXT 
MRSA0402-8 ERY, GEN, MUP, TET, OXA, SXT 
MRSA0403-20 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0405-20 ERY, GEN, CIP, OXA 
MRSA0406-8 ERY, GEN, MUP, CIP, NET, TET, OXA 
MRSA0408-33 ERY, GEN, MUP, CIP, OXA 
MRSA0408-34 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0409-17 ERY, CIP, NET, TET, OXA, SXT 
MRSA0701-15 ERY, GEN, CIP, OXA 
MRSA0701-26 OXA 
MRSA0703-8 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0704-15 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0704-18 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0704-20 ERY, GEN, CIP, NET, OXA 
MRSA0704-3 ERY, GEN, MUP, CIP, TET, OXA, SXT 
MRSA0705-13 ERY, GEN, RD, CIP, TET, FD, OXA, SXT 
MRSA0705-17 ERY, GEN, CIP, OXA 
MRSA0705-7 GEN, CIP. OXA 
MRSA0705-8 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0707-17 OXA 
MRSA0707-26 ERY, GEN, CIP, TET, OXA 
MRSA0708-1 ERY, CIP, OXA 
MRSA0708-10 ERY, CIP, OXA 
MRSA0709-22 ERY, CIP, OXA 
MRSA0801-1 ERY, GEN, CIP, NET, TET, OXA 
MRSA0801-13 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0801-16 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0801-2 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0801-21 ERY, GEN, LZD, CIP, NET, OXA, SXT 
MRSA0801-26 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0801-27 ERY, GEN, MUP, CIP, NET, TET, OXA 
MRSA0801-30 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0801-4 ERY, GEN, CIP, TET, OXA 
MRSA0801-9 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0802-14 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0802-19 OXA 
MRSA0802-2 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0802-3 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0803-28 ERY, CIP, OXA, SXT 
MRSA0803-29 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0803-30 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA003-35 ERY, GEN, CIP, NET, TET, OXA, SXT 
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(continue)  
Strain No Resistance profiles 
MRSA0804-1 ERY, CIP, OXA, SXT 
MRSA0804-14 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0804-20 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0804-24 ERY, GEN, CIP, OXA 
MRSA0805-1 ERY, FD, OXA, SXT 
MRSA0805-10 GEN, CIP, OXA, SXT 
MRSA0805-11 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0805-15 ERY, GEN, MUP, DA, CIP, TE, FD, OXA, SXT 
MRSA0805-17 ERY, GEN, CIP, NET, TET, FD, OXA, SXT 
MRSA0805-19 ERY, GEN, RD, CIP, OXA 
MRSA0805-20 ERY, GEN, MUP, CIP, NET, TET, OXA, SXT 
MRSA0805-21 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0805-22 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0805-23 ERY, GEN, CIP, OXA, SXT 
MRSA0805-24 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0805-3 ERY, GEN, NET, TET, OXA 
MRSA0805-4 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0805-5 ERY, GEN, TET, OXA, SXT 
MRSA0805-6 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0805-9 ERY, CIP, OXA, SXT 
MRSA0806-1 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0806-11 OXA 
MRSA0806-13 OXA 
MRSA0806-14 ERY, GEN, OXA, SXT 
MRSA0806-18 ERY, GEN, CIP, NET, OXA 
MRSA0806-21 ERY, CIP, OXA, SXT 
MRSA0806-22 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0806-26 ERY, GEN, NET, TET, OXA 
MRSA0806-33 ERY, GEN, CIP, OXA 
MRSA0807-1 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0807-13 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0807-14 ERY, GEN, CIP, NET, OXA 
MRSA0807-19 ERY, GEN, CIP, OXA 
MRSA0807-7 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0807-8 ERY, GEN, CIP, NET, TET, OXA 
MRSA0808-17 ERY, GEN, MUP, CIP, NET, TET, OXA, SXT 
MRSA0808-19 ERY, GEN, CIP, OXA 
MRSA0808-21 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0808-24 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0808-25 ERY, GEN, CIP, OXA 
MRSA0808-26 ERY, GEN, CIP, NET, OXA 
MRSA0808-35 ERY, GEN, TET, OXA, SXT 
MRSA0809-1 ERY, GEN, DA, CIP, TET, OXA, SXT 
MRSA0809-10 ERY, CIP, TET, OXA, SXT 
MRSA0809-14 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-15 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-24 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-25 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0809-27 ERY, CIP, OXA, SXT 
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Abbreviations: CIP, ciprofloxacin; DA, clindamycin; ERY, erythromycin; FD, fusidic 
acid; GEN, gentamicin; LZD, linezolid; NET, netilmicin; RD, rifampicin; TEC, 
teicoplanin; TET, tetracycline; SXT, trimethoprim-sulfamethoxazole; MUP, mupirocin; 
OXA, oxacillin 
  
(continue)  
Strain No Resistance profiles 
MRSA0809-30 ERY. GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-32 ERY, GEN, RD, DA, CIP, TET, FD, OXA, SXT 
MRSA0809-33 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-36 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0809-38 ERY, GEN, CIP, NET, TET, OXA 
MRSA0810-10 ERY, CIP, FD, OXA 
MRSA0810-13 ERY, GEN. CIP, TET, OXA, SXT 
MRSA0810-15 ERY, GEN, CIP, NET, OXA 
MRSA0810-16 ERY, GEN, CIP, OXA 
MRSA0810-17 ERY, CIP, FD, OXA 
MRSA0810-18 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0810-2 ERY, CIP, TET, OXA, SXT 
MRSA0810-22 ERY, CIP, TET, OXA, SXT 
MRSA0810-23 ERY, GEN, CIP, TET, OXA 
MRSA0810-6 ERY, CIP, FD, OXA 
MRSA0810-7 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0810-9 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0811-10 ERY, GEN, CIP, OXA 
MRSA0811-11 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0811-13 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0811-16 ERY, GEN, NET, TET, OXA, SXT 
MRSA0811-2 ERY, CIP, OXA, SXT 
MRSA0811-22 ERY, CIP, OXA, SXT 
MRSA0811-24 ERY, GEN, OXA, SXT 
MRSA0811-25 ERY, GEN, RD, CIP, NET, TET, FD, OXA 
MRSA0811-26 ERY, GEN, CIP, OXA, SXT 
MRSA0811-28 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0811-30 ERY, CIP, TET, OXA, SXT 
MRSA0811-5 ERY, GEN, CIP, TET, OXA 
MRSA0811-8 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0812-1 ERY, CIP, OXA, SXT 
MRSA0812-11 OXA 
MRSA0812-15 ERY, GEN, CIP, NET, OXA, SXT 
MRSA0812-17 ERY, GEN, CIP, TET, OXA, SXT 
MRSA0812-2 ERY, GEN, DA, CIP, TET, OXA, SXT 
MRSA0812-22 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0812-23 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0812-27 ERY, GEN, NET, TET, OXA, SXT 
MRSA0812-30 ERY, GEN, CIP, TET, FD, OXA, SXT 
MRSA0812-31 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0812-33 ERY, GEN, RD, CIP, TET, FD, OXA, SXT 
MRSA0812-35 ERY, GEN, CIP, NET, TET, OXA, SXT 
MRSA0812-36 ERY, GEN, CIP, OXA, SXT 
MRSA0812-37 ERY, GEN, CIP, NET, TET, OXA, SXT 
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APPENDIX 4 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified beta-lactam resistant gene (blaZ) from MRSA0810-6 
 
> gb|DQ016068.1|  Staphylococcus aureus strain E19778 beta-lactamase (blaZ) gene,  
partial cds 
Length=519 
 
 Score =  470 bits (254),  Expect = 3e-129 
 Identities = 264/269 (98%), Gaps = 0/269 (0%) 
 Strand=Plus/Minus 
 
Query  23   TATTATAAGGTACTTGTTCTAACAAAATAGCACTATTTATCGCTTTTGAAGTTGAAGCAG  82 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||  
Sbjct  288  TATTATAAGGTACTTGTTCTAACAAAATAGCACTATTTATCGCTTTTGAAGTTGAAGCAT  229 
 
Query  83   AGGCAAATCTCTTATCGGCATTAAATTTTACTTCCTTACCACTTTTAGTATCTAATGCAT  142 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  228  AGGCAAATCTCTTATCGGCATTAAATTTTACTTCCTTACCACTTTTAGTATCTAATGCAT  169 
 
Query  143  AGACACCAATATTAGCATTATATTTCTTTTCTAAATTATTTAACTCTTTAGCATGTGAAC  202 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  168  AGACACCAATATTAGCATTATATTTCTTTTCTAAATTATTTAACTCTTTAGCATGTGAAC  109 
 
Query  203  TGGGTGAATTACATGCACTTAGAACTAAAGCAATTGCAATTAAAAGTATTAACTTTTTCA  262 
            ||| ||||||||||||||||| |||||||||||||||||||||||||||||||||||||| 
Sbjct  108  TGGTTGAATTACATGCACTTAAAACTAAAGCAATTGCAATTAAAAGTATTAACTTTTTCA  49 
 
Query  263  AAAGATACCCTCCGATATTACAGTTGTAA  291 
            ||| ||||||||| ||||||||||||||| 
Sbjct  48   AAATATACCCTCCAATATTACAGTTGTAA  20 
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APPENDIX 5 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified tetracycline resistance protein class M (tetM) from MRSA0809-10 
 
    235 atggatttcttagcagaagtatatcgttcattatcagttttagat 
        M  D  F  L  A  E  V  Y  R  S  L  S  V  L  D  
    190 ggggcaattctactgatttctgcaaaagatggcgtacaagcacaa 
        G  A  I  L  L  I  S  A  K  D  G  V  Q  A  Q  
    145 actcgtatattatttcatgcacttaggaaaatggggattcccaca 
        T  R  I  L  F  H  A  L  R  K  M  G  I  P  T  
    100 atcttttttatcaataagattgaccaaaatggaattgatttatca 
        I  F  F  I  N  K  I  D  Q  N  G  I  D  L  S  
     55 acggtttatcaggatattaaagagaaacttctgccgaaattgtaa 11      
        T  V  Y  Q  D  I  K  E  K  L  L  P  K  L  *  
 
> gb|AEA35199.1|  tetracycline resistance protein class M [uncultured bacterium] 
Length=136 
 
 Score =  142 bits (359),  Expect = 6e-42, Method: Compositional matrix adjust. 
 Identities = 70/70 (100%), Positives = 70/70 (100%), Gaps = 0/70 (0%) 
 
Query  1    MDFLAEVYRSLSVLDGAILLISAKDGVQAQTRILFHALRKMGIPTIFFINKIDQNGIDLS  60 
                 MDFLAEVYRSLSVLDGAILLISAKDGVQAQTRILFHALRKMGIPTIFFINKIDQNGIDLS 
Sbjct  44   MDFLAEVYRSLSVLDGAILLISAKDGVQAQTRILFHALRKMGIPTIFFINKIDQNGIDLS  103 
 
Query  61   TVYQDIKEKL  70 
                   TVYQDIKEKL 
Sbjct  104  TVYQDIKEKL  113 
 
 
 
 
 
APPENDIX 6 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified tetracycline resistance protein class K (tetK) from MRSA0704-15 
 
    116 ataggaacagcagtatatggaaaattatctgattatataaatata 
        I  G  T  A  V  Y  G  K  L  S  D  Y  I  N  I  
     71 aaaaaattgttaattattggtattagtttgagctgtcttggttca 
        K  K  L  L  I  I  G  I  S  L  S  C  L  G  S  
     26 ttgattgcttttattggtcanatcac 1       
        L  I  A  F  I  G  X  I  
 
> gb|AEA35190.1|  tetracycline resistance protein class K [uncultured bacterium] 
 gb|AEA35191.1|  tetracycline resistance protein class K [uncultured bacterium] 
 gb|AEA35192.1|  tetracycline resistance protein class K [uncultured bacterium] 
Length=54 
 
 Score = 67.8 bits (164),  Expect = 3e-14, Method: Compositional matrix adjust. 
 Identities = 36/36 (100%), Positives = 36/36 (100%), Gaps = 0/36 (0%) 
 
Query  1   IGTAVYGKLSDYINIKKLLIIGISLSCLGSLIAFIG  36 
                 IGTAVYGKLSDYINIKKLLIIGISLSCLGSLIAFIG 
Sbjct  1    IGTAVYGKLSDYINIKKLLIIGISLSCLGSLIAFIG  36 
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APPENDIX 7 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified ermA from MRSA0812-37 
 
 
> gb|CP002643.1|  Staphylococcus aureus subsp. aureus T0131, complete genome 
Length=29139 
Sort alignments for this subject sequence by:                                                      E value  Score  Percent identity Query start position  
Subject start position 
Features in this part of subject sequence:rRNA adenine N-6-methyltransferase 
 
 Score =  174 bits (94),  Expect = 7e-41 
 Identities = 98/100 (98%), Gaps = 1/100 (1%) 
 Strand=Plus/Plus 
 
Query  1        ATCTGC-ACGAGCTTTGGGTTTACTATTAATGGTGGAGANGGATATAAAAATGCTCAAAA  59 
                |||||| |||||||||||||||||||||||||||||||| |||||||||||||||||||| 
Sbjct  1733787  ATCTGCAACGAGCTTTGGGTTTACTATTAATGGTGGAGATGGATATAAAAATGCTCAAAA  1733846 
 
Query  60       AAGTACCACCACTATATTTTCATCCTAAGCCAAGTGTAGA  99 
                |||||||||||||||||||||||||||||||||||||||| 
Sbjct  1733847  AAGTACCACCACTATATTTTCATCCTAAGCCAAGTGTAGA  1733886 
 
 
APPENDIX 8 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified ermC from MRSA0811-16 
 
    107 atattgcagtttaaatttcctaaaaaccaatcctataaaatattt 
        I  L  Q  F  K  F  P  K  N  Q  S  Y  K  I  F  
     62 ggtaatataccttataacataagtacggatataatacgcaaaatt 
        G  N  I  P  Y  N  I  S  T  D  I  I  R  K  I  
     17 gtttttgatagtatagc 1       
        V  F  D  S  I  
 
 
 
> gb|AAL75490.1|  ErmC [Staphylococcus aureus] 
 gb|AAL75491.1|  ErmC [Staphylococcus aureus] 
 gb|AAL75492.1|  ErmC [Staphylococcus aureus] 
Length=127 
 
 Score = 72.8 bits (177),  Expect = 2e-15, Method: Compositional matrix adjust. 
 Identities = 35/35 (100%), Positives = 35/35 (100%), Gaps = 0/35 (0%) 
 
Query  1   ILQFKFPKNQSYKIFGNIPYNISTDIIRKIVFDSI  35 
                 ILQFKFPKNQSYKIFGNIPYNISTDIIRKIVFDSI 
Sbjct  56  ILQFKFPKNQSYKIFGNIPYNISTDIIRKIVFDSI  90 
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APPENDIX 9 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified aac(6’)-aph(2”) from MRSA0707-26 
 
     1 attggntatggacaaatatataaaatgtatgatgagttatatact 
        I  G  Y  G  Q  I  Y  K  M  Y  D  E  L  Y  T  
     46 gattatcattatccaaaaactgatgagatagtctatggtatggat 
        D  Y  H  Y  P  K  T  D  E  I  V  Y  G  M  D  
     91 caatttataggagagccaaattattggagtaaagga 126     
        Q  F  I  G  E  P  N  Y  W  S  K  G  
 
> ref|NP_115315.1|  N-acetyltransferase [Staphylococcus aureus subsp. aureus Mu50] 
 ref|NP_816984.1|  6'-aminoglycoside N-acetyltransferase [Enterococcus faecalis  
V583] 
 ref|NP_863643.1|  bifunctional aminoglycoside modifying enzyme AacA-AphD [Staphylococcus aureus] 112 more sequence titles 
 Length=479 
 GENE ID: 1119947 aacA | N-acetyltransferase 
[Staphylococcus aureus subsp. aureus Mu50] (10 or fewer PubMed links) 
 
 Score = 91.7 bits (226),  Expect = 6e-21, Method: Compositional matrix adjust. 
 Identities = 42/42 (100%), Positives = 42/42 (100%), Gaps = 0/42 (0%) 
 
Query  1    IGYGQIYKMYDELYTDYHYPKTDEIVYGMDQFIGEPNYWSKG  42 
            IGYGQIYKMYDELYTDYHYPKTDEIVYGMDQFIGEPNYWSKG 
Sbjct  70   IGYGQIYKMYDELYTDYHYPKTDEIVYGMDQFIGEPNYWSKG  111 
 
 
 
APPENDIX 10 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified ileS2 from MRSA0406-8 
  11 attattaacaataataataatatagagtggtttccttctcatatt 
        I  I  N  N  N  N  N  I  E  W  F  P  S  H  I  
     56 aaggaagggagaatgggaaatttcttagaaaatatggttgattgg 
        K  E  G  R  M  G  N  F  L  E  N  M  V  D  W  
    101 aacattggtagaaatagatattggggaacaccattaaatgtatgg 
        N  I  G  R  N  R  Y  W  G  T  P  L  N  V  W  
    146 atttgcaatgattgtaatcacgaatacgcaccaagtagtattaag 
        I  C  N  D  C  N  H  E  Y  A  P  S  S  I  K  
    191 gatttacaaaataattccatcaataaaattgatgaagatattgag 
        D  L  Q  N  N  S  I  N  K  I  D  E  D  I  E  
    236 ttgcatagaccttatgttgataatatcactcttagttgccctaag 
        L  H  R  P  Y  V  D  N  I  T  L  S  C  P  K  
    281 tgtaatgggaaaatgtctcgagtagaagaagtaatcgatgtttgg 
        C  N  G  K  M  S  R  V  E  E  V  I  D  V  W  
    326 tttgatagcggctctatgccgtttgctcagcatcattatcctttt 
        F  D  S  G  S  M  P  F  A  Q  H  H  Y  P  F  
    371 gataaccagaaaatttttaatcaacactttcnnnnnaattttatt 415     
        D  N  Q  K  I  F  N  Q  H  F  X  X  N  F  I  
> ref|YP_492689.1|  isoleucyl-tRNA synthetase [Staphylococcus aureus subsp. aureus  
USA300_FPR3757] 
 ref|ZP_04796222.1|  isoleucyl-tRNA synthetase [Staphylococcus epidermidis W23144] 
 ref|ZP_04824236.1|  isoleucyl-tRNA synthetase [Staphylococcus epidermidis BCM-HMP0060] 
 18 more sequence titles Length=1024 
 
 GENE ID: 3912750 ileS | isoleucyl-tRNA synthetase 
[Staphylococcus aureus subsp. aureus USA300_FPR3757] (10 or fewer PubMed links) 
 
 Score =  271 bits (692),  Expect = 1e-82, Method: Compositional matrix adjust. 
 Identities = 123/126 (98%), Positives = 124/126 (98%), Gaps = 0/126 (0%) 
 
Query  10   WFPSHIKEGRMGNFLENMVDWNIGRNRYWGTPLNVWICNDCNHEYAPSSIKDLQNNSINK  69 
            WFPSHIKEGRMGNFLENMVDWNIGRNRYWGTPLNVWICNDCNHEYAPSSIKDLQNNSINK 
Sbjct  417  WFPSHIKEGRMGNFLENMVDWNIGRNRYWGTPLNVWICNDCNHEYAPSSIKDLQNNSINK  476 
 
Query  70   IDEDIELHRPYVDNITLSCPKCNGKMSRVEEVIDVWFDSGSMPFAQHHYPFDNQKIFNQH  129 
            IDEDIELHRPYVDNITLSCPKCNGKMSRVEEVIDVWFDSGSMPFAQHHYPFDNQKIFNQH 
Sbjct  477  IDEDIELHRPYVDNITLSCPKCNGKMSRVEEVIDVWFDSGSMPFAQHHYPFDNQKIFNQH  536 
 
Query  130  FXXNFI  135 
            F  +FI 
Sbjct  537  FPADFI  542 
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APPENDIX 11 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified mupA from MRSA0406-8 
> gb|EF433950.1|  Staphylococcus aureus strain MB1348 nonfunctional polymorphic  
mupirocin-resistance protein (mupA) gene, complete sequence 
Length=3233 
 
 Score = 1910 bits (1034),  Expect = 0.0 
 Identities = 1118/1158 (97%), Gaps = 26/1158 (2%) 
 Strand=Plus/Minus 
 
Query  5     TCTTAAA-AATCGGGCTCCGTACTTATTAATTAATTCAGTTGGATTAATAACGTTTCCTT  63 
             ||||||| |||| ||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1906  TCTTAAAGAATC-GGCTCCGTACTTATTAATTAATTCAGTTGGATTAATAACGTTTCCTT  1848 
 
Query  64    TACTTTTAGACAtttttttACCATTACTGTCTAGAATATGTCCTAAAGATAAAGCACGTT  123 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1847  TACTTTTAGACATTTTTTTACCATTACTGTCTAGAATATGTCCTAAAGATAAAGCACGTT  1788 
 
Query  124   TATAAGAAGATTTTCCTTTTAGAATAGTAGAAATTACTAGTAAACTGTAAAACCAGCCTC  183 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1787  TATAAGAAGATTTTCCTTTTAGAATAGTAGAAATTACTAGTAAACTGTAAAACCAGCCTC  1728 
 
Query  184   TCGTTTGATCAACTCCTTCTGCAATAAAATCAGCTGGAAAGTGTTGATTAAAAATTTTCT  243 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1727  TCGTTTGATCAACTCCTTCTGCAATAAAATCAGCTGGAAAGTGTTGATTAAAAATTTTCT  1668 
 
Query  244   GGTTATCAAAAGGATAATGATGCTGAGCAAACGGCATAGAGCCGCTATCAAACCAAACAT  303 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1667  GGTTATCAAAAGGATAATGATGCTGAGCAAACGGCATAGAGCCGCTATCAAACCAAACAT  1608 
 
Query  304   CGATTACTTCTTCTACTCGAGACATTTTCCCATTACACTTAGGGCAACTAAGAGTGATAT  363 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1607  CGATTACTTCTTCTACTCGAGACATTTTCCCATTACACTTAGGGCAACTAAGAGTGATAT  1548 
 
Query  364   TATCAACATAAGGTCTATGCAACTCAATATCTTCATCAATTTTATTGATGGAATTATTTT  423 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1547  TATCAACATAAGGTCTATGCAACTCAATATCTTCATCAATTTTATTGATGGAATTATTTT  1488 
 
Query  424   GTAAATCCTTAATACTACTTGGTGCGTATTCGTGATTACAATCATTGCAAATCCATACAT  483 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1487  GTAAATCCTTAATACTACTTGGTGCGTATTCGTGATTACAATCATTGCAAATCCATACAT  1428 
 
Query  484   TTAATGGTGTTCCCCAATATCTATTTCTACCAATGTTCCAATCAACCATATTTTCTAAGA  543 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1427  TTAATGGTGTTCCCCAATATCTATTTCTACCAATGTTCCAATCAACCATATTTTCTAAGA  1368 
 
Query  544   AATTTCCCATTCTCCCTTCCTTAATATGAGAAGGAAACCACTCTATATTATTATTATTGT  603 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1367  AATTTCCCATTCTCCCTTCCTTAATATGAGAAGGAAACCACTCTATATTATTATTATTGT  1308 
 
Query  604   TAATAATTTCATTCTTAAAATTAGTTGTTTTAATAAACCAACCTTCCATCGCATAATATA  663 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1307  TAATAATTTCATTCTTAAAATTAGTTGTTTTAATAAACCAACCTTCCATCGCATAATATA  1248 
 
Query  664   TCAAAGGATTACCACATCTCCAACAATGAGGATAATTATGCTCatatttttgttttttat  723 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1247  TCAAAGGATTACCACATCTCCAACAATGAGGATAATTATGCTCATATTTTTGTTTTTTAT  1188 
 
Query  724   ataaaagttgttttttggataataattttatgatttctatatcactatttttAGCTTTAT  783 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1187  ATAAAAGTTGTTTTTTGGATAATAATTTTATGATTTCTATATCACTATTTTTAGCTTTAT  1128 
 
Query  784   TACCAACTAATTCAGGGAACCTATCATTATATACTCCTTCTCTTGTTATAACATTTAAGA  843 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  1127  TACCAACTAATTCAGGGAACCTATCATTATATACTCCTTCTCTTGTTATAACATTTAAGA  1068 
 
Query  844   AATCCAAATCACGCTCTAAAACCAATTGGTAGTCATCTTCCC-ATGAGCTGGTGCTATAT  902 
             |||||||||||||||||||||||||||||||||||||||||| ||||||||||||||||| 
Sbjct  1067  AATCCAAATCACGCTCTAAAACCAATTGGTAGTCATCTTCCCCATGAGCTGGTGCTATAT  1008 
 
Query  903   GAACAATACCAGTTCCTTCTGAGTTAGTAACAA-TTCTCCATCAACAACGTAATATGCAT  961 
             ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Sbjct  1007  GAACAATACCAGTTCCTTCTGAGTTAGTAACAAATTCTCCATCAACAACGTAATATGCAT  948 
 
Query  962   TAACTAAAACCGTCGCTT-CAAA-GGNNGGA-TGTATTTTNAATTTATTAANTTACTTNC  1018 
             |||||||| ||||||||| |||| ||  ||| |||||||| |||| ||||| |||||| | 
Sbjct  947   TAACTAAA-CCGTCGCTTTCAAAAGGA-GGAATGTATTTTAAATTAATTAAATTACTTCC  890 
 
Query  1019  TGAAAGGGTATCA-TA-TTTCGTATTTTTTCAGTTAATNATAGANT-AAT-AGGATCTTG  1074 
             ||||| ||||||| || |||||||||||| |||||| | ||||| | ||| || |||| | 
Sbjct  889   TGAAAAGGTATCAATAATTTCGTATTTTT-CAGTTATT-ATAGAATTAATTAG-ATCT-G  834 
 
Query  1075  TAGCTA-GATAATA-TACTCAATTTCTACCCCNANTTTTTGA-TANN-A-GATCTT-ANT  1128 
             |||||| |||| || |||||| |||||||||  | ||||||| ||   | |||||| | | 
Sbjct  833   TAGCTAAGATA-TAATACTCATTTTCTACCCGAA-TTTTTGAATAATTAAGATCTTTATT  776 
 
Query  1129  TATAGCTA-TGCTACATT  1145 
             |||||||| ||||||||| 
Sbjct  775   TATAGCTAATGCTACATT  758 
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APPENDIX 12 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified macrolide efflux (msrA) from MRSA0812-36 
> gb|EF092840.1|  Staphylococcus epidermidis macrolide efflux resistance (msrA)  
gene, partial cds 
Length=974 
 
 Score =  187 bits (101),  Expect = 1e-44 
 Identities = 105/107 (98%), Gaps = 0/107 (0%) 
 Strand=Plus/Minus 
 
Query  1    CTACACCATTTGCACCTACGAGCGCTATATTTTTGCCATATGGTATTTGGAATCGTACTT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  877  CTACACCATTTGCACCTACGAGCGCTATATTTTTGCCATATGGTATTTGGAATCGTACTT  818 
 
Query  61   GTGTTAGCAGTTTTTGACTCCCTTTAACCAATGTTAAATTTTGTGCA  107 
            ||||||||||||||||||| |||||||||||||||| |||||||||| 
Sbjct  817  GTGTTAGCAGTTTTTGACTTCCTTTAACCAATGTTAGATTTTGTGCA  771 
 
 
 
APPENDIX 13 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified transposon Tn5801-like tetracycline resistance protein (tetM) from 
MRSA0805-15. 
> gb|EU918655.2|  Staphylococcus aureus strain 1680 transposon Tn5801-like tetracycline  
resistance protein (tetM) gene, complete cds 
Length=5520 
 Score = 1243 bits (673),  Expect = 0.0 
 Identities = 676/677 (99%), Gaps = 1/677 (0%) 
 Strand=Plus/Minus 
 
Query  1     TTAATGATAAGTGGATTTTCTCCCATACTGATTAACAAGGAAGCATGAGAATGCCGTAAC  60 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5516  TTAATGATAAGTGGATTTTCTCCCATACTGATTAACAAGGAAGCATGAGAATGCCGTAAC  5457 
 
Query  61    CCATGGATTCTGATTCGATGGATACCAGCCAGCTTAGCATAGCGTTCAATAGCATATGAT  120 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5456  CCATGGATTCTGATTCGATGGATACCAGCCAGCTTAGCATAGCGTTCAATAGCATATGAT  5397 
 
Query  121   AGTGTATGTTTTTGGGTAGGAATACCGTTATAGCTCATTACAAAGTCTGTCTGAATTAGA  180 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5396  AGTGTATGTTTTTGGGTAGGAATACCGTTATAGCTCATTACAAAGTCTGTCTGAATTAGA  5337 
 
Query  181   TTTTGTTGTACTTCCTTCCATTCGGATAAATAAGTTAATGTGCATTTATCTAATACAATA  240 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5336  TTTTGTTGTACTTCCTTCCATTCGGATAAATAAGTTAATGTGCATTTATCTAATACAATA  5277 
 
Query  241   TGACGAACGCTCGCCTTTGTTTTTGGTTCAACAAATCTATAATTCGATTGATTCTTGTAA  300 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5276  TGACGAACGCTCGCCTTTGTTTTTGGTTCAACAAATCTATAATTCGATTGATTCTTGTAA  5217 
 
Query  301   TAGAGTGTTTTGTTGATGGTTAGTACTCCTGAGTCAAAATCAATATCTTCCCATTGAATG  360 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5216  TAGAGTGTTTTGTTGATGGTTAGTACTCCTGAGTCAAAATCAATATCTTCCCATTGAATG  5157 
 
Query  361   GCAGTAGCTTCACCAATTCGCATTCCAGTCATAAATAAAAACCACAGAGAGATAAATAAA  420 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5156  GCAGTAGCTTCACCAATTCGCATTCCAGTCATAAATAAAAACCACAGAGAGATAAATAAA  5097 
 
Query  421   AAGTGTTGATAGTAATCTTCTTTGTAAATTAGAGAGATTActttttcaaattcttctttt  480 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5096  AAGTGTTGATAGTAATCTTCTTTGTAAATTAGAGAGATTACTTTTTCAAATTCTTCTTTT  5037 
 
Query  481   gtccaaaattcaattttagacttttgctttttcACATTGCCAATAATCTTAGATGGATTT  540 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  5036  GTCCAAAATTCAATTTTAGACTTTTGCTTTTTCACATTGCCAATAATCTTAGATGGATTT  4977 
 
Query  541   GTGGTGGTTATCCCAAGGACAATTGCTCGATCCATAGCAACTGAAAATAGTCCTTGAACA  600 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4976  GTGGTGGTTATCCCAAGGACAATTGCTCGATCCATAGCAACTGAAAATAGTCCTTGAACA  4917 
 
Query  601   GCTCTTACATAAGAAGACTTACACTTCTTTGATAATTTTAGTTGCCAATTTTGCACATCA  660 
             |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  4916  GCTCTTACATAAGAAGACTTACACTTCTTTGATAATTTTAGTTGCCAATTTTGCACATCA  4857 
 
Query  661   ATAGGCTCTAATATCGG  677 
             |||||||| |||||||| 
Sbjct  4856  ATAGGCTC-AATATCGG  4841 
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APPENDIX 14 
Allignment and mutation studies for fusA and rpoB genes using Mega4 programme 
               
A (fusA gene) 
 
B (fusA gene) 
 
C (rpoB gene) 
  
Reference 
sequence 
S. aureus 
MU5 MRSA 
strains 
from this 
study 
Nucleotide 
substitution  
MRSA 
strains 
from this 
study 
Reference 
sequence 
MRSA25
2 
Nucleotide 
substitution  
MRSA 
strains 
from this 
study 
Reference 
sequence 
218 
 
APPENDIX 15 
GenBank flat file for mutational changes in rpoB gene for MRSA0308-10 
 
LOCUS      HQ914953                375 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0308-10 RNA polymerase subunit beta (rpoB) gene, partial cds. 
ACCESSION  HQ914953 
VERSION    HQ914953 
KEYWORDS     
SOURCE      Staphylococcus aureus 
 ORGANISM  Staphylococcus aureus 
                        Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 375) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus isolated in Malaysia                            
 JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 375) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission          
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of   
                                                                 Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers    
source          1..375 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0308-10" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
gene            <1..>375 
                    /gene="rpoB" 
CDS            <1..>375 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94022" 
                    /translation="MERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQF 
                    MDQANPLDELTHKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLI 
                    NSLSSYARVNEFGFIETPYRKVE" 
ORIGIN       
          1 atggaaagag ttgtacgtga aagaatgtca attcaagata ctgagtctat cacacctcaa 
        61 caattaatta atattcgacc tgttattgca tctattaaag aattctttgg tagctctcaa 
      121 ttatcacaat tcatggacca agcaaaccca ttagatgagt taacgcataa acgtcgtcta 
      181 tcagcattag gacctggtgg tttaacacgt gaacgtgctc aaatggaagt acgtgacgtt 
      241 cactactctc actatggccg tatgtgtcca attgaaacac ctgagggacc aaacattgga 
      301 ttgattaact cattatcaag ttatgcacgt gtaaatgaat tcggctttat tgaaacacca 
      361 tatcgtaaag ttgaa 
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APPENDIX 16 
GenBank flat file for mutational changes in rpoB gene for MRSA0308-23 
 
LOCUS      HQ914957                374 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0308-23 RNA polymerase subunit beta (rpoB) gene,  
                       partial cds. 
ACCESSION  HQ914957 
VERSION    HQ914957 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 374) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus   
              isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 374) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                  Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..374 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0308-23" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>374 
                    /gene="rpoB" 
    CDS            <1..>374 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94026" 
                    /translation="MERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQF 
                    MDQANPLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGPNIGLI 
                    NSLSSYARVNEFGFIETPYRKV" 
ORIGIN       
        1 atggaaagag ttgtacgtga aagaatgtca attcaagata ctgagtctat cacacctcaa 
      61 caattaatta atattcgacc tgttattgca tctattaaag aattctttgg aagctctcaa 
      121 ttatcacaat tcatggacca agcaaaccca ttagctgagt taacgcataa acgtcatcta 
      181 tcagcattag gacctggtgg tttaacacgt gaacgtgctc aaatggaagt acgtgacgtt 
      241 cactactctc actatggccg tatgtgtcca attcaaacac ctgagggacc aaacattgga 
      301 ttgattaact cattatcaag ttatgcacgt gtaaatgaat tcggctttat tgaaacacca 
      361 tatcgtaaag ttga 
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APPENDIX 17 
GenBank flat file for mutational changes in rpoB gene for MRSA0310-26 
 
LOCUS      HQ914958                384 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0310-26 RNA polymerase subunit beta (rpoB) gene,  
                       partial cds. 
ACCESSION  HQ914958 
VERSION    HQ914958 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 384) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus  
             isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 384) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                  Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..384 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0310-26" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene        <1..>384 
                    /gene="rpoB" 
    CDS         <1..>384 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94027" 
                    /translation="GVVENXVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQL 
                    SQFMDQANPLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGPNI 
                    GLINSLSSYARVNEFGFIETPYRKVE" 
ORIGIN       
          1 ggtgtagttg agaacngagt tgtacgtgaa agaatgtcaa ttcaagatac tgagtctatc 
        61 acacctcaac aattaattaa tattcgacct gttattgcat ctattaaaga attctttggt 
      121 agctctcaat tatcacaatt catggaccaa gcaaacccat tagctgagtt aacgcataaa 
      181 cgtcatctat cagcattagg acctggtggt ttaacacgtg aacgtgctca aatggaagta 
      241 cgtgacgttc actactctca ctatggccgt atgtgtccaa ttcaaacacc tgagggacca 
      301 aacattggat tgattaactc attatcaagt tatgcacgtg taaatgaatt cggctttatt 
      361 gaaacaccat atcgtaaagt tgaa 
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APPENDIX 18 
GenBank flat file for mutational changes in rpoB gene for MRSA0705-13 
 
LOCUS      HQ914959                378 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0705-13 RNA polymerase subunit beta (rpoB) gene, partial cds. 
ACCESSION  HQ914959 
VERSION    HQ914959 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 378) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus  
              isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 378) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                   Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..378 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0705-13" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>378 
                    /gene="rpoB" 
    CDS            <1..>378 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94028" 
                    /translation="RMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQ 
                    FMDQANPLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGPNIGL 
                    INSLSSYARVNEFGFIETPYRKVE" 
ORIGIN       
          1 agaatggaaa gagttgtacg tgaaagaatg tcaattcaag atactgagtc tatcacacct 
        61 caacaattaa ttaatattcg acctgttatt gcatctatta aagaattctt tggtagctct 
      121 caattatcac aattcatgga ccaagcaaac ccattagctg agttaacgca taaacgtcat 
      181 ctatcagcat taggacctgg tggtttaaca cgtgaacgtg ctcaaatgga agtacgtgac 
      241 gttcactact ctcactatgg ccgtatgtgt ccaattcaaa cacctgaggg accaaacatt 
      301 ggattgatta actcattatc aagttatgca cgtgtaaatg aattcggctt tattgaaaca 
      361 ccatatcgta aagttgaa 
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APPENDIX 19 
GenBank flat file for mutational changes in rpoB gene for MRSA0809-1 
// 
LOCUS      HQ914960                360 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0809-1 RNA polymerase subunit beta (rpoB) gene,  
                      partial cds. 
ACCESSION  HQ914960 
VERSION    HQ914960 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 360) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 360) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                   Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..360 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0809-1" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>360 
                    /gene="rpoB" 
    CDS            <1..>360 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94029" 
                    /translation="RERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQAN 
                    PLAELTNKRRLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIETPEGPNIGLINSLSS 
                    YARVNEFGFIETPYRKVE" 
ORIGIN       
          1 cgtgaaagaa tgtcaattca agatactgag tctatcacac ctcaacaatt aattaatatt 
        61 cgacctgtta ttgcatctat taaagaattc tttggtagct ctcaattatc acaattcatg 
      121 gaccaagcaa acccattagc tgagttaacg aataaacgtc gtctatcagc attaggacct 
      181 ggtggtttaa cacgtgaacg tgctcaaatg gaagtacgtg acgttcacta ctctcactat 
      241 ggccgtatgt gtccaattga aacacctgag ggaccaaaca ttggattgat taactcatta 
      301 tcaagttatg cacgtgtaaa tgaattcggc tttattgaaa caccatatcg taaagttgaa 
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APPENDIX 20 
GenBank flat file for mutational changes in rpoB gene for MRSA0809-32 
// 
LOCUS      HQ914961                366 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0809-32 RNA polymerase subunit beta (rpoB) gene,  
                       partial cds. 
ACCESSION  HQ914961 
VERSION    HQ914961 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 366) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus  
             isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 366) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                  Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..366 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0809-32" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>366 
                    /gene="rpoB" 
    CDS            <1..>366 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94030" 
                    /translation="VVRERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQ 
                    ANPLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGPNIGLINSL 
                    SSYARVNEFGFIETPYRKVE" 
ORIGIN       
          1 gttgtacgtg aaagaatgtc aattcaagat actgagtcta tcacacctca acaattaatt 
        61 aatattcgac ctgttattgc atctattaaa gaattctttg gtagctctca attatcacaa 
      121 ttcatggacc aagcaaaccc attagctgag ttaacgcata aacgtcatct atcagcatta 
      181 ggacctggtg gtttaacacg tgaacgtgct caaatggaag tacgtgacgt tcactactct 
      241 cactatggcc gtatgtgtcc aattcaaaca cctgagggac caaacattgg attgattaac 
      301 tcattatcaa gttatgcacg tgtaaatgaa ttcggcttta ttgaaacacc atatcgtaaa 
      361 gttgaa 
 
  
224 
 
APPENDIX 21 
GenBank flat file for mutational changes in rpoB gene for MRSA0308-10 
 
LOCUS      HQ914962                359 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0811-25 RNA polymerase subunit beta (rpoB) gene,  
                       partial cds. 
ACCESSION  HQ914962 
VERSION    HQ914962 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 359) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L.  
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus  
             isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 359) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur 
50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..359 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0811-25" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>359 
                    /gene="rpoB" 
    CDS            <1..>359 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94031" 
                    /translation="RERMSIQDTESITPQQLINIRPVIASIKEFFGSSQLSQFMDQAN 
                    PLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGPNIGLINSLSS 
                    YARVNEFGFIETPYRKV" 
ORIGIN       
          1 cgtgaaagaa tgtcaattca agatactgag tctatcacac ctcaacaatt aattaatatt 
        61 cgacctgtta ttgcatctat taaagaattc tttggtagct ctcaattatc acaattcatg 
      121 gaccaagcaa acccattagc tgagttaacg cataaacgtc atctatcagc attaggacct 
      181 ggtggtttaa cacgtgaacg tgctcaaatg gaagtacgtg acgttcacta ctctcactat 
      241 ggccgtatgt gtccaattca aacacctgag ggaccaaaca ttggattgat taactcatta 
      301 tcaagttatg cacgtgtaaa tgaattcggc tttattgaaa caccatatcg taaagttga 
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APPENDIX 22 
GenBank flat file for mutational changes in rpoB gene for MRSA0812-33 
// 
LOCUS      HQ914963                390 bp    DNA    linear  BCT 27-JUL-2011 
DEFINITION  Staphylococcus aureus strain MRSA0812-33 RNA polymerase subunit beta (rpoB) gene,  
                       partial cds. 
ACCESSION  HQ914963 
VERSION    HQ914963 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 390) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Prevalence and molecular characterizaiton of rifampicin resistance in Staphylococcus aureus  
             isolated in Malaysia 
JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 390) 
AUTHORS  Lim,K.T., Abu Hanifah,Y., Mohd Yusof,M.Y. and Thong,K.L. 
TITLE    Direct Submission 
JOURNAL  Submitted (21-JAN-2011) Institute of Biological Sciences, Faculty of Science, University of  
                   Malaya, Kuala Lumpur 50603, Malaysia 
FEATURES            Location/Qualifiers 
    source          1..390 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0812-33" 
                    /host="Homo sapiens" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
    gene            <1..>390 
                    /gene="rpoB" 
    CDS            <1..>390 
                    /gene="rpoB" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="RNA polymerase subunit beta" 
                    /protein_id="AEK94032" 
                    /translation="IGLSRMERVVRERMSIQDTESITPQQLINIRPVIASIKEFFGSS 
                    QLSQFMDQANPLAELTHKRHLSALGPGGLTRERAQMEVRDVHYSHYGRMCPIQTPEGP 
                    NIGLINSLSSYARVNEFGFIETPYRKVE" 
ORIGIN       
          1 atcggtttat caagaatgga aagagttgta cgtgaaagaa tgtcaattca agatactgag 
        61 tctatcacac ctcaacaatt aattaatatt cgacctgtta ttgcatctat taaagaattc 
      121 tttggtagct ctcaattatc acaattcatg gaccaagcaa acccattagc tgagttaacg 
      181 cataaacgtc atctatcagc attaggacct ggtggtttaa cacgtgaacg tgctcaaatg 
      241 gaagtacgtg acgttcacta ctctcactat ggccgtatgt gtccaattca aacacctgag 
      301 ggaccaaaca ttggattgat taactcatta tcaagttatg cacgtgtaaa tgaattcggc 
      361 tttattgaaa caccatatcg naaagttgaa 
// 
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APPENDIX 23 
GenBank flat file for mutational changes in fusA gene for MRSA0307-23 
 
LOCUS      JN597292                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0307-23 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597292 
VERSION    JN597292 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0307-23" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST03007-23" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="25-Jul-2003" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93396" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELYLDILVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 ctttacttag acatcttagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 24 
GenBank flat file for mutational changes in fusA gene for MRSA0308-23 
// 
LOCUS      JN597293                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0308-23 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597293 
VERSION    JN597293 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0308-23" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0308-23" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="07-Aug-2003" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93397" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 25 
GenBank flat file for mutational changes in fusA gene for MRSA0310-26 
// 
LOCUS      JN597294                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0310-26 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597294 
VERSION    JN597294 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0310-26" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0310-26" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="30-Oct-2003" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93398" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 26 
GenBank flat file for mutational changes in fusA gene for MRSA0801-26 
// 
LOCUS      JN597295                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0801-26 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597295 
VERSION    JN597295 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0801-26" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0801-2" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="29-Jan-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93399" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDISVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatctcagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 27 
GenBank flat file for mutational changes in fusA gene for MRSA0805-15 
// 
LOCUS      JN597296                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0805-15 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597296 
VERSION    JN597296 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0805-15" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0805-15" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="12-May-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93400" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 28 
GenBank flat file for mutational changes in fusA gene for MRSA0805-17 
// 
LOCUS      JN597297                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0805-17 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597297 
VERSION    JN597297 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0805-17" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0805-17" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="13-May-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93401" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFLEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDISVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcctagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatctcagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 29 
GenBank flat file for mutational changes in fusA gene for MRSA0807-8 
// 
LOCUS      JN597298                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0807-8 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597298 
VERSION    JN597298 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0807-8" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0807-8" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="18-Jul-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93402" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELYLDILVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 ctttacttag acatcttagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 30 
GenBank flat file for mutational changes in fusA gene for MRSA0809-32 
// 
LOCUS      JN597299                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0809-32 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597299 
VERSION    JN597299 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0809-32" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0809-32" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="22-Sep-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93403" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 31 
GenBank flat file for mutational changes in fusA gene for MRSA0810-7 
// 
LOCUS      JN597300                1740 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0810-7 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597300 
VERSION    JN597300 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..1740 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0810-7" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0810-7" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="07-Oct-2008" 
    gene            <1..>1740 
                    /gene="fusA" 
    CDS            <1..>1740 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93404" 
                    /translation="RILYYTGRIHKIGETHEGASQMDWMEQEQDRGITITSATTTAAW 
                    EGHRVNIIDTPGHVDFTVEVERSLRVLDGAVTVLDAQSGVEPQTETVWRQATTYGVPR 
                    IVFVNKMDKLGANFEYSVSTLHDRLQANAAPIQLPIGAEDEFEAIIDLVEMKCFKYTN 
                    DLGTEIEEIEIPEDHLDRAEEARASLIEAVAETSDELMEKYLGDEEISVSELKEAIRQ 
                    ATTNVEFYPVLCGTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASNPEEEVIAKAD 
                    DSAEFAALAFKVMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMHANS 
                    RQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSKADQ 
                    DKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELYLDILVDRMKKEFNVECNVGAP 
                    MVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVVPRE 
                    YIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKEAAK 
                    KCDPVILEPMMKVT" 
ORIGIN       
        1 cgtattcttt attacactgg ccgtatccac aaaattggtg aaacacacga aggtgcttca 
      61 caaatggact ggatggagca agaacaagac cgtggtatta ctatcacatc tgctacaaca 
      121 acagcagctt gggaaggtca ccgtgtaaac attatcgata cacctggaca cgtagacttc 
      181 actgtagaag ttgaacgttc attacgtgta cttgacggag cagttacagt acttgatgca 
      241 caatcaggtg ttgaacctca aactgaaaca gtttggcgtc aggctacaac ttatggtgtt 
      301 ccacgtatcg tatttgtaaa caaaatggac aaattaggtg ctaacttcga atactctgta 
      361 agtacattac atgatcgttt acaagctaac gctgctccaa tccaattacc aattggtgcg 
      421 gaagacgaat tcgaagcaat cattgactta gttgaaatga aatgtttcaa atatacaaat 
      481 gatttaggta ctgaaattga agaaattgaa attcctgaag accacttaga tagagctgaa 
      541 gaagctcgtg ctagcttaat cgaagcagtt gcagaaacta gcgacgaatt aatggaaaaa 
      601 tatcttggtg acgaagaaat ttcagtttct gaattaaaag aagctatccg ccaagctact 
      661 actaacgtag aattctaccc agtactttgt ggtacagctt tcaaaaacaa aggtgttcaa 
      721 ttaatgcttg acgctgtaat tgattactta ccttcaccac tagacgttaa accaattatt 
      781 ggtcaccgtg ctagcaaccc tgaagaagaa gtaatcgcga aagcagacga ttcagctgaa 
      841 ttcgctgcat tagcgttcaa agttatgact gacccttatg ttggtaaatt gacattcttc 
      901 cgtgtgtatt caggtacaat gacatctggt tcatacgtta agaactctac taaaggtaaa 
      961 cgtgaacgtg taggtcgttt attacaaatg cacgctaact cacgtcaaga aatcgatact 
    1021 gtatactctg gagatatcgc tgctgcggta ggtcttaaag atacaggtac tggtgatact 
    1081 ttatgtggtg agaaaaatga cattatcttg gaatcaatgg aattcccaga gccagttatt 
    1141 cacttatcag tagagccaaa atctaaagct gaccaagata aaatgactca agctttagtt 
    1201 aaattacaag aagaagaccc aacattccat gcacacactg acgaagaaac tggacaagtt 
    1261 atcatcggtg gtatgggtga gctttactta gacatcttag tagaccgtat gaagaaagaa 
    1321 ttcaacgttg aatgtaacgt aggtgctcca atggtttcat atcgtgaaac attcaaatca 
    1381 tctgcacaag ttcaaggtaa attctctcgt caatctggtg gtcgtggtca atacggtgat 
    1441 gttcacattg aattcacacc aaacgaaaca ggcgcaggtt tcgaattcga aaacgctatc 
    1501 gttggtggtg tagttcctcg tgaatacatt ccatcagtag aagctggtct taaagatgct 
    1561 atggaaaatg gtgtcttagc aggttatcct ttaattgatg ttaaagctaa attatatgat 
    1621 ggttcatacc atgatgtcga ttcatctgaa atggccttca aaattgctgc atcattagca 
    1681 cttaaagaag ctgctaaaaa atgtgatcct gtaatcttag aaccaatgat gaaagtaact 
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APPENDIX 32 
GenBank flat file for mutational changes in fusA gene for MRSA0810-10 
// 
LOCUS      JN597301                1740 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0810-10 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597301 
VERSION    JN597301 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..1740 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0810-10" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0810-10" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="04-Oct-2008" 
    gene            <1..>1740 
                    /gene="fusA" 
    CDS            <1..>1740 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93405" 
                    /translation="RILYYTGRIHKIGETHEGASQMDWMEQEQDRGITITSATTTAAW 
                    EGHRVNIIDTPGHVDFTVEVERSLRVLDGAVTVLDAQSGVEPQTETVWRQATTYGVPR 
                    IVFVNKMDKLGANFEYSVSTLHDRLQANAAPIQLPIGAEDEFEAIIDLVEMKCFKYTN 
                    DLGTEIEEIEIPEDHLDRAEEARASLIEAVAETSDELMEKYLGDEEISVSELKEAIRQ 
                    ATTNVEFYPVLCGTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASNPEEEVIAKAD 
                    DSAEFAALAFKVMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMHANS 
                    RQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSKADQ 
                    DKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELYLDILVDRMKKEFNVECNVGAP 
                    MVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVVPRE 
                    YIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKEAAK 
                    KCDPVILEPMMKVT" 
ORIGIN       
        1 cgtattcttt attacactgg ccgtatccac aaaattggtg aaacacacga aggtgcttca 
      61 caaatggact ggatggagca agaacaagac cgtggtatta ctatcacatc tgctacaaca 
      121 acagcagctt gggaaggtca ccgtgtaaac attatcgata cacctggaca cgtagacttc 
      181 actgtagaag ttgaacgttc attacgtgta cttgacggag cagttacagt acttgatgca 
      241 caatcaggtg ttgaacctca aactgaaaca gtttggcgtc aggctacaac ttatggtgtt 
      301 ccacgtatcg tatttgtaaa caaaatggac aaattaggtg ctaacttcga atactctgta 
      361 agtacattac atgatcgttt acaagctaac gctgctccaa tccaattacc aattggtgcg 
      421 gaagacgaat tcgaagcaat cattgactta gttgaaatga aatgtttcaa atatacaaat 
      481 gatttaggta ctgaaattga agaaattgaa attcctgaag accacttaga tagagctgaa 
      541 gaagctcgtg ctagcttaat cgaagcagtt gcagaaacta gcgacgaatt aatggaaaaa 
      601 tatcttggtg acgaagaaat ttcagtttct gaattaaaag aagctatccg ccaagctact 
      661 actaacgtag aattctaccc agtactttgt ggtacagctt tcaaaaacaa aggtgttcaa 
      721 ttaatgcttg acgctgtaat tgattactta ccttcaccac tagacgttaa accaattatt 
      781 ggtcaccgtg ctagcaaccc tgaagaagaa gtaatcgcga aagcagacga ttcagctgaa 
      841 ttcgctgcat tagcgttcaa agttatgact gacccttatg ttggtaaatt gacattcttc 
      901 cgtgtgtatt caggtacaat gacatctggt tcatacgtta agaactctac taaaggtaaa 
      961 cgtgaacgtg taggtcgttt attacaaatg cacgctaact cacgtcaaga aatcgatact 
    1021 gtatactctg gagatatcgc tgctgcggta ggtcttaaag atacaggtac tggtgatact 
    1081 ttatgtggtg agaaaaatga cattatcttg gaatcaatgg aattcccaga gccagttatt 
    1141 cacttatcag tagagccaaa atctaaagct gaccaagata aaatgactca agctttagtt 
    1201 aaattacaag aagaagaccc aacattccat gcacacactg acgaagaaac tggacaagtt 
    1261 atcatcggtg gtatgggtga gctttactta gacatcttag tagaccgtat gaagaaagaa 
    1321 ttcaacgttg aatgtaacgt aggtgctcca atggtttcat atcgtgaaac attcaaatca 
    1381 tctgcacaag ttcaaggtaa attctctcgt caatctggtg gtcgtggtca atacggtgat 
    1441 gttcacattg aattcacacc aaacgaaaca ggcgcaggtt tcgaattcga aaacgctatc 
    1501 gttggtggtg tagttcctcg tgaatacatt ccatcagtag aagctggtct taaagatgct 
    1561 atggaaaatg gtgtcttagc aggttatcct ttaattgatg ttaaagctaa attatatgat 
    1621 ggttcatacc atgatgtcga ttcatctgaa atggccttca aaattgctgc atcattagca 
    1681 cttaaagaag ctgctaaaaa atgtgatcct gtaatcttag aaccaatgat gaaagtaact 
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APPENDIX 33 
GenBank flat file for mutational changes in fusA gene for MRSA0810-17 
// 
LOCUS      JN597302                1740 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0810-17 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597302 
VERSION    JN597302 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 1740) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..1740 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0810-17" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0810-17" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="19-Oct-2008" 
    gene            <1..>1740 
                    /gene="fusA" 
    CDS            <1..>1740 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93406" 
                    /translation="RILYYTGRIHKIGETHEGASQMDWMEQEQDRGITITSATTTAAW 
                    EGHRVNIIDTPGHVDFTVEVERSLRVLDGAVTVLDAQSGVEPQTETVWRQATTYGVPR 
                    IVFVNKMDKLGANFEYSVSTLHDRLQANAAPIQLPIGAEDEFEAIIDLVEMKCFKYTN 
                    DLGTEIEEIEIPEDHLDRAEEARASLIEAVAETSDELMEKYLGDEEISVSELKEAIRQ 
                    ATTNVEFYPVLCGTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASNPEEEVIAKAD 
                    DSAEFAALAFKVMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMHANS 
                    RQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSKADQ 
                    DKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELYLDILVDRMKKEFNVECNVGAP 
                    MVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVVPRE 
                    YIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKEAAK 
                    KCDPVILEPMMKVT" 
ORIGIN       
        1 cgtattcttt attacactgg ccgtatccac aaaattggtg aaacacacga aggtgcttca 
      61 caaatggact ggatggagca agaacaagac cgtggtatta ctatcacatc tgctacaaca 
      121 acagcagctt gggaaggtca ccgtgtaaac attatcgata cacctggaca cgtagacttc 
      181 actgtagaag ttgaacgttc attacgtgta cttgacggag cagttacagt acttgatgca 
      241 caatcaggtg ttgaacctca aactgaaaca gtttggcgtc aggctacaac ttatggtgtt 
      301 ccacgtatcg tatttgtaaa caaaatggac aaattaggtg ctaacttcga atactctgta 
      361 agtacattac atgatcgttt acaagctaac gctgctccaa tccaattacc aattggtgcg 
      421 gaagacgaat tcgaagcaat cattgactta gttgaaatga aatgtttcaa atatacaaat 
      481 gatttaggta ctgaaattga agaaattgaa attcctgaag accacttaga tagagctgaa 
      541 gaagctcgtg ctagcttaat cgaagcagtt gcagaaacta gcgacgaatt aatggaaaaa 
      601 tatcttggtg acgaagaaat ttcagtttct gaattaaaag aagctatccg ccaagctact 
      661 actaacgtag aattctaccc agtactttgt ggtacagctt tcaaaaacaa aggtgttcaa 
      721 ttaatgcttg acgctgtaat tgattactta ccttcaccac tagacgttaa accaattatt 
      781 ggtcaccgtg ctagcaaccc tgaagaagaa gtaatcgcga aagcagacga ttcagctgaa 
      841 ttcgctgcat tagcgttcaa agttatgact gacccttatg ttggtaaatt gacattcttc 
      901 cgtgtgtatt caggtacaat gacatctggt tcatacgtta agaactctac taaaggtaaa 
      961 cgtgaacgtg taggtcgttt attacaaatg cacgctaact cacgtcaaga aatcgatact 
    1021 gtatactctg gagatatcgc tgctgcggta ggtcttaaag atacaggtac tggtgatact 
    1081 ttatgtggtg agaaaaatga cattatcttg gaatcaatgg aattcccaga gccagttatt 
    1141 cacttatcag tagagccaaa atctaaagct gaccaagata aaatgactca agctttagtt 
    1201 aaattacaag aagaagaccc aacattccat gcacacactg acgaagaaac tggacaagtt 
    1261 atcatcggtg gtatgggtga gctttactta gacatcttag tagaccgtat gaagaaagaa 
    1321 ttcaacgttg aatgtaacgt aggtgctcca atggtttcat atcgtgaaac attcaaatca 
    1381 tctgcacaag ttcaaggtaa attctctcgt caatctggtg gtcgtggtca atacggtgat 
    1441 gttcacattg aattcacacc aaacgaaaca ggcgcaggtt tcgaattcga aaacgctatc 
    1501 gttggtggtg tagttcctcg tgaatacatt ccatcagtag aagctggtct taaagatgct 
    1561 atggaaaatg gtgtcttagc aggttatcct ttaattgatg ttaaagctaa attatatgat 
    1621 ggttcatacc atgatgtcga ttcatctgaa atggccttca aaattgctgc atcattagca 
    1681 cttaaagaag ctgctaaaaa atgtgatcct gtaatcttag aaccaatgat gaaagtaact 
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APPENDIX 34 
GenBank flat file for mutational changes in fusA gene for MRSA08120-30 
// 
LOCUS      JN597303                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0812-30 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597303 
VERSION    JN597303 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0812-30" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0812-30" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="28-Dec-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93407" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 35 
GenBank flat file for mutational changes in fusA gene for MRSA0811-25 
// 
LOCUS      JN597304                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0811-25 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597304 
VERSION    JN597304 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0811-25" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0811-25" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="21-Nov-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93408" 
                    /translation="VMTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKCDPVILEPMMKVT" 
ORIGIN       
        1 gttatgactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgtgatcctg taatcttaga accaatgatg aaagtaact 
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APPENDIX 36 
GenBank flat file for mutational changes in fusA gene for MRSA0812-33 
// 
LOCUS      JN597305                879 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0812-33 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597305 
VERSION    JN597305 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 879) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..879 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0812-33" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0812-33" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="31-Dec-2008" 
    gene            <1..>879 
                    /gene="fusA" 
    CDS            <1..>879 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93409" 
                    /translation="VWTDPYVGKLTFFRVYSGTMTSGSYVKNSTKGKRERVGRLLQMH 
                    ANSRQEIDTVYSGDIAAAVGLKDTGTGDTLCGEKNDIILESMEFPEPVIHLSVEPKSK 
                    ADQDKMTQALVKLQEEDPTFHAHTDEETGQVIIGGMGELHLDIKVDRMKKEFNVECNV 
                    GAPMVSYRETFKSSAQVQGKFSRQSGGRGQYGDVHIEFTPNETGAGFEFENAIVGGVV 
                    PREYIPSVEAGLKDAMENGVLAGYPLIDVKAKLYDGSYHDVDSSEMAFKIAASLALKE 
                    AAKKWDPVILKPMMKVT" 
ORIGIN       
        1 gtttggactg acccttatgt tggtaaatta acattcttcc gtgtgtattc aggtacaatg 
      61 acatctggtt catacgttaa gaactctact aaaggtaaac gtgaacgtgt aggtcgttta 
      121 ttacaaatgc acgctaactc acgtcaagaa atcgatactg tatactctgg agatatcgct 
      181 gctgcggtag gtcttaaaga tacaggtact ggtgatactt tatgtggtga gaaaaatgac 
      241 attatcttgg aatcaatgga attcccagag ccagttattc acttatcagt agagccaaaa 
      301 tctaaagctg accaagataa aatgactcaa gctttagtta aattacaaga agaagaccca 
      361 acattccatg cacacactga cgaagaaact ggacaagtta tcatcggtgg tatgggtgag 
      421 cttcacttag acatcaaagt agaccgtatg aagaaagaat tcaacgttga atgtaacgta 
      481 ggtgctccaa tggtttcata tcgtgaaaca ttcaaatcat ctgcacaagt tcaaggtaaa 
      541 ttctctcgtc aatctggtgg tcgtggtcaa tacggtgatg ttcacattga attcacacca 
      601 aacgaaacag gcgcaggttt cgaattcgaa aacgctatcg ttggtggtgt agttcctcgt 
      661 gaatacattc catcagtaga agctggtctt aaagatgcta tggaaaatgg tgttttagca 
      721 ggttatcctt taattgatgt taaagctaaa ttatatgatg gttcatacca tgatgtcgat 
      781 tcatctgaaa tggccttcaa aattgctgca tcattagcac ttaaagaagc tgctaaaaaa 
      841 tgggatcctg taatcttaaa accaatgatg aaagtaact 
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APPENDIX 37 
GenBank flat file for mutational changes in fusA gene for MRSA0810-6 
// 
LOCUS      JN597306                799 bp    DNA    linear  BCT 18-JAN-2012 
DEFINITION  Staphylococcus aureus strain MRSA0810-6 elongation factor G (fusA) 
            gene, partial cds. 
ACCESSION  JN597306 
VERSION    JN597306 
KEYWORDS    . 
SOURCE      Staphylococcus aureus 
  ORGANISM  Staphylococcus aureus 
            Bacteria; Firmicutes; Bacillales; Staphylococcus. 
REFERENCE  1  (bases 1 to 799) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Rifampicin and Fusidic Acid Resistance among Methiciilin-Resistant 
            Staphylococcus aureus Strains from a Tertiary Hospital in Malaysia 
  JOURNAL  Unpublished 
REFERENCE  2  (bases 1 to 799) 
  AUTHORS  Lim,K.T., Hanifah,Y.A., Teh,C.S.J., Mohd Yusof,M.Y. and Thong,K.L. 
  TITLE    Direct Submission 
  JOURNAL  Submitted (19-AUG-2011) Institut of Biological Sciences, Faculty of 
            Science, University of Malaya, Kuala Lumpur, Kuala Lumpur 50603, 
            Malaysia 
FEATURES            Location/Qualifiers 
    source          1..799 
                    /organism="Staphylococcus aureus" 
                    /mol_type="genomic DNA" 
                    /strain="MRSA0810-6" 
                    /host="Homo sapiens" 
                    /specimen_voucher="ST0810-6" 
                    /db_xref="taxon:1280" 
                    /country="Malaysia" 
                    /collection_date="01-Oct-2008" 
    gene            <1..>799 
                    /gene="fusA" 
    CDS            <1..>799 
                    /gene="fusA" 
                    /codon_start=1 
                    /transl_table=11 
                    /product="elongation factor G" 
                    /protein_id="AEX93410" 
                    /translation="RILYYTGRIHKIGETHEGASQMDWMEQEQDRGITITSATTTAAW 
                    EGHRVNIIDTPGHVDFTVEVERSLRVLDGAVTVLDAQSGVEPQTETVWRQATTYGVPR 
                    IVFVNKMDKLGANFEYSVSTLHDRLQANAAPIQLPIGAEDEFEAIIDLVEMKCFKYTN 
                    DLGTEIEEIEIPEDHLDRAEEARASLIEAVAETSDELMEKYLGDEEISVSELKEAIRQ 
                    ATTNVEFYPVLCGTAFKNKGVQLMLDAVIDYLPSPLDVKPIIGHRASN" 
ORIGIN       
        1 cgtattcttt attacactgg ccgtatccac aaaattggtg aaacacacga aggtgcttca 
      61 caaatggact ggatggagca agaacaagac cgtggtatta ctatcacatc tgctacaaca 
      121 acagcagctt gggaaggtca ccgtgtaaac attatcgata cacctggaca cgtagacttc 
      181 actgtagaag ttgaacgttc attacgtgta cttgacggag cagttacagt acttgatgca 
      241 caatcaggtg ttgaacctca aactgaaaca gtttggcgtc aggctacaac ttatggtgtt 
      301 ccacgtatcg tatttgtaaa caaaatggac aaattaggtg ctaacttcga atactctgta 
      361 agtacattac atgatcgttt acaagctaac gctgctccaa tccaattacc aattggtgcg 
      421 gaagacgaat tcgaagcaat cattgactta gttgaaatga aatgtttcaa atatacaaat 
      481 gatttaggta ctgaaattga agaaattgaa attcctgaag accacttaga tagagctgaa 
      541 gaagctcgtg ctagcttaat cgaagcagtt gcagaaacta gcgacgaatt aatggaaaaa 
      601 tatcttggtg acgaagaaat ttcagtttct gaattaaaag aagctatccg ccaagctact 
      661 actaacgtag aattctaccc agtactttgt ggtacagctt tcaaaaacaa aggtgttcaa 
      721 ttaatgcttg acgctgtaat tgattactta ccttcaccac tagacgttaa accaattatt 
      781 ggtcaccgtg ctagcaacc 
// 
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APPENDIX 38 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified enterotoxin type A (sea) from MRSA0811-1 
 
      5 atctattattacaatgaaaaagctaaaactgaaaataaagagagt 
        I  Y  Y  Y  N  E  K  A  K  T  E  N  K  E  S  
     50 cacgatcaatttttacagcatactatattgtttaaaggctttttt 
        H  D  Q  F  L  Q  H  T  I  L  F  K  G  F  F  
     95 acagatcattcgtggtataacgatttattagtagattttgattca 
        T  D  H  S  W  Y  N  D  L  L  V  D  F  D  S  
    140 aaggatattgttgataaatataaagggaaaaaagtagacttgtat 
        K  D  I  V  D  K  Y  K  G  K  K  V  D  L  Y  
    185 ggtgcttattatggttatcaatgtgcgggtggtacaccaaacaaa 
        G  A  Y  Y  G  Y  Q  C  A  G  G  T  P  N  K  
    230 acagcttgtatgtatggtggtgtaacgttacatgataataatcga 
        T  A  C  M  Y  G  G  V  T  L  H  D  N  N  R  
    275 ttgaccgaagagaaaaaagtgccgatcaatttatggctagacggt 
        L  T  E  E  K  K  V  P  I  N  L  W  L  D  G  
    320 aaacaaaatacagtacctttggaaacggttaaaacgaataagaaa 
        K  Q  N  T  V  P  L  E  T  V  K  T  N  K  K  
    365 aatgtaactgttcaggagttggatcttcaagcaagacgttattta 
        N  V  T  V  Q  E  L  D  L  Q  A  R  R  Y  L  
    410 caggaaaaatataatttatataactctgatgtttttgatgggaag 
        Q  E  K  Y  N  L  Y  N  S  D  V  F  D  G  K  
    455 gttcagaggggattaatcgtgtttcatacttctacagaaccttcg 
        V  Q  R  G  L  I  V  F  H  T  S  T  E  P  S  
    500 gttaattacgaatttatttg 519     
        V  N  Y  E  F  I  
 
 
> gb|AAV84102.1|  enterotoxin A [Staphylococcus aureus] 
Length=261 
 
 Score =  353 bits (905),  Expect = 4e-121, Method: Compositional matrix adjust. 
 Identities = 168/170 (99%), Positives = 169/170 (99%), Gaps = 0/170 (0%) 
 
Query  1    IYYYNEKAKTENKESHDQFLQHTILFKGFFTDHSWYNDLLVDFDSKDIVDKYKGKKVDLY  60 
                  IYYYNEKAKTENKESHDQFLQHTILFKGFFTDHSWYNDLLVDFDSKDIVDKYKGKKVDLY 
Sbjct  56   IYYYNEKAKTENKESHDQFLQHTILFKGFFTDHSWYNDLLVDFDSKDIVDKYKGKKVDLY  115 
 
Query  61   GAYYGYQCAGGTPNKTACMYGGVTLHDNNRLTEEKKVPINLWLDGKQNTVPLETVKTNKK  120 
                  GAYYGYQCAGGTPNKTACMYGGVTLHDNNRLTEEKKVPINLWLDGKQNTVPLETVKTNKK 
Sbjct  116  GAYYGYQCAGGTPNKTACMYGGVTLHDNNRLTEEKKVPINLWLDGKQNTVPLETVKTNKK  175 
 
Query  121  NVTVQELDLQARRYLQEKYNLYNSDVFDGKVQRGLIVFHTSTEPSVNYEF  170 
                   NVTVQELDLQARRYLQEKYNLYNSDVFDGKVQRGLIVFHTSTEPSVNY+  
Sbjct  176  NVTVQELDLQARRYLQEKYNLYNSDVFDGKVQRGLIVFHTSTEPSVNYDL  225 
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APPENDIX 39 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified enterotoxin type C (sec) from MRSA0309-10 
 
 
     81 atttcttttgaagtacaaactgataagaaaagtgtaacagctcaa 
        I  S  F  E  V  Q  T  D  K  K  S  V  T  A  Q  
    126 gaactagacataaaagctaggaattttttaattaataaaaaaaat 
        E  L  D  I  K  A  R  N  F  L  I  N  K  K  N  
    171 ttgtatgagtttaacagttcaccatatgaaacaggatatataaaa 
        L  Y  E  F  N  S  S  P  Y  E  T  G  Y  I  K  
    216 tttattgaaaataacggcaatactttttggtatgatatgat 256     
        F  I  E  N  N  G  N  T  F  W  Y  D  M  
 
 
> gb|AAP37185.1|  enterotoxin sec variant [Staphylococcus aureus] 
Length=222 
 
 Score =  121 bits (304),  Expect = 6e-33, Method: Compositional matrix adjust. 
 Identities = 58/58 (100%), Positives = 58/58 (100%), Gaps = 0/58 (0%) 
 
Query  1    ISFEVQTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFWYDM  58 
                  ISFEVQTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFWYDM 
Sbjct  136  ISFEVQTDKKSVTAQELDIKARNFLINKKNLYEFNSSPYETGYIKFIENNGNTFWYDM  193 
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APPENDIX 40 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified enterotoxin type G (seg) from MRSA0811-30 
 
    593 atgttgnatgctcaacccgatcctaaattagacgaactaaataaa 
        M  L  X  A  Q  P  D  P  K  L  D  E  L  N  K  
    548 gtaagtgattataaaaataataagggaactatgggtaatgtaatg 
        V  S  D  Y  K  N  N  K  G  T  M  G  N  V  M  
    503 aatctttatacgtctccacctgttgaaggaagaggagttattaat 
        N  L  Y  T  S  P  P  V  E  G  R  G  V  I  N  
    458 tctagacagtttttatctcatgatttaatttttccaattgagtat 
        S  R  Q  F  L  S  H  D  L  I  F  P  I  E  Y  
    413 aagagttataatgaggttaaaactgaattagaaaatacagaatta 
        K  S  Y  N  E  V  K  T  E  L  E  N  T  E  L  
    368 gctaacaattataaagataaaaaagtagacatttttggcgttcca 
        A  N  N  Y  K  D  K  K  V  D  I  F  G  V  P  
    323 tatttttatacatgtataatacctaaatctgaaccggatataaac 
        Y  F  Y  T  C  I  I  P  K  S  E  P  D  I  N  
    278 caaaattttggaggttgttgtatgtatggtggtcttacatttaat 
        Q  N  F  G  G  C  C  M  Y  G  G  L  T  F  N  
    233 agttcagaaaatgaaagagataaattaattactgtacaggtaaca 
        S  S  E  N  E  R  D  K  L  I  T  V  Q  V  T  
    188 atcgacaatagacaatcacttggatttacaataactacaaataag 
        I  D  N  R  Q  S  L  G  F  T  I  T  T  N  K  
    143 aatatggttactattcaggaactagattacaaagcaagacactgg 
        N  M  V  T  I  Q  E  L  D  Y  K  A  R  H  W  
     98 ctcactaaagaaaaaaagctatacgagtttgatggttctgcattt 
        L  T  K  E  K  K  L  Y  E  F  D  G  S  A  F  
     53 gaatctggatatataaaatttactgaaaagaacaatacaagtttt 
        E  S  G  Y  I  K  F  T  E  K  N  N  T  S  F  
      8 tggtttga 1       
        W  F  
 
> gb|EGL85846.1|  enterotoxin type G [Staphylococcus aureus subsp. aureus 21305] 
Length=258 
 
 Score =  404 bits (1038),  Expect = 7e-141, Method: Compositional matrix adjust. 
 Identities = 194/194 (100%), Positives = 194/194 (100%), Gaps = 0/194 (0%) 
 
Query  4    AQPDPKLDELNKVSDYKNNKGTMGNVMNLYTSPPVEGRGVINSRQFLSHDLIFPIEYKSY  63 
                  AQPDPKLDELNKVSDYKNNKGTMGNVMNLYTSPPVEGRGVINSRQFLSHDLIFPIEYKSY 
Sbjct  25   AQPDPKLDELNKVSDYKNNKGTMGNVMNLYTSPPVEGRGVINSRQFLSHDLIFPIEYKSY  84 
 
Query  64   NEVKTELENTELANNYKDKKVDIFGVPYFYTCIIPKSEPDINQNFGGCCMYGGLTFNSSE  123 
                   NEVKTELENTELANNYKDKKVDIFGVPYFYTCIIPKSEPDINQNFGGCCMYGGLTFNSSE 
Sbjct  85   NEVKTELENTELANNYKDKKVDIFGVPYFYTCIIPKSEPDINQNFGGCCMYGGLTFNSSE  144 
 
Query  124  NERDKLITVQVTIDNRQSLGFTITTNKNMVTIQELDYKARHWLTKEKKLYEFDGSAFESG  183 
                   NERDKLITVQVTIDNRQSLGFTITTNKNMVTIQELDYKARHWLTKEKKLYEFDGSAFESG 
Sbjct  145  NERDKLITVQVTIDNRQSLGFTITTNKNMVTIQELDYKARHWLTKEKKLYEFDGSAFESG  204 
 
Query  184  YIKFTEKNNTSFWF  197 
                    YIKFTEKNNTSFWF 
Sbjct  205  YIKFTEKNNTSFWF  218 
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APPENDIX 41 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified enterotoxin I (sei) from MRSA0805-10 
 
     11 atagatttaaaaggcgtcacagataaaaatctacctattgcaaat 
        I  D  L  K  G  V  T  D  K  N  L  P  I  A  N  
     56 caactcgaattttcaacaggtaccaatgatttgatctcagaatct 
        Q  L  E  F  S  T  G  T  N  D  L  I  S  E  S  
    101 aataattgggacgaaataagtaaatttaaaggaaagaaactggat 
        N  N  W  D  E  I  S  K  F  K  G  K  K  L  D  
    146 atttttggcattgattataatggtccttgtaaatctaaatacatg 
        I  F  G  I  D  Y  N  G  P  C  K  S  K  Y  M  
    191 tttggaggggccactttatcaggacaatacttaaattctgctaga 
        F  G  G  A  T  L  S  G  Q  Y  L  N  S  A  R  
    236 aaaatccctattaatctttgggttaatggcaaacataaaacaatt 
        K  I  P  I  N  L  W  V  N  G  K  H  K  T  I  
    281 tctactgacaaaatagcaactaataaaaaactagtaacagctcaa 
        S  T  D  K  I  A  T  N  K  K  L  V  T  A  Q  
    326 gaaattgatgttaaattaaggagatatcttcaagaagaatacaat 
        E  I  D  V  K  L  R  R  Y  L  Q  E  E  Y  N  
    371 atatatggtcataataacactggtaaaggcaaagaatatggatat 
        I  Y  G  H  N  N  T  G  K  G  K  E  Y  G  Y  
    416 aaatctaaattttattcaggttttaataatgggaaagttttattt 
        K  S  K  F  Y  S  G  F  N  N  G  K  V  L  F  
    461 catttaaataatgaaaaatcattttcatatgatttgttttataca 
        H  L  N  N  E  K  S  F  S  Y  D  L  F  Y  T  
    506 ggagatggactgcctgtaaagtttttt 532     
        G  D  G  L  P  V  K  F  F  
 
> dbj|BAB85991.1|  enterotoxin I [Staphylococcus aureus] 
Length=218 
 
 Score =  349 bits (896),  Expect = 3e-120, Method: Compositional matrix adjust. 
 Identities = 172/174 (99%), Positives = 172/174 (99%), Gaps = 0/174 (0%) 
 
Query  1    IDLKGVTDKNLPIANQLEFSTGTNDLISESNNWDEISKFKGKKLDIFGIDYNGPCKSKYM  60 
                  IDLKGVTDKNLPIANQLEFSTGTNDLISESNNWDEISKFKGKKLDIFGIDYNGPCKSKYM 
Sbjct  19   IDLKGVTDKNLPIANQLEFSTGTNDLISESNNWDEISKFKGKKLDIFGIDYNGPCKSKYM  78 
 
Query  61   FGGATLSGQYLNSARKIPINLWVNGKHKTISTDKIATNKKLVTAQEIDVKLRRYLQEEYN  120 
                   FGGATLSGQYLNSARKIPINLWVNGKHKTISTDKIATNKKLVTAQEIDVKLRRYLQEEYN 
Sbjct  79   FGGATLSGQYLNSARKIPINLWVNGKHKTISTDKIATNKKLVTAQEIDVKLRRYLQEEYN  138 
 
Query  121  IYGHNNTGKGKEYGYKSKFYSGFNNGKVLFHLNNEKSFSYDLFYTGDGLPVKFF  174 
                   IYGHNNTGKGKEYGYKSKFYSGFNNGKVLFHLNNEKSFSYDLFYTGDGLPV F  
Sbjct  139  IYGHNNTGKGKEYGYKSKFYSGFNNGKVLFHLNNEKSFSYDLFYTGDGLPVSFL  192 
  
245 
 
APPENDIX 42 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified enfoliative toxin D (etd) from MRSA0806-13 
    304 atggctaaaaaagatccgactaaagttatattcacacctggttcg 
        M  A  K  K  D  P  T  K  V  I  F  T  P  G  S  
    259 actaaaacagaagatggagtatataaaactccatatggacaattt 
        T  K  T  E  D  G  V  Y  K  T  P  Y  G  Q  F  
    214 gtagcagaagaaattaatgaacacccatatggacaaggaactgat 
        V  A  E  E  I  N  E  H  P  Y  G  Q  G  T  D  
    169 ttgtctataattaaactaaaacccaataaagacggaaagtctgca 
        L  S  I  I  K  L  K  P  N  K  D  G  K  S  A  
    124 ggtgatttaattccccctgcaaagattgcagattctatagatttg 
        G  D  L  I  P  P  A  K  I  A  D  S  I  D  L  
     79 caacaaggtgacaaaataagcttgctcggatacccttataacttt 
        Q  Q  G  D  K  I  S  L  L  G  Y  P  Y  N  F  
     34 tctactaattctttatatagaagtgaaattgaaa 1       
        S  T  N  S  L  Y  R  S  E  I  E  
 
> dbj|BAC22944.1|  exfoliative toxin D [Staphylococcus aureus] 
 gb|EGL88744.1|  exfoliative toxin B [Staphylococcus aureus subsp. aureus 21305] 
Length=281 
 
 Score =  208 bits (530),  Expect = 2e-65, Method: Compositional matrix adjust. 
 Identities = 101/101 (100%), Positives = 101/101 (100%), Gaps = 0/101 (0%) 
 
Query  1    MAKKDPTKVIFTPGSTKTEDGVYKTPYGQFVAEEINEHPYGQGTDLSIIKLKPNKDGKSA  60 
                  MAKKDPTKVIFTPGSTKTEDGVYKTPYGQFVAEEINEHPYGQGTDLSIIKLKPNKDGKSA 
Sbjct  103  MAKKDPTKVIFTPGSTKTEDGVYKTPYGQFVAEEINEHPYGQGTDLSIIKLKPNKDGKSA  162 
 
Query  61   GDLIPPAKIADSIDLQQGDKISLLGYPYNFSTNSLYRSEIE  101 
                  GDLIPPAKIADSIDLQQGDKISLLGYPYNFSTNSLYRSEIE 
Sbjct  163  GDLIPPAKIADSIDLQQGDKISLLGYPYNFSTNSLYRSEIE  203 
 
 
APPENDIX 43 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified extracellular fibrinogen-binding protein (efb) from MRSA0812-17 
    382 ataggtattactacaactacaattgcgtcaacagcagatgcgagc 
        I  G  I  T  T  T  T  I  A  S  T  A  D  A  S  
    337 gaaggatacggtccaagagaaaagaaaccagtgagtattaatcac 
        E  G  Y  G  P  R  E  K  K  P  V  S  I  N  H  
    292 aatatcgtagagtacaatgatggtacttttaaatatcaatctaga 
        N  I  V  E  Y  N  D  G  T  F  K  Y  Q  S  R  
    247 ccaaaatttaactcaacacctaaatatattaaattcaaacatgac 
        P  K  F  N  S  T  P  K  Y  I  K  F  K  H  D  
    202 tataatattttagaatttaacgatggtacattcgaatatggtgca 
        Y  N  I  L  E  F  N  D  G  T  F  E  Y  G  A  
    157 cgtccacaatttaataaaccagcagcgaaaactgatgcaactatt 
        R  P  Q  F  N  K  P  A  A  K  T  D  A  T  I  
    112 aaaaaagaacaaaaattgattcaagctcaaaatcttgtgagagaa 
        K  K  E  Q  K  L  I  Q  A  Q  N  L  V  R  E  
     67 tttgaaaaaacacatactgtcagtgcacacagaaaagcacaaaag 
        F  E  K  T  H  T  V  S  A  H  R  K  A  Q  K  
     22 gcagtcaacttagttncgtn 1       
        A  V  N  L  V  X  X  
 
> gb|AEV78151.1|  Extracellular fibrinogen-binding protein Efb [Staphylococcus  
aureus subsp. aureus M013] 
Length=165 
 
 Score =  259 bits (661),  Expect = 3e-86, Method: Compositional matrix adjust. 
 Identities = 124/125 (99%), Positives = 124/125 (99%), Gaps = 0/125 (0%) 
 
Query  1    IGITTTTIASTADASEGYGPREKKPVSINHNIVEYNDGTFKYQSRPKFNSTPKYIKFKHD  60 
                  IGITTTTIASTADASEGYGPREKKPVSINHNIVEYNDGTFKYQSRPKFNSTPKYIKFKHD 
Sbjct  16   IGITTTTIASTADASEGYGPREKKPVSINHNIVEYNDGTFKYQSRPKFNSTPKYIKFKHD  75 
 
Query  61   YNILEFNDGTFEYGARPQFNKPAAKTDATIKKEQKLIQAQNLVREFEKTHTVSAHRKAQK  120 
                  YNILEFNDGTFEYGARPQFNKPAAKTD TIKKEQKLIQAQNLVREFEKTHTVSAHRKAQK 
Sbjct  76   YNILEFNDGTFEYGARPQFNKPAAKTDVTIKKEQKLIQAQNLVREFEKTHTVSAHRKAQK  135 
 
Query  121  AVNLV  125 
                    AVNLV 
Sbjct  136  AVNLV  140 
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APPENDIX 44 
Standard Nucloetide-nucleotide BLAST search results for DNA sequence of the 
amplified extracellular fibrinogen-binding protein (fnbA) from MRSA0812-17 
> gb|JN848741.1|  Staphylococcus aureus strain C290 fibronectin binding protein  
A (fnbA) gene, partial cds 
Length=1089 
 Score =  287 bits (155),  Expect = 2e-74 
 Identities = 156/157 (99%), Gaps = 0/157 (0%) 
 Strand=Plus/Minus 
 
Query  16   CTANTTCAATCAGATTACTTTCAGTTGTATATTCTTTCGTATCTTCAACTGTTGTATGAT  75 
            ||| |||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  517  CTAATTCAATCAGATTACTTTCAGTTGTATATTCTTTCGTATCTTCAACTGTTGTATGAT  458 
 
Query  76   CGCTCACTGCGCCAGTTACAATACCTTTTGTAGACTCTTCGTCAAATTCAACTAAGTTAG  135 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  457  CGCTCACTGCGCCAGTTACAATACCTTTTGTAGACTCTTCGTCAAATTCAACTAAGTTAG  398 
 
Query  136  ACTCAGTAGTAACCTGACCACCACCTGGGTTTGTATC  172 
            ||||||||||||||||||||||||||||||||||||| 
Sbjct  397  ACTCAGTAGTAACCTGACCACCACCTGGGTTTGTATC  361 
 
APPENDIX 45 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified gamma hemolysin (hlg) from MRSA0801-21 
> gb|CP002110.1|  Staphylococcus aureus subsp. aureus TCH60, complete genome 
Length=2802675 
 Features in this part of subject sequence: 
   gamma hemolysin 
   gamma hemolysin 
 Score = 1439 bits (779),  Expect = 0.0 
 Identities = 850/885 (96%), Gaps = 2/885 (0%) 
 Strand=Plus/Plus 
Query  1       ATATCAATTCTGTCCTTTCACTTTGATTTCGTGTGTCTTCCAATTGACTTCATATTTCAC  60 
               ||||||||||||||||||||||||||||||||| |||||||||||||||||||||||||| 
Sbjct  842914  ATATCAATTCTGTCCTTTCACTTTGATTTCGTGAGTCTTCCAATTGACTTCATATTTCAC  842973 
Query  61      AGTGTAGTTTCTATTTTTAAATGCATTATGGACTCTGTGACCATCTAAATAACTGTTGCC  120 
              |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  842974  AGTGTAGTTTCTATTTTTAAATGCATTATGGACTCTGTGACCATCTAAATAACTGTTGCC  843033 
Query  121     ATAATGTGTTGATCTTTTAATGGCATGAGTGACATCCATATTTCTTCCATAAGTGATTTC  180 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  843034  ATAATGTGTTGATCTTTTAATGGCATGAGTGACATCCATATTTCTTCCATAAGTGATTTC  843093 
Query  181     AAATTCGCTCGTGTCGCCTGAACCTTTTTCATGAGATACTGTTGCGATAAATGAAGGGTT  240 
               ||||||||||||||||| |||||||||||| ||||||||||||||||||||||||||||| 
Sbjct  843094  AAATTCGCTCGTGTCGCTTGAACCTTTTTCGTGAGATACTGTTGCGATAAATGAAGGGTT  843153 
Query  241     AAATCCACTTTGCACAAGAGGTGGTAATTCGCTGTCTGGAACAAAATAATCTCTTGGATC  300 
               |||||||||||| |||||||||||||| |||||||||||||| ||||||||||| ||||| 
Sbjct  843154  AAATCCACTTTGTACAAGAGGTGGTAACTCGCTGTCTGGAACGAAATAATCTCTAGGATC  843213 
Query  301     TTTGCTATTTGGTTTGTATCCTACGAATAAATCACTATCAAATGCTGACTTTTGACCTGA  360 
               ||| ||||  |||||||| ||||| |||||||| |||||||||||||| ||||||||||| 
Sbjct  843214  TTTACTATGAGGTTTGTAGCCTACAAATAAATCGCTATCAAATGCTGATTTTTGACCTGA  843273 
Query  361     TGCAGTGACGAATGAATTCGCTTTGACACCCCATAAAACACTTTTTGAGTTTTGTTGTTC  420 
               | ||||| ||||||||||||||||||| |||||||||||||||||||||||||||||||| 
Sbjct  843274  TTCAGTGGCGAATGAATTCGCTTTGACGCCCCATAAAACACTTTTTGAGTTTTGTTGTTC  843333 
Query  421     CACTTCACTGACATAATTTTGTTGTGTATAGCTAATCGATTTAGAGTAGTTAAAGGATCC  480 
                |||||||| ||||||||||||||||||||||||||||||||||| |||||||| ||||| 
Sbjct  843334  TACTTCACTTACATAATTTTGTTGTGTATAGCTAATCGATTTAGAATAGTTAAATGATCC  843393 
Query  481     ATTACCACCGAGTGATGGGGCTGATTGGAAATTACCGCCGATATTGTATCCTAATGTCTG  540 
               ||||||||| |||||||||||||||||||||||||| || |||||||||||||||||||| 
Sbjct  843394  ATTACCACCAAGTGATGGGGCTGATTGGAAATTACCACCAATATTGTATCCTAATGTCTG  843453 
Query  541     GCTCACATTTGTAGATTCAATTTTATTTTTCGGTAAATAATTGATTAAAGAAACAT-TTG  599 
                || || ||||||||||||||||||||||||||||||||||||||||||||||||| ||  
Sbjct  843454  ACTTACGTTTGTAGATTCAATTTTATTTTTCGGTAAATAATTGATTAAAGAAACATATTT  843513 
Query  600     GATCATTTGTTTTTAACCCAATATTATATTGGAAGGGCCAACGCATAGATTTAATATGAT  659 
                |||||||||||| || ||||||||||||||||| ||||||||||||||||||||||||| 
Sbjct  843514  -ATCATTTGTTTTCAAACCAATATTATATTGGAATGGCCAACGCATAGATTTAATATGAT  843572 
Query  660     TTGTATTTTTATAGTTATAATATGTTGTTCGAGAGCTAATGAATCCTTGCATCTTTAGGA  719 
               ||||||||||||||||||||||||||||||||||||||||||||||||||||||||| || 
Sbjct  843573  TTGTATTTTTATAGTTATAATATGTTGTTCGAGAGCTAATGAATCCTTGCATCTTTAAGA  843632 
Query  720     TCAAAGCATCTTTGTTATATTTTTTATCCTTCACAAAGTCGAATTGGATATTTTGAGTCA  779 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  843633  TCAAAGCATCTTTGTTATATTTTTTATCCTTCACAAAGTCGAATTGGATATTTTGAGTCA  843692 
Query  780     CTCCCCATTTATTACTTGTTTTATCTTCTGTCCTTTTGATAATTTCTACATCGTTTCCTT  839 
               | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  843693  CGCCCCATTTATTACTTGTTTTATCTTCTGTCCTTTTGATAATTTCTACATCGTTTCCTT  843752 
Query  840     TACCGATGTCTTCAGTATCATTGGCAGCTTTAGCATTTTCTAATA  884 
               ||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  843753  TACCGATGTCTTCAGTATCATTGGCAGCTTTAGCATTTTCTAATA  843797 
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APPENDIX 46 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified intercellular adhesion protein A (icaA) from MRSA0801-21 
 
     25 atgattgagaatttcaaacatgatccaaaacttggtgcagttaca 
        M  I  E  N  F  K  H  D  P  K  L  G  A  V  T  
     70 ggtaatcctagaattcgaaataagagttctattttaggtaaaatt 
        G  N  P  R  I  R  N  K  S  S  I  L  G  K  I  
    115 caaacgatagaatatgcaagtttaattggctgtattaagcgaagt 
        Q  T  I  E  Y  A  S  L  I  G  C  I  K  R  S  
    160 cagacacttgctggcgcagtcaatactatttcgggtgtcttcact 
        Q  T  L  A  G  A  V  N  T  I  S  G  V  F  T  
    205 ctatttaaaaaaagtgcagttgtcgacgttggctactgggatact 
        L  F  K  K  S  A  V  V  D  V  G  Y  W  D  T  
    250 gatatgattaccgaagatattgcagtttcttggaaattgcattta 
        D  M  I  T  E  D  I  A  V  S  W  K  L  H  L  
    295 cgtggatatcgtattaagtatgaaccgcttgccatgtgttggatg 
        R  G  Y  R  I  K  Y  E  P  L  A  M  C  W  M  
    340 ttggttccagaaacattgggaggtctttggaagcaacgcgtgaga 
        L  V  P  E  T  L  G  G  L  W  K  Q  R  V  R  
    385 tgggctcaagggggacacgaagtattactacgagacttttttagc 
        W  A  Q  G  G  H  E  V  L  L  R  D  F  F  S  
    430 acaatgaaaacgaaaaggtttcctttatatattttgatgtttgag 
        T  M  K  T  K  R  F  P  L  Y  I  L  M  F  E  
    475 caaatcatctcaattttatgggtatatatagtgcttctatattta 
        Q  I  I  S  I  L  W  V  Y  I  V  L  L  Y  L  
    520 ggctatttgttcataacagcaaacttcttagactatacatttatg 
        G  Y  L  F  I  T  A  N  F  L  D  Y  T  F  M  
    565 acatatagtttttcaatatttctactatcatcatttactatgact 
        T  Y  S  F  S  I  F  L  L  S  S  F  T  M  T  
    610 tttataaacgttattcaatttacagtcgcactctttattgatagt 
        F  I  N  V  I  Q  F  T  V  A  L  F  I  D  S  
    655 cgctacgagaaaaagaatatggctggactcatatttgtaagttgg 
        R  Y  E  K  K  N  M  A  G  L  I  F  V  S  W  
    700 tatccgacagtatactggattattacg 726     
        Y  P  T  V  Y  W  I  I  T  
> ref|ZP_05687633.1|  intercellular adhesion protein A [Staphylococcus aureus A9635] 
 gb|EEV69097.1|  intercellular adhesion protein A [Staphylococcus aureus A9635] 
Length=412 
 
 Score =  480 bits (1236),  Expect = 5e-168, Method: Compositional matrix adjust. 
 Identities = 233/234 (99%), Positives = 233/234 (99%), Gaps = 0/234 (0%) 
 
Query  1    MIENFKHDPKLGAVTGNPRIRNKSSILGKIQTIEYASLIGCIKRSQTLAGAVNTISGVFT  60 
                  MIENFKHDPKLGAVTGNPRIRNKSSILGKIQTIEYASLIGCIKRSQTLAGAVNTISGVFT 
Sbjct  147  MIENFKHDPKLGAVTGNPRIRNKSSILGKIQTIEYASLIGCIKRSQTLAGAVNTISGVFT  206 
 
Query  61   LFKKSAVVDVGYWDTDMITEDIAVSWKLHLRGYRIKYEPLAMCWMLVPETLGGLWKQRVR  120 
                   LFKKSAVVDVGYWDTDMITEDIAVSWKLHLRGYRIKYEPLAMCWMLVPETLGGLWKQRVR 
Sbjct  207  LFKKSAVVDVGYWDTDMITEDIAVSWKLHLRGYRIKYEPLAMCWMLVPETLGGLWKQRVR  266 
 
Query  121  WAQGGHEVLLRDFFSTMKTKRFPLYILMFEQIISILWVYIVLLYLGYLFITANFLDYTFM  180 
                    WAQGGHEVLLRDFFSTMKTKRFPLYILMFEQIISILWVYIVLLYLGYLFITANFLDYTFM 
Sbjct  267  WAQGGHEVLLRDFFSTMKTKRFPLYILMFEQIISILWVYIVLLYLGYLFITANFLDYTFM  326 
 
Query  181  TYSFSIFLLSSFTMTFINVIQFTVALFIDSRYEKKNMAGLIFVSWYPTVYWIIT  234 
                    TYSFSIFLLSSFTMTFINVIQFTVALFIDSRYEKKNMAGLIFVSWYPTVYWII  
Sbjct  327  TYSFSIFLLSSFTMTFINVIQFTVALFIDSRYEKKNMAGLIFVSWYPTVYWIIN  380 
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APPENDIX 47 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified bone sialoprotein-binding protein (sdrE) from MRSA0812-17 
 
    593 atgcgctttgcagttgcacaaccagcagcagttgcttcaaacaat 
        M  R  F  A  V  A  Q  P  A  A  V  A  S  N  N  
    548 gtaaatgatttaattaaagtgacgaagcaaacaatcaaagttggc 
        V  N  D  L  I  K  V  T  K  Q  T  I  K  V  G  
    503 gatggtaaagataatgtggcagcagcgcatgacggtaaagatatt 
        D  G  K  D  N  V  A  A  A  H  D  G  K  D  I  
    458 gaatatgatacagagtttacaattgacaataaagtcaaaaaaggc 
        E  Y  D  T  E  F  T  I  D  N  K  V  K  K  G  
    413 gatacaatgacgattaattatgataagaatgtaattccttcggat 
        D  T  M  T  I  N  Y  D  K  N  V  I  P  S  D  
    368 ttaacagataaaaatgatcctatcgatattactgatccatcagga 
        L  T  D  K  N  D  P  I  D  I  T  D  P  S  G  
    323 gaggtcattgctaaaggaacatttgataaagcaactaagcaaatc 
        E  V  I  A  K  G  T  F  D  K  A  T  K  Q  I  
    278 acatatacatttacagactatgtagataaatatgaagatataaaa 
        T  Y  T  F  T  D  Y  V  D  K  Y  E  D  I  K  
    233 tcacgcttaactctatattcgtatattgataaaaaaacagttcca 
        S  R  L  T  L  Y  S  Y  I  D  K  K  T  V  P  
    188 aatgagacaagtttgaatttaacatttgctacagcaggtaaagaa 
        N  E  T  S  L  N  L  T  F  A  T  A  G  K  E  
    143 acaagccaaaatgtcactgttgattatcaagatccaatggtccat 
        T  S  Q  N  V  T  V  D  Y  Q  D  P  M  V  H  
     98 ggtgattcaaacattcaatctatctttacaaaattagatgaagat 
        G  D  S  N  I  Q  S  I  F  T  K  L  D  E  D  
     53 aagcaaactattgaacaacaaatttatgttaacccatga 15      
        K  Q  T  I  E  Q  Q  I  Y  V  N  P  *  
 
 
> ref|ZP_03565541.1|  bone sialoprotein-binding protein [Staphylococcus aureus subsp.  
aureus str. JKD6009] 
Length=797 
 
 Score =  387 bits (994),  Expect = 3e-127, Method: Compositional matrix adjust. 
 Identities = 192/192 (100%), Positives = 192/192 (100%), Gaps = 0/192 (0%) 
 
Query  1    MRFAVAQPAAVASNNVNDLIKVTKQTIKVGDGKDNVAAAHDGKDIEYDTEFTIDNKVKKG  60 
                  MRFAVAQPAAVASNNVNDLIKVTKQTIKVGDGKDNVAAAHDGKDIEYDTEFTIDNKVKKG 
Sbjct  260  MRFAVAQPAAVASNNVNDLIKVTKQTIKVGDGKDNVAAAHDGKDIEYDTEFTIDNKVKKG  319 
 
Query  61   DTMTINYDKNVIPSDLTDKNDPIDITDPSGEVIAKGTFDKATKQITYTFTDYVDKYEDIK  120 
                   DTMTINYDKNVIPSDLTDKNDPIDITDPSGEVIAKGTFDKATKQITYTFTDYVDKYEDIK 
Sbjct  320  DTMTINYDKNVIPSDLTDKNDPIDITDPSGEVIAKGTFDKATKQITYTFTDYVDKYEDIK  379 
 
Query  121  SRLTLYSYIDKKTVPNETSLNLTFATAGKETSQNVTVDYQDPMVHGDSNIQSIFTKLDED  180 
                   SRLTLYSYIDKKTVPNETSLNLTFATAGKETSQNVTVDYQDPMVHGDSNIQSIFTKLDED 
Sbjct  380  SRLTLYSYIDKKTVPNETSLNLTFATAGKETSQNVTVDYQDPMVHGDSNIQSIFTKLDED  439 
 
Query  181  KQTIEQQIYVNP  192 
                    KQTIEQQIYVNP 
Sbjct  440  KQTIEQQIYVNP  451 
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APPENDIX 48 
Standard Open Reading Frame BLAST search results for DNA sequence of the 
amplified panton-valentine leukocidin (pvl) from MRSA0805-10 
 
    397 atgtctggacatgatccaaatttatttgttggatataaaccatat 
        M  S  G  H  D  P  N  L  F  V  G  Y  K  P  Y  
    352 agtcaaaatccgagagactattttgtgccagacaatgaattaccc 
        S  Q  N  P  R  D  Y  F  V  P  D  N  E  L  P  
    307 ccattagtacacagtggtttcaatccttcatttattgcaactgtt 
        P  L  V  H  S  G  F  N  P  S  F  I  A  T  V  
    262 tctcatgaaaaaggctcaggagatacaagtgaatttgaaataacg 
        S  H  E  K  G  S  G  D  T  S  E  F  E  I  T  
    217 tatggcagaaatatggatgttactcatgctactagaagaacaaca 
        Y  G  R  N  M  D  V  T  H  A  T  R  R  T  T  
    172 cactatggcaatagttatttagaaggatctagaatacacaacgca 
        H  Y  G  N  S  Y  L  E  G  S  R  I  H  N  A  
    127 tttgtaaacagaaattacacagttaaatatgaagtgaactggaaa 
        F  V  N  R  N  Y  T  V  K  Y  E  V  N  W  K  
     82 actcatgaaattaaagtgaaaggacataattga 50      
        T  H  E  I  K  V  K  G  H  N  *  
> gb|AEO79837.1|  LukPVS [Staphylococcus aureus] 
Length=119 
 Score =  240 bits (612),  Expect = 1e-79, Method: Compositional matrix adjust. 
 Identities = 115/115 (100%), Positives = 115/115 (100%), Gaps = 0/115 (0%) 
Query  1    MSGHDPNLFVGYKPYSQNPRDYFVPDNELPPLVHSGFNPSFIATVSHEKGSGDTSEFEIT  60 
                 MSGHDPNLFVGYKPYSQNPRDYFVPDNELPPLVHSGFNPSFIATVSHEKGSGDTSEFEIT 
Sbjct  5    MSGHDPNLFVGYKPYSQNPRDYFVPDNELPPLVHSGFNPSFIATVSHEKGSGDTSEFEIT  64 
 
Query  61   YGRNMDVTHATRRTTHYGNSYLEGSRIHNAFVNRNYTVKYEVNWKTHEIKVKGHN  115 
                  YGRNMDVTHATRRTTHYGNSYLEGSRIHNAFVNRNYTVKYEVNWKTHEIKVKGHN 
Sbjct  65   YGRNMDVTHATRRTTHYGNSYLEGSRIHNAFVNRNYTVKYEVNWKTHEIKVKGHN  119 
 
 
APPENDIX 49 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified agr type I (agrB, agrD, agrC gene) from MRSA0806-21 
> emb|AJ617710.1|  Staphylococcus aureus agrB gene (partial), agrD gene and agrC  
gene (partial), strain gt54b-cp5 
Length=1891 
 Score =  723 bits (391),  Expect = 0.0 
 Identities = 394/395 (99%), Gaps = 1/395 (0%) 
 Strand=Plus/Minus 
Query  19   tcccagtaataaaatcaaaaaataagttaaataatGTATTCATTTTAAGTCCTCCTTAAT  78 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  584  TCCCAGTAATAAAATCAAAAAATAAGTTAAATAATGTATTCATTTTAAGTCCTCCTTAAT  525 
 
Query  79   AAAGAAAATAGGTAATAATGTAATAGCTTCTATTATGATGCCTAATTGAATGAATTGGGC  138 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  524  AAAGAAAATAGGTAATAATGTAATAGCTTCTATTATGATGCCTAATTGAATGAATTGGGC  465 
 
Query  139  AAATGGCTCTTTGATGATAAGTGTGATAATGAAAAAGGTTAAACTAACAATAATCGCATA  198 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  464  AAATGGCTCTTTGATGATAAGTGTGATAATGAAAAAGGTTAAACTAACAATAATCGCATA  405 
 
Query  199  ATAtttttttCGTTTAATAAGTCGCACAGGAATGGGCTTCTTTTTAGTTGCTGCAGGAGC  258 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  404  ATATTTTTTTCGTTTAATAAGTCGCACAGGAATGGGCTTCTTTTTAGTTGCTGCAGGAGC  345 
 
Query  259  ATATACTGAGATTATACCTAAAGAAATAACTGTTAAAATAATCATAATTAATGGATTAAT  318 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  344  ATATACTGAGATTATACCTAAAGAAATAACTGTTAAAATAATCATAATTAATGGATTAAT  285 
 
Query  319  ATGAAAATTTACTATTACTAAAGGTAAGAGTATAAATAATAAAATACTTTCCACATAACA  378 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  284  ATGAAAATTTACTATTACTAAAGGTAAGAGTATAAATAATAAAATACTTTCCACATAACA  225 
 
Query  379  CCAAAAGGAAGAAGGTGCATGTGCAC-ATGTGCAT  412 
            |||||||||||||||||||||||||| |||||||| 
Sbjct  224  CCAAAAGGAAGAAGGTGCATGTGCACCATGTGCAT  190 
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APPENDIX 50 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified agr type II (agrD, agrC, agrB gene) from MRSA0812-36 
> emb|AJ617719.1|  Staphylococcus aureus agrD gene, agrC gene (partial) and agrB  
gene (partial), strain gt111-cp8 
Length=1890 
 Score =  961 bits (520),  Expect = 0.0 
 Identities = 523/525 (99%), Gaps = 0/525 (0%) 
 Strand=Plus/Minus 
Query  1    ATGCTACACACTTTCTAAAATAACTTTTACTATTTGTCGTATAAATTCGTTAATTCNGCG  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||| ||| 
Sbjct  714  ATGCTACACACTTTCTAAAATAACTTTTACTATTTGTCGTATAAATTCGTTAATTCAGCG  655 
Query  61   GGTACTTTAGGTTCATCAAATAAACTGCTGCAAGCGTTTACGCCACCGACAATTCCGATT  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  654  GGTACTTTAGGTTCATCAAATAAACTGCTGCAAGCGTTTACGCCACCGACAATTCCGATT  595 
 
Query  121  GCTTTAGCTAATTTAATTATAAAATCAAAAAACATATTAACAAGTGTATTCATGATTAAT  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  594  GCTTTAGCTAATTTAATTATAAAATCAAAAAACATATTAACAAGTGTATTCATGATTAAT  535 
 
Query  181  CCTCCTTAGGGaaaaaaaTAGGTAATAATGTAATAGATTCTACTAAAATTCCTAATAACA  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  534  CCTCCTTAGGGAAAAAAATAGGTAATAATGTAATAGATTCTACTAAAATTCCTAATAACA  475 
 
Query  241  TAAATTGAGCATAAAATGGATGTATTATTAAGGATAGAATCAAAACTAATAAATACATAA  300 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  474  TAAATTGAGCATAAAATGGATGTATTATTAAGGATAGAATCAAAACTAATAAATACATAA  415 
 
Query  301  TTATAGATAAATACTTTTTACGTTTTACTAATTTTATTGGTATAGGTTGCTTTTTCGTTG  360 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  414  TTATAGATAAATACTTTTTACGTTTTACTAATTTTATTGGTATAGGTTGCTTTTTCGTTG  355 
 
Query  361  CTGCAGGTGCATAAATAACAACGGAAATCAATCCTATAATAGATAAGGCCAGTAAATAAG  420 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  354  CTGCAGGTGCATAAATAACAACGGAAATCAATCCTATAATAGATAAGGCCAGTAAATAAG  295 
 
Query  421  TAAAATTAATGTCTATATTAATTAGAAAATAAGGTACAAATACAAATGTTAAAATACTTT  480 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  294  TAAAATTAATGTCTATATTAATTAGAAAATAAGGTACAAATACAAATGTTAAAATACTTT  235 
 
Query  481  GTATGTAACAAAGTATCGAAGACTTTGCATGTGCACCATGTGCAT  525 
            ||||||||||||||||||||||||||||||| ||||||||||||| 
Sbjct  234  GTATGTAACAAAGTATCGAAGACTTTGCATGAGCACCATGTGCAT  190 
 
APPENDIX 51 
Standard Nucleotide-nucleotide BLAST search results for DNA sequence of the 
amplified agr type III (agrD, agrC, agrB gene) from MRSA0806-13 
> emb|AJ617720.1|  Staphylococcus aureus agrD gene, agrC gene (partial) and agrB  
gene (partial), strain gt108-cp8 
Length=1892 
 Score =  516 bits (279),  Expect = 4e-143 
 Identities = 280/281 (99%), Gaps = 0/281 (0%) 
 Strand=Plus/Minus 
Query  1    TTGGGTATATGGTTCTTTTACAAAAAGTGTGATAATGAAAAGAATTGTACTAATTATAAT  60 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  470  TTGGGTATATGGTTCTTTTACAAAAAGTGTGATAATGAAAAGAATTGTACTAATTATAAT  411 
Query  61   TGAAAAATATCTTTTTTGCTTTACAAGCCTCGCTGGGATAGGCTTCTTCTTAGTGGCTGC  120 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  410  TGAAAAATATCTTTTTTGCTTTACAAGCCTCGCTGGGATAGGCTTCTTCTTAGTGGCTGC  351 
Query  121  AGGTGCATATTTAATCACTACTCCAACACTTATTAATGCTAAAAACATCATTAGTGTTTC  180 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  350  AGGTGCATATTTAATCACTACTCCAACACTTATTAATGCTAAAAACATCATTAGTGTTTC  291 
 
Query  181  ATTAATATGAAAATGCAATACTAATAGAGGTAGCACAATAAAAAGTGTAATGCTTTCTAT  240 
            |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  290  ATTAATATGAAAATGCAATACTAATAGAGGTAGCACAATAAAAAGTGTAATGCTTTCTAT  231 
 
Query  241  ATAACACCAAAAAGATGAAGGTGCATGTGCANCATGTGCAT  281 
            ||||||||||||||||||||||||||||||| ||||||||| 
Sbjct  230  ATAACACCAAAAAGATGAAGGTGCATGTGCACCATGTGCAT  190 
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APPENDIX 52 
New spa type (t6405) assigned from ridom spa server for MRSA0802-3 
 
 
 
APPENDIX 53 
Multilocus query result for MLST type ST239
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APPENDIX 54 
Allelic profile query for MLST type ST239 
 
 
APPENDIX 55 
New dru types assigned from dru server
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